id,Year,Page,COR,LOE,Recommendation,SourceFile
id_00001,2024,10,Class 1,C-EO,A first aid provider who is assisting a person with a potentially serious illness or injury should immediately activate the emergency response system.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00002,2024,10,Class 1,C-EO,A first aid provider who is assisting a person with a potentially serious illness or injury should remain with the person until trained rescuers arrive as long as it is safe to do so.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00003,2024,10,Class 1,C-EO,"If the area is unsafe, the first aid provider should move an ill or injured person to a safe location if possible and safe for the first aid provider to do so.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00004,2024,10,Class 1,C-EO,"If a person has been injured, is responsive, and is breathing normally and the nature of the injury suggests a neck, back, hip, or pelvic injury, the person should be left in the position in which they were found to avoid potential further injury unless the area is unsafe.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00005,2024,10,Class 1,C-EO,"An awake and alert person who is having difficulty breathing should be allowed to assume a position most comfortable for breathing, which will be sitting up in most situations.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00006,2024,10,Class 1,C-EO,Individuals who are ill or injured should be protected from hyperthermia or hypothermia due to exposure.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00007,2024,10,2A,C-LD,It is reasonable to position a person with decreased alertness of nontraumatic cause who is breathing normally in a recovery (side-lying) position. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00008,2024,12,2A,C-LD,"If a person shows evidence of shock with a normal level of alertness, it is reasonable to place or maintain the person in a supine position.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00009,2024,12,2A,C-LD,"If a person showing signs of shock is at risk for airway obstruction (decreased alertness, active vomiting) or cannot be continuously watched, it is reasonable to place the person in the recovery position.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00010,2024,12,2B,C-LD,"If there is no evidence of trauma or injury (eg, simple fainting, shock from nontraumatic bleeding, sepsis, dehydration), raising the feet about 6 to 12 in (≈30°–45°) from supine position may be reasonable while awaiting the arrival of EMS.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00011,2024,12,2B,C-EO,"If a person is placed in a leg-raised position that results in pain, discomfort, or worsened symptoms, returning the person to a supine position may be considered. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00012,2024,13,2B,C-LD,"The effectiveness/usefulness of oxygen adminis- tered in the first aid setting for adults or children exhibiting signs or symptoms of shortness of breath, difficulty breathing, or hypoxia is unknown.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00013,2024,13,Class 3: No Benefit,B-R,It is not beneficial to administer oxygen over room air in the first aid setting for adults experiencing acute stroke.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00014,2024,14,Class 1,C-EO,A physical examination and history should be the primary assessment methods for first aid provid- ers to evaluate an ill or injured person.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00015,2024,14,2A,C-EO,It is reasonable for first aid providers to use pulse oximetry results in the context of a complete assessment and to be aware of the limitations of pulse oximetry before acting on any results. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00016,2024,15,Class 1,B-R,First aid providers should assist a person with asthma who is having difficulty breathing with the administration of their own prescribed bronchodilators as needed.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00017,2024,15,2A,B-R,"It is reasonable to use either an inhaler with a spacer or a nebulizer when assisting a person with asthma to use their own inhaled bronchodilator medication, in preference to using an inhaler alone.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00018,2024,15,2A,B-R,"If a commercially available spacer is not available, it is reasonable to use an improvised spacer when assisting a person who is having an asthma attack to use their own inhaled bronchodilator medication. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00019,2024,16,Class 1,B-NR,"If stroke is suspected, the EMS system should be activated immediately.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00020,2024,16,Class 1,B-NR,"The use of a stroke recognition scale such as the Face, Arms, Speech, Time (FAST) or Cincinnati Prehospital Stroke Scale is recommended to aid in the recognition of acute stroke in adults.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00021,2024,16,2A,C-EO,It is reasonable for first aid providers to measure capillary blood glucose in adults with suspected stroke if it is available and does not delay activating EMS. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00022,2024,18,Class 1,B-NR,"If pediatric stroke is suspected, EMS should be activated, and the person should be transported to an ED.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00023,2024,18,2A,C-EO,It is reasonable to consider stroke when common pediatric symptoms are present in association with other neurological signs and symptoms.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00024,2024,18,Class 3: No Benefit,C-EO,Adult stroke scores are not validated in the pediatric population and should not solely be used to identify the broad presentation of stroke in children. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00025,2024,19,Class 1,C-LD,"In adults with acute chest pain, the emergency response system should be activated to initiate transport to the closest ED by EMS.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00026,2024,19,2B,B-NR,"While awaiting the arrival of EMS, first aid provid- ers may encourage alert adults experiencing non- traumatic chest pain to chew and swallow aspirin (162–325 mg), unless the person experiencing pain has a known aspirin allergy or has been advised by a health care professional not to take aspirin.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00027,2024,19,2B,C-EO,"If there is any uncertainty that aspirin should be taken, it is reasonable to wait for EMS arrival without administration of aspirin. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00028,2024,20,Class 1,B-NR,"If a person experiences anaphylaxis and an epinephrine autoinjector is available, the person should self-administer the autoinjector.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00029,2024,20,Class 1,C-EO,A first aid provider should assist a person experi- encing anaphylaxis to use their autoinjector if assistance is required.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00030,2024,20,Class 1,C-EO,"If a person experiences anaphylaxis, the emer- gency response system should be activated.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00031,2024,20,2B,B-NR,"If a person with anaphylaxis does not respond to the initial dose of epinephrine and arrival of EMS will exceed 5 to 10 minutes, a repeat dose may be considered. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00032,2024,21,Class 1,C-LD,"First aid providers should activate EMS for individuals with first-time seizure; seizures last- ing >5 minutes; >1 seizure that occurs without the person returning to baseline mental status in between; seizures occurring in the water; seizures with traumatic injuries, difficulty breathing, or choking; seizure in an infant <6 months of age; seizure in pregnant individuals; or if the individual does not return to baseline within 5 to 10 minutes once seizure activity has stopped.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00033,2024,21,Class 1,C-EO,"First aid providers should minimize the risk of injury to the individual who is having a seizure by helping the person to the ground, placing the person on their side in the recovery position, and clearing the area around them.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00034,2024,21,Class 1,C-EO,"First aid providers should stay with the person having a seizure. Downloaded from http://ahajournals.org by on June 19, 2025",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00035,2024,22,Class 3: No Benefit,B-R,"For children who have experienced a febrile seizure, administration of antipyretics such as acetaminophen, ibuprofen, or paracetamol is not effective for stopping a seizure or preventing a subsequent febrile seizure.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00036,2024,22,Class 3: Harm,C-EO,The person having the seizure should not be restrained.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00037,2024,22,Class 3: Harm,C-EO,"Nothing should be put in the mouth and no food, liquids, or oral medicines should be given to a person who is experiencing a seizure or who has decreased responsiveness after a seizure. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00038,2024,23,Class 1,C-LD,"For a person with suspected hypoglycemia who is awake and able to swallow, the first aid provider should encourage the person to swallow oral glucose.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00039,2024,23,Class 1,C-EO,"EMS should be activated for a person with hypoglycemia who is unable to swallow, has a seizure, or does not improve within 10 minutes of oral glucose administration.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00040,2024,23,2A,B-NR,"If they are available, it is reasonable to use oral glucose tablets in preference to gel or dietary sources of glucose to treat hypoglycemia.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00041,2024,23,2A,C-LD,It is reasonable to use simple dietary sugars as an alternative if glucose tablets or gel is not available to treat hypoglycemia.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00042,2024,23,2B,C-LD,"For children with suspected hypoglycemia who are awake but unwilling or unable to swallow glucose, it may be reasonable to apply a slurry of granulated sugar and water under the tongue.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00043,2024,25,Class 1,C-LD,"If a person experiences signs or symptoms of presyncope (including pallor, sweating, lightheadedness, visual changes, and weakness) of vasovagal or orthostatic origin, that person should maintain or assume a safe position such as assisted sitting or lying down.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00044,2024,25,2A,C-LD,"Once the person with presyncope is in a safe position, it can be beneficial for that person to use physical PCMs to avoid syncope.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00045,2024,25,2B,C-LD,Lower-body PCMs may be preferable to upper-body and abdominal PCMs in first aid for presyncope.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00046,2024,25,2B,C-EO,"If no improvement occurs within 1 to 2 minutes, if syncope occurs, or if symptoms worsen or reoccur, the first aid provider should activate emergency services.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00047,2024,26,Class 1,B-NR,"If a person experiences anaphylaxis due to a bee, wasp, or hornet sting and an epinephrine autoinjector is available, the person should self-administer the autoinjector.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00048,2024,26,Class 1,C-EO,A first aid provider should assist a person experiencing anaphylaxis to use the autoinjector if assistance is required.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00049,2024,26,Class 1,C-EO,"If a person experiences anaphylaxis due to a bee, wasp, or hornet sting, the emergency response system should be activated.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00050,2024,26,Class 1,C-EO,Stings to the eye should be evaluated by a trained medical professional.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00051,2024,26,2A,B-NR,Removal of a stinger remaining in the skin as soon as possible by plucking or scraping can be beneficial.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00052,2024,26,2A,C-EO,Over-the-counter oral antihistamines can be used to alleviate local itching.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00053,2024,26,2A,C-EO,Topical corticosteroids can be used to alleviate local itching.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00054,2024,26,2A,C-EO,"It is reasonable to wash the area of a bee, wasp, or hornet sting with soap and water.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00055,2024,26,2B,C-EO,Administration of over-the-counter acetaminophen and nonsteroidal anti-inflammatory agents may be considered to alleviate local pain.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00056,2024,26,2B,C-EO,Administration of ice or cold packs may be con- sidered for local pain relief. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00057,2024,28,Class 1,B-R,Tick bites occurring in regions with high prevalence of Lyme disease should receive prompt consultation with a health care professional within 72 hours after removal of an engorged tick.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00058,2024,28,Class 1,B-NR,We recommend removal of a tick as soon as possible.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00059,2024,28,Class 1,C-LD,"To remove a tick, we recommend grasping the head of the tick as close to the skin as possible with tweezers or a commercial tick removal device and pulling upward with steady, even pressure. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00060,2024,29,Class 1,B-NR,"As soon as exposure to poison ivy, oak, or sumac is recognized, the exposed area should be washed with soap and water or a commercially available decontamination product.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00061,2024,29,2B,B-NR,"The usefulness of over-the-counter topical steroids to alleviate local symptoms from poison ivy, oak, or sumac is uncertain.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00062,2024,29,2B,C-EO,"Cool compresses may be considered for relief of local symptoms from exposure to poison ivy, oak, or sumac.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00063,2024,29,2B,C-EO,"Oatmeal baths may be considered for relief of local symptoms from exposure to poison ivy, oak, or sumac.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00064,2024,29,2B,C-EO,"The usefulness of over-the-counter antihistamines to alleviate local symptoms from poison ivy, oak, or sumac is uncertain. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00065,2024,30,Class 1,C-EO,Emergency services should be activated for any person bitten by a venomous or possibly venomous snake.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00066,2024,30,2A,C-LD,It is reasonable to rest and immobilize the bitten extremity and minimize exertion by the person who was bitten if it does not delay access to emergency medical care.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00067,2024,30,2A,C-EO,It is reasonable to remove rings and other con- stricting objects from the bitten extremity.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00068,2024,30,Class 3: No Benefit,C-LD,Application of ice to a snakebite wound is of unproven benefit and may be harmful in some situations.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00069,2024,32,Class 1,C-EO,"A first aid provider should observe a person with a jellyfish sting for systemic reaction and call emergency services for difficulty breathing, signs of shock, or severe pain.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00070,2024,32,2A,C-LD,It is reasonable to remove any remaining tentacles by lifting or pulling while avoiding manual contact. Rinsing the affected area with seawater to remove the tentacle is a reasonable alternative if mechanical removal is not available.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00071,2024,32,2A,C-LD,"After removal of tentacles, it is reasonable to use nonscalding hot water immersion/irrigation or to apply a heat source to relieve pain.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00072,2024,32,2B,C-LD,Topical lidocaine cream or gel may be reasonable for pain control if hot water is not available. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00073,2024,33,Class 1,C-EO,"Emergency services should be called if a person bitten by a spider or stung by a scorpion develops symptoms throughout the body such as difficulty breathing, muscle rigidity, dizziness, or confusion.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00074,2024,33,Class 1,C-EO,"A person bitten by a spider or stung by a scorpion should seek medical care if pain extends beyond the site of the bite/sting, becomes severe, and is not controlled by over-the-counter pain medica- tions; if an open wound develops; or if the person experiences symptoms throughout the body.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00075,2024,33,2A,C-LD,Over-the-counter acetaminophen and nonsteroi- dal anti-inflammatory agents can be used to allevi- ate local pain from scorpion stings.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00076,2024,33,2A,C-LD,"If the skin is intact, topical lidocaine can be useful to relieve local pain from scorpion stings.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00077,2024,33,2A,C-LD,Ice can be useful for local pain relief from scor- pion stings. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00078,2024,34,Class 1,B-R,"A person with signs and symptoms of hypother- mia should be protected from further heat loss by moving from the cold environment to a warm one, having saturated clothing removed, being allowed to passively rewarm with blankets, and being actively rewarmed if resources are available.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00079,2024,34,Class 1,C-LD,"If a person with hypothermia cannot be immedi- ately moved from a cold environment to a warm one, they should be protected from further heat loss by insulation from the ground, covering of head and neck, and shielding from heat loss by wind using a plastic or foil layer in addition to a dry insulating layer.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00080,2024,34,Class 1,C-LD,"When using rewarming devices of any kind, the first aid provider should follow the manufacturer’s instructions for the device used, place insulation between the heat source and skin, and frequently monitor for burns and pressure injury.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00081,2024,34,Class 1,C-EO,"If a person with hypothermia has a decreased level of responsiveness such as unresponsive- ness, inability to remain awake, mumbling speech, confusion, or inability to participate in removal of clothing or has pallor, cyanosis, or frozen skin, the emergency response system should be activated while the person is rewarmed by any available method.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00082,2024,34,Class 1,C-EO,"For patients experiencing cold stress or mild hypothermia who are alert and can safely con- sume oral food or fluids, it is recommended to provide high-calorie foods or drinks.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00083,2024,34,2A,C-LD,"If a person with hypothermia with a decreased level of responsiveness is wearing damp (not saturated) clothing such as polyester fleece and cannot be immediately moved into a warm environment, active rewarming through the damp clothing is reasonable to initiate with the hypo- thermia wrap technique, using chemical heat blankets, plastic or foil layers, and insulative blankets.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00084,2024,34,Class 3: No Benefit,C-LD,It is not beneficial to use body-to-body rewarming for active rewarming over other active rewarming techniques such as chemical heat packs or forced air systems.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00085,2024,34,Class 3: No Benefit,C-EO,It is not effective to treat a person with hypothermia by using small glove or boot insert chemical heat packs as the sole or primary means of rewarming.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00086,2024,36,Class 1,C-LD,The preferred method for warming frostbitten tissue is clean lukewarm water immersion at 37° C to 40° C (99° F–104° F).,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00087,2024,36,Class 1,C-LD,"Frostbitten tissue should be rewarmed at the earliest opportunity, as long as there is no risk of refreezing.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00088,2024,36,Class 1,C-LD,"If clean lukewarm water immersion is not feasible, frostbitten tissue should be allowed to rewarm spontaneously in warm room air or next to the person’s own warm skin.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00089,2024,36,Class 1,C-LD,A person with frostbite should seek prompt medical attention.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00090,2024,36,Class 1,C-EO,Jewelry or other constricting materials should be removed from a frostbitten extremity as soon as possible.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00091,2024,36,Class 1,C-EO,A person with moderate to severe hypothermia should receive core rewarming before frostbite is treated.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00092,2024,36,Class 1,C-EO,"If possible, a person should protect frostbitten tissue from further injury and avoid walking on frozen feet and toes.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00093,2024,36,Class 1,C-EO,"For frozen and thawed tissue and between the toes and fingers, bulky, clean, dry gauze or sterile cotton dressings should be applied. Circumfer- ential dressings should be wrapped loosely to allow for swelling without placing pressure on the underlying tissue.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00094,2024,36,2B,C-EO,It may be reasonable to give ibuprofen to a person with frostbite to prevent further tissue damage and to treat pain.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00095,2024,36,Class 3: No Benefit,C-EO,It is not recommended for first aid providers to debride blisters associated with frostbite. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00096,2024,38,Class 1,C-EO,"For people with exertional hyperthermia or heatstroke, first aid providers should move the individual from the hot environment, remove excess clothing, limit exertion, and provide cool liquids if the person is able to swallow.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00097,2024,38,Class 1,C-EO,"For people with heatstroke (heat illness with altered mental status), first aid providers should activate emergency services.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00098,2024,38,2A,C-LD,"For adults with heatstroke, it is reasonable to initiate immediate active cooling by using whole- body (neck-down) cool- to cold-water immersion for 15 minutes or until neurological symptoms resolve (whichever occurs first).",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00099,2024,38,2A,C-LD,"For adults with heatstroke, it is reasonable to initiate other forms of active cooling, including commercial ice packs, cold showers, ice sheets and towels, cooling vests and jackets, and evaporative, fanning, or a combination of techniques when water immersion is not available.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00100,2024,38,2A,C-EO,"For children with heatstroke, it is reasonable to initi- ate immediate active cooling by using whole-body (neck-down) cool- to cold-water immersion for 15 minutes or until neurological symptoms resolve (whichever occurs first).",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00101,2024,38,2A,C-EO,"For children with heatstroke, it is reasonable to initiate other forms of active cooling, including commercial ice packs, cold showers, ice sheets and towels, cooling vests and jackets, and evaporative, fanning, or a combination of techniques when water immersion is not available.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00102,2024,38,2B,C-EO,"It may be reasonable for first aid providers, who are trained and willing, to measure core temperature during active cooling for heatstroke. The target core temperature to cool until is 39° C (102.2° F). Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00103,2024,39,Class 1,C-LD,"In the absence of shock, confusion, or inability to swallow, first aid providers should assist or encourage individuals with exertional dehydration to orally rehydrate with any available rehydration drink or potable water.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00104,2024,39,2A,B-R,"It is reasonable to choose 4% to 9% carbohydrate- electrolyte drink over potable water, 0% to 3.9% carbohydrate-electrolyte drinks, coconut water, or low-fat cow’s milk, if each is readily available. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00105,2024,40,Class 1,B-R,"It is beneficial for first aid providers to receive training in responding to opioid overdose, including the provision of naloxone.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00106,2024,40,Class 1,B-NR,"A first aid provider who encounters a person with suspected opioid overdose who is unresponsive and not breathing or not breathing normally should activate the emergency response system, provide high-quality CPR (compressions plus ventilation), and administer naloxone. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00107,2024,43,Class 1,B-NR,Immediate skin decontamination is recommended after a chemical exposure.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00108,2024,43,Class 1,B-NR,"Unless otherwise recommended by local guide- lines or chemical-specific information, skin exposed to caustic chemical should be irrigated with running water for at least 15 minutes.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00109,2024,43,Class 1,C-LD,"It can be beneficial to follow local guidelines, fol- low chemical-specific procedures, or consult a regional poison center when assisting a person with chemical exposures.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00110,2024,43,Class 1,C-EO,"Contaminated clothing, jewelry, and other surrounding material should be removed from the area of a chemical exposure.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00111,2024,43,Class 1,C-EO,"EMS should be called when a person with chemi- cal exposure has respiratory symptoms, systemic symptoms, or large chemical exposures.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00112,2024,43,2A,C-LD,It is reasonable to brush off any dry chemical be- fore irrigation with water. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00113,2024,44,Class 1,B-NR,Decontamination by irrigation should be performed immediately after chemical exposure to the eyes.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00114,2024,44,Class 1,C-LD,"Unless otherwise recommended by local guide- lines, irrigation with a copious amount of tap water for 15 minutes should be performed.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00115,2024,44,Class 1,C-EO,"When providing first aid for chemical eye injury, first aid providers should avoid contaminating other individuals, areas, or the other eye with the caustic substance.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00116,2024,44,2A,B-NR,"Eye irrigation with normal saline, Ringer’s lactate solution, or a commercial eye wash solution if immediately available is reasonable.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00117,2024,44,2A,C-LD,It is reasonable for individuals with ocular exposure to industrial chemicals to adhere to local guidelines or recommendations from a poison center. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00118,2024,45,Class 1,C-LD,Direct manual pressure should be applied to achieve initial control of external bleeding.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00119,2024,45,2A,C-LD,A hemostatic dressing can be useful as adjunctive therapy to improve the effectiveness of direct manual pressure.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00120,2024,45,2B,C-LD,"Once bleeding has been controlled, it may be reasonable to apply a pressure dressing to maintain bleeding cessation.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00121,2024,45,2B,C-LD,"The utility of indirect manual pressure (ie, pres- sure points) for bleeding control is uncertain.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00122,2024,45,2B,C-EO,Mechanical pressure such as pressure bandages or devices might be considered in some situa- tions when direct manual pressure is not feasible. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00123,2024,46,Class 1,B-NR,"For life-threatening extremity bleeding, a tourniquet should be applied and tightened until the bleeding stops.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00124,2024,46,2A,C-LD,A commercial tourniquet is probably superior to an improvised tourniquet.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00125,2024,46,2A,C-EO,"If an improvised tourniquet is used, it is reason- able for the tourniquet to be at least 2 in width. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00126,2024,47,Class 1,C-EO,An open chest wound is a medical emergency requiring immediate activation of the emergency response system.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00127,2024,47,Class 1,C-EO,"If a dressing is placed, the first aid provider should monitor the person for worsening of breathing/symptoms and loosen or remove the dressing if breathing worsens.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00128,2024,47,2A,C-LD,"In the first aid situation, it is reasonable to leave an open chest wound exposed to ambient air; place a clean, nonocclusive, dry dressing (eg, gauze dressing, part of a tee shirt); or place a specialized dressing such as a vented chest seal. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00129,2024,48,Class 1,C-EO,Superficial wounds and abrasions should be thoroughly irrigated until there is no obvious debris or foreign matter in the wound.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00130,2024,48,Class 1,C-EO,A superficial wound caused by an animal or human bite or with contamination with human or animal saliva should be evaluated in a medical facility as soon as possible.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00131,2024,48,2A,B-R,It is reasonable to use running tap water or sterile saline solutions for wound irrigation instead of antiseptic agents such as povidone-iodine.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00132,2024,48,2A,B-R,It is reasonable to cover clean superficial wounds and abrasions with an occlusive dressing to promote wound healing.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00133,2024,48,2A,C-EO,"If a person with superficial wound or abrasion develops redness, swelling, foul-smelling wound drainage, increased pain, or fever, it is reasonable to remove the dressing, inspect the wound, and obtain medical care. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00134,2024,49,Class 1,C-EO,"For a person with a suspected spinal injury, the first aid provider should have the person remain as still as possible (unless safety considerations warrant movement) and activate the emergency response system.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00135,2024,50,Class 1,B-NR,A person with signs and symptoms of a concus- sion should be immediately removed from activity (play/sports) and not allowed to return to activity until evaluated by a health care professional.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00136,2024,50,Class 1,C-EO,"For a person with signs or symptoms of severe head injury (such as loss of consciousness, worsening headache, vomiting, altered mental status, seizures, visual changes, swelling, or deformities of the scalp), EMS should be activated. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00137,2024,51,Class 1,C-EO,A person with a painful extremity injury that limits use should avoid activities that cause pain and seek medical attention.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00138,2024,51,2A,C-LD,It can be useful for first aid providers to apply cold (such as with ice and water surrounded by a damp cloth) to an acute sprain or strain for pain and swelling. Cold application should be limited to 20 to 30 minutes per application without direct contact on the skin to avoid cold injury.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00139,2024,51,2B,C-LD,First aid providers may consider applying a com- pression wrap after an acute ankle sprain or strain to promote comfort after an injury. Application of the compression wrap should be performed with- out compromising circulation. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00140,2024,52,Class 1,C-EO,"If a fracture is associated with an open wound and severe bleeding, the First Aid for Severe External Bleeding and First Aid for Life- Threatening Extremity Bleeding That Is Not Controlled by Direct Pressure recommendations should be followed.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00141,2024,52,Class 1,C-EO,"If a fractured extremity is blue, purple, or pale, the emergency response system should be activated immediately.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00142,2024,52,2A,C-EO,"Splinting of a fractured extremity can be useful to reduce pain, reduce risk for further injury, and facilitate transport to a medical facility.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00143,2024,52,2B,C-EO,It may be reasonable to treat a deformed frac- tured extremity in the position found unless straightening the fracture is necessary to facilitate safe and prompt transport to a medical facility.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00144,2024,52,2B,C-EO,Covering open wounds associated with a suspected fracture with a clean dressing may be useful to lower the risk for further contamination and infection. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00145,2024,53,Class 1,B-NR,"Thermal burns should be cooled immediately, preferably with clean running water.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00146,2024,53,Class 1,C-LD,Preadolescent children with thermal burns being actively cooled with running water should be monitored for signs or symptoms of hypothermia.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00147,2024,53,2B,B-NR,It may be reasonable to cool thermal burns for 5 to 20 minutes.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00148,2024,53,2B,C-LD,"If clean running water is not available, it may be reasonable to cool superficial burns (with the skin intact) with ice wrapped in cloth.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00149,2024,54,Class 1,B-NR,"A person with a full-thickness burn or with a partial- thickness burn that is larger than the person’s palm or involves the person’s face, hands, feet, or genitals should promptly seek evaluation by a health care professional.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00150,2024,54,Class 1,C-EO,"For a person with evidence of smoke inhalation injury such as facial burns, difficulty breathing, singed nasal hairs, or soot around the nose or mouth, EMS should be activated.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00151,2024,54,Class 1,C-EO,"A person with thermal burns should promptly remove all jewelry, belts, and other tight items from burned areas.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00152,2024,54,2A,B-NR,It is reasonable to give over-the-counter pain medications for pain from thermal burns.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00153,2024,54,2B,B-R,"After cooling, for small partial-thickness burns being managed at home, it may be reasonable to apply petrolatum, petrolatum-based antibiotic ointment, honey, or aloe vera and a clean nonadherent dressing to open burn wounds.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00154,2024,54,2B,C-EO,"After cooling, while awaiting evaluation by a health care professional, it may be reasonable to loosely cover a burn that has intact skin or an intact blister with a clean cloth or nonadherent dry dressing. Recommendation-Specific Supportive Text",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00155,2024,56,Class 1,C-EO,"When a permanent tooth becomes avulsed (knocked out), initial actions include removing visible debris from the tooth by brief rinsing (<10 seconds), taking care not to damage the tooth or attached tissue, and attempting to replant the tooth in the socket.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00156,2024,56,Class 1,C-EO,"When a permanent tooth is avulsed, the person should seek dental or medical care immediately. They should bring the tooth if not successfully replanted.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00157,2024,56,2A,C-LD,"If an avulsed permanent tooth cannot be immediately replanted, it can be beneficial to place the tooth in Hanks Balanced Salt Solution, oral rehydration salt solutions, propolis, or rice water (if preprepared), or to wrap the tooth in cling film to prevent dehydration.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00158,2024,56,2B,C-LD,"If an avulsed permanent tooth cannot be immedi- ately replanted and the aforementioned solutions or interventions are not available, storage of the tooth in cow’s milk or saliva may be considered.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00159,2024,56,2B,C-EO,"If an avulsed permanent tooth cannot be immedi- ately replanted and none of the above storage mediums are available, a probiotic, egg white, or almond milk may be considered.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00160,2024,57,Class 1,C-LD,"A person who sustains a high-velocity eye injury (such as injuries from grinding, nailing, or machinery), penetrating eye injury from a sharp or metal object, irregular pupil after trauma, eye bleeding after trauma, or loss of vision after trauma should seek immediate medical attention.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00161,2024,57,Class 1,C-LD,A person who has persistent foreign-body sensation in the eye should seek immediate medical attention.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00162,2024,57,Class 1,C-LD,"A person who develops a foreign-body sensa- tion in the eye associated with contact lens use should remove the contact lens, discontinue con- tact lens use, and seek medical attention.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00163,2024,57,Class 1,C-EO,A person with a foreign-body sensation in the eye should not rub their eye.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00164,2024,57,Class 1,C-EO,"Taping a hard plastic eye shield, paper cup, or plastic cup over the eye can help prevent unintentional touching of the eye.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00165,2024,57,2A,C-EO,"It is reasonable for a person with a foreign body in the eye from a low-energy mechanism (eg, dust, dirt, other object blown into the eye by wind; eyelash in the eye) to attempt to remove the for- eign body by allowing natural tears to wash out the object or by irrigating the eye with tap water or a commercial eye wash solution.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00166,2024,57,2A,C-EO,It is reasonable to take over-the-counter oral acetaminophen or NSAIDs to treat residual discomfort after ocular foreign-body removal. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00167,2024,58,Class 1,C-LD,A person experiencing epistaxis should sit with their head slightly forward with their nostrils pinched for 10 to 15 minutes.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00168,2024,58,Class 1,C-EO,A person experiencing epistaxis that does not stop after 15 minutes of continuous manual pressure or who becomes lightheaded from epistaxis should seek medical attention.,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00169,2024,58,Class 1,C-EO,"A person with epistaxis due to trauma should seek medical attention if they experience signs of brain in- jury, obvious nasal deformity, or signs of facial fracture.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00170,2024,58,2A,C-LD,"It is reasonable for a person experiencing epistaxis who is taking anticoagulant or antiplatelet medication, or who has a blood-clotting disorder, to seek care from a health care professional, unless bleeding has stopped.",hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00171,2024,58,2B,C-LD,The usefulness of cryotherapy (ice) for managing epistaxis in the first aid setting is unknown. Recommendation-Specific Supportive Text,hewett-brumberg-et-al-2024-american-heart-association-and-american-red-cross-guidelines-for-first-aid.pdf
id_00172,2021,9,Class 1,B-NR,"In patients who require coronary revascu- larization, treatment decisions should be based on clinical indication, regardless of sex1-7 or race or ethnicity,8-10 and efforts to reduce disparities of care are war- ranted.11,12",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00173,2021,10,Class 1,C-LD,"In patients undergoing revascularization, deci- sions should be patient centered—that is, considerate of the patient’s preferences and goals, cultural beliefs, health literacy, and social determinants of health—and made in collabora- tion with the patient’s support system.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00174,2021,10,Class 1,C-LD,"In patients undergoing coronary angiography or revascularization, adequate information about benefits, risks, therapeutic conse- quences, and potential alternatives in the performance of percutaneous and surgi- cal myocardial revascularization should be given, when feasible, with sufficient time for informed decision-making to improve clinical outcomes.3-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00175,2021,12,Class 1,B-NR,"In patients for whom the optimal treatment strategy is unclear, a Heart Team approach that includes representatives from interven- tional cardiology, cardiac surgery, and clinical cardiology is recommended to improve patient outcomes.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00176,2021,13,Class 1,B-NR,"In patients who are being considered for CABG, calculation of the STS risk score is recommended to help stratify patient risk.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00177,2021,14,2B,B-NR,"In patients with multivessel CAD, an assessment of CAD complexity, such as the SYNTAX score, may be useful to guide revascularization.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00178,2021,14,Class 1,A,"In patients with angina or an anginal equiva- lent, undocumented ischemia, and angio- graphically intermediate stenoses, the use of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) is recommended to guide the decision to proceed with PCI.1-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00179,2021,14,Class 3: No Benefit,B-R,"In stable patients with angiographically inter- mediate stenoses and FFR >0.80 or iFR >0.89, PCI should not be performed.7-10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00180,2021,15,2A,B-NR,"In patients with intermediate stenosis of the left main artery, intravascular ultrasound (IVUS) is reasonable to help define lesion severity.1-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00181,2021,16,Class 1,A,"In patients with STEMI and ischemic symp- toms for <12 hours, PCI should be performed to improve survival.1-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00182,2021,16,Class 1,B-R,"In patients with STEMI and cardiogenic shock or hemodynamic instability, PCI or CABG (when PCI is not feasible) is indicated to improve survival, irrespective of the time delay from MI onset.6,7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00183,2021,16,Class 1,B-NR,"In patients with STEMI who have mechanical complications (eg, ventricular septal rupture, mitral valve insufficiency because of papillary muscle infarction or rupture, or free wall rup- ture), CABG is recommended at the time of surgery, with the goal of improving survival.8,9",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00184,2021,16,2A,B-R,"In patients with STEMI who are treated with fibrinolytic therapy, angiography within 3 to 24 hours with the intent to perform PCI is reason- able to improve clinical outcomes.14-20",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00185,2021,16,2A,B-NR,"In patients with STEMI who are stable and presenting 12 to 24 hours after symptom onset, PCI is reasonable to improve clinical outcomes.21,22",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00186,2021,16,2A,B-NR,"In patients with STEMI in whom PCI is not feasible or successful, with a large area of myocardium at risk, emergency or urgent CABG can be effective as a reperfusion modality to improve clinical outcomes.23,24",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00187,2021,16,2A,C-EO,"In patients with STEMI complicated by ongo- ing ischemia, acute severe heart failure, or life- threatening arrhythmia, PCI can be beneficial to improve clinical outcomes, irrespective of time delay from MI onset.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00188,2021,16,Class 3: No Benefit,B-R,"In asymptomatic stable patients with STEMI who have a totally occluded infarct artery >24 hours after symptom onset and are without evidence of severe ischemia, PCI should not be performed.25,26",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00189,2021,16,Class 3: Harm,C-EO,"In patients with STEMI, emergency CABG should not be performed after failed primary PCI: •  In the absence of ischemia or a large area of myocardium at risk, or •  If surgical revascularization is not feasible because of a no-reflow state or poor distal targets.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00190,2021,18,Class 1,A,"In selected hemodynamically stable patients with STEMI and multivessel disease, after successful primary PCI, staged PCI of a sig- nificant non-infarct artery stenosis is recom- mended to reduce the risk of death or MI.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00191,2021,18,2A,C-EO,"In selected patients with STEMI with com- plex multivessel non-infarct artery disease, after successful primary PCI, elective CABG is reasonable to reduce the risk of cardiac events.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00192,2021,18,2B,B-R,"In selected hemodynamically stable patients with STEMI and low-complexity multivessel disease, PCI of a non-infarct artery stenosis may be considered at the time of primary PCI to reduce cardiac event rates.1,2,5-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00193,2021,18,Class 3: Harm,B-R,"In patients with STEMI complicated by car- diogenic shock, routine PCI of a non-infarct artery at the time of primary PCI should not be performed because of the higher risk of death or renal failure.8-10 Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00194,2021,21,Class 1,A,"In patients with NSTE-ACS who are at ele- vated risk of recurrent ischemic events and are appropriate candidates for revascular- ization, an invasive strategy with the intent to proceed with revascularization is indi- cated to reduce cardiovascular events.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00195,2021,21,Class 1,B-R,"In patients with NSTE-ACS and cardiogenic shock who are appropriate candidates for revascularization, emergency revascular- ization is recommended to reduce risk of death.5-9",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00196,2021,21,Class 1,C-LD,"In appropriate patients with NSTE-ACS who have refractory angina or hemody- namic or electrical instability, an immediate invasive strategy with intent to perform revascularization is indicated to improve outcomes.10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00197,2021,21,2A,B-R,"In patients with NSTE-ACS who are initially stabilized and are at high risk of clinical events, it is reasonable to choose an early invasive strategy (within 24 hours) over a delayed invasive strategy to improve out- comes.11-16",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00198,2021,21,2A,B-R,"In patients with NSTE-ACS who are initially stabilized and are at intermediate or low risk of clinical events, an invasive strategy with intent to perform revascularization is reason- able before hospital discharge to improve outcomes.11-16",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00199,2021,21,2A,B-NR,"In patients with NSTE-ACS who have failed PCI and have ongoing ischemia, hemodynamic compromise, or threatened occlusion of an artery with substantial myocardium at risk, who are appropriate candidates for CABG, emer- gency CABG is reasonable.5-7,17",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00200,2021,21,Class 3: Harm,B-R,"In patients with NSTE-ACS who present in cardiogenic shock, routine multivessel PCI of non-culprit lesions in the same setting should not be performed.18,19",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00201,2021,23,Class 1,B-R,"In patients with SIHD and multivessel CAD appropriate for CABG with severe left ventric- ular systolic dysfunction (left ventricular ejec- tion fraction <35%), CABG is recommended to improve survival.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00202,2021,23,2A,B-NR,"In selected patients with SIHD and multivessel CAD appropriate for CABG and mild-to-moder- ate left ventricular systolic dysfunction (ejection fraction 35%–50%), CABG (to include a left internal mammary artery [LIMA] graft to the LAD) is reasonable to improve survival.3-8 Left main CAD",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00203,2021,23,Class 1,B-R,"In patients with SIHD and significant left main stenosis, CABG is recommended to improve survival.9-12",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00204,2021,23,2A,B-NR,"In selected patients with SIHD and significant left main stenosis for whom PCI can provide equivalent revascularization to that possible with CABG, PCI is reasonable to improve survival.9 Multivessel CAD",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00205,2021,23,2B,B-R,"In patients with SIHD, normal ejection frac- tion, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for CABG, CABG may be reasonable to improve survival.10,13-15",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00206,2021,23,2B,B-R,"In patients with SIHD, normal ejection frac- tion, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for PCI, the usefulness of PCI to improve survival is uncertain.14-24 Stenosis in the proximal LAD artery",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00207,2021,23,2B,B-R,"In patients with SIHD, normal left ventricular ejection fraction, and significant stenosis in the proximal LAD, the usefulness of coronary revascularization to improve survival is uncer- tain.10,14,17,24-27 Single- or double-vessel disease not involving the proximal LAD",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00208,2021,23,Class 3: No Benefit,B-R,"In patients with SIHD, normal left ventricular ejection fraction, and 1- or 2-vessel CAD not involving the proximal LAD, coronary revas- cularization is not recommended to improve survival.10,14,16,26,28,29",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00209,2021,23,Class 3: Harm,B-NR,"In patients with SIHD who have ≥1 coronary arteries that are not anatomically or function- ally significant (<70% diameter of non–left main coronary artery stenosis, FFR >0.80), coronary revascularization should not be performed with the primary or sole intent to improve survival.26,30 Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00210,2021,26,2A,B-R,"In patients with SIHD and multivessel CAD appropriate for either CABG or PCI, revas- cularization is reasonable to lower the risk of cardiovascular events such as spontaneous MI, unplanned urgent revascularizations, or cardiac death.1-8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00211,2021,27,Class 1,A,"In patients with refractory angina despite medical therapy and with significant coronary artery stenoses amenable to revascularization, revascularization is recommended to improve symptoms.1-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00212,2021,27,Class 3: Harm,C-LD,"In patients with angina but no anatomic or physiological criteria for revascularization, nei- ther CABG nor PCI should be performed.7,8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00213,2021,27,Class 1,B-R,"In patients who require revascularization for significant left main CAD with high-complexity CAD, it is recommended to choose CABG over PCI to improve survival.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00214,2021,27,2A,B-R,"In patients who require revascularization for multivessel CAD with complex or diffuse CAD (eg, SYNTAX score >33), it is reasonable to choose CABG over PCI to confer a survival advantage.2-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00215,2021,28,Class 1,A,"In patients with diabetes and multivessel CAD with the involvement of the LAD, who are appropriate candidates for CABG, CABG (with a LIMA to the LAD) is recommended in pref- erence to PCI to reduce mortality and repeat revascularizations.1-8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00216,2021,28,2A,B-NR,"In patients with diabetes who have multivessel CAD amenable to PCI and an indication for revascularization and are poor candidates for surgery, PCI can be useful to reduce long-term ischemic outcomes.9,10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00217,2021,28,2B,B-R,"In patients with diabetes who have left main stenosis and low- or intermediate-complexity CAD in the rest of the coronary anatomy, PCI may be considered an alternative to CABG to reduce major adverse cardiovascular out- comes.5,11",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00218,2021,29,2A,B-NR,"In patients with previous CABG with a patent LIMA to the LAD who need repeat revascu- larization, if PCI is feasible, it is reasonable to choose PCI over CABG.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00219,2021,29,2A,C-LD,"In patients with previous CABG and refractory angina on GDMT that is attributable to LAD disease, it is reasonable to choose CABG over PCI when an internal mammary artery (IMA) can be used as a conduit to the LAD.3,4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00220,2021,29,2B,B-NR,"In patients with previous CABG and complex CAD, it may be reasonable to choose CABG over PCI when an IMA can be used as a con- duit to the LAD.3,4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00221,2021,30,2A,B-NR,"In patients with multivessel CAD amenable to treatment with either PCI or CABG who are unable to access, tolerate, or adhere to DAPT for the appropriate duration of treatment, CABG is reasonable in preference to PCI.1-10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00222,2021,30,2A,C-LD,"In pregnant patients with STEMI not caused by spontaneous coronary artery dissection (SCAD), it is reasonable to perform primary PCI as the preferred revascularization strategy.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00223,2021,30,2A,C-LD,"In pregnant patients with NSTE-ACS, an inva- sive strategy is reasonable if medical therapy is ineffective for the management of life- threatening complications.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00224,2021,30,Class 1,B-NR,"In older adults, as in all patients, the treatment strategy for CAD should be based on an indi- vidual patient’s preferences, cognitive function, and life expectancy.1,2 Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00225,2021,31,Class 1,C-LD,"In patients with CKD undergoing contrast media injection for coronary angiography, measures should be taken to minimize the risk of contrast-induced acute kidney injury (AKI).1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00226,2021,31,Class 1,C-EO,"In patients with STEMI and CKD, coronary angiography and revascularization are recom- mended, with adequate measures to reduce the risk of AKI.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00227,2021,31,2A,B-NR,"In high-risk patients with NSTE-ACS and CKD, it is reasonable to perform coronary angiography and revascularization, with ade- quate measures to reduce the risk of AKI.4,5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00228,2021,31,2A,C-EO,"In low-risk patients with NSTE-ACS and CKD, it is reasonable to weigh the risk of coronary angiography and revascularization against the potential benefit.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00229,2021,31,Class 3: No Benefit,B-R,"In asymptomatic patients with stable CAD and CKD, routine angiography and revasculariza- tion are not recommended if there is no com- pelling indication.6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00230,2021,32,Class 3: No Benefit,B-R,"In patients with non–left main or noncomplex CAD who are undergoing noncardiac sur- gery, routine coronary revascularization is not recommended solely to reduce perioperative cardiovascular events.1",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00231,2021,33,Class 1,B-NR,"In patients with ventricular fibrillation, polymor- phic ventricular tachycardia (VT), or cardiac arrest, revascularization of significant CAD is recommended to improve survival.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00232,2021,33,Class 3: No Benefit,C-LD,"In patients with CAD and suspected scar- mediated sustained monomorphic VT, revas- cularization is not recommended for the sole purpose of preventing recurrent VT.5-9",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00233,2021,33,2B,C-LD,"In patients with SCAD who have hemody- namic instability or ongoing ischemia despite conservative therapy, revascularization may be considered if feasible.1-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00234,2021,33,Class 3: Harm,C-LD,Routine revascularization for SCAD should not be performed.1-5,lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00235,2021,34,2A,C-LD,"In patients with cardiac allograft vasculopathy and severe, proximal, discrete coronary lesions, revascularization with PCI is reasonable.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00236,2021,35,Class 1,A,"In patients with ACS undergoing PCI, a radial approach is indicated in preference to a femoral approach to reduce the risk of death, vascular complications, or bleeding.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00237,2021,35,Class 1,A,"In patients with SIHD undergoing PCI, the radial approach is recommended to reduce access site bleeding and vascular complica- tions.4-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00238,2021,35,Class 1,A,"In patients undergoing PCI, DES should be used in preference to BMS to prevent reste- nosis, MI, or acute stent thrombosis.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00239,2021,36,2A,B-R,"In patients undergoing coronary stent implan- tation, IVUS can be useful for procedural guidance, particularly in cases of left main or complex coronary artery stenting, to reduce ischemic events.1-10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00240,2021,36,2A,B-R,"In patients undergoing coronary stent implan- tation, OCT is a reasonable alternative to IVUS for procedural guidance, except in ostial left main disease.11-13",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00241,2021,36,2A,C-LD,"In patients with stent failure, IVUS or OCT is reasonable to determine the mechanism of stent failure.14-17",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00242,2021,37,Class 3: No Benefit,A,"In patients with STEMI, routine aspiration throm- bectomy before primary PCI is not useful.1-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00243,2021,37,2A,B-R,"In patients with fibrotic or heavily calcified lesions, plaque modification with rotational atherectomy can be useful to improve proce- dural success.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00244,2021,37,2B,B-NR,"In patients with fibrotic or heavily calcified lesions, plaque modification with orbital ather- ectomy, balloon atherotomy, laser angioplasty, or intracoronary lithotripsy may be considered to improve procedural success.4-8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00245,2021,38,2A,B-R,"In select patients with previous CABG under- going PCI of a SVG, the use of an embolic protection device, when technically feasible, is reasonable to decrease the risk of distal embolization.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00246,2021,38,2A,B-NR,"In patients with previous CABG, if PCI of a diseased native coronary artery is feasible, then it is reasonable to choose PCI of the native coronary artery over PCI of the severely diseased SVG.4-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00247,2021,38,Class 3: No Benefit,C-LD,"In patients with a chronic occlusion of a SVG, percutaneous revascularization of the SVG should not be performed.7,8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00248,2021,39,2B,B-R,"In patients with suitable anatomy who have refractory angina on medical therapy, after treatment of non-CTO lesions, the benefit of PCI of a CTO to improve symptoms is uncer- tain.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00249,2021,39,Class 1,A,"In patients who develop clinical in-stent reste- nosis (ISR) for whom repeat PCI is planned, a DES should be used to improve outcomes if anatomic factors are appropriate and the patient is able to comply with DAPT.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00250,2021,39,2A,C-EO,"In patients with symptomatic recurrent dif- fuse ISR with an indication for revasculariza- tion, CABG can be useful over repeat PCI to reduce recurrent events.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00251,2021,39,2B,B-NR,"In patients who develop recurrent ISR, brachy- therapy may be considered to improve symp- toms.5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00252,2021,40,2B,B-R,"In selected high-risk patients, elective inser- tion of an appropriate hemodynamic support device as an adjunct to PCI may be reason- able to prevent hemodynamic compromise during PCI.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00253,2021,40,Class 1,B-R,"In patients undergoing PCI, a loading dose of aspirin, followed by daily dosing, is recom- mended to reduce ischemic events.1-4* *Contraindications to ticagrelor: previous intracranial hemorrhage or ongoing bleeding. Contraindications to prasugrel: previous intracranial hemorrhage, previ- ous ischemic stroke or transient ischemic attack, or ongoing bleeding. Prasugrel should be used with caution at a lower dose in patients ≥75 years of age or with a body weight <60 kg. Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00254,2021,41,Class 1,B-R,"In patients with ACS undergoing PCI, a load- ing dose of P2Y12 inhibitor, followed by daily dosing, is recommended to reduce ischemic events.5-15",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00255,2021,41,Class 1,C-LD,"In patients with SIHD undergoing PCI, a loading dose of clopidogrel, followed by daily dosing, is recommended to reduce ischemic events.8,12,15-19",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00256,2021,41,Class 1,C-LD,"In patients undergoing PCI within 24 hours after fibrinolytic therapy, a loading dose of 300 mg of clopidogrel, followed by daily dosing, is recommended to reduce ischemic events.5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00257,2021,41,2A,B-R,"In patients with ACS undergoing PCI, it is reasonable to use ticagrelor or prasugrel in preference to clopidogrel to reduce ischemic events, including stent thrombosis.6,14,20",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00258,2021,41,2B,B-R,"In patients <75 years of age undergoing PCI within 24 hours after fibrinolytic therapy, ticagrelor may be a reasonable alternative to clopidogrel to reduce ischemic events.21",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00259,2021,41,Class 3: Harm,B-R,"In patients undergoing PCI who have a history of stroke or transient ischemic attack, prasug- rel should not be administered.6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00260,2021,43,2B,B-R,"In patients undergoing PCI who are P2Y12 inhibitor naïve, intravenous cangrelor may be reasonable to reduce periprocedural ischemic events.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00261,2021,43,2A,C-LD,"In patients with ACS undergoing PCI with large thrombus burden, no-reflow, or slow flow, intravenous glycoprotein IIb/IIIa inhibitor agents are reasonable to improve procedural success.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00262,2021,43,Class 3: No Benefit,B-R,"In patients with SIHD undergoing PCI, the routine use of an intravenous glycoprotein IIb/ IIIa inhibitor agent is not recommended.3-5",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00263,2021,44,Class 1,C-EO,"In patients undergoing PCI, administration of intravenous unfractionated heparin (UFH) is useful to reduce ischemic events.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00264,2021,44,Class 1,C-LD,"In patients with heparin-induced thrombocyto- penia undergoing PCI, bivalirudin or argatro- ban should be used to replace UFH to avoid thrombotic complications.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00265,2021,44,2B,A,"In patients undergoing PCI, bivalirudin may be a reasonable alternative to UFH to reduce bleeding.3-12",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00266,2021,44,2B,B-R,"In patients treated with upstream subcutane- ous enoxaparin for unstable angina or NSTE- ACS, the use of intravenous enoxaparin may be considered at the time of PCI to reduce ischemic events.13-17",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00267,2021,44,Class 3: Harm,B-R,"In patients on therapeutic subcutaneous enoxaparin, in whom the last dose was admin- istered within 12 hours of PCI, UFH should not be used for PCI and may increase bleed- ing.14,18,19",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00268,2021,45,Class 1,B-NR,"For patients undergoing CABG, establishment of multidisciplinary, evidence-based periopera- tive management programs is recommended to optimize analgesia, minimize opioid expo- sure, prevent complications and to reduce time to extubation, length of stay, and health care costs.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00269,2021,46,Class 1,B-R,"In patients undergoing isolated CABG, the use of a radial artery is recommended in prefer- ence to a saphenous vein conduit to graft the second most important, significantly stenosed, non–LAD vessel to improve long-term cardiac outcomes.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00270,2021,46,Class 1,B-NR,"In patients undergoing CABG, an IMA, prefer- ably the left, should be used to bypass the LAD when bypass of the LAD is indicated to improve survival and reduce recurrent isch- emic events.4-9",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00271,2021,46,2A,B-NR,"In patients undergoing CABG, bilateral IMA (BIMA) grafting by experienced operators can be beneficial in appropriate patients to improve long-term cardiac outcomes.3,10-12",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00272,2021,47,Class 1,C-LD,"In patients undergoing valve surgery, aortic surgery, or other cardiac operations who have significant CAD, CABG is recommended with a goal of reducing ischemic events.1-11",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00273,2021,47,2B,C-LD,"In patients undergoing valve surgery, aortic surgery, or other cardiac operations who have intermediate CAD, CABG may be reasonable with a goal of reducing ischemic events.5,7,10,12 Table 12.  Best Practices for the Use of Bypass Conduits in CABG Objectively assess palmar arch completeness and ulnar compensation before harvesting the radial artery. Use the arm with the best ulnar compensation for radial artery harvesting.",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00274,2021,48,2A,B-NR,"In patients undergoing CABG, the routine use of epiaortic ultrasound scanning can be useful to evaluate the presence, location, and severity of plaque in the ascending aorta to reduce the incidence of atheroembolic complications.1-10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00275,2021,49,2A,B-R,"In patients with significant calcification of the aorta, the use of techniques to avoid aortic manipulation (off-pump techniques or beating heart) is reasonable to decrease the incidence of perioperative stroke when performed by experienced surgeons.1,2",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00276,2021,49,2B,B-R,"In patients with significant pulmonary disease, off-pump surgery may be reasonable to reduce perioperative risk when performed by experienced surgeons.2-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00277,2021,49,Class 1,B-R,"In patients undergoing CABG, an intraopera- tive continuous insulin infusion should be initiated to maintain serum glucose level <180 mg/dL to reduce sternal wound infection.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00278,2021,49,Class 1,B-R,"In patients undergoing CABG, the use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration of <180 mg/dL while avoid- ing hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection.3-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00279,2021,49,Class 1,B-NR,"In patients undergoing CABG, a comprehen- sive approach to reduce sternal wound infec- tion is recommended.7-14",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00280,2021,49,2B,B-R,"In patients undergoing CABG, the usefulness of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration <140 mg/dL is uncertain.4,15",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00281,2021,51,Class 1,B-R,"In patients undergoing CABG who are already taking daily aspirin preoperatively, it is recom- mended that they continue taking aspirin until the time of surgery to reduce ischemic events.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00282,2021,51,Class 1,B-NR,"In patients referred for urgent CABG, clopi- dogrel and ticagrelor should be discontinued for at least 24 hours before surgery to reduce major bleeding complications.8-11",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00283,2021,51,Class 1,B-NR,"In patients undergoing CABG, discontinuation of short-acting glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban) for 4 hours and abciximab for 12 hours before surgery is rec- ommended to reduce the risk of bleeding and transfusion.12-14",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00284,2021,51,2A,B-NR,"In patients undergoing elective CABG who receive P2Y12 receptor inhibitors before sur- gery, it is reasonable to discontinue clopidogrel for 5 days, ticagrelor for 3 days, and prasugrel for 7 days before CABG to reduce risk of major bleeding and blood product transfu- sion.8,9,11,15-23",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00285,2021,51,Class 3: No Benefit,B-R,"In patients undergoing elective CABG who are not already taking aspirin, the initiation of aspi- rin (100–300 mg daily) in the immediate pre- operative period (<24 hours before surgery) is not recommended.24,25",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00286,2021,52,2A,B-R,"In patients undergoing CABG, who do not have a contraindication to beta blockers, the administration of beta blockers before surgery can be beneficial to reduce the incidence of postoperative atrial fibrillation.1-8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00287,2021,52,2A,B-R,"In patients undergoing CABG, preoperative amiodarone is reasonable to reduce the inci- dence of postoperative atrial fibrillation.9-11",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00288,2021,52,2B,B-NR,"In patients undergoing CABG, who do not have a contraindication to beta blockers, preoperative use of beta blockers may be effective in reducing in-hospital and 30-day mortality rates.12-18",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00289,2021,52,2B,B-NR,"In patients undergoing CABG, the role of preop- erative beta blockers for the prevention of acute postoperative myocardial ischemia, stroke, AKI, or ventricular arrhythmia is uncertain.12-14,18",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00290,2021,53,2A,A,"In selected patients undergoing PCI, shorter- duration DAPT (1–3 months) is reasonable, with subsequent transition to P2Y12 inhibitor monotherapy to reduce the risk of bleeding events.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00291,2021,53,Class 1,A,"In patients undergoing CABG, aspirin (100–325 mg daily) should be initiated within 6 hours postoperatively and then continued indefinitely to reduce the occurrence of SVG closure and adverse cardiovascular events.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00292,2021,53,2B,B-R,"In selected patients undergoing CABG, DAPT with aspirin and ticagrelor or clopidogrel for 1 year may be reasonable to improve vein graft patency compared with aspirin alone.8-10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00293,2021,55,Class 3: No Benefit,C-LD,"In patients with SIHD and normal left ven- tricular function, the routine use of chronic oral beta blockers is not beneficial to reduce cardiovascular events after complete revascu- larization.1-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00294,2021,55,Class 1,B-R,"In patients after CABG, beta blockers are recommended and should be started as soon as possible to reduce the incidence or clinical sequelae of postoperative atrial fibrillation.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00295,2021,56,Class 1,B-R,"In patients with atrial fibrillation who are undergoing PCI and are taking oral anticoagu- lant therapy, it is recommended to discontinue aspirin treatment after 1 to 4 weeks while maintaining P2Y12 inhibitors in addition to a non–vitamin K oral anticoagulant (rivaroxaban, dabigatran, apixaban, or edoxaban) or warfarin to reduce the risk of bleeding.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00296,2021,56,2A,B-R,"In patients with atrial fibrillation who are undergoing PCI, are taking oral anticoagu- lant therapy, and are treated with DAPT or a P2Y12 inhibitor monotherapy, it is reasonable to choose a non–vitamin K oral anticoagulant over warfarin to reduce the risk of bleeding.1,3,4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00297,2021,56,Class 1,A,"In patients who have undergone revasculariza- tion, a comprehensive cardiac rehabilitation program (home based or center based) should be prescribed either before hospital discharge or during the first outpatient visit to reduce deaths and hospital readmissions and improve quality of life.1-4",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00298,2021,56,Class 1,C-LD,"Patients who have undergone revasculariza- tion should be educated about CVD risk factors and their modification to reduce car- diovascular events.5-7 Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00299,2021,57,Class 1,A,"In patients who use tobacco and have undergone coronary revascularization, a combination of behavioral interventions plus pharmacotherapy is recommended to maxi- mize cessation and reduce adverse cardiac events.1-3",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00300,2021,57,Class 1,A,"In patients who use tobacco and have under- gone coronary revascularization, smoking ces- sation interventions are recommended during hospitalization and should include supportive follow-up for at least 1 month after discharge to facilitate tobacco cessation and reduce morbidity and mortality.4-6",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00301,2021,59,Class 1,B-R,"In patients who have undergone coronary revascularization who have symptoms of depression, anxiety, or stress, treatment with cognitive behavioral therapy, psychological counseling, and/or pharmacological interven- tions is beneficial to improve quality of life and cardiac outcomes.1-7",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00302,2021,59,2B,C-LD,"In patients who have undergone coronary revascularization, it may be reasonable to screen for depression and refer or treat when it is indicated to improve quality of life and recovery.8,9",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00303,2021,59,Class 1,B-NR,"With the goal of improving patient outcomes, it is recommended that cardiac surgery and PCI programs participate in state, regional, or national clinical data registries and receive periodic reports of their risk-adjusted out- comes as a quality assessment and improve- ment strategy.1-8",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00304,2021,59,2A,C-LD,"With the goal of improving patient outcomes, it is reasonable for cardiac surgery and PCI pro- grams to have a quality improvement program that routinely 1) reviews institutional quality programs and outcomes, 2) reviews individual operator outcomes, 3) provides peer review of difficult or complicated cases, and 4) performs random case reviews.9,10",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00305,2021,59,2B,C-EO,"Smaller volume cardiac surgery and PCI programs may consider affiliating with a high- volume center to improve patient care. Downloaded from http://ahajournals.org by on June 19, 2025",lawton-et-al-2021-acc-aha-scai-guideline-for-coronary-artery-revascularization-a-report-of-the-american-college-of.pdf
id_00306,2025,10,Class 1,B-NR,"In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact (FMC)* to identify patients with STEMI.1,2",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00307,2025,10,Class 1,C-LD,"In patients with suspected ACS in which the initial ECG is nondiagnostic of STEMI, serial ECGs to detect potential ischemic changes should be performed, especially when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.†3,4 STEMI",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00308,2025,10,Class 1,B-NR,"In patients with suspected STEMI, immediate emergency medical services (EMS) transport to a PCI-capable hospital for primary PCI (PPCI‡) is the recommended triage strategy, with an FMC–to-first-device time system goal of ≤90 minutes.5–7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00309,2025,10,Class 1,B-NR,"In patients with suspected STEMI, early advance notification of the receiving PCI-capable hospital by EMS personnel and activation of the cardiac catheterization team is recommended to reduce time to reperfusion.1,8,9 *FMC indicates the time point when the patient is initially assessed by a health care professional who can obtain and interpret the ECG and deliver initial inter- ventions (eg, defibrillation). †Modified from the “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain.”10 ‡PPCI refers to emergency PCI in the setting of STEMI to achieve reperfusion in patients without previous fibrinolytic treatment.",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00310,2025,12,Class 1,B-NR,"In patients with suspected ACS, acquisition and interpretation of an ECG within 10 minutes is recommended to help guide patient management.*1,2 Table 4.  Types of Acute Myocardial Infarction According to the Universal Definition of Myocardial Infarction Type 1* Caused by acute coronary atherothrombosis, usually precipitated by atherosclerotic plaque disruption (rupture or erosion) and often associated with partial or complete vessel thrombosis. Type 2",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00311,2025,13,Class 1,B-NR,"In patients with suspected ACS in whom the initial ECG is nondiagnostic, serial 12-lead ECGs should be performed to detect potential ischemic changes, especially when clinical suspicion of ACS is high, symptoms are persistent, or clinical condition deteriorates.*3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00312,2025,13,Class 1,B-NR,"In patients with suspected ACS, cTn should be measured as soon as possible, preferably using a high-sensitivity cTn (hs-cTn) assay.*4–7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00313,2025,13,Class 1,B-NR,"In patients with suspected ACS with an initial hs-cTn or cTn that is nondiagnostic, the recommended time intervals for repeat measurements after the initial sample collection (time zero) are 1 to 2 hours for hs-cTn and 3 to 6 hours for conventional cTn assays.*8–12 *Adapted from the “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain.”13",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00314,2025,16,Class 1,C-LD,"Patients with cardiac arrest and STEMI who have been resuscitated should preferentially be transferred by EMS to a PPCI-capable center.1,2",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00315,2025,16,Class 1,B-NR,"Patients who have been resuscitated after cardiac arrest and are noncomatose or who are comatose with favorable prognostic features and with evidence of STEMI, should undergo PPCI to improve survival.3–7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00316,2025,16,2B,C-LD,"In patients with cardiac arrest who are comatose, have unfavorable prognostic features, and evi- dence of STEMI, PPCI may be reasonable after individualized assessment.4,7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00317,2025,16,Class 3: No Benefit,A,"In resuscitated patients who are comatose after cardiac arrest, electrically and hemodynamically stable, and without evidence of STEMI, immediate angiography is not recommended due to lack of benefit.8–14",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00318,2025,17,Class 1,C-LD,"In patients with ACS and confirmed hypoxia (oxygen saturation <90%), supplemental oxygen to increase oxygen saturations to ≥90% is recommended to improve myocardial oxygen supply and decrease anginal symptoms.1",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00319,2025,17,Class 3: No Benefit,A,"In patients with ACS and oxygen saturations ≥90%, routine administration of supplemental oxygen is not recommended because it does not improve cardiovascular outcomes.2–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00320,2025,18,Class 1,A,"In patients with ACS, an initial oral loading dose of aspirin, followed by daily low-dose aspirin, is recommended to reduce death and MACE.1–5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00321,2025,19,Class 1,A,"In patients with ACS, an oral P2Y12 inhibitor should be administered in addition to aspirin to reduce MACE.1–5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00322,2025,19,Class 3: Harm,B-R,"In patients with a history of stroke or transient ischemic attack, prasugrel should not be adminis- tered because of worse net clinical outcomes.*†4 In-Hospital Management in Patients With NSTE-ACS",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00323,2025,19,Class 1,B-R,"In patients with NSTE-ACS undergoing PCI, prasugrel or ticagrelor is recommended to reduce MACE and stent thrombosis.4–6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00324,2025,19,Class 1,B-R,"In patients with NSTE-ACS who are managed without planned invasive evaluation, ticagrelor is recommended to reduce MACE.5,7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00325,2025,19,Class 1,B-R,"In patients with NSTE-ACS, clopidogrel is recommended to reduce MACE when prasugrel or ticagrelor are unavailable, cannot be tolerated, or are contraindicated.1",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00326,2025,19,2B,B-NR,"In patients with NSTE-ACS planned for an inva- sive strategy with timing of angiography antici- pated to be >24 hours, upstream treatment with clopidogrel or ticagrelor may be considered to reduce MACE.1,5,8 In-Hospital Management in Patients With STEMI",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00327,2025,19,Class 1,B-R,"In patients with STEMI managed with PPCI, prasugrel or ticagrelor should be administered to reduce MACE and stent thrombosis.4,5,9,10",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00328,2025,19,Class 1,C-LD,"In patients with STEMI managed with PPCI, clopidogrel is recommended to reduce MACE and stent thrombosis when prasugrel or ticagrelor are unavailable, cannot be tolerated, or are contraindicated.11",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00329,2025,19,Class 1,A,"In patients with STEMI managed with fibrinolytic therapy, clopidogrel should be administered concurrently to reduce death and MACE.2,3 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization”12 and the †”2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Manage- ment of Patients With Chronic Coronary Disease.”13",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00330,2025,22,2B,B-R,"Among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor, intravenous cangrelor may be reasonable to reduce periprocedural ischemic events.*1–4 *Reproduced from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00331,2025,23,2A,C-LD,"In patients with ACS undergoing PCI with large thrombus burden, no-reflow, or slow flow, adjunctive use of an intravenous or intracoronary glycoprotein IIb/IIIa inhibitor is reasonable to improve procedural success and reduce infarct size.*,1,2",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00332,2025,23,Class 3: Harm,B-R,"In patients with ACS, glycoprotein IIb/IIIa inhibitors should not be administered routinely due to lack of ischemic benefit and increased risk of bleeding.3–5 *Adapted from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00333,2025,24,Class 1,B-R,"In patients with NSTE-ACS, intravenous unfractionated heparin (UFH) is useful to reduce ischemic events.†1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00334,2025,24,Class 1,B-R,"In patients with NSTE-ACS in whom an early invasive approach is not anticipated, either enoxaparin or fondaparinux are recommended alternatives to UFH to reduce ischemic events.5–11 Anticoagulant Therapy in Patients Undergoing Coronary Revascularization",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00335,2025,24,Class 1,C-LD,"In patients with ACS undergoing coronary revascularization (CABG or PCI) in the same admission, parenteral anticoagulation should be continued until revascularization to reduce ischemic events.12,13 Anticoagulant Therapy to Support PCI in ACS (STEMI and NSTE-ACS)",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00336,2025,24,Class 1,C-EO,"In patients with ACS undergoing PCI, intravenous UFH is useful to reduce ischemic events.†",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00337,2025,24,Class 1,B-R,"In patients with STEMI undergoing PCI, bivalirudin is useful as an alternative to UFH to reduce mortality and bleeding.†14–19",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00338,2025,24,2B,B-R,"In patients with NSTE-ACS undergoing PCI, bivalirudin may be reasonable as an alternative to UFH to reduce bleeding.†16,20–23",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00339,2025,24,2B,B-R,"In patients with ACS, intravenous enoxaparin may be considered as an alternative to UFH at the time of PCI to reduce ischemic events.‡7,8,24–26",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00340,2025,24,Class 3: Harm,B-R,"In patients with ACS, fondaparinux should not be used to support PCI because of the risk of catheter thrombosis.5,27 STEMI: Anticoagulant Therapy Treated With Fibrinolytic Therapy",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00341,2025,24,Class 1,A,"In patients with STEMI treated with fibrinolytic therapy, parenteral anticoagulation should be continued for the duration of the hospital stay (maximum of 8 days) or until revascularization is performed to reduce ischemic events.9,10,27–29",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00342,2025,24,Class 1,A,"In patients with STEMI treated with fibrinolytic therapy who are not intended to undergo an invasive approach, enoxaparin is the recommended anticoagulant to reduce ischemic events.9,10,28,29",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00343,2025,24,Class 1,B-R,"In patients with STEMI treated with fibrinolytic therapy who are not intended to undergo an inva- sive approach, fondaparinux is a recommended alternative to reduce ischemic events.27,30 *At the time of diagnosis and prior to invasive coronary angiography if planned. †Adapted or ‡modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”31",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00344,2025,27,Class 1,A,"In patients with ACS, high-intensity statin therapy is recommended to reduce the risk of MACE.*1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00345,2025,27,Class 1,A,"In patients with ACS who are already on maximally tolerated statin therapy with low- density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (≥1.8 mmol/L), adding a nonstatin lipid-lowering agent is recommended to further reduce the risk of MACE.†5–7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00346,2025,27,Class 1,B-R,"In patients with ACS who are statin intolerant, nonstatin lipid-lowering therapy is recommended to lower LDL-C and reduce the risk of MACE.8–10",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00347,2025,27,2A,B-R,"In patients with ACS who are already on maximally tolerated statin therapy with LDL-C 55 to 69 mg/dL (≥1.4 to <1.8 mmol/L), adding a nonstatin lipid-lowering agent is reasonable to reduce the risk of MACE.*5–7,11–13",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00348,2025,27,2B,B-R,"In patients with ACS, the concurrent initiation of ezetimibe in combination with maximally tolerated statin may be considered to reduce the risk of MACE.5 *Modified or †adapted from the “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease.”14",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00349,2025,30,Class 1,A,"In patients with ACS without contraindications, early (<24 hours) initiation of oral beta-blocker therapy is recommended to reduce risk of reinfarction and ventricular arrhythmias.1–5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00350,2025,30,Class 1,A,"In high-risk patients with ACS (LVEF ≤40%, hypertension, diabetes mellitus, or STEMI with anterior location), an oral angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) is indicated to reduce all-cause death and MACE.1–6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00351,2025,30,Class 1,B-R,"In patients with ACS and LVEF ≤40%, and with HF symptoms and/or diabetes mellitus, a mineralocorticoid receptor antagonist is indicated to reduce all-cause death and MACE.7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00352,2025,30,2A,A,"In patients with ACS who are not considered high risk, an oral ACEi or an ARB is reasonable to reduce MACE.4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00353,2025,31,Class 1,B-NR,All communities should create and maintain regional systems of STEMI care that coordinate prehospital and hospital-based STEMI care processes with the goal of reducing total ischemic time and improving survival in patients with STEMI.1–6,rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00354,2025,33,Class 1,A,"In patients with STEMI presenting <12 hours after symptom onset, PPCI should be performed with a goal of FMC to device activation of ≤90 minutes, or ≤120 minutes in patients requiring hospital transfer, to improve survival.1–7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00355,2025,33,Class 1,B-R,"In patients with ACS and cardiogenic shock or hemodynamic instability, emergency revascularization of the culprit vessel by PCI or CABG is indicated to improve survival, irrespective of time from symptom onset.8–11",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00356,2025,33,2A,B-NR,"In patients with STEMI presenting 12 to 24 hours after symptom onset, PPCI is reasonable to improve clinical outcomes.*12–15",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00357,2025,33,2A,C-LD,"In patients with STEMI presenting >24 hours after symptom onset with the presence of ongoing ischemia or life-threatening arrhythmia, PPCI is reasonable to improve clinical outcomes.†12,14",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00358,2025,33,Class 3: No Benefit,B-R,"In patients who are stable with STEMI who have a totally occluded infarct-related artery >24 hours after symptom onset and are without evidence of ongoing ischemia, acute severe HF, or life-threatening arrhythmia, PPCI should not be performed due to lack of benefit.†16,17 *Reproduced or †modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”18",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00359,2025,34,2A,B-NR,"In patients with STEMI in whom PCI is not feasible or successful, with a large area of myocardium at risk, emergency or urgent CABG surgery can be effective to improve clinical outcomes.*1,2 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00360,2025,34,Class 1,A,"In patients with STEMI and an estimated time from FMC to device activation of ≤120 minutes or those with a contraindication to fibrinolytic therapy, transfer to a PCI-capable hospital for PPCI is recommended to reduce MACE.1–3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00361,2025,34,Class 1,A,"In patients with STEMI and symptom onset of <12 hours and anticipated delay to PPCI >120 minutes from FMC, fibrinolytic therapy should be administered in patients without contraindication to reduce MACE.4–10 Downloaded from http://ahajournals.org by on June 19, 2025",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00362,2025,35,2A,B-NR,"In patients with STEMI and symptom onset of 12 to 24 hours, transfer to a PCI-capable hospital for PPCI is reasonable to reduce infarct size and MACE.11,12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00363,2025,35,Class 3: Harm,B-R,"In patients with only ST-segment depres- sion, except when true posterior STEMI is suspected, fibrinolytic therapy should not be administered due to risk of hemorrhagic stroke and major noncerebral bleeding.13",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00364,2025,36,Class 1,A,"In patients with STEMI, transfer to a PCI-capable center immediately after fibrinolytic therapy is recommended.1–5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00365,2025,36,Class 1,B-R,"In patients with STEMI with suspected failed reperfusion after fibrinolytic therapy, immediate angiography with rescue PCI is recommended to reduce the risk of death or recurrent MI.*6–9",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00366,2025,36,Class 1,B-R,"In patients with STEMI treated with fibrino- lytic therapy, early angiography between 2 and 24 hours with the intent to perform PCI is recommended to reduce the rates of death or MI.*1–5,10,11 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00367,2025,37,Class 1,A,"In patients with NSTE-ACS who are at intermediate or high risk of ischemic events and are appropriate candidates for revascularization, an invasive approach with the intent to proceed with revascularization is recommended during hospitalization to reduce MACE.*1–6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00368,2025,37,Class 1,A,"In patients with NSTE-ACS who are at low risk of ischemic events, either a routine invasive or selective invasive approach is recommended to help identify those who may require revascularization and to reduce MACE.1–4,7 Timing of Coronary Angiography for Those in Whom an Invasive Approach Is Planned",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00369,2025,37,Class 1,C-LD,"In patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability, an immediate invasive strategy with intent to perform revascularization is indicated to reduce MACE.†8–11",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00370,2025,37,2A,B-R,"In patients with NSTE-ACS who are at high risk‡ of ischemic events, it is reasonable to choose an early invasive strategy (within 24 hours) to reduce MACE.†8,9,11,12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00371,2025,37,2A,B-R,"In patients with NSTE-ACS who are not at high risk and are intended for an invasive strategy, it is reasonable to perform angiography before hospital discharge to reduce MACE.*8,11 *Reproduced or †modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”7 ‡Predictors of risk are outlined in Figure 8.",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00372,2025,40,Class 1,A,"In patients with ACS undergoing PCI, a radial approach is preferred to a femoral approach to reduce bleeding, vascular complications, and death.*1–6 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”7",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00373,2025,41,Class 3: No Benefit,A,"Among patients with STEMI undergoing PPCI, manual aspiration thrombectomy should not be performed routinely prior to PCI given lack of clinical benefit.*1–4 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00374,2025,41,Class 1,A,"In patients with ACS undergoing coronary stent implantation in left main artery or in complex lesions, intracoronary imaging with intravascular ultrasound (IVUS) or optical coherence tomogra- phy (OCT) is recommended for procedural guidance to reduce ischemic events.*1–11 *Adapted from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00375,2025,42,Class 1,A,"In selected, hemodynamically stable patients with STEMI and multivessel disease (MVD), after successful PCI of the infarct-related artery, PCI of significantly stenosed* noninfarct-related arteries is recommended to reduce the risk of death or MI and improve angina-related quality of life (QOL).†1–9",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00376,2025,42,2A,C-EO,"In appropriate patients with STEMI and complex MVD, after successful PCI of the infarct-related artery, elective CABG surgery for significantly stenosed noninfarct-related arteries involving the left anterior descending artery or left main disease is reasonable to reduce the risk of cardiovascular events.†",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00377,2025,42,2B,B-R,"In selected hemodynamically stable patients with STEMI and low-complexity MVD (those not intended for CABG surgery), multivessel PCI of significantly stenosed noninfarct-related arteries at the time of PPCI may be preferred over a staged approach to reduce the risk of cardiovascular events.10–12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00378,2025,42,Class 3: Harm,B-R,"In patients with STEMI complicated by cardiogenic shock, routine PCI of a noninfarct-related artery at the time of PPCI should not be performed because of the higher risk of death or renal failure.*13–15 *Significantly stenosed refers to lesions that are severely diseased as defined by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization” as a visually estimated diameter stenosis severity of ≥70% for non–left main disease and ≥50% for left main disease.16 †Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”16",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00379,2025,44,Class 1,C-EO,"In patients with NSTE-ACS with MVD, the mode of revascularization (CABG or multivessel PCI) should be based on the disease complexity and patient’s comorbidities. Multivessel CAD and Candidates for PCI",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00380,2025,44,Class 1,B-R,"In stable patients with NSTE-ACS with MVD but without left main stenosis who are not intended for CABG surgery and undergoing culprit-lesion PCI, PCI of significant nonculprit lesions (at the time of the index procedure or as a staged procedure) is recommended to reduce the risk of MACE.1–6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00381,2025,44,2B,B-R,"In patients with NSTE-ACS in whom multivessel PCI is being considered, physiological assessment of a nonculprit stenosis may be considered to guide revascularization decisions.7–9",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00382,2025,44,Class 3: Harm,B-R,"In patients with NSTE-ACS complicated by cardiogenic shock, routine PCI of a nonculprit artery at the time of index procedure should not be performed because of the higher risk of death or kidney failure.*10,11 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.”12",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00383,2025,45,Class 1,B-R,"In patients with ACS and cardiogenic shock or hemodynamic instability, emergency revascularization of the culprit vessel by PCI or with CABG is indicated to improve survival, irrespective of time from symptom onset.1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00384,2025,45,Class 3: Harm,B-R,"In patients with ACS complicated by cardiogenic shock, routine PCI of a noninfarct-related artery at the time of PPCI should not be performed because of the higher risk of death or renal failure.*5–7 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”8",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00385,2025,46,2A,B-R,"In selected* patients with STEMI and severe or refractory cardiogenic shock, insertion of a microaxial intravascular flow pump is reasonable to reduce death.1",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00386,2025,46,2A,B-NR,"In patients with mechanical complication of ACS, short-term MCS devices are reasonable for hemodynamic stabilization as a bridge to surgery.2–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00387,2025,46,Class 3: No Benefit,B-R,"In patients with AMI and cardiogenic shock, the routine use of intra-aortic balloon pump (IABP) or venoarterial extracorporeal membrane oxygenation (VA-ECMO) is not recommended due to a lack of survival benefit.5–9 *See supportive text.",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00388,2025,48,Class 1,C-EO,Patients with a mechanical complication of ACS should be managed in a facility with cardiac surgical expertise.,rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00389,2025,48,2A,B-NR,"In patients with a mechanical complication of ACS, short-term MCS devices are reasonable for hemodynamic stabilization as a bridge to surgery.1–3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00390,2025,49,Class 1,A,"In patients post MI, implantable cardioverter- defibrillator (ICD) implantation is recommended in selected patients with an LVEF ≤40% (Table 17) at least 40 days post MI and at least 90 days postrevascularization to reduce death.*1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00391,2025,49,2A,C-EO,"In patients post ACS, ICD implantation is reasonable in patients with clinically relevant ventricular arrhythmias >48 hours and within 40 days post MI to improve survival.*5,6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00392,2025,49,2B,B-R,"In patients early after MI, usefulness of a temporary wearable cardioverter-defibrillator is uncertain in patients with an LVEF ≤35% to improve survival.7 Bradyarrhythmias",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00393,2025,49,Class 1,B-NR,"In patients presenting with an AMI with sustained evidence of second-degree Mobitz type II atrioventricular block, high-grade atrioventricu- lar block, alternating bundle-branch block, or third-degree atrioventricular block (persistent or infranodal), permanent pacing is indicated.†8,9 *Adapted from the “2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.” †Adapted from the “2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay.”",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00394,2025,51,Class 1,C-EO,"Patients with ACS and with ongoing angina, hemo- dynamic instability, uncontrolled arrhythmias, sub- optimal reperfusion, or cardiogenic shock should be admitted to a CICU to reduce cardiovascular events.",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00395,2025,52,2B,B-R,"In patients with ACS and acute or chronic anemia, blood transfusion to achieve a hemoglobin level ≥10 g/dL may be reasonable to reduce cardiovascular events.1",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00396,2025,52,Class 1,C-LD,"In patients with ACS, telemetry monitoring is recommended to reduce cardiovascular events with duration determined by cardiac risk.1,2",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00397,2025,53,Class 1,C-LD,"In patients with ACS, an assessment of LVEF is recommended prior to hospital discharge to guide therapy and for risk stratification.1–3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00398,2025,54,Class 1,A,"Patients with ACS should be referred to an outpatient CR program prior to hospital discharge to reduce death, MI, hospital readmis- sions, and improve functional status and QOL.1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00399,2025,54,2A,B-R,"In patients with ACS, a home-based CR program is a reasonable alternative to a center-based CR program to improve functional status and QOL.5–9",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00400,2025,56,Class 1,A,"In patients with ACS who are not at high bleeding risk, DAPT with aspirin and an oral P2Y12 inhibi- tor should be administered for at least 1 year to reduce MACE.1–6 Bleeding Reduction Strategies",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00401,2025,56,Class 1,A,"In patients with ACS who have tolerated DAPT with ticagrelor, transition to ticagrelor monotherapy ≥1 month post PCI is useful to reduce bleeding risk.7–11",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00402,2025,56,Class 1,A,"In patients at high risk of gastrointestinal bleeding, a proton pump inhibitor (PPI) is rec- ommended in combination with DAPT, oral antico- agulants, or both to reduce risk of bleeding.12–15",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00403,2025,56,2B,B-R,"In patients with ACS undergoing PCI, de- escalation of DAPT (switching from ticagrelor or prasugrel to clopidogrel) after 1 month may be reasonable to reduce bleeding risk.16–20",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00404,2025,56,2B,B-R,"In patients with ACS undergoing PCI who are at high bleeding risk, transition to single antiplatelet therapy (aspirin or P2Y12 inhibitor) after 1 month may be reasonable to reduce bleeding risk.21",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00405,2025,59,Class 1,B-R,"In patients with ACS who require oral anticoagulant therapy, aspirin should be discontinued after 1 to 4 weeks of triple antithrombotic therapy, with continued use of a P2Y12 inhibitor (preferably clopidogrel) and an oral anticoagulant to reduce bleeding risk.*1–5 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”6",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00406,2025,60,Class 1,C-LD,"In patients after ACS, a fasting lipid panel is recommended 4 to 8 weeks after initiation or dose adjustment of lipid-lowering therapy to assess response or adherence to therapy.*1,2 *Modified from the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cho- lesterol.”3",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00407,2025,61,2B,B-R,"In patients after ACS, low-dose colchicine may be reasonable to reduce risk of MACE.1–5",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00408,2025,62,Class 1,A,"In patients with ACS without a contraindication, annual influenza vaccination is recommended to reduce the risk of death and MACE.1–4",rao-et-al-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-patients-with-acute-coronary-syndromes-a-report (1).pdf
id_00409,2021,8,Class 1,B-NR,An initial assessment of chest pain is recommended to triage patients effectively on the basis of the likelihood that symptoms may be attributable to myocardial ischemia.1-7,gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00410,2021,8,Class 1,C-LD,"Chest pain should not be described as atypical, because it is not helpful in determining the cause and can be misinterpreted as benign in nature. Instead, chest pain should be described as cardiac, possibly cardiac, or noncardiac because these terms are more specific to the potential underlying diagnosis.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00411,2021,10,Class 1,C-LD,"In patients with chest pain, a focused history that includes characteristics and duration of symptoms relative to presentation as well as associated features, and cardiovascular risk factor assessment should be obtained.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00412,2021,11,Class 1,B-NR,"Women who present with chest pain are at risk for underdiagnosis, and potential cardiac causes should always be considered.1-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00413,2021,11,Class 1,B-NR,"In women presenting with chest pain, it is recommended to obtain a history that emphasizes accompanying symptoms that are more common in women with ACS.1-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00414,2021,12,Class 1,C-LD,"In patients with chest pain who are >75 years of age, ACS should be considered when accompanying symptoms such as shortness of breath, syncope, or acute delirium are present, or when an unexplained fall has occurred.1",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00415,2021,12,Class 1,C-LD,Cultural competency training is recommended to help achieve the best outcomes in patients of diverse racial and ethnic backgrounds who present with chest pain.,gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00416,2021,12,Class 1,C-LD,"Among patients of diverse race and ethnicity presenting with chest pain in whom English may not be their primary language, addressing language barriers with the use of formal translation services is recommended.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00417,2021,13,Class 1,C-LD,"In patients with acute chest pain, it is recommended that 9-1-1 be activated by patients or bystanders to initiate transport to the closest ED by emergency medical services (EMS).1",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00418,2021,13,Class 1,C-EO,"In patients presenting with chest pain, a focused cardiovascular examination should be performed initially to aid in the diagnosis of ACS or other potentially serious causes of chest pain (eg, aortic dissection, PE, or esophageal rupture) and to identify complications.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00419,2021,14,Class 1,B-NR,"Unless a noncardiac cause is evident, an ECG should be performed for patients seen in the office setting with stable chest pain; if an ECG is unavailable the patient should be referred to the ED so one can be obtained.1-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00420,2021,14,Class 1,C-LD,"Patients with clinical evidence of ACS or other life-threatening causes of acute chest pain seen in the office setting should be transported urgently to the ED, ideally by EMS.1-9",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00421,2021,14,Class 1,C-LD,"In all patients who present with acute chest pain regardless of the setting, an ECG should be acquired and reviewed for STEMI within 10 minutes of arrival.1-3,6,7,10",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00422,2021,14,Class 1,C-LD,"In all patients presenting to the ED with acute chest pain and suspected ACS, cTn should be measured as soon as possible after presentation.8,9",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00423,2021,14,Class 3: Harm,C-LD,"For patients with acute chest pain and suspected ACS initially evaluated in the office setting, delayed transfer to the ED for cTn or other diagnostic testing should be avoided.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00424,2021,15,Class 1,C-EO,"In patients with chest pain in which an initial ECG is nondiagnostic, serial ECGs to detect potential ischemic changes should be performed, especially when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.1",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00425,2021,15,Class 1,C-EO,"Patients with chest pain in whom the initial ECG is consistent with an ACS should be treated according to STEMI and NSTE-ACS guidelines.1,2",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00426,2021,15,2A,B-NR,"In patients with chest pain and intermediate- to-high clinical suspicion for ACS in whom the initial ECG is nondiagnostic, supplemental electrocardiographic leads V7 to V9 are reasonable to rule out posterior MI.3-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00427,2021,15,Class 1,C-EO,"In patients presenting with acute chest pain, a chest radiograph is useful to evaluate for other potential cardiac, pulmonary, and thoracic causes of symptoms. Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00428,2021,16,Class 1,B-NR,"In patients presenting with acute chest pain, serial cTn I or T levels are useful to identify abnormal values and a rising or falling pattern indicative of acute myocardial injury.1-21",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00429,2021,16,Class 1,B-NR,"In patients presenting with acute chest pain, high-sensitivity cTn is the preferred biomarker because it enables more rapid detection or exclusion of myocardial injury and increases diagnostic accuracy.17,21-25",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00430,2021,16,Class 1,C-EO,"Clinicians should be familiar with the analytical performance and the 99th percentile upper reference limit that defines myocardial injury for the cTn assay used at their institution.23,26",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00431,2021,16,Class 3: No Benefit,B-NR,"With availability of cTn, creatine kinase myocardial (CK-MB) isoenzyme and myoglobin are not useful for diagnosis of acute myocardial injury.27-32 Figure 4. Electrocardiographic-Directed Management of Chest Pain ECG indicates electrocardiogram; MI, myocardial infarction; NSTE-ACS, non–ST-segment–elevation acute coronary syndrome; and STEMI, ST- segment–elevation myocardial infarction. Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00432,2021,22,Class 1,B-NR,"In patients presenting with acute chest pain and suspected ACS, clinical decision pathways (CDPs) should categorize patients into low-, intermediate-, and high-risk strata to facilitate disposition and subsequent diagnostic evaluation.1-14",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00433,2021,22,Class 1,B-NR,"In the evaluation of patients presenting with acute chest pain and suspected ACS for whom serial troponins are indicated to exclude myocardial injury, recommended time intervals after the initial troponin sample collection (time zero) for repeat measurements are: 1 to 3 hours for high-sensitivity troponin and 3 to 6 hours for conventional troponin assays.15-17",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00434,2021,22,Class 1,C-LD,"To standardize the detection and differentiation of myocardial injury in patients presenting with acute chest pain and suspected ACS, institutions should implement a CDP that includes a protocol for troponin sampling based on their particular assay.18,19",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00435,2021,22,Class 1,C-LD,"In patients with acute chest pain and suspected ACS, previous testing when available should be considered and incorporated into CDPs.20-24",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00436,2021,22,2A,B-NR,"For patients with acute chest pain, a normal ECG, and symptoms suggestive of ACS that began at least 3 hours before ED arrival, a single hs-cTn concentration that is below the limit of detection on initial measurement (time zero) is reasonable to exclude myocardial injury.13,25-29",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00437,2021,25,Class 1,B-NR,Patients with acute chest pain and a 30-day risk of death or MACE <1% should be designated as low risk.1-11,gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00438,2021,25,2A,B-R,"In patients with acute chest pain and suspected ACS who are deemed low-risk (<1% 30-day risk of death or MACE), it is reasonable to discharge home without admission or urgent cardiac testing.12-16",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00439,2021,26,Class 1,C-EO,"For intermediate-risk patients with acute chest pain, TTE is recommended as a rapid, bedside test to establish baseline ventricular and valvular function, evaluate for wall motion abnormalities, and to assess for pericardial effusion.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00440,2021,26,2A,A,"For intermediate-risk patients with acute chest pain, management in an observation unit is reasonable to shorten length of stay and lower cost relative to an inpatient admission.1-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00441,2021,27,Class 1,A,"For intermediate-risk patients with acute chest pain and no known CAD eligible for diagnostic testing after a negative or inconclusive evaluation for ACS, CCTA is useful for exclusion of atherosclerotic plaque and obstructive CAD.1-11",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00442,2021,27,Class 1,C-EO,"For intermediate-risk patients with acute chest pain, moderate-severe ischemia on current or prior (≤1 year) stress testing, and no known CAD established by prior anatomic testing,",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00443,2021,27,2A,C-LD,"For intermediate-risk patients with acute chest pain with evidence of previous mildly abnormal stress test results (≤1 year), CCTA is reasonable for diagnosing obstructive CAD.12,13 Stress Testing",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00444,2021,27,Class 1,B-NR,"For intermediate-risk patients with acute chest pain and no known CAD who are eligible for cardiac testing, either exercise ECG, stress echocardiography, stress PET/SPECT MPI, or stress CMR is useful for the diagnosis of myocardial ischemia.1,4,10,14-36 Sequential or Add-on Diagnostic Testing",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00445,2021,27,2A,B-NR,"For intermediate-risk patients with acute chest pain and no known CAD, with a coronary artery stenosis of 40% to 90% in a proximal or middle coronary artery on CCTA, FFR-CT can be useful for the diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of coronary revascularization.37-43",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00446,2021,27,2A,C-EO,"For intermediate-risk patients with acute chest pain and no known CAD, as well as an inconclusive prior stress test, CCTA can be useful for excluding the presence of atherosclerotic plaque and obstructive CAD.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00447,2021,27,2A,C-EO,"For intermediate-risk patients with acute chest pain and no known CAD, with an inconclusive CCTA, stress imaging (with echocardiography, PET/SPECT MPI, or CMR) can be useful for the diagnosis of myocardial ischemia.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00448,2021,28,Class 1,A,"For intermediate-risk patients with acute chest pain who have known CAD and present with new onset or worsening symptoms, GDMT should be optimized before additional cardiac testing is performed.1,2 Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00449,2021,29,Class 1,A,"For intermediate-risk patients with acute chest pain who have worsening frequency of symptoms with significant left main, proximal left anterior descending stenosis, or multivessel CAD on prior anatomic testing or history of prior coronary revascularization, ICA is recommended.3-8",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00450,2021,29,2A,B-NR,"For intermediate-risk patients with acute chest pain and known nonobstructive CAD, CCTA can be useful to determine progression of atherosclerotic plaque and obstructive CAD.9-11",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00451,2021,29,2A,B-NR,"For intermediate-risk patients with acute chest pain and coronary artery stenosis of 40% to 90% in a proximal or middle segment on CCTA, FFR-CT is reasonable for diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of coronary revascularization.12-17",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00452,2021,29,2A,B-NR,"For intermediate-risk patients with acute chest pain and known CAD who have new onset or worsening symptoms, stress imaging (PET/ SPECT MPI, CMR, or stress echocardiography) is reasonable.18-21",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00453,2021,31,Class 1,B-NR,"For patients with acute chest pain and suspected ACS who have new ischemic changes on electrocardiography, troponin- confirmed acute myocardial injury, new- onset left ventricular systolic dysfunction (ejection fraction <40%), newly diagnosed moderate-severe ischemia on stress testing, hemodynamic instability, and/or a high clinical decision pathway (CDP) risk score should be designated as high risk for short-term MACE.1-3",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00454,2021,31,Class 1,C-EO,"For patients with acute chest pain and suspected ACS who are designated as high risk, ICA is recommended.4-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00455,2021,31,2A,B-NR,"For high-risk patients with acute chest pain who are troponin positive in whom obstructive CAD has been excluded by CCTA or ICA, CMR or echocardiography can be effective in establishing alternative diagnoses.8-12",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00456,2021,31,Class 1,C-LD,"In patients with prior CABG surgery presenting with acute chest pain who do not have ACS, performing stress imaging is effective to evaluate for myocardial ischemia or CCTA for graft stenosis or occlusion.1-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00457,2021,31,Class 1,C-LD,"In patients with prior CABG surgery presenting with acute chest pain, who do not have ACS8-14 or who have an indeterminate/nondiagnostic stress test, ICA is useful.8",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00458,2021,32,Class 1,B-NR,"In patients who experience acute unremitting chest pain while undergoing dialysis, transfer by EMS to an acute care setting is recommended.1-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00459,2021,33,2A,B-NR,"In patients presenting with acute chest pain, it is reasonable to consider cocaine and methamphetamine use as a cause of their symptoms.1-3",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00460,2021,33,Class 1,B-R,"For patients with acute chest pain and suspected ACS who are deemed low risk by a CDP, patient decision aids are beneficial to improve understanding and effectively facilitate risk communication.1,2",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00461,2021,33,Class 1,B-R,"For patients with acute chest pain and suspected ACS who are deemed intermediate risk by a CDP, shared decision-making between the clinician and patient regarding the need for admission, for observation, discharge, or further evaluation in an outpatient setting is recommended for improving patient understanding and reducing low-value testing.1,2",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00462,2021,34,Class 1,C-EO,"In patients with acute chest pain in whom other potentially life-threatening nonischemic cardiac conditions are suspected (eg, aortic pathology, pericardial effusion, endocarditis), TTE is recommended for diagnosis.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00463,2021,34,Class 1,C-EO,"In patients with acute chest pain where there is clinical concern for aortic dissection, computed tomography angiography (CTA) of the chest, abdomen, and pelvis is recommended for diagnosis and treatment planning.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00464,2021,34,Class 1,C-EO,"In patients with acute chest pain where there is clinical concern for aortic dissection, TEE or CMR should be performed to make the diagnosis if CT is contraindicated or unavailable. Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00465,2021,35,Class 1,B-NR,"In stable patients with acute chest pain with high clinical suspicion for PE, CTA using a PE protocol is recommended.1-4",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00466,2021,35,Class 1,C-EO,"For patients with acute chest pain and possible PE, need for further testing should be guided by pretest probability.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00467,2021,35,Class 1,B-NR,"In patients with acute chest pain and myocardial injury who have nonobstructive coronary arteries on anatomic testing, CMR with gadolinium contrast is effective to distinguish myopericarditis from other causes, including myocardial infarction and nonobstructive coronary arteries (MINOCA).1-6",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00468,2021,35,Class 1,B-NR,"In patients with acute chest pain with suspected acute myopericarditis, CMR is useful if there is diagnostic uncertainty, or to determine the presence and extent of myocardial and pericardial inflammation and fibrosis.7-12",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00469,2021,35,Class 1,C-EO,"In patients with acute chest pain and suspected myopericarditis, TTE is effective to determine the presence of ventricular wall motion abnormalities, pericardial effusion, valvular abnormalities, or restrictive physiology.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00470,2021,35,2B,C-LD,"In patients with acute chest pain with suspected acute pericarditis, noncontrast or contrast cardiac CT scanning may be reasonable to determine the presence and degree of pericardial thickening.7,8,13 Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00471,2021,36,Class 1,C-EO,"In patients presenting with acute chest pain with suspected or known history of VHD, TTE is useful in determining the presence, severity, and cause of VHD.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00472,2021,36,Class 1,C-EO,"In patients presenting with acute chest pain with suspected or known VHD in whom TTE diagnostic quality is inadequate, TEE (with 3D imaging if available) is useful in determining the severity and cause of VHD.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00473,2021,36,2A,C-EO,"In patients presenting with acute chest pain with known or suspected VHD, CMR imaging is reasonable as an alternative to TTE and/or",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00474,2021,37,Class 1,C-EO,"Patients with acute chest pain should be evaluated for noncardiac causes if they have persistent or recurring symptoms despite a negative stress test or anatomic cardiac evaluation, or a low-risk designation by a CDP.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00475,2021,38,2A,C-LD,"In patients with recurrent acute chest pain without evidence of a cardiac or pulmonary cause, evaluation for gastrointestinal causes is reasonable.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00476,2021,38,2A,B-R,"For patients with recurrent, similar presentations for acute chest pain with no evidence of a physiological cause on prior diagnostic evaluation including a negative workup for myocardial ischemia, referral to a cognitive-behavioral therapist is reasonable.1-14",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00477,2021,39,Class 1,B-NR,"In patients with sickle cell disease who report acute chest pain, emergency transfer by EMS to an acute care setting is recommended.1-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00478,2021,39,Class 1,C-LD,"In patients with sickle cell disease who report acute chest pain, ACS should be excluded.3-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00479,2021,40,Class 1,B-NR,"For patients with stable chest pain and no known CAD presenting to the outpatient clinic, a model to estimate pretest probability of obstructive CAD is effective to identify patients at low risk for obstructive CAD and favorable prognosis in whom additional diagnostic testing can be deferred.1-5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00480,2021,40,2A,B-R,"For patients with stable chest pain and no known CAD categorized as low risk, CAC testing is reasonable as a first-line test for excluding calcified plaque and identifying patients with a low likelihood of obstructive CAD.6-9",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00481,2021,40,2A,B-NR,"For patients with stable chest pain and no known CAD categorized as low risk, exercise testing without imaging is reasonable as a first-line test for excluding myocardial ischemia and determining functional capacity in patients with an interpretable ECG.10",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00482,2021,41,Class 1,A,"For intermediate-high risk patients with stable chest pain and no known CAD, CCTA is effective for diagnosis of CAD, for risk stratification, and for guiding treatment decisions.1-12 Stress Testing",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00483,2021,41,Class 1,B-R,"For intermediate-high risk patients with stable chest pain and no known CAD, stress imaging (stress echocardiography, PET/SPECT MPI or CMR) is effective for diagnosis of myocardial ischemia and for estimating risk of MACE.8,13-35",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00484,2021,41,2A,B-R,"For intermediate-high risk patients with stable chest pain and no known CAD for whom rest/stress nuclear MPI is selected, PET is reasonable in preference to SPECT, if available to improve diagnostic accuracy and decrease the rate of nondiagnostic test results.36-39",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00485,2021,41,2A,B-R,"For intermediate-high risk patients with stable chest pain and no known CAD with an interpretable ECG and ability to achieve maximal levels of exercise (≥5 METs), exercise electrocardiography is reasonable.8,13,15,40-45",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00486,2021,41,2B,B-NR,"In intermediate-high risk patients with stable chest pain selected for stress MPI using SPECT, the use of attenuation correction or prone imaging may be reasonable to decrease the rate of false-positive findings.46-51 Assessment of Left Ventricular Function",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00487,2021,41,Class 1,B-NR,"In intermediate-high risk patients with stable chest pain who have pathological Q waves, symptoms or signs suggestive of heart failure, complex ventricular arrhythmias, or a heart murmur with unclear diagnosis, use of TTE is effective for diagnosis of resting left ventricular systolic and diastolic ventricular function and detection of myocardial, valvular, and pericardial abnormalities.13,14,52 Sequential or Add-on Testing: What to Do if Index Test Results are Positive or Inconclusive",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00488,2021,41,2A,B-NR,"For intermediate-high risk patients with stable chest pain and known coronary stenosis of 40% to 90% in a proximal or middle coronary segment on CCTA, FFR-CT can be useful for diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of coronary revascularization.12,53-58",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00489,2021,41,2A,B-NR,"For intermediate-high risk patients with stable chest pain after an inconclusive or abnormal exercise ECG or stress imaging study, CCTA is reasonable.5,59-63",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00490,2021,41,2A,B-NR,"For intermediate-high risk patients with stable chest pain and no known CAD undergoing stress testing, the addition of CAC testing can be useful.64-70 Downloaded from http://ahajournals.org by on June 19, 2025",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00491,2021,44,Class 1,A,"For patients with obstructive CAD and stable chest pain, it is recommended to optimize GDMT.1-3",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00492,2021,44,Class 1,C-EO,"For patients with known nonobstructive CAD and stable chest pain, it is recommended to optimize preventive therapies.4,5",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00493,2021,45,Class 1,A,"For patients with obstructive CAD who have stable chest pain despite GDMT and moderate- severe ischemia, ICA is recommended for guiding therapeutic decision-making.1-4",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00494,2021,45,Class 1,A,"For patients with obstructive CAD who have stable chest pain despite optimal GDMT, those referred for ICA without prior stress testing benefit from FFR or instantaneous wave free ratio.3,5-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00495,2021,45,Class 1,B-R,"For symptomatic patients with obstructive CAD who have stable chest pain with CCTA- defined ≥50% stenosis in the left main coronary artery, obstructive CAD with FFR with CT ≤0.80, or severe stenosis (≥70%) in all 3 main vessels, ICA is effective for guiding therapeutic decision-making.4,8",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00496,2021,45,2A,B-NR,"For patients who have stable chest pain with previous coronary revascularization, CCTA is reasonable to evaluate bypass graft or stent patency (for stents ≥3 mm).9-13 Stress Testing",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00497,2021,45,Class 1,B-NR,"For patients with obstructive CAD who have stable chest pain despite optimal GDMT, stress PET/SPECT MPI, CMR, or echocardiography is recommended for diagnosis of myocardial ischemia, estimating risk of MACE, and guiding therapeutic decision-making.14-36",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00498,2021,45,2A,B-R,"For patients with obstructive CAD who have stable chest pain despite optimal GDMT, when selected for rest/stress nuclear MPI, PET is reasonable in preference to SPECT, if available, to improve diagnostic accuracy and decrease the rate of nondiagnostic test results.37",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00499,2021,45,2A,B-NR,"For patients with obstructive CAD who have stable chest pain despite GDMT, exercise treadmill testing can be useful to determine if the symptoms are consistent with angina pectoris, assess the severity of symptoms, evaluate functional capacity and select management, including cardiac rehabilitation.4,38-40",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00500,2021,45,2A,B-NR,"For patients with obstructive CAD who have stable chest pain symptoms undergoing stress PET MPI or stress CMR, the addition of MBFR is useful to improve diagnosis accuracy and enhance risk stratification.31-36",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00501,2021,47,Class 1,C-LD,"In patients who have had prior CABG surgery presenting with stable chest pain whose noninvasive stress test results show moderate- to-severe ischemia,1-7 or in those suspected to have myocardial ischemia with indeterminate/ nondiagnostic stress test, ICA is recommended for guiding therapeutic decision-making.1",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00502,2021,47,2A,C-LD,"In patients who have had prior CABG surgery presenting with stable chest pain who are suspected to have myocardial ischemia, it is reasonable to perform stress imaging or CCTA to evaluate for myocardial ischemia or graft stenosis or occlusion.8-15",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00503,2021,48,2A,B-NR,"For symptomatic patients with known nonobstructive CAD who have stable chest pain, CCTA is reasonable for determining atherosclerotic plaque burden and progression to obstructive CAD, and guiding therapeutic decision-making.1-7",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00504,2021,48,2A,B-NR,"For patients with known coronary stenosis from 40% to 90% on CCTA, FFR can be useful for diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of ICA.8-14 Stress Testing",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00505,2021,48,2A,C-LD,"For patients with known extensive nonobstructive CAD with stable chest pain symptoms, stress imaging (PET/SPECT, CMR, or echocardiography) is reasonable for the diagnosis of myocardial ischemia.15-24",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00506,2021,49,2A,B-NR,"For patients with persistent stable chest pain and nonobstructive CAD and at least mild myocardial ischemia on imaging, it is reasonable to consider invasive coronary function testing to improve the diagnosis of coronary microvascular dysfunction and to enhance risk stratification.1-4",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00507,2021,49,2A,B-NR,"For patients with persistent stable chest pain and nonobstructive CAD, stress PET MPI with MBFR is reasonable to diagnose microvascular dysfunction and enhance risk stratification.5-11",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00508,2021,49,2A,B-NR,"For patients with persistent stable chest pain and nonobstructive CAD, stress CMR with the addition of MBFR measurement is reasonable to improve diagnosis of coronary myocardial dysfunction and for estimating risk of MACE.12-14",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00509,2021,49,2B,C-EO,"For patients with persistent stable chest pain and nonobstructive CAD, stress echocardiography with the addition of coronary flow velocity reserve measurement may be reasonable to improve diagnosis of coronary myocardial dysfunction and for estimating risk of MACE.",gulati-et-al-2021-aha-acc-ase-chest-saem-scct-scmr-guideline-for-the-evaluation-and-diagnosis-of-chest-pain-a-report-of.pdf
id_00560,2024,12,Class 1,B-NR,"For patients with HCM or at risk for HCM, shared decision-making is recommended in developing a plan of care (including, but not limited to, decisions regarding genetic evaluation, activity, lifestyle, and therapy choices) that includes a full disclosure of the risks, benefits, and anticipated outcomes of all options, as well the opportunity for the patient and caregivers to express their goals and concerns.1–5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00561,2024,12,Class 1,C-LD,"In patients with HCM in whom SRT is indicated, the procedure should be performed at experienced centers (comprehensive or primary HCM centers) with demonstrated excellence in clinical outcomes for these procedures (Tables 4 and 5).1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00562,2024,12,2A,C-LD,"In patients with HCM, consultation with or referral to a comprehensive or primary HCM center is reasonable to aid in complex disease-related management decisions (Table 4).4–14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00563,2024,13,Class 1,B-NR,"In patients with suspected HCM, comprehensive physical examination and complete medical and",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00564,2024,15,Class 1,B-NR,"In patients with suspected HCM, a transthoracic echocardiogram (TTE) is recommended in the initial evaluation.1–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00565,2024,15,Class 1,B-NR,"For patients with HCM who experience a change in clinical status or a new clinical event, repeat TTE is recommended.9,14–17",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00566,2024,15,Class 1,B-NR,"For patients with HCM and resting peak LVOT gradient <50 mm Hg, a TTE with provocative maneuvers is recommended.18–21",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00567,2024,15,Class 1,B-NR,"For symptomatic patients with HCM who do not have a resting or provocable outflow tract peak gradient ≥50 mm Hg on TTE, exercise TTE is recommended for the detection and quantification of dynamic LVOTO.20–25",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00568,2024,15,Class 1,B-NR,"For patients with HCM who are undergoing surgical septal myectomy, intraoperative transesophageal echocardiogram (TEE) is recommended to assess mitral valve anatomy and function and adequacy of septal myectomy.26–29",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00569,2024,15,Class 1,B-NR,"For patients with HCM who are undergoing alcohol septal ablation, TTE or intraoperative TEE with intracoronary ultrasound-enhancing contrast injection of the candidate’s septal perforator(s) is recommended.30–34",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00570,2024,15,Class 1,B-NR,"For patients with HCM who have undergone SRT, TTE within 3 to 6 months after the procedure is recommended to evaluate the procedural results.35–38",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00571,2024,15,Class 1,B-NR,"Screening: In first-degree relatives of patients with HCM, a TTE is recommended as part of initial family screening and periodic follow-up (Figure 1, Table 7).3–5,7,14,32",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00572,2024,15,Class 1,B-NR,"Screening: In individuals who are genotype- positive, phenotype-negative, echocardiography is recommended at periodic intervals depending on age (1-2 years in children and adolescents, 3-5 years in adults) and change in clinical status (Figure 1, Table 7).39–43",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00573,2024,15,2A,C-LD,"For patients with HCM, TEE can be useful if TTE is inconclusive in clinical decision-making regarding medical therapy, and in situations such as planning for myectomy, exclusion of subaortic membrane or MR secondary to structural abnormalities of the mitral valve apparatus, or in the assessment of the feasibility of alcohol septal ablation.26–29",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00574,2024,15,2A,B-NR,"For patients with HCM in whom the diagnosis of apical HCM, apical aneurysm, or atypical patterns of hypertrophy is inconclusive on TTE, the use of an intravenous ultrasound-enhancing agent is reason- able, particularly if other imaging modalities such as CMR are not readily available or are contraindi- cated.44,45",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00575,2024,15,2A,C-LD,"For asymptomatic patients with HCM who do not have a resting or provocable outflow tract peak gradient ≥50 mm Hg on standard TTE, exercise TTE is reasonable for the detection and quantification of dynamic LVOTO.15,19,20,22–25",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00576,2024,17,Class 1,B-NR,"For patients suspected of having HCM in whom echocardiography is inconclusive, CMR imaging is indicated for diagnostic clarification.1–7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00577,2024,17,Class 1,B-NR,"For patients with LVH in whom there is a suspicion of alternative diagnoses, including infiltrative or stor- age disease as well as athlete’s heart, CMR imaging is useful (Figure 1).1–7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00578,2024,17,Class 1,B-NR,"For patients with HCM who are not otherwise identified as high risk for SCD, or in whom a deci- sion to proceed with ICD remains uncertain after clinical assessment that includes personal or family history, echocardiography, and ambulatory electrocar- diographic monitoring, CMR imaging is beneficial to assess for maximum LV wall thickness, EF, LV apical aneurysm, and extent of myocardial replacement fibrosis with late gadolinium enhancement (LGE).1–15",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00579,2024,17,Class 1,B-NR,"For patients with obstructive HCM in whom the ana- tomic mechanism of obstruction is inconclusive on echocardiography, CMR imaging is indicated to inform the selection and planning of SRT.16–20",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00580,2024,17,2B,C-EO,"For patients with HCM, repeat contrast-enhanced CMR imaging on a periodic basis (every 3-5 years) for the purpose of SCD risk stratification may be considered to evaluate changes in LGE and other morphologic changes, including EF, development of apical aneurysm, or LV wall thickness (Figure 1,",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00581,2024,18,2B,C-LD,"In adult patients with suspected HCM, cardiac CT may be considered for diagnosis if the echocardiogram is not diagnostic and CMR imaging is unavailable.1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00582,2024,18,Class 1,B-NR,"In patients with HCM, a 12-lead ECG is recommended in the initial evaluation and as part of periodic follow-up (every 1-2 years) (Figure 1, Table 7).1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00583,2024,18,Class 1,B-NR,"In patients with HCM, 24- to 48-hour ambulatory electrocardiographic monitoring is recommended in the initial evaluation and as part of periodic follow-up (every 1-2 years) to identify patients who are at risk for SCD and to guide management of arrhythmias (Figure 1).4–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00584,2024,18,Class 1,B-NR,"In patients with HCM who develop palpitations or lightheadedness, extended (>24 hours) elec- trocardiographic monitoring or event recording is recommended for arrhythmia diagnosis and clinical correlation.6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00585,2024,18,Class 1,B-NR,"In first-degree relatives of patients with HCM, a 12-lead ECG is recommended as a component of the screening algorithm (Figure 1, Table 7).1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00586,2024,18,Class 1,B-NR,"In patients with HCM who are deemed to be at high risk for developing AF based on the presence of risk factors or as determined by a validated risk score, and who are eligible for anticoagulation, extended ambulatory monitoring is recommended to screen for AF as part of initial evaluation and annual follow-up (Figure 1).7–12",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00587,2024,18,2B,B-NR,"In adult patients with HCM without risk factors for AF and who are eligible for anticoagulation, extended ambulatory monitoring may be considered to assess for asymptomatic paroxysmal AF as part of initial evaluation and periodic follow-up (every 1-2 years).7–12",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00588,2024,19,Class 1,B-NR,"For patients with symptomatic HCM for whom there is uncertainty regarding the presence or severity of LVOTO on noninvasive imaging studies, invasive hemodynamic assessment with cardiac catheterization is recommended.1–4",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00589,2024,19,Class 1,B-NR,"In patients with HCM who have symptoms or evidence of myocardial ischemia, coronary angiography (CT or invasive) is recommended.5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00590,2024,19,Class 1,B-NR,"In patients with HCM who are at risk of coronary atherosclerosis, coronary angiography (CT or invasive) is recommended before surgical myectomy.6 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00591,2024,20,Class 1,B-NR,"For symptomatic patients with HCM who do not have resting or provocable outflow tract peak gradient ≥50 mm Hg on TTE, exercise TTE is recommended for the detection and quantification of dynamic LVOTO.1–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00592,2024,20,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV), cardiopul- monary exercise stress testing should be performed to quantify the degree of functional limitation and aid in selection of patients for heart transplantation or mechanical circulatory support.7–9",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00593,2024,20,Class 1,B-NR,"In pediatric patients with HCM, regardless of symptom status, exercise stress testing is recom- mended to determine functional capacity and to provide prognostic information.10",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00594,2024,20,2A,B-NR,"In adult patients with HCM, exercise stress testing is reasonable to determine functional capacity and to provide prognostic information as part of initial evaluation.9,11,12",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00595,2024,20,2A,C-LD,"For asymptomatic patients with HCM who do not have a resting or provocable outflow tract peak gradient ≥50 mm Hg on standard TTE, exercise TTE is reasonable for the detection and quantification of dynamic LVOTO.1,3–6,13,14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00596,2024,20,2B,C-LD,"In patients with obstructive HCM and ambiguous functional capacity, exercise stress testing may be reasonable to guide therapy (Figure 1).15,16",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00597,2024,20,2B,C-EO,"In patients with HCM for whom it is unclear if their functional capacity has declined, exercise stress testing may be considered every 2 to 3 years (Figure 1).",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00598,2024,21,Class 1,B-NR,"In patients with HCM, evaluation of familial inheritance, including a 3-generation family history, is recommended as part of the initial assessment.1–7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00599,2024,21,Class 1,B-NR,"In patients with HCM, genetic testing is beneficial to elucidate the genetic basis to facilitate the identification of family members at risk for developing HCM (cascade testing).8–11",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00600,2024,21,Class 1,B-NR,"In patients with an atypical clinical presentation of HCM or when another genetic condition is suspected to be the cause, a workup including genetic testing for HCM and other genetic causes of unexplained cardiac hypertrophy (“HCM phenocopies”) is recommended.12–14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00601,2024,21,Class 1,B-NR,"In patients with HCM, genetic counseling by an expert in the genetics of cardiovascular disease is recommended so that risks, benefits, test results, and their clinical significance can be reviewed and discussed with the patient in a shared decision-making process.1–3,15 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00602,2024,22,Class 1,B-NR,"When performing genetic testing in a proband with HCM, the initial tier of genes tested should include genes with strong evidence to be disease-causing in HCM.*8,11,16,17",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00603,2024,22,Class 1,B-NR,"In first-degree relatives of patients with HCM, both clinical screening (ECG and 2D echocardiogram) and cascade genetic testing (when a pathogenic/ likely pathogenic variant has been identified in the proband) should be offered.3,7,12,18–20",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00604,2024,22,Class 1,B-NR,"In families where a sudden unexplained death has occurred with a postmortem diagnosis of HCM, postmortem genetic testing is beneficial to facilitate cascade genetic testing and clinical screening in first-degree relatives.21,22",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00605,2024,22,Class 1,B-NR,"In patients with HCM who have undergone genetic testing, serial reevaluation of the clinical significance of the variant(s) identified is recommended to assess for variant reclassification, which may impact diagnosis and cascade genetic testing in family members23–25 (Figures 1 and 2).",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00606,2024,22,Class 1,B-NR,"In affected families with HCM, preconception and prenatal reproductive and genetic counseling should be offered.1–3,15",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00607,2024,22,2B,B-NR,"In adult patients with HCM, the usefulness of genetic testing in the assessment of risk of SCD is uncertain.10,25–27",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00608,2024,22,2B,B-NR,"In patients with HCM who have a variant of uncertain significance (VUS), the usefulness of clinical genetic testing of phenotype-negative relatives for the purpose of variant reclassification is uncertain.4,7,8,28",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00609,2024,22,Class 3: No Benefit,B-NR,"For patients with HCM who have undergone genetic testing and were found to have no pathogenic variants (ie, harbor only benign or likely benign variants), cascade genetic testing of the family is not useful.4,8–10",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00610,2024,22,Class 3: No Benefit,B-NR,"Ongoing clinical screening is not indicated in genotype-negative relatives in families with genotype-positive HCM, unless the disease- causing variant is downgraded to a VUS, likely benign, or benign variant during follow-up.23,29–32 *Strong evidence HCM genes include, at the time of this publication: MYH7,",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00611,2024,25,Class 1,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, serial clinical assess- ment, electrocardiography, and cardiac imaging are recommended at periodic intervals depending on age (every 1-2 years in children and adolescents and every 3-5 years in adults) and change in clinical status (Figures 1 and 2, Table 7).1–5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00612,2024,25,2A,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive sports of any intensity is reasonable.6,7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00613,2024,25,Class 3: No Benefit,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, ICD is not recommended for primary prevention.2–6,8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00614,2024,26,Class 1,B-NR,"In adult patients with HCM, a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1 to 2 years thereafter is recommended and should include evaluation of these risk factors (Figures 1 and 3, Table 8)1–25: a.   Personal history of cardiac arrest or sustained ventricular arrhythmias; b.   Personal history of syncope suspected by clinical history to be arrhythmic; c.   Family history in close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias; d.   Maximal LV wall thickness, EF, LV apical aneurysm; e.   NSVT episodes on continuous ambulatory electrocardiographic monitoring.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00615,2024,26,Class 1,B-NR,"For adult patients with HCM who are not otherwise identified as high risk for SCD, or in whom a decision to proceed with ICD placement remains uncertain after clinical assessment that includes personal/ family history, echocardiography, and ambulatory electrocardiographic monitoring, CMR imaging is beneficial to assess for maximum LV wall thickness, EF, LV apical aneurysm, and extent of myocardial fibrosis with LGE (Table 8).1,11,12,15–20",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00616,2024,26,2A,B-NR,"For patients who are ≥16 years of age with HCM, it is reasonable to obtain echocardiography-derived left atrial diameter and maximal LVOT gradient to aid in calculating an estimated 5-year sudden death risk that may be useful during shared decision-making for ICD placement (Table 8).2,22",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00617,2024,28,Class 1,B-NR,"For children and adolescents with HCM, a compre- hensive, systematic noninvasive SCD risk assess- ment at initial evaluation and every 1 to 2 years thereafter is recommended and should include evaluation of these risk factors (Figures 1 and 3, Table 8)1–8: a.   Personal history of cardiac arrest or sustained ventricular arrhythmias; b.   Personal history of syncope suspected by clinical history to be arrhythmic; c.   Family history in close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias; d.   Maximal LV wall thickness, EF, LV apical aneu- rysm; e.   NSVT episodes on continuous ambulatory elec- trocardiographic monitoring.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00618,2024,28,Class 1,C-LD,"For children and adolescents with HCM who have a borderline risk for SCD, or in whom a decision to proceed with ICD placement remains uncertain after clinical assessment that includes personal and family history, echocardiography, and ambulatory electro- cardiographic monitoring, CMR imaging is beneficial to assess for extent of myocardial fibrosis with LGE (Table 8).9–11",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00619,2024,28,2A,B-NR,"For patients <16 years of age with HCM, it is rea- sonable to calculate an estimated 5-year sudden death risk that includes echocardiographic param- eters (interventricular septal thickness in diastole, LV posterior wall thickness in end-diastole, left atrial diameter, maximal LVOT gradient) and genotype, which may be useful during shared decision-making for ICD placement (Table 8).1,12",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00620,2024,29,Class 1,C-EO,"In patients with HCM, application of individual clinical judgment is recommended when assessing the prognostic strength of conventional risk marker(s) within the clinical profile of the individual patient, as well as a thorough and balanced discussion of the evidence, benefits, and estimated risks to engage the fully informed patient’s active participation in ICD decision-making.1–5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00621,2024,29,Class 1,B-NR,"For patients with HCM and previous documented cardiac arrest or sustained VT, ICD placement is recommended (Figure 3, Table 8).2–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00622,2024,29,2A,B-NR,"For adult patients with HCM with ≥1 major risk factors for SCD, it is reasonable to offer an ICD. These major risk factors include (Figure 3, Table 8)2,3,7–21: a.   Sudden death judged definitively or likely attributable to HCM in ≥1 first-degree or close relatives who are ≤50 years of age; b.   Massive LVH ≥30 mm in any LV segment; c.   ≥1 recent episodes of syncope suspected by clinical history to be arrhythmic (ie, unlikely to be of neurocardiogenic [vasovagal] etiology, or related to LVOTO); d.    LV apical aneurysm with transmural scar or LGE; e.    LV systolic dysfunction (EF <50%).",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00623,2024,29,2A,B-NR,"For children with HCM who have ≥1 conventional risk factors, including unexplained syncope, massive LVH, NSVT, or family history of early HCM-related SCD, ICD placement is reasonable after considering the relatively high complication rates of long-term ICD placement in younger patients (Figure 3, Table 8).22–30",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00624,2024,29,2A,B-NR,"For patients with HCM with ≥1 major SCD risk factors, discussion of the estimated 5-year sudden death risk and mortality rates can be useful during the shared decision-making process for ICD placement (Figure 3, Table 8).3,19,29,30",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00625,2024,29,2B,B-NR,"In select adult patients with HCM and without major SCD risk factors after clinical assessment, or in whom the decision to proceed with ICD placement remains otherwise uncertain, ICD may be considered in patients with extensive LGE by contrast-enhanced CMR imaging or NSVT present on ambulatory moni- toring (Figure 3, Table 8).2,3,16,19,31–33",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00626,2024,29,2B,B-NR,"In pediatric patients with HCM, it can be useful to consider additional factors such as extensive LGE on contrast-enhanced CMR imaging and systolic dysfunction in risk stratification for ICD shared decision-making (Figure 3, Table 8).34,35",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00627,2024,31,Class 1,B-NR,"In patients with HCM who are receiving an ICD, either a single-chamber transvenous ICD or a subcutaneous ICD is recommended after a shared decision-making discussion that takes into consideration patient preferences, age, lifestyle, and potential need for pacing for bradycardia or VT termination.1–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00628,2024,31,Class 1,B-NR,"In patients with HCM who are receiving a transvenous ICD, single-coil ICD leads are recommended in preference to dual-coil leads, if defibrillation threshold is deemed adequate.7–9",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00629,2024,31,2A,B-NR,"In patients with HCM who are receiving an ICD, dual-chamber ICDs are reasonable for patients with a need for atrial or atrioventricular sequential pacing for bradycardia/conduction abnormalities, or as an attempt to relieve symptoms of obstructive HCM (most commonly in patients >65 years of age).10–13",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00630,2024,31,2A,C-LD,"In selected adult patients with nonobstructive HCM receiving an ICD who have NYHA class II to ambula- tory class IV HF, left bundle branch block (LBBB), and LVEF <50%, cardiac resynchronization therapy (CRT) for symptom reduction is reasonable.14–18",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00631,2024,31,2B,C-LD,"In patients with HCM in whom a decision has been made for ICD implantation and who have paroxysmal atrial tachycardias or AF, dual-chamber ICDs may be reasonable, but this decision must be balanced against higher complication rates of dual-chamber devices.19–24",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00632,2024,32,Class 1,B-NR,"In patients with obstructive HCM and symptoms* attributable to LVOTO, nonvasodilating beta blockers, titrated to effectiveness or maximally tolerated doses, are recommended.1–3 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00633,2024,33,Class 1,B-R,"For patients with obstructive HCM who have persistent symptoms* attributable to LVOTO despite beta blockers or nondihydropyridine calcium channel blockers, adding a myosin inhibitor (adult patients only), or disopyramide (in combination with an atrioventricular nodal blocking agent), or SRT performed at experienced centers,§ is recommended.7–14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00634,2024,33,Class 1,C-LD,"For patients with obstructive HCM and acute hypotension who do not respond to fluid administration, intravenous phenylephrine (or other vasoconstrictors without inotropic activity), alone or in combination with beta-blocking drugs, is recommended.15",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00635,2024,33,2B,C-EO,"For patients with obstructive HCM and persistent dyspnea with clinical evidence of volume overload and high left-sided filling pressures despite other HCM GDMT, cautious use of low-dose oral diuretics may be considered.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00636,2024,33,2B,C-EO,"For patients with obstructive HCM, discontinuation of vasodilators (eg, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers) or digoxin may be reasonable because these agents can worsen symptoms caused by dynamic outflow tract obstruction.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00637,2024,34,Class 1,B-NR,"In patients with obstructive HCM who remain symptomatic despite GDMT, SRT in eligible patients,* performed at experienced HCM centers,† is recom- mended for relieving LVOTO (Tables 4 and 5).1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00638,2024,34,Class 1,B-NR,"In symptomatic patients with obstructive HCM who have associated cardiac disease requiring surgical treatment (eg, associated anomalous papillary muscle, markedly elongated anterior mitral leaflet, intrinsic mitral valve disease, multivessel CAD, valvular aortic stenosis), surgical myectomy, performed at experienced HCM centers,† is recommended (Tables 4 and 5).4–7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00639,2024,34,Class 1,C-LD,"In adult patients with obstructive HCM who remain severely symptomatic, despite GDMT and in whom surgery is contraindicated or the risk is considered unacceptable because of serious comorbidities or advanced age, alcohol septal ablation in eligible patients,* performed at experienced HCM centers,† is recommended (Tables 4 and 5).8–10",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00640,2024,34,2B,B-NR,"In patients with obstructive HCM, earlier (NYHA class II) surgical myectomy performed at comprehensive HCM centers (Tables 4 and 5) may be reasonable in the presence of additional clinical factors, including3,11–22: a.   Severe and progressive pulmonary hypertension thought to be attributable to LVOTO or associated MR; b.   Left atrial enlargement with ≥1 episodes of symptomatic AF; c.   Poor functional capacity attributable to LVOTO as documented on treadmill exercise testing; d.   Children and young adults with very high resting",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00641,2024,34,2B,C-LD,"For symptomatic patients with obstructive HCM, SRT in eligible patients,* performed at experienced HCM centers† (Tables 4 and 5), may be considered as an alternative to escalation of medical therapy after shared decision-making including risks and benefits of all treatment options.1,10,23–25",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00642,2024,36,Class 1,C-LD,"In patients with nonobstructive HCM with preserved EF and symptoms of exertional angina or dyspnea, beta blockers or nondihydropyridine calcium channel blockers are recommended.1–5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00643,2024,36,2A,C-EO,"In patients with nonobstructive HCM with preserved EF, it is reasonable to add oral diuretics when exertional dyspnea persists despite the use of beta blockers or nondihydropyridine calcium channel blockers.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00644,2024,36,2B,C-LD,"In patients with nonobstructive HCM with preserved EF, the usefulness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the treatment of symptoms (angina and dyspnea) is not well established.6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00645,2024,36,2B,C-LD,"In highly selected patients with apical HCM with severe dyspnea or angina (NYHA functional class III or class IV) despite maximal medical therapy, and with preserved EF and small LV cavity size (LV end-diastolic volume <50 mL/m2 and LV stroke volume <30 mL/m2), apical myectomy by experi- enced surgeons at comprehensive centers may be considered to reduce symptoms.7",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00646,2024,36,2B,C-EO,"In asymptomatic patients with nonobstructive HCM, the benefit of beta blockers or calcium channel blockers is not well established.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00647,2024,36,2B,B-R,"For younger (eg, ≤45 years of age) patients with nonobstructive HCM due to a pathogenic or likely pathogenic cardiac sarcomere genetic variant, and a mild phenotype,* valsartan may be beneficial to slow adverse cardiac remodeling.8 *Mild phenotype indicates NYHA functional class I or II, maximal LV wall thick- ness 13 to 25 mm, no secondary prevention ICDs, no history of appropriate ICD shocks, and no AF.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00648,2024,37,Class 1,C-LD,"In patients with HCM who develop systolic dysfunction with an LVEF <50%, GDMT for HF with reduced EF is recommended.1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00649,2024,37,Class 1,C-LD,"In patients with HCM and systolic dysfunction, diagnostic testing to assess for concomitant causes of systolic dysfunction (eg, CAD) is recommended.4,5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00650,2024,37,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite GDMT), CPET should be performed to quantify the degree of functional limitation and aid in selection of patients for heart transplantation or mechanical circulatory support.6,7 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00651,2024,38,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite GDMT) or with life-threatening ventricular arrhythmias refractory to maximal GDMT, assessment for heart transplantation in accordance with current listing criteria is recommended.8–13",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00652,2024,38,Class 1,B-R,"In patients with HCM who develop persistent systolic dysfunction (LVEF <50%), cardiac myosin inhibitors should be discontinued.14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00653,2024,38,2A,C-EO,"For patients with HCM who develop systolic dysfunction (LVEF <50%), it is reasonable to discontinue previously indicated negative inotropic agents (specifically, verapamil, diltiazem, or disopyramide).",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00654,2024,38,2A,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite GDMT) who are candidates for heart transplantation, continuous-flow LVAD therapy is reasonable as a bridge to heart transplantation.15–19",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00655,2024,38,2A,C-LD,"In patients with HCM and persistent LVEF <50%, ICD placement can be beneficial.3,20",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00656,2024,38,2A,C-LD,"In patients with HCM and LVEF <50%, NYHA functional class II to class IV symptoms despite GDMT, and LBBB, CRT can be beneficial to improve symptoms.21–25",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00657,2024,41,Class 1,B-NR,"In patients with HCM and clinical AF, anticoagulation is recommended with direct-acting oral anticoagu- lants (DOACs) as first-line option and vitamin K antagonists as second-line option, independent of CHA2DS2-VASc score.1–5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00658,2024,41,Class 1,C-LD,"In patients with HCM and subclinical AF detected by internal or external cardiac device or monitor of >24 hours’ duration for a given episode, anticoagulation is recommended with DOACs as first-line option and vitamin K antagonists as second-line option, inde- pendent of CHA2DS2-VASc score.1,6–8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00659,2024,41,Class 1,C-LD,"In patients with AF in whom rate control strategy is planned, beta blockers, verapamil, or diltiazem are recommended, with the choice of agents according to patient preferences and comorbid conditions.9,10",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00660,2024,41,2A,C-LD,"In patients with HCM and subclinical AF detected by internal or external device or monitor, of >5 minutes’ duration but <24 hours’ duration for a given episode, anticoagulation with DOACs as first-line option and vitamin K antagonists as second-line option can be beneficial, taking into consideration duration of AF episodes, total AF burden, underlying risk factors, and bleeding risk.1,6–8,11",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00661,2024,41,2A,B-NR,"In patients with HCM and poorly tolerated AF, a rhythm-control strategy with cardioversion or antiar- rhythmic drugs can be beneficial with the choice of an agent according to AF symptom severity, patient preferences, and comorbid conditions.9,12–24",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00662,2024,41,2A,B-NR,"In patients with HCM and symptomatic AF, as part of an AF rhythm-control strategy, catheter ablation for AF can be effective when drug therapy is ineffective, contraindicated, or not the patient’s preference.12,25,26",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00663,2024,41,2A,B-NR,"In patients with HCM and AF who require surgical myectomy, concomitant surgical AF ablation proce- dure can be beneficial for AF rhythm control.13,27–29 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00664,2024,44,Class 1,B-NR,"In patients with HCM and recurrent, poorly toler- ated life-threatening ventricular tachyarrhythmias refractory to maximal antiarrhythmic drug therapy and ablation, heart transplantation assessment is indicated in accordance with current listing criteria.1,2",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00665,2024,44,Class 1,C-LD,"In children with HCM and recurrent ventricular arrhythmias despite beta-blocker use, antiarrhythmic drug therapy (eg, amiodarone,3,4 mexiletine,6 sotalol3,4) is recommended, with the choice of agent guided by age, underlying comorbidities, severity of disease, patient prefer- ences, and balance of efficacy and safety.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00666,2024,44,Class 1,C-LD,"In patients with HCM and pacing-capable ICDs, programming antitachycardia pacing is recommended to minimize risk of shocks.7,8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00667,2024,44,2A,C-LD,"In patients with HCM and recurrent symptomatic sustained monomorphic VT, or recurrent ICD shocks despite optimal device programming, and in whom antiarrhythmic drug therapy is either ineffective, not tolerated, or not preferred, catheter ablation can be useful for reducing arrhythmia burden.9–11 *Indicates the LOE for amiodarone. †Indicates the LOE for dofetilide, mexi- letine, or sotalol.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00668,2024,45,Class 1,B-R,"For patients with HCM, mild- to moderate-intensity* recreational† exercise is beneficial to improve cardiorespiratory fitness, physical functioning, and quality of life, and for overall health in keeping with physical activity guidelines for the general population.1–3",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00669,2024,45,Class 1,C-EO,"For athletes with HCM, a comprehensive evaluation and shared decision-making about sports participation with an expert professional is recommended.4",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00670,2024,45,2A,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive sports of any intensity is reasonable.5,6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00671,2024,45,2A,B-NR,"For patients with HCM, participation in vigorous* recreational activities is reasonable after an annual comprehensive evaluation and shared decision-making with an expert professional who balances potential benefits and risks, with this process being repeated annually.4,5,7,8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00672,2024,45,2B,B-NR,"For patients with HCM who are capable of a high level of physical performance, participation in competitive sports† may be considered after review by an expert provider with experience managing athletes with HCM who conducts an annual comprehensive evaluation and shared decision- making that balances potential benefits and risks.5,9–14",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00673,2024,45,Class 3: No Benefit,B-NR,"For most patients with HCM, universal restriction from vigorous physical activity or competitive sports is not indicated.5,11–13",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00674,2024,47,2A,C-EO,"For patients with HCM, it is reasonable to follow Federal Motor Carrier Safety Administration cardiovascular disease guidelines that permit driving commercial motor vehicles, if they do not have an ICD or any major risk factors for SCD and are using a GDMT plan.1",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00675,2024,47,2A,C-EO,"For pilot aircrew with a diagnosis of HCM, it is reasonable to follow Federal Aviation Administration guidelines that permit consideration of multicrew flying duties, provided they are asymptomatic, are deemed low risk for SCD, and can complete a maxi- mal treadmill stress test at 85% peak heart rate.2",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00676,2024,47,2B,C-EO,"It is reasonable for patients with HCM to consider occupations that require manual labor, heavy lifting, or a high level of physical performance after a comprehensive clinical evaluation, risk stratification for SCD, and implementation of GDMT in the con- text of shared decision-making.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00677,2024,47,Class 1,B-NR,"For pregnant women with HCM and AF or other indications for anticoagulation, low-molecular-weight heparin or vitamin K antagonists (at maximum therapeutic dose of <5 mg daily) are recommended for stroke prevention.1,2 Recommendations for Occupation in Patients With HCM (Continued) COR LOE Recommendations Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00678,2024,48,Class 1,C-LD,"In pregnant women with HCM, selected beta blockers should be administered for symptoms related to outflow tract obstruction or arrhythmias, with monitoring of fetal growth.3,4",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00679,2024,48,Class 1,C-LD,"In most pregnant women with HCM, vaginal delivery is recommended as the first-choice delivery option.3,5",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00680,2024,48,Class 1,B-NR,"In affected families with HCM, preconceptional and prenatal reproductive and genetic counseling should be offered.3–6",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00681,2024,48,Class 1,C-EO,"For pregnant women with HCM, care should be coordinated between their cardiologist and an obstetrician. For patients with HCM who are deemed high risk, consultation is advised with an expert in maternal-fetal medicine.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00682,2024,48,2A,C-LD,"For women with clinically stable HCM who wish to become pregnant, it is reasonable to advise that pregnancy is generally safe as part of a shared discussion regarding potential maternal and fetal risks, and initiation of GDMT.7–10",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00683,2024,48,2A,C-LD,"In pregnant women with HCM, cardioversion for new or recurrent AF, particularly if symptomatic, is reasonable.6,11",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00684,2024,48,2A,C-LD,"In pregnant women with HCM, general or epidural anesthesia is reasonable, with precautions to avoid hypotension.8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00685,2024,48,2A,C-EO,"In pregnant women with HCM, it is reasonable to perform serial echocardiography, particularly during the second or third trimester when hemodynamic load is highest, or if clinical symptoms develop.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00686,2024,48,2B,C-EO,"In pregnant women with HCM, fetal echocardiography may be considered for diagnosis of fetal HCM in the context of prenatal counseling.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00687,2024,49,Class 1,C-EO,"In patients with HCM, adherence to the ACC/AHA primary prevention guideline is recommended to reduce risk of cardiovascular events.1",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00688,2024,49,Class 1,B-NR,"In patients with HCM who are overweight or obese, counseling and comprehensive lifestyle interventions are recommended for achieving and maintaining weight loss1 and possibly lowering the risk of developing LVOTO, HF, and AF.2–4",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00689,2024,49,Class 1,C-LD,"In patients with HCM and hypertension, lifestyle modifications and medical therapy for hypertension are recommended,1 with preference for beta blockers and nondihydropyridine calcium channel blockers in patients with obstructive HCM.",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00690,2024,49,Class 1,C-LD,"In patients with HCM, assessment for symptoms of sleep-disordered breathing is recommended, and, if present, referral to a sleep medicine specialist for evaluation and treatment is recommended.5–8",ommen-et-al-2024-aha-acc-amssm-hrs-paces-scmr-guideline-for-the-management-of-hypertrophic-cardiomyopathy-a-report-of.pdf
id_00791,2023,5,2A,B-R,"For term and late preterm newborn infants ≥34 weeks’ gestation who do not require resuscitation, delayed cord clamping (DCC) (≥30 seconds) can be beneficial when compared to early cord clamping (<30 seconds).",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00792,2023,5,2B,B-R,"For nonvigorous term and late preterm infants (35–42 weeks’ gestation), intact cord milking may be reasonable when compared to early cord clamping (<30 seconds).",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00793,2023,5,Class 3: No Benefit,C-LD,"For term and late preterm newborn infants ≥34 weeks’ gestation who do not require ­resuscitation, intact cord milking is not known to be beneficial when compared to DCC (≥30 seconds). Recommendation-Specific Supportive Text",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00794,2023,5,2A,B-R,"For preterm newborn infants <34 weeks’ gestation who do not require resuscitation, delaying cord clamping (≥30 seconds) can be beneficial when compared to early cord clamping (<30 seconds).",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00795,2023,5,2B,B-R,"For preterm newborn infants between 28 and 34 weeks’ gestation who do not require resuscitation and in whom DCC cannot be performed, intact cord milking may be reasonable.",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00796,2023,5,Class 3: No Benefit,B-R,"For preterm newborn infants <28 weeks’ gestation, intact cord milking is not recommended. Recommendation-Specific Supportive Text",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00797,2023,7,2A,B-NR,"It can be beneficial to use a T-piece resuscitator instead of a self-inflating bag, with or without a positive end-expiratory pressure valve, for administering positive-pressure ventilation to newborn infants, particularly for preterm infants. Recommendation-Specific Supportive Text",yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00798,2023,7,2B,C-LD,It may be reasonable to use a supraglottic airway as the primary interface to administer PPV instead of a face mask for newborn infants delivered at ≥34 0/7 weeks’ gestation. Recommendation-Specific Supportive Text,yamada-et-al-2023-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-neonatal.pdf
id_00799,2023,8,Class 1,B-NR,"In patients with aSAH, use of clinical scales (eg, the Hunt and Hess [HH] grade or World Federation of Neurosurgical Societies [WFNS] grade) is recom- mended to determine initial clinical sever- ity and predict outcome.28,29",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00800,2023,8,2A,B-NR,"In patients with high-grade aSAH, aneu- rysm treatment is reasonable, after careful discussion of likely prognosis with family members, to optimize patient outcome.28,30",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00801,2023,8,2A,B-NR,"In patients with aSAH and advanced age, aneurysm treatment is reasonable, after care- ful discussion of prognosis with family mem- bers, to improve survival and outcome.31–33",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00802,2023,8,Class 3: No Benefit,B-NR,"In patients with aSAH who do not improve after correction of modifiable conditions and are deemed unsalvageable because of evi- dence of irreversible neurological injury, treat- ment of the aneurysm is not beneficial.34,35",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00803,2023,9,Class 1,B-NR,"In patients with acute onset of severe headache, prompt diagnostic workup and evaluation are recommended to diagnose/ exclude aSAH and minimize morbidity and mortality.43–46",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00804,2023,9,Class 1,B-NR,"In patients with acute onset of severe head- ache who present >6 hours from symptom onset or who have a new neurological defi- cit, a noncontrast head CT and, if negative for aSAH, lumbar puncture (LP) should be performed to diagnose/exclude aSAH.47,48",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00805,2023,9,2A,B-NR,"In patients with acute onset of severe head- ache who present <6 hours from symptom onset and without new neurological deficit, a noncontrast head CT performed on a high-quality scanner and interpreted by a board-certified neuroradiologist is reason- able to diagnose/exclude aSAH.49–53",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00806,2023,9,2B,B-NR,"In patients with acute onset of severe headache without a new neurological deficit, application of the Ottawa SAH Rule may be reasonable to identify those at high risk for aSAH.45,54,55 Evaluation for cause of aSAH",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00807,2023,9,Class 1,B-NR,"In patients with spontaneous SAH with high level of concern for aneurysmal source and a negative or inconclusive CT angiography (CTA), digital subtraction angiography (DSA) is indicated to diag- nose/exclude cerebral aneurysm(s).56–59",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00808,2023,9,2A,B-NR,"In patients with SAH from confirmed cerebral aneurysm(s), DSA can be useful to determine the optimal strategy for aneurysm intervention.60,61 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00809,2023,11,Class 1,B-NR,"For patients with aSAH, timely transfer from hospitals with low case volume to higher-volume centers with multidisci- plinary neurointensive care services, com- prehensive stroke center capabilities, and experienced cerebrovascular surgeons/ neuroendovascular interventionalists is recommended to improve outcomes.67–77",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00810,2023,11,Class 1,B-NR,"For patients with aSAH, care should be provided in a dedicated neurocritical care unit by a multidisciplinary team.78–80 Table 3.  Ottawa SAH Rule For alert patients >15 y of age with new severe nontraumatic headache reaching maximum intensity within 1 h. Patients require additional investigation for SAH if they meet any of the following criteria:",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00811,2023,13,Class 1,C-EO,"In patients with aSAH and unsecured aneurysm, frequent blood pressure (BP) monitoring and BP control with short- acting medication(s) is recommended to avoid severe hypotension, hypertension, and BP variability.",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00812,2023,13,Class 1,C-EO,"In patients with aSAH who are receiving anticoagulants, emergency anticoagula- tion reversal with appropriate reversal agents should be performed to prevent rebleeding.",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00813,2023,13,Class 3: No Benefit,A,"In patients with aSAH, routine use of anti- fibrinolytic therapy is not useful to improve functional outcome.85–87",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00814,2023,14,Class 1,B-NR,"For patients with aSAH, surgical or endovascular treatment of the ruptured aneurysm should be performed as early as feasible after presentation, preferably within 24 hours of onset, to improve outcome.40,98–104 Treatment goal",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00815,2023,14,Class 1,B-NR,"For patients with aSAH, complete oblit- eration of the ruptured aneurysm is indi- cated whenever feasible to reduce the risk of rebleeding and retreatment.105–107",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00816,2023,14,2A,C-EO,"For patients with aSAH in whom com- plete obliteration of the ruptured aneu- rysm by either clipping or primary coiling treatment is not feasible in the acute phase, partial obliteration to secure the rupture site and retreatment in a delayed fashion in those with functional recovery are reasonable to prevent rebleeding. Modality of treatment: general",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00817,2023,14,Class 1,B-R,"For patients with aSAH from ruptured aneurysms of the posterior circulation that are amenable to coiling, coiling is indicated in preference to clipping to improve outcome.108–110",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00818,2023,14,Class 1,B-R,"For patients with aSAH deemed salvageable and with depressed level of consciousness due to large intrapa- renchymal hematoma, emergency clot evacuation should be performed to reduce mortality.111,112",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00819,2023,14,Class 1,C-EO,"For patients with aSAH, the ruptured aneu- rysm should be evaluated by specialist(s) with endovascular and surgical expertise to determine the relative risks and benefits of surgical or endovascular treatment accord- ing to patient and aneurysm characteristics.",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00820,2023,14,2B,B-R,"For patients >70 years of age with aSAH, the superiority of coiling or clipping to improve outcome is not well established.113,114",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00821,2023,14,2B,C-LD,"For patients <40 years of age with aSAH, clipping of the ruptured aneurysm might be considered the preferred mode of treatment to improve durability of the treatment and outcome.113,115 Modality of treatment: for aneurysms equally suitable for clipping and coiling",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00822,2023,14,Class 1,A,"For patients with good-grade aSAH from ruptured aneurysms of the anterior circulation equally suitable for both primary coiling and clipping, primary coiling is recommended in preference to clipping to improve 1-year functional outcome.110,116",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00823,2023,14,2A,B-R,"For patients with good-grade aSAH from ruptured aneurysms of the anterior circulation equally suitable for both primary coiling and clipping, both treat- ment options are reasonable to achieve favorable long-term outcome.108,109,117 Endovascular adjuncts",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00824,2023,14,2A,C-LD,"For patients with aSAH from ruptured wide-neck aneurysms not amenable to surgical clipping or primary coiling, endo- vascular treatment with stent-assisted coiling or flow diverters is reasonable to reduce the risk of rebleed.118,119",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00825,2023,14,2A,C-LD,"For patients with aSAH from ruptured fusiform/blister aneurysms, the use of flow diverters is reasonable to reduce mortality.120,121",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00826,2023,14,Class 3: Harm,B-NR,"For patients with aSAH from ruptured saccular aneurysms amenable to either primary coiling or clipping, stents or flow diverters should not be used to avoid higher risk of complications.122,123 Recommendations for Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms (Continued) COR LOE Recommendations Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00827,2023,17,2A,B-R,"In patients with aSAH, the intraoperative use of mannitol or hypertonic saline can be effective in reducing ICP and cerebral edema.135,136",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00828,2023,17,2A,B-NR,"In patients with aSAH, anesthetic goals should include minimizing postprocedural pain, nausea, and vomiting.137–140",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00829,2023,17,2A,B-NR,"In patients with aSAH, prevention of intraoperative hyperglycemia and hypogly- cemia during aneurysm surgery is reason- able to improve outcomes.141–147",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00830,2023,17,2A,C-LD,"In patients with aSAH and an unsecured ruptured aneurysm, frequent intraopera- tive BP monitoring and BP control are reasonable to prevent ischemia and rerupture.148–153",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00831,2023,17,2B,B-NR,"In patients with aSAH, intraoperative neuromonitoring may be reasonable to guide anesthetic and operative management.154–159",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00832,2023,17,2B,C-LD,"In patients with aSAH and an uncontrolled intraoperative aneurysmal rupture, adenosine may be considered to facilitate aneurysm clip placement by inducing cardiac standstill and temporary profound pause.160,161",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00833,2023,17,Class 3: No Benefit,B-R,"In patients with good-grade aSAH, the routine use of induced mild hypothermia during aneurysm surgery is not benefi- cial.147,162–168",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00834,2023,19,Class 1,B-NR,"In patients with aSAH who require mechanical ventilation for >24 hours, implementation of a standardized ICU care bundle is recommended to reduce the duration of mechanical ventilation and hospital-acquired pneumonia.177,178 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00835,2023,20,2B,B-NR,"In patients with aSAH who develop severe acute respiratory distress syndrome (ARDS) and life-threatening hypoxemia, rescue maneuvers such as prone position- ing and alveolar recruitment maneuvers with ICP monitoring may be reasonable to improve oxygenation.179–182 Intravascular volume and electrolyte management",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00836,2023,20,2A,B-R,"In patients with aSAH, close monitor- ing and goal-directed treatment of volume status are reasonable to maintain euvolemia.183–185",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00837,2023,20,2A,B-R,"In patients with aSAH, use of mineralocor- ticoids is reasonable to treat natriuresis and hyponatremia.186,187",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00838,2023,20,Class 3: Harm,B-R,"In patients with aSAH, induction of hyper- volemia is potentially harmful because of the association with excess morbid- ity.188–190 Other",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00839,2023,20,Class 1,C-LD,"In patients with aSAH whose ruptured aneurysm has been secured, pharmaco- logical or mechanical venous thromboem- bolism (VTE) prophylaxis is recommended to reduce the risk for VTE.191–193",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00840,2023,20,2A,B-NR,"In patients with aSAH, effective glycemic control, strict hyperglycemia management, and avoidance of hypoglycemia are rea- sonable to improve outcome.141,142,194,195",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00841,2023,20,2B,C-LD,"In patients with aSAH with fever refractory to antipyretic medications, the effective- ness of therapeutic temperature manage- ment (TTM) during the acute phase of aSAH is uncertain.196–198",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00842,2023,22,Class 1,B-R,"In patients with aSAH, use of evidence- based protocols and order sets is recom- mended to improve standardization of care.243–250",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00843,2023,22,Class 1,B-NR,"In patients with aSAH, frequent neuro- logical assessment with a neurological assessment tool such as the GCS or National Institutes of Health Stroke Scale (NIHSS) is recommended to monitor DCI and other secondary complica- tions.246,251–254",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00844,2023,22,Class 1,B-NR,"In patients with aSAH, frequent vital sign and neurological monitoring is recommended for detection of neu- rological change and prevention of secondary cerebral insults and poor outcomes.244,246,250,255–257 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00845,2023,23,Class 1,B-NR,"In patients with aSAH, a validated dysphagia screening protocol should be implemented before initiation of oral intake to reduce the incidence of pneumo- nia.244,246,258–261",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00846,2023,23,2A,C-LD,"In patients with aSAH, specialized nursing stroke competencies and certification can be effective to positively affect outcomes, timeliness of care, and adherence to stroke protocols.248,262–264",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00847,2023,23,2A,C-LD,"In patients with aSAH and a secured aneurysm, an early, evidence-based mobility algorithm is reasonable to improve level of function at discharge and global functional outcome at 12 months.249,265–268",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00848,2023,25,2A,B-NR,"In patients with aSAH with suspected vasospasm or limited neurological exami- nation, CTA or CT perfusion (CTP) can be useful to detect vasospasm and predict DCI.270–275",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00849,2023,25,2A,B-NR,"In patients with aSAH, transcranial Doppler (TCD) ultrasound monitoring is reasonable to detect vasospasm and predict DCI.253,276–280",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00850,2023,25,2A,B-NR,"In patients with high-grade aSAH, con- tinuous EEG (cEEG) monitoring can be useful to predict DCI.276,280–292",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00851,2023,25,2B,B-NR,"In patients with high-grade aSAH, invasive monitoring of brain tissue oxygenation, lactate/pyruvate ratio, and glutamate may be considered to predict DCI.293–305",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00852,2023,26,Class 1,A,"In patients with aSAH, early initiation of enteral nimodipine is beneficial in preventing DCI and improving functional outcomes.316–319",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00853,2023,26,2A,B-NR,"In patients with aSAH, maintaining euvolemia can be beneficial in preventing DCI and improving functional outcomes.320,321",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00854,2023,26,2B,B-NR,"In patients with aSAH and symptomatic vasospasm, elevating systolic BP values may be reasonable to reduce the progres- sion and severity of DCI.322–325",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00855,2023,26,2B,B-NR,"In patients with aSAH and severe vaso- spasm, use of intra-arterial vasodilator therapy may be reasonable to reverse cerebral vasospasm and reduce the pro- gression and severity of DCI.326–335",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00856,2023,26,2B,B-NR,"In patients with aSAH and severe vasospasm, cerebral angioplasty may be reasonable to reverse cerebral vasospasm and reduce the progression and severity of DCI.336–344",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00857,2023,26,Class 3: No Benefit,A,"In patients with aSAH, routine use of statin therapy to improve outcomes is not recommended.345,346",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00858,2023,26,Class 3: No Benefit,A,"In patients with aSAH, routine use of intra- venous magnesium to improve neurologi- cal outcomes is not recommended.347,348",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00859,2023,26,Class 3: Harm,B-R,"For patients with aSAH at risk of DCI, prophylactic hemodynamic augmenta- tion should not be performed to reduce iatrogenic patient harm.189,211,349,350 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00860,2023,30,Class 1,B-NR,"In patients with aSAH and acute symptomatic hydrocephalus, urgent CSF diversion (EVD and/or lumbar drainage) should be performed to improve neurological outcome.236,384–387",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00861,2023,30,Class 1,B-NR,"In patients with aSAH and hydrocephalus who require an EVD, implementation and adherence to an EVD bundled protocol that addresses insertion, management, education, and monitoring are recom- mended to reduce complication and infection rates.388–396",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00862,2023,30,Class 1,B-NR,"In patients with aSAH and associated chronic symptomatic hydrocephalus, per- manent CSF diversion is recommended to improve neurological outcome.397–400",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00863,2023,30,Class 3: No Benefit,C-LD,"In patients with aSAH, routine fenestration of the lamina terminalis is not indicated for reducing the rate of shunt dependency.401",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00864,2023,31,2A,B-NR,"In patients with aSAH and either fluctuat- ing neurological examination, depressed mental state, ruptured MCA aneurysm, high-grade SAH, ICH, hydrocephalus, or cortical infarction, cEEG monitoring is reasonable to detect seizures.291,405,406",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00865,2023,31,2B,B-NR,"In patients with aSAH and high-seizure- risk features (ie, ruptured MCA aneurysm, high-grade SAH, ICH, hydrocephalus, and cortical infarction), use of prophylactic antiseizure medication(s) may be reason- able to prevent seizures.407–413",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00866,2023,31,Class 3: No Benefit,B-R,"In patients with aSAH without high- seizure-risk features (ie, ruptured MCA aneurysm, high-grade SAH, ICH, hydrocephalus, and cortical infarction), prophylactic treatment with antiseizure medication is not beneficial.406–408,410,414 Table 4.  Elements for an EVD Infection Control Bundled Protocol388–395 Insertion and technique Management Monitoring and education EVD setup Type of dressing Health care professional training (insertion and management) Aseptic technique Frequency of dressing change Staff education and competency Skin preparation Flushing of EVD system Monitoring number of EVD catheter days EVD insertion location (ICU, OR, other) CSF sampling frequency Monitoring rates of infection EVD insertion health care professional (neuro- surgery, ICU, resident, APP) CSF sampling technique Uniform definition for ventriculostomy-associ- ated infection Catheter selection (size, antibiotic impregnated) EVD manipulation Use of EVD order panel Procedure timeout Catheter or system exchange Nursing handoff EVD clamping and weaning Mobilization safety",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00867,2023,32,Class 3: Harm,B-NR,"In patients with aSAH, phenytoin for seizure prevention and/or antiseizure prophylaxis is associated with excess morbidity and mortality.407–411,413,415,416 Patients who present with seizures",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00868,2023,32,2A,B-NR,"In patients with aSAH who present with seizures, treatment with antiseizure medications for ≤7 days is reasonable to reduce seizure-related complications in the perioperative period.411,417,418",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00869,2023,32,Class 3: No Benefit,B-NR,"In patients with aSAH without prior epilepsy who present with seizures, treat- ment with antiseizure medications beyond 7 days is not effective for reducing future SAH-associated seizure risk.408,410,411",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00870,2023,33,Class 1,B-NR,"In patients with aSAH, use of validated grading scores or patient-reported outcome measures prior to hospital discharge is recommended to screen for physical, cognitive, behavioral, and QOL deficits.39,425–431",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00871,2023,33,Class 1,B-NR,"In patients with aSAH, use of validated screening tools in the postacute period is recommended to identify post-aSAH depression and anxiety.429,432 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00872,2023,34,Class 1,B-NR,"In patients with aSAH and depression, psychotherapy and pharmacotherapy are recommended to reduce symptoms of depression.429,432–435",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00873,2023,34,Class 1,B-NR,"In patients with aSAH, use of a validated screening tool in the postacute period is useful to identify cognitive dysfunc- tion.430,436–439",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00874,2023,34,Class 1,B-NR,"In patients with aSAH, an early multidisci- plinary team–based approach to treatment and rehabilitation is recommended to reduce LOS and identify discharge needs.231,440",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00875,2023,34,2A,B-NR,"In patients with aSAH and no other medi- cal or neurological contraindications, early rehabilitation after the ruptured aneurysm is secured is reasonable to improve func- tional outcome and reduce LOS.267,441–445",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00876,2023,34,2B,C-LD,"In patients with aSAH in a coma, early use of neurostimulants may be reasonable to promote consciousness recovery.446–448",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00877,2023,34,Class 3: No Benefit,A,"In patients with aSAH without depres- sion, fluoxetine therapy is not effective to enhance poststroke functional sta- tus.449–452",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00878,2023,36,Class 1,B-NR,"In adult patients with aSAH, screening and intervention for depression, anxiety, and sexual dysfunction are recommended to improve long-term outcomes.461–465",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00879,2023,36,2A,B-NR,"In patients with aSAH, it is reasonable to choose the MoCA over the MMSE to identify cognitive impairment.438,466,467",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00880,2023,36,2B,B-NR,"In patients with aSAH, counseling patients and caregivers on the high long-term risk of cognitive dysfunction can be beneficial to identify long-term needs.468 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00881,2023,37,Class 1,B-NR,"In patients with aSAH who have under- gone aneurysm repair, perioperative cerebrovascular imaging is recommended to identify remnants or recurrence of the aneurysm that may require further treat- ment.113,116,131",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00882,2023,37,Class 1,B-NR,"In patients with aSAH who have undergone aneurysm repair, follow-up cerebrovascular imaging is recommended to identify recurrence or regrowth of the treated aneurysm, changes in another known aneurysm, or development of de novo aneurysm(s) that may require further treatment to reduce the risk of aSAH.116,131 Downloaded from http://ahajournals.org by on June 19, 2025",hoh-et-al-2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage-a-guideline-from-the.pdf
id_00993,2021,10,Class 1,B-R,"In patients suspected of having a stroke or TIA, an ECG is recommended to screen for atrial fibrillation (AF) and atrial flutter and to assess for other concomitant cardiac condi- tions.40,41",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00994,2021,10,Class 1,B-NR,"In patients with ischemic stroke or TIA, a diag- nostic evaluation is recommended for gaining insights into the etiology of and planning opti- mal strategies for preventing recurrent stroke, with testing completed or underway within 48 hours of onset of stroke symptoms.42–45",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00995,2021,10,Class 1,B-NR,"In patients with symptomatic anterior circulation cerebral infarction or TIA who are candidates for revascularization, noninva- sive cervical carotid imaging with carotid ultrasonography, CT angiography (CTA), or magnetic resonance angiography (MRA) is recommended to screen for stenosis.46–50",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00996,2021,10,Class 1,B-NR,"In patients suspected of having a stroke or TIA, CT or MRI of the brain is recommended to confirm the diagnosis of symptomatic ischemic cerebral vascular disease.51–53",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00997,2021,10,Class 1,B-NR,"In patients with a confirmed diagnosis of symptomatic ischemic cerebrovascular disease, blood tests, including complete blood count, prothrombin time, partial throm- boplastin time, glucose, HbA1c, creatinine, and fasting or nonfasting lipid profile, are recommended to gain insight into risk factors for stroke and to inform therapeutic goals.54,55",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00998,2021,10,2A,B-R,"In patients with cryptogenic stroke, echocar- diography with or without contrast is reason- able to evaluate for possible cardiac sources of or transcardiac pathways for cerebral embolism.56,57",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_00999,2021,10,2A,B-R,"In patients with cryptogenic stroke who do not have a contraindication to anticoagula- tion, long-term rhythm monitoring with mobile cardiac outpatient telemetry, implantable loop recorder, or other approach is reasonable to detect intermittent AF.58–60",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01000,2021,10,2A,B-NR,"In patients suspected of having ischemic stroke, if CT or MRI does not demonstrate symptomatic cerebral infarct, follow-up CT or MRI of the brain is reasonable to confirm diagnosis.61–65",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01001,2021,10,2A,B-NR,"In patients suspected of having had a TIA, if the initial head imaging (CT or MRI) does not demonstrate a symptomatic cerebral infarct, follow-up MRI is reasonable to predict risk of early stroke and to support the diagnosis.66–69",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01002,2021,10,2A,C-LD,"In patients with cryptogenic stroke, tests for inherited or acquired hypercoagulable state, bloodstream or cerebral spinal fluid infections, infections that can cause central nervous system (CNS) vasculitis (eg, HIV and syphilis), drug use (eg, cocaine and amphetamines), and markers of systemic inflammation and genetic tests for inherited diseases associated with stroke are reason- able to perform as clinically indicated to identify contributors to or relevant risk factors for stroke.70–72",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01003,2021,10,2A,C-LD,"In patients with ischemic stroke or TIA, noninvasive imaging of the intracranial large arteries and imaging of the extracranial vertebrobasilar arterial system with MRA or CTA can be effective to identify atheroscle- rotic disease, dissection, moyamoya, or other etiologically relevant vasculopathies.73–75",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01004,2021,10,2B,B-NR,"In patients with ischemic stroke and a treatment plan that includes anticoagulant therapy, CT or MRI of the brain before therapy is started may be considered to assess for hemorrhagic transformation and final size of infarction.76",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01005,2021,10,2B,C-LD,"In patients with ESUS, transesophageal echocardiography (TEE), cardiac CT, or cardiac MRI might be reasonable to identify possible cardioaortic sources of or transcardiac pathways for cerebral embolism.57,77–79",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01006,2021,10,2B,C-LD,"In patients with ischemic stroke or TIA in whom patent foramen ovale (PFO) closure would be contemplated, TCD (transcranial Doppler) with embolus detection might be reasonable to screen for right-to-left shunt.57,80",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01007,2021,14,2A,B-R,"In patients with stroke and TIA, it is reason- able to counsel individuals to follow a Mediterranean-type diet, typically with empha- sis on monounsaturated fat, plant-based foods, and fish consumption, with either high extra virgin olive oil or nut supplementation, in preference to a low-fat diet, to reduce risk of recurrent stroke.95,96",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01008,2021,14,2A,B-R,"In patients with stroke or TIA and hypertension who are not currently restricting their dietary sodium intake, it is reasonable to recommend that individuals reduce their sodium intake by at least 1g/d sodium (2.5 g/d salt) to reduce the risk of cardiovascular disease (CVD) events (including stroke).97,98",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01009,2021,16,Class 1,C-LD,"In patients with stroke or TIA who are capable of physical activity, engaging in at least moderate- intensity aerobic activity for a minimum of 10 min- utes 4 times a week or vigorous-intensity aerobic activity for a minimum of 20 minutes twice a week is indicated to lower the risk of recurrent stroke and the composite cardiovascular end point of recurrent stroke, MI, or vascular death.110",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01010,2021,16,2A,B-R,"In patients with stroke or TIA who are able and willing to increase physical activity, engaging in an exercise class that includes counseling to change physical activity behavior can be beneficial for reducing cardiometabolic risk fac- tors and increasing leisure time physical activity participation.111–114",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01011,2021,16,2A,C-EO,"In patients with deficits after stroke that impair their ability to exercise, supervision of an exercise program by a health care professional such as a physical therapist or cardiac reha- bilitation professional, in addition to routine rehabilitation, can be beneficial for secondary stroke prevention.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01012,2021,16,2B,B-NR,"In individuals with stroke or TIA who sit for long periods of uninterrupted time during the day, it may be reasonable to recommend breaking up sedentary time with intervals as short as 3 minutes of standing or light exer- cise every 30 minutes for their cardiovascular health.115",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01013,2021,17,Class 1,A,"In patients with stroke or TIA who smoke tobacco, counseling with or without drug therapy (nicotine replacement, bupropion, or varenicline) is recommended to assist in quit- ting smoking.139–142",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01014,2021,17,Class 1,B-NR,"Patients with stroke or TIA who continue to smoke tobacco should be advised to stop smoking (and, if unable, to reduce their daily smoking) to lower the risk of recurrent stroke.143–146",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01015,2021,17,Class 1,B-NR,In patients with stroke or TIA. avoidance of environmental (passive) tobacco smoke is recommended to reduce risk of recurrent stroke.147–150,kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01016,2021,18,Class 1,B-NR,"Patients with ischemic stroke or TIA who drink >2 alcoholic drinks a day for men or >1 alco- holic drink a day for women should be coun- seled to eliminate or reduce their consumption of alcohol to reduce stroke risk.141,161–163",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01017,2021,18,Class 1,C-EO,"In patients with stroke or TIA who use stimulants (eg, amphetamines, amphetamine derivatives, cocaine, or khat) and in patients with infective endocarditis (IE) in the context of intravenous drug use, it is recommended that health care providers inform them that this behavior is a health risk and counsel them to stop.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01018,2021,18,Class 1,C-EO,"In patients with stroke or TIA who have a substance use disorder (drugs or alcohol), specialized services are recommended to help manage this dependency.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01019,2021,20,Class 1,A,"In patients with hypertension who experience a stroke or TIA, treatment with a thiazide diuretic, angiotensin-converting enzyme inhibitor, or angiotensin II receptor blockers is useful for lowering BP and reducing recurrent stroke risk.185–189",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01020,2021,20,Class 1,B-R,"In patients with hypertension who experience a stroke or TIA, an office BP goal of <130/80 mm Hg is recommended for most patients to reduce the risk of recurrent stroke and vascu- lar events.185,190–194",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01021,2021,20,Class 1,B-NR,"In patients with hypertension who experience a stroke or TIA, individualized drug regimens that take into account patient comorbidities, agent pharmacological class, and patient preference are recommended to maximize drug efficacy.188,189,195,196",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01022,2021,20,2A,B-R,"In patients with no history of hypertension who experience a stroke or TIA and have an aver- age office BP of ≥130/80 mm Hg, antihyper- tensive medication treatment can be beneficial to reduce the risk of recurrent stroke, ICH, and other vascular events.190,191,193,197",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01023,2021,21,Class 1,A,"In patients with ischemic stroke with no known coronary heart disease, no major cardiac sources of embolism, and LDL cholesterol (LDL-C) >100 mg/dL, atorvastatin 80 mg daily is indicated to reduce risk of stroke recurrence.208,209",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01024,2021,21,Class 1,A,"In patients with ischemic stroke or TIA and ath- erosclerotic disease (intracranial, carotid, aortic, or coronary), lipid-lowering therapy with a statin and also ezetimibe, if needed, to a goal LDL-C of <70 mg/dL is recommended to reduce the risk of major cardiovascular events.210",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01025,2021,21,2A,B-NR,"In patients with ischemic stroke who are very high risk (defined as stroke plus another major ASCVD or stroke plus multiple high-risk conditions), are taking maximally tolerated statin and ezetimibe therapy and still have an LDL-C >70 mg/dL, it is reasonable to treat with PCSK9 (proprotein convertase subtili- sin/kexin type 9) inhibitor therapy to prevent ASCVD events.211–213 Monitoring",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01026,2021,21,Class 1,A,"In patients with stroke or TIA and hyperlip- idemia, patients’ adherence to changes in lifestyle and the effects of LDL-C–lowering medication should be assessed by measure- ment of fasting lipids and appropriate safety indicators 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter, based on need to assess adher- ence or safety.214,215",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01027,2021,23,2A,B-R,"In patients with ischemic stroke or TIA, with fasting triglycerides 135 to 499 mg/dL and LDL-C of 41 to 100 mg/dL, on moderate- or high-intensity statin therapy, with HbA1c <10%, and with no history of pancreatitis, AF, or severe heart failure, treatment with icosa- pent ethyl (IPE) 2 g twice a day is reasonable to reduce risk of recurrent stroke.219,220",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01028,2021,23,2A,B-NR,"In patients with severe hypertriglyceridemia (ie, fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), it is reasonable to identify and address causes of hypertriglyceridemia and, if triglycerides are persistently elevated or increasing, to further reduce triglycerides in order to lower the risk of ASCVD events by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consump- tion of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy.221–223",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01029,2021,24,Class 1,A,"In patients with an ischemic stroke or TIA who also have diabetes, the goal for glycemic control should be individualized based on the risk for adverse events, patient characteris- tics and preferences, and, for most patients, especially those <65 years of age and without life-limiting comorbid illness, achieving a goal of HbA1c ≤7% is recommended to reduce risk for microvascular complications.229,230",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01030,2021,24,Class 1,B-R,"In patients with an ischemic stroke or TIA who also have diabetes, treatment of diabetes should include glucose-lowering agents with proven cardiovascular benefit to reduce the risk for future major adverse cardiovas- cular events (ie, stroke, MI, cardiovascular death).231–236",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01031,2021,24,Class 1,C-EO,"In patients with an ischemic stroke or TIA who also have diabetes, multidimensional care (ie, lifestyle counseling, medical nutritional therapy, diabetes self-management education, support, and medication) is indicated to achieve glyce- mic goals and to improve stroke risk factors.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01032,2021,24,2A,B-R,"In patients with prediabetes and ischemic stroke or TIA, lifestyle optimization (ie, healthy diet, regular physical activity, and smoking cessation) can be beneficial for the preven- tion of progression to diabetes.237,238",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01033,2021,24,2A,C-EO,"In patients with TIA or ischemic stroke, it is reasonable to screen for prediabetes/dia- betes using HbA1c which, among available methods (HbA1c, fasting plasma glucose, oral glucose tolerance), has the advantage of convenience because it does not require fast- ing and is measured in a single blood sample.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01034,2021,24,2B,B-R,"In patients with an ischemic stroke or TIA who also have diabetes, the usefulness of achieving intensive glucose control (ie, HbA1c ≤7%) beyond the acute phase of the ischemic event for prevention of recurrent stroke is unknown.239–244",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01035,2021,24,2B,B-R,"In patients with prediabetes and ischemic stroke or TIA, particularly those with a body mass index (BMI) ≥35 kg/mP2, ≥35 kg/m2 those <60 years of age, or women with a history of gestational diabetes, metformin may be beneficial to control blood sugar and to prevent progression to diabetes.245–247",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01036,2021,24,2B,B-R,"In patients ≤6 months after TIA or ischemic stroke with insulin resistance, HbA1c <7.0%, and without heart failure or bladder cancer, treatment with pioglitazone may be consid- ered to prevent recurrent stroke.248",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01037,2021,27,Class 1,B-R,"In patients with ischemic stroke or TIA and who are overweight or obese, weight loss is recommended to improve the ASCVD risk factor profile.259,276–279",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01038,2021,27,Class 1,B-R,"In patients with ischemic stroke or TIA who are obese, referral to an intensive, multicompo- nent, behavioral lifestyle-modification program is recommended to achieve sustained weight loss.238,258,280,281",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01039,2021,27,Class 1,C-EO,"In patients with ischemic stroke or ASCVD, calculation of BMI is recommended at the time of their event and annually thereafter, to screen for and to classify obesity.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01040,2021,28,2A,B-R,"In patients with an ischemic stroke or TIA and OSA, treatment with positive airway pressure (eg, continuous positive airway pressure [CPAP]) can be beneficial for improved sleep apnea, BP, sleepiness, and other apnea- related outcomes.302–314",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01041,2021,28,2B,B-R,"In patients with an ischemic stroke or TIA, an evaluation for OSA may be considered for diagnosing sleep apnea.302,303,315,316",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01042,2021,29,Class 1,B-R,"In patients with a stroke or TIA caused by 50% to 99% stenosis of a major intracranial artery, aspirin 325 mg/d is recommended in prefer- ence to warfarin to reduce the risk of recurrent ischemic stroke and vascular death.335,336",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01043,2021,29,2A,B-NR,"In patients with recent stroke or TIA (within 30 days) attributable to severe stenosis (70%–99%) of a major intracranial artery, the addition of clopidogrel 75 mg/d to aspirin for up to 90 days is reasonable to further reduce recurrent stroke risk.336–339",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01044,2021,29,2B,B-NR,"In patients with recent (within 24 hours) minor stroke or high-risk TIA and concomitant ipsilat- eral >30% stenosis of a major intracranial artery, the addition of ticagrelor 90 mg twice a day to aspirin for up to 30 days might be considered to further reduce recurrent stroke risk.340",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01045,2021,29,2B,C-LD,"In patients with stroke or TIA attributable to 50% to 99% stenosis of a major intracranial artery, the addition of cilostazol 200 mg/day to aspirin or clopidogrel might be considered to reduce recurrent stroke risk.341–344 Downloaded from http://ahajournals.org by on June 19, 2025",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01046,2021,30,2B,C-EO,"In patients with stroke or TIA attributable to 50% to 99% stenosis of a major intracranial artery, the usefulness of clopidogrel alone, the combination of aspirin and dipyridam- ole, ticagrelor alone, or cilostazol alone for secondary stroke prevention is not well established. Risk Factor Management",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01047,2021,30,Class 1,B-NR,"In patients with a stroke or TIA attributable to 50% to 99% stenosis of a major intracranial artery, maintenance of SBP below 140 mm Hg, high-intensity statin therapy, and at least moderate physical activity are recom- mended to prevent recurrent stroke and vascular events.110,210,337,345–349 Angioplasty and Stenting",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01048,2021,30,2B,C-LD,"In patients with severe stenosis (70%-99%) of a major intracranial artery and actively pro- gressing symptoms or recurrent TIA or stroke after institution of aspirin and clopidogrel therapy, achievement of SBP <140 mm Hg, and high- intensity statin therapy (so-called medical failures), the usefulness of angio- plasty alone or stent placement to prevent ischemic stroke in the territory of the stenotic artery is unknown.350–352",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01049,2021,30,Class 3: Harm,A,"In patients with stroke or TIA attributable to severe stenosis (70%–99%) of a major intracranial artery, angioplasty and stenting should not be performed as an initial treat- ment, even for patients who were taking an antithrombotic agent at the time of the stroke or TIA.353–359",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01050,2021,30,Class 3: Harm,B-NR,"In patients with a stroke or TIA attributable to moderate stenosis (50%–69%) of a major intracranial artery, angioplasty or stenting is associated with excess morbidity and mortal- ity compared with medical management alone.336,354,355,360 Other Procedures",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01051,2021,30,Class 3: No Benefit,B-R,"In patients with stroke or TIA attributable to 50% to 99% stenosis or occlusion of a major intracranial artery, extracranial-intracra- nial bypass surgery is not recommended.361",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01052,2021,32,Class 1,A,"In patients with a TIA or nondisabling ischemic stroke within the past 6 months and ipsilateral severe (70%–99%) carotid artery stenosis, carotid endarterectomy (CEA) is recommended to reduce the risk of future stroke, provided that perioperative morbidity and mortality risk is estimated to be <6%.369",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01053,2021,32,Class 1,A,"In patients with ischemic stroke or TIA and symptomatic extracranial carotid stenosis who are scheduled for carotid artery stent- ing (CAS) or CEA, procedures should be performed by operators with established periprocedural stroke and mortality rates of <6% to reduce the risk of surgical adverse events.370",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01054,2021,32,Class 1,A,"In patients with carotid artery stenosis and a TIA or stroke, intensive medical therapy, with antiplatelet therapy, lipid-lowering therapy, and treatment of hypertension, is recom- mended to reduce stroke risk.210",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01055,2021,32,Class 1,B-R,"In patients with recent TIA or ischemic stroke and ipsilateral moderate (50%–69%) carotid steno- sis as documented by catheter-based imaging or noninvasive imaging, CEA is recommended to reduce the risk of future stroke, depending on patient-specific factors such as age, sex, and comorbidities, if the perioperative morbidity and mortality risk is estimated to be <6%.369",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01056,2021,32,2A,B-R,"In patients ≥70 years of age with stroke or TIA in whom carotid revascularization is being considered, it is reasonable to select CEA over CAS to reduce the periprocedural stroke rate.371",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01057,2021,32,2A,B-R,"In patients in whom revascularization is planned within 1 week of the index stroke, it is reasonable to choose CEA over CAS to reduce the periprocedural stroke rate.372 Downloaded from http://ahajournals.org by on June 19, 2025",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01058,2021,33,2A,C-LD,"In patients with TIA or nondisabling stroke, when revascularization is indicated, it is reasonable to perform the procedure within 2 weeks of the index event rather than delay surgery to increase the likelihood of stroke- free outcome.373",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01059,2021,33,2A,C-LD,In patients with symptomatic severe stenosis (≥70%) in whom anatomic or medical condi- tions are present that increase the risk for surgery (such as radiation-induced stenosis or restenosis after CEA) it is reasonable to choose CAS to reduce the periprocedural complication rate.374,kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01060,2021,33,2B,A,"In symptomatic patients at average or low risk of complications associated with endovascular intervention, when the ICA stenosis is ≥70% by noninvasive imaging or >50% by catheter-based imaging and the anticipated rate of periprocedural stroke or death is <6%, CAS may be considered as an alternative to CEA for stroke preven- tion, particularly in patients with significant cardiovascular comorbidities predispos- ing to cardiovascular complications with endarterectomy.375",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01061,2021,33,2B,B-NR,"In patients with a recent stroke or TIA (past 6 months), the usefulness of transcarotid artery revascularization (TCAR) for prevention of recurrent stroke and TIA is uncertain.376",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01062,2021,33,Class 3: No Benefit,A,"In patients with recent TIA or ischemic stroke and when the degree of stenosis is <50%, revascularization with CEA or CAS to reduce the risk of future stroke is not recom- mended.369",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01063,2021,33,Class 3: No Benefit,A,"In patients with a recent (within 120 days) TIA or ischemic stroke ipsilateral to atherosclerotic stenosis or occlusion of the middle cerebral or carotid artery, extracranial- intracranial bypass surgery is not recom- mended.377",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01064,2021,34,Class 1,A,"In patients with recently symptomatic extra- cranial vertebral artery stenosis, intensive medical therapy (antiplatelet therapy, lipid lowering, BP control) is recommended to reduce stroke risk.378",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01065,2021,34,2B,B-R,"In patients with ischemic stroke or TIA and extracranial vertebral artery stenosis who are having symptoms despite optimal medical treatment, the usefulness of stenting is not well established.378",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01066,2021,34,2B,C-EO,"In patients with ischemic stroke or TIA and extracranial vertebral artery stenosis who are having symptoms despite optimal medical treatment, the usefulness of open surgical procedures, including vertebral endarterec- tomy and vertebral artery transposition, is not well established.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01067,2021,35,Class 1,B-R,"In patients with a stroke or TIA and evidence of an aortic arch atheroma, intensive lipid management to an LDL cholesterol target <70 mg/dL is recommended to prevent recur- rent stroke.210",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01068,2021,35,Class 1,C-LD,"In patients with a stroke or TIA and evidence of an aortic arch atheroma, antiplatelet therapy is recommended to prevent recurrent stroke.380–385",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01069,2021,36,2A,C-LD,"In patients with moyamoya disease and a history of ischemic stroke or TIA, surgi- cal revascularization with direct or indirect extracranial-intracranial bypass can be beneficial for the prevention of ischemic stroke or TIA.391–397",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01070,2021,36,2B,C-LD,"In patients with moyamoya disease and a his- tory of ischemic stroke or TIA, the use of anti- platelet therapy, typically aspirin monotherapy, for the prevention of ischemic stroke or TIA may be reasonable.393,394,397–401",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01071,2021,37,2B,B-R,"In patients with ischemic stroke related to small vessel disease, the usefulness of cilostazol for secondary stroke prevention is uncertain.382,384,408–410",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01072,2021,38,Class 1,A,"In patients with nonvalvular AF and stroke or TIA, oral anticoagulation (eg, apixaban, dabi- gatran, edoxaban, rivaroxaban, or warfarin) is recommended to reduce the risk of recurrent stroke.419–426",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01073,2021,38,Class 1,B-R,"In patients with AF and stroke or TIA, oral anticoagulation is indicated to reduce the risk of recurrent stroke regardless of whether the AF pattern is paroxysmal, persistent, or permanent.427",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01074,2021,38,Class 1,B-R,"In patients with stroke or TIA and AF who do not have moderate to severe mitral stenosis or a mechanical heart valve, apixaban, dabi- gatran, edoxaban, or rivaroxaban is recom- mended in preference to warfarin to reduce the risk of recurrent stroke.419–426",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01075,2021,38,Class 1,B-NR,"In patients with atrial flutter and stroke or TIA, anticoagulant therapy similar to that in AF is indicated to reduce the risk of recurrent stroke.427",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01076,2021,38,Class 1,C-EO,"In patients with AF and stroke or TIA, without moderate to severe mitral stenosis or a mechanical heart valve, who are unable to maintain a therapeutic INR level with warfa- rin, use of dabigatran, rivaroxaban, apixaban, or edoxaban is recommended to reduce the risk of recurrent stroke.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01077,2021,38,2A,B-NR,"In patients with stroke at high risk of hemor- rhagic conversion in the setting of AF, it is reasonable to delay initiation of oral antico- agulation beyond 14 days to reduce the risk of ICH.428–431",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01078,2021,38,2A,C-EO,"In patients with TIA in the setting of nonvalvu- lar AF, it is reasonable to initiate anticoagu- lation immediately after the index event to reduce the risk of recurrent stroke.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01079,2021,38,2B,B-R,"In patients with stroke or TIA in the setting of nonvalvular AF who have contraindications for lifelong anticoagulation but can tolerate at least 45 days, it may be reasonable to consider percutaneous closure of the left atrial appendage with the Watchman device to reduce the chance of recurrent stroke and bleeding.432–436",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01080,2021,38,2B,B-NR,"In patients with stroke at low risk for hemor- rhagic conversion in the setting of AF, it may be reasonable to initiate anticoagulation 2 to 14 days after the index event to reduce the risk of recurrent stroke.428,429,437",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01081,2021,38,2B,B-NR,"In patients with AF and stroke or TIA who have end-stage renal disease or are on dialysis, it may be reasonable to use warfarin or apixaban (dose adjusted if indicated) for anticoagulation to reduce the chance of recurrent stroke.438",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01082,2021,41,Class 1,B-R,"In patients with ischemic stroke or TIA and valvular AF (moderate to severe mitral steno- sis or any mechanical heart valve), warfarin is recommended to reduce the risk of recurrent stroke or TIA.452–457",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01083,2021,41,Class 1,C-LD,"In patients with a mechanical mitral valve and a history of ischemic stroke or TIA before valve replacement, aspirin (75–100 mg/d) is recom- mended in addition to warfarin with an INR target of 3.0 (range, 2.5–3.5) to reduce the risk of thrombosis and recurrent stroke or TIA.458,459",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01084,2021,41,Class 1,C-EO,"In patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease (eg, mitral annular calcification or mitral valve prolapse) who do not have AF or another indication for anticoagulation, anti- platelet therapy is recommended to reduce the risk of recurrent stroke or TIA.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01085,2021,41,Class 1,C-EO,"In patients with a bioprosthetic aortic or mitral valve, a history of ischemic stroke or TIA before valve replacement, and no other indication for anticoagulation therapy beyond 3 to 6 months from the valve placement, long-term therapy with aspirin is recommended in preference to long-term anticoagulation to reduce the risk of recur- rent stroke or TIA.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01086,2021,41,2A,B-NR,"In patients with ischemic stroke or TIA and IE who present with recurrent emboli and persistent vegetations despite appropri- ate antibiotic therapy, early surgery (during initial hospitalization before completion of a full therapeutic course of antibiotics) is reasonable to reduce the risk of recurrent embolism if there is no evidence of intracra- nial hemorrhage or extensive neurological damage.460–465",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01087,2021,41,2A,C-EO,"In patients with history of ischemic stroke or TIA and a mechanical aortic valve, anti- coagulation with higher-intensity warfarin to achieve an INR of 3.0 (range, 2.5–3.5) or the addition of aspirin (75–100 mg/d) can be beneficial to reduce the risk of thromboem- bolic events.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01088,2021,41,2B,B-NR,"In patients with ischemic stroke or TIA and native left-sided valve endocarditis who exhibit mobile vegetations >10 mm in length, early surgery (during initial hospitalization before completion of a full therapeutic course of anti- biotics) may be considered to reduce the risk of recurrent embolism if there is no evidence of intracranial hemorrhage or extensive neurologi- cal damage.460–465",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01089,2021,41,2B,B-NR,"In patients with ischemic stroke or TIA and IE, early valve surgery (during initial hospital- ization before completion of a full therapeutic course of antibiotics) may be considered in patients with an indication for surgery who have no evidence of intracranial hemorrhage or extensive neurological damage.466,467",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01090,2021,41,2B,B-NR,"In patients with IE and major ischemic stroke, delaying valve surgery for at least 4 weeks may be considered for patients with IE and major ischemic stroke or intracranial hemorrhage if the patient is hemodynamically stable.460,468",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01091,2021,41,Class 3: Harm,B-R,"In patients with ischemic stroke or TIA and mechanical heart valves, treatment with dabigatran causes harm.*457 *A similar recommendation in another guideline is worded slightly differently; however, the process used to reach consensus was the same in both cases.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01092,2021,44,Class 1,B-NR,"In patients with stroke or TIA and LV thrombus, anticoagulation with therapeutic warfarin for at least 3 months is recommended to reduce the risk of recurrent stroke.504–508",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01093,2021,44,2A,C-EO,"In patients with stroke or TIA in the setting of acute MI, it is reasonable to perform advanced cardiac imaging (eg, contrasted echocar- diogram or cardiac MRI) to assess for the presence of LV thrombus.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01094,2021,44,2B,C-LD,"In patients with stroke or TIA and new LV thrombus (<3 months), the safety of antico- agulation with a direct oral anticoagulant to reduce risk of recurrent stroke is uncertain.509",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01095,2021,44,2B,C-EO,"In patients with stroke or TIA in the setting of acute anterior MI with reduced ejection fraction (EF; <50%) but no evidence of LV thrombus, empirical anticoagulation for at least",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01096,2021,46,Class 1,C-EO,"In patients with ischemic stroke or TIA and left atrial or left atrial appendage thrombus in the setting of ischemic, nonischemic, or restrictive cardiomyopathy and LV dysfunction, antico- agulant therapy with warfarin is recommended for at least 3 months to reduce the risk of recurrent stroke or TIA.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01097,2021,46,2A,C-LD,"In patients with ischemic stroke or TIA in the setting of a mechanical assist device, treatment with warfarin and aspirin can be beneficial to reduce the risk of recurrent stroke or TIA.516–523",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01098,2021,46,2A,C-EO,"In patients with ischemic stroke or TIA in the setting of LV noncompaction, treatment with warfarin can be beneficial to reduce the risk of recurrent stroke or TIA.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01099,2021,46,2B,B-R,"In patients with ischemic stroke or TIA in sinus rhythm with ischemic or nonischemic cardio- myopathy and reduced EF without evidence of left atrial or LV thrombus, the effectiveness of anticoagulation compared with antiplatelet therapy is uncertain, and the choice should be individualized.524–528",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01100,2021,46,Class 3: Harm,B-R,"In patients with stroke or TIA and LV assist devices (LVADs), treatment with dabigatran instead of warfarin for the primary or second- ary prevention of ischemic stroke or TIA causes harm.529",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01101,2021,48,Class 1,C-EO,"In patients with a nonlacunar ischemic stroke of undetermined cause and a PFO, recom- mendations for PFO closure versus medical management should be made jointly by the patient, a cardiologist, and a neurologist, taking into account the probability of a causal role for the PFO.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01102,2021,48,2A,B-R,"In patients 18 to 60 years of age with a nonla- cunar ischemic stroke of undetermined cause despite a thorough evaluation and a PFO with high-risk anatomic features,* it is reasonable to choose closure with a transcatheter device and long-term antiplatelet therapy over anti- platelet therapy alone for preventing recurrent stroke.552–557",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01103,2021,48,2B,C-LD,"In patients 18 to 60 years of age with a nonla- cunar ischemic stroke of undetermined cause despite a thorough evaluation and a PFO without high-risk anatomic features,* the ben- efit of closure with a transcatheter device and long-term antiplatelet therapy over antiplatelet therapy alone for preventing recurrent stroke is not well established,552–557",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01104,2021,48,2B,C-LD,"In patients 18 to 60 years of age with a nonlacunar ischemic stroke of undetermined cause despite a thorough evaluation and a PFO, the comparative benefit of closure with a transcatheter device versus warfarin is unknown.554 *In the evidence, each study defines high-risk anatomic features in a different way.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01105,2021,50,Class 1,C-LD,"In patients with ischemic stroke or TIA and Fontan palliation, anticoagulation with warfarin is recommended to reduce the risk of recur- rent stroke or TIA.572,573",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01106,2021,50,2A,C-EO,"In patients with cyanotic congenital heart disease and other complex lesions, ischemic stroke or TIA of presumed cardioembolic origin, therapy with warfarin is reasonable to reduce the risk of recurrent stroke or TIA. Downloaded from http://ahajournals.org by on June 19, 2025",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01107,2021,52,2A,C-LD,"In patients with stroke or TIA found to have a left-sided cardiac tumor, resection of the tumor can be beneficial to reduce the risk of recurrent stroke.586–588",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01108,2021,52,Class 1,C-EO,"In patients with ischemic stroke or TIA after an extracranial carotid or vertebral arterial dis- section, treatment with antithrombotic therapy for at least 3 months is indicated to prevent recurrent stroke or TIA.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01109,2021,52,2A,B-R,"In patients with ischemic stroke or TIA who are <3 months after an extracranial carotid or vertebral arterial dissection, it is reasonable to use either aspirin or warfarin to prevent recur- rent stroke or TIA.593,594",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01110,2021,52,2B,C-LD,"In patients with stroke or TIA and extracranial carotid or vertebral artery dissection who have recurrent events despite antithrombotic therapy, endovascular therapy may be consid- ered to prevent recurrent stroke or TIA.595,596",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01111,2021,53,2A,C-LD,"In patients with ischemic stroke or TIA of unknown source despite thorough diagnostic evaluation and no other thrombotic history who are found to have prothrombin 20210A mutation, activated protein C resistance, elevated factor VIII levels, or deficiencies of protein C, protein S, or antithrombin III, anti- platelet therapy is reasonable to reduce the risk of recurrent stroke or TIA.600–606",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01112,2021,54,Class 1,B-NR,"In patients with ischemic stroke or TIA who have an isolated antiphospholipid antibody but do not fulfill the criteria for antiphospho- lipid syndrome, antiplatelet therapy alone is recommended to reduce the risk of recurrent stroke.612",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01113,2021,54,2A,B-R,"In patients with ischemic stroke or TIA with confirmed antiphospholipid syndrome treated with warfarin, it is reasonable to choose a target INR between 2 and 3 over a target INR >3 to effectively balance the risk of excessive bleeding against the risk of thrombosis.613–615",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01114,2021,54,2A,C-LD,"In patients with ischemic stroke or TIA who meet the criteria for the antiphospholipid syndrome, it is reasonable to anticoagulate with warfarin to reduce the risk of recurrent stroke or TIA.615",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01115,2021,54,Class 3: Harm,B-R,"In patients with ischemic stroke or TIA, antiphospholipid syndrome with history of thrombosis and triple-positive antiphospholipid antibodies (ie, lupus anticoagulant, anticardio- lipin, and anti– β2 glycoprotein-I), rivaroxaban is not recommended because it is associated with excess thrombotic events compared with warfarin.616–618",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01116,2021,55,Class 3: No Benefit,B-R,"In patients with ischemic stroke or TIA with hyperhomocysteinemia, supplementation with folate, vitamin B6, and vitamin B12 is not effective for preventing subsequent stroke.625,626",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01117,2021,56,2A,B-NR,"In patients with ischemic stroke or TIA in the setting of AF and cancer, it is reasonable to consider anticoagulation with DOACs in preference to warfarin for stroke preven- tion.647–650",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01118,2021,57,Class 1,B-NR,"In patients with sickle cell disease (SCD) and prior ischemic stroke or TIA, chronic blood transfusion(s) to reduce hemoglobin S to <30% of total hemoglobin is recommended for the prevention of recurrent ischemic stroke.655–658",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01119,2021,57,2A,B-R,"In patients with SCD with prior ischemic stroke or TIA for whom transfusion therapy is not available or practical, treatment with hydroxyurea is reasonable for the prevention of recurrent ischemic stroke.659–665",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01120,2021,58,Class 1,B-NR,"In patients with ischemic stroke or TIA and symptoms attributed to giant cell arteri- tis, immediate initiation of oral high-dose glucocorticoids is recommended to reduce recurrent stroke risk.672–681",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01121,2021,58,2A,B-NR,"In patients with ischemic stroke or TIA and diagnosis of giant cell arteritis, methotrexate or tocilizumab therapy adjunctive to steroids is reasonable to lower the risk of recurrent stroke.682–690",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01122,2021,58,2A,B-NR,"In patients with ischemic stroke or TIA and diagnosis of primary CNS angiitis, induc- tion therapy with glucocorticoids and/or immunosuppressants followed by long-term maintenance therapy with steroid-sparing immunosuppressants is reasonable to lower the risk of stroke recurrence.691–696",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01123,2021,58,Class 3: Harm,B-R,"In patients with ischemic stroke or TIA and confirmed diagnosis of giant cell arteritis, infliximab is associated with recurrent ocular symptoms and markers of disease activity and should not be administered.697–704",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01124,2021,59,Class 1,B-NR,"In patients with ischemic stroke or TIA and infectious vasculitis such as varicella zoster virus (VZV) cerebral vasculitis, neurosyphilis, or bacterial meningitis, treating the underlying infectious etiology is indicated to reduce the risk of stroke.710–716",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01125,2021,59,2A,C-LD,"In patients with ischemic stroke or TIA in the context of HIV vasculopathy, daily aspirin plus HIV viral control with combined antiretroviral therapy is reasonable to reduce the risk of recurrent stroke.717–723",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01126,2021,60,Class 1,C-LD,"In patients with ischemic stroke or TIA and cystathionine β-synthase deficiency, pyridoxine (in responsive patients) and a low-methionine, cysteine-enhanced diet supplemented with pyridoxine, vitamin B12, and folate are recommended to reduce plasma homocysteine to population normal levels and thereby reduce the risk of recurrent ischemic stroke.739,740",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01127,2021,60,2B,B-NR,"In patients with ischemic stroke or TIA and Anderson-Fabry disease, agalsidase alfa or agalsidase beta is of uncertain value in preventing recurrent stroke or TIA.741",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01128,2021,61,Class 1,B-NR,"In patients with carotid web in the distribu- tion of ischemic stroke and TIA, without other attributable causes of stroke, antiplatelet therapy is recommended to prevent recurrent ischemic stroke or TIA.748,749",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01129,2021,61,2B,C-LD,"In patients with carotid web in the distribution of ischemic stroke refractory to medical man- agement, with no other attributable cause of stroke despite comprehensive workup, carotid stenting or CEA may be considered to prevent recurrent ischemic stroke.748–750",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01130,2021,62,Class 1,C-LD,"In patients with fibromuscular dysplasia (FMD) and a history of ischemic stroke or TIA without other attributable causes, antiplatelet therapy, BP control, and lifestyle modification are recommended for the prevention of future ischemic events.752,753",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01131,2021,62,2A,C-EO,"In patients with a history of ischemic stroke or TIA attributable to dissection, with FMD, and no evidence of intraluminal thrombus, it is reasonable to administer antiplatelet therapy for the prevention of future ischemic events.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01132,2021,62,2B,C-LD,"In patients with cervical carotid artery FMD and recurrent ischemic stroke without other attributable causes despite optimal medical management, carotid angioplasty with or without stenting may be reasonable to prevent ischemic stroke.754",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01133,2021,62,2A,C-LD,"In patients with vertebrobasilar dolichoectasia and a history of ischemic stroke or TIA without other attributable causes, the use of antiplatelet or anticoagulant therapy is reasonable for the prevention of recurrent ischemic events.760–764",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01134,2021,63,Class 3: No Benefit,B-R,"In patients with ESUS, treatment with direct oral anticoagulants is not recommended to reduce risk of secondary stroke.779,780",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01135,2021,63,Class 3: No Benefit,B-NR,"In patients with ESUS, treatment with ticagre- lor is not recommended to reduce the risk of secondary stroke.781",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01136,2021,64,Class 1,A,"In patients with noncardioembolic ischemic stroke or TIA, antiplatelet therapy is indicated in preference to oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events while minimizing the risk of bleeding.789,790",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01137,2021,64,Class 1,A,"For patients with noncardioembolic ischemic stroke or TIA, aspirin 50 to 325 mg daily, clopidogrel 75 mg, or the combination of aspi- rin 25 mg and extended-release dipyridamole 200 mg twice daily is indicated for secondary prevention of ischemic stroke.*791–794",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01138,2021,64,2B,B-NR,"For patients already taking aspirin at the time of noncardioembolic ischemic stroke or TIA, the effectiveness of increasing the dose of aspirin or changing to another antiplatelet medication is not well established.410,798–800",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01139,2021,67,Class 1,C-EO,"In patients with ischemic stroke or TIA, voluntary hospital-based or outpatient-focused quality monitoring and improvement programs are recommended to improve short-term and long-term adherence to nationally accepted, evidence-based guidelines for secondary stroke prevention.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01140,2021,67,2A,B-R,"In patients with ischemic stroke or TIA, a mul- tidisciplinary outpatient team-based approach (ie, care provision with active medication adjust- ment from advanced practice providers, nurses, or pharmacists) can be effective to control BP, lipids, and other vascular risk factors.810–817",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01141,2021,67,2A,B-R,"In patients presenting to their primary care provider as the first contact after TIA or minor stroke, it is reasonable to use a decision sup- port tool that improves diagnostic accuracy, stratifies patients in risk categories to support appropriate triage, and prompts the initiation of medications and counseling for lifestyle modification for secondary stroke prevention to reduce the 90-day risk of recurrent stroke or TIA.818",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01142,2021,69,Class 1,B-R,"In patients with ischemic stroke or TIA, behavior change interventions targeting stroke literacy, lifestyle factors, and medica- tion adherence are recommended to reduce cardiovascular events.131,134,840",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01143,2021,69,2A,B-R,"In patients with ischemic stroke or TIA, teaching self-management skills or using behavior change theory (eg, motivational interviewing) can be ben- eficial in improving medication adherence.840–843",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01144,2021,69,2A,B-R,"In patients with stroke or TIA, combined exercise-based and behavior change interven- tions are probably indicated in preference to behavior interventions alone, exercise interven- tions alone, or usual care to reduce physiologi- cal stroke risk factors such as SBP.111–113,829",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01145,2021,69,2A,B-R,"In patients with TIA or nondisabling stroke, engagement in targeted secondary prevention programs (eg, cardiac rehabilitation programs or exercise and lifestyle counseling programs) can be beneficial to reduce risk factors and recurrent ischemic events.133,134",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01146,2021,69,2A,B-NR,"For patients with disabling stroke who are discharged from acute services, engaging in targeted secondary prevention programs (eg, an adapted cardiac rehabilitation program or struc- tured exercise including aerobic activity and healthy lifestyle counseling) can be beneficial to reduce vascular risk factors and mortality.111,844",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01147,2021,69,Class 3: No Benefit,B-R,"In patients with stroke or TIA, provision of health information or advice about stroke prevention is essential; however, information or advice alone, in the absence of a behavioral intervention, is not an effective means to change modifiable, lifestyle-related risk factors in order to reduce future ischemic events.129,829,845",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01148,2021,71,Class 1,C-EO,"In patients with stroke or TIA, evaluating and addressing social determinants of health (eg, literacy level, language proficiency, medica- tion affordability, food insecurity, housing, and transportation barriers) when managing stroke risk factors is recommended to reduce healthcare disparities.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01149,2021,71,Class 1,C-EO,"In patients with stroke or TIA, monitoring the achievement of nationally accepted, evidence- based performance measures is recommended to allow inequities to be identified and addressed.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01150,2021,71,Class 1,C-EO,"In patients with stroke or TIA, systematic adoption of the Agency for Healthcare Research and Quality Universal Precautions Toolkit for Health Literacy is recommended to integrate health literacy into the secondary prevention of stroke.",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01151,2021,71,2B,B-R,"In patients from urban, predominantly minority, or low-socioeconomic-status groups with stroke or TIA, the optimal intervention model for improving stroke risk factor control and reducing disparities is unknown.815,856–859",kleindorfer-et-al-2021-guideline-for-the-prevention-of-stroke-in-patients-with-stroke-and-transient-ischemic-attack-a.pdf
id_01152,2023,20,Class 1,B-NR,"Patients with AF, regardless of sex1 and gender diversity, race and ethnicity,2 or adverse social determinants of health (SDOH),3,4* should be equitably offered guideline-directed stroke risk reduction therapies as well as rate or rhythm control strategies and LRFM as indicated to improve quality of life (QOL) and prevent adverse outcomes. *Including lower income, lower education, inadequate or lack of insurance cov- erage, or rurality.3–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01153,2023,21,2B,B-R,"In patients with AF, the use of evidence-based decision aids might be useful to guide stroke reduction therapy treatment decisions throughout the disease course to improve engagement, decisional quality, and patient satisfaction.1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01154,2023,22,Class 1,B-NR,"In patients with newly diagnosed AF, a transthoracic echocardiogram1–4 to assess cardiac structure, laboratory testing to include a complete blood count, metabolic panel, and thyroid function,5–7 and when clinical suspicion exists, targeted testing to assess for other medical conditions associated with AF are recommended to determine stroke and bleeding risk factors, as well as underlying conditions that will guide further management.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01155,2023,22,Class 3: No Benefit,B-NR,"In patients with newly diagnosed AF, protocolized testing for ischemia, acute coronary syndrome (ACS), and pulmonary embolism (PE) should not routinely be performed to assess the etiology of AF unless there are additional signs or symptoms to indicate those disorders.8–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01156,2023,23,Class 1,B-NR,"Among individuals without a known history of AF, it is recommended that an initial AF diagnosis be made by a clinician using visual interpretation of the electrocardiographic signals, regardless of the type of rhythm or monitoring device.1–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01157,2023,23,Class 1,B-NR,"In patients with an intracardiac rhythm device capable of a diagnosis of AF, such as from an atrial pacemaker lead, a diagnosis of AF should only be made after it is visually confirmed by reviewing intracardiac tracings to exclude signal artifacts and other arrhythmias.6–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01158,2023,23,2A,B-R,"For patients who have had a systemic thromboembolic event without a known history of AF and in whom maximum sensitivity to detect AF is sought, an implantable cardiac monitor is reasonable.10,11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01159,2023,23,2A,B-NR,"Among patients with a diagnosis of AF, it is reason- able to infer AF frequency, duration, and burden using automated algorithms available from electrocardio- graphic monitors, implantable cardiac monitors, and cardiac rhythm devices with an atrial lead, recognizing that periodic review can be required to exclude other arrythmias.1,4,5,12",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01160,2023,23,2A,B-R,"Among patients with AF in whom cardiac monitor- ing is advised, it is reasonable to recommend use of a consumer-accessible electrocardiographic device that provides a high-quality tracing to detect recur- rences.13",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01161,2023,24,Class 1,B-NR,"Patients at increased risk of AF should receive com- prehensive guideline-directed LRFM for AF, targeting obesity,1 physical inactivity,2 unhealthy alcohol con- sumption,3 smoking,4 diabetes,5 and hypertension.6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01162,2023,25,Class 1,B-R,"In patients with AF who are overweight or obese (with body mass index [BMI] >27 kg/m2), weight loss is recommended, with an ideal target of at least 10% weight loss to reduce AF symptoms, burden, recurrence, and progression to persistent AF.1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01163,2023,25,Class 1,B-R,"In individuals with AF,* moderate-to-vigorous exercise training to a target of 210 minutes per week is rec- ommended to reduce AF symptoms1–3 and burden,2,3 increase maintenance of sinus rhythm,3–5 increase functional capacity, and improve QOL.3,5,6 *In patients without AF related to excessive exercise training.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01164,2023,26,Class 1,B-NR,"Patients with a history of AF who smoke cigarettes should be strongly advised to quit smoking and should receive GDMT for tobacco cessation1,2 to mitigate increased risks of AF-related cardiovascular complications and other adverse outcomes.3–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01165,2023,26,Class 1,B-R,Patients with AF seeking a rhythm-control strategy should minimize or eliminate alcohol consumption to reduce AF recurrence and burden.1–3,joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01166,2023,26,Class 3: No Benefit,B-NR,"For patients with AF, recommending caffeine abstention to prevent AF episodes is of no benefit, although it may reduce symptoms in patients who report caffeine triggers or worsens AF symptoms.1–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01167,2023,27,Class 1,B-NR,"For patients with AF and hypertension, optimal BP control is recommended to reduce AF recurrence and AF-related cardiovascular events.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01168,2023,28,2B,B-NR,"Among patients with AF, it may be reasonable to screen for obstructive sleep apnea, given its high prevalence in patients with AF, although the role of treatment of sleep-disordered breathing (SDB) to maintain sinus rhythm is uncertain.1–13",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01169,2023,28,Class 1,A,"Patients with AF should receive comprehensive care addressing guideline-directed LRFM, AF symptoms, risk of stroke, and other associated medical conditions to reduce AF burden, progression, or consequences.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01170,2023,28,2A,B-R,"In patients with AF, use of clinical care pathways, such as nurse-led AF clinics, is reasonable to promote comprehensive, team-based care and to enhance adherence to evidence-based therapies for AF and associated conditions.4–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01171,2023,29,Class 1,B-NR,"Patients with AF should be evaluated for their annual risk of thromboembolic events using a validated clinical risk score, such as CHA2DS2-VASc.1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01172,2023,29,Class 1,B-NR,"Patients with AF should be evaluated for factors that specifically indicate a higher risk of bleeding, such as previous bleeding and use of drugs that increase bleeding risk, in order to identify possible interven- tions to prevent bleeding on anticoagulation.5–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01173,2023,29,2A,C-LD,"Patients with AF at intermediate annual risk of thromboembolic events by risk scores (eg, equiva- lent to CHA2DS2-VASc score of 1 in men or 2 in women), who remain uncertain about the benefit of anticoagulation, can benefit from consideration of factors that might modify their risk of stroke to help inform the decision.*",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01174,2023,29,Class 3: No Benefit,B-NR,"In patients who are deemed at high risk for stroke, bleeding risk scores should not be used in isolation to determine eligibility for oral anticoagulation but instead to identify and modify bleeding risk factors and to inform medical decision-making.8–10 *Factors may include AF burden or other features in Table 3.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01175,2023,31,Class 1,B-R,"In patients diagnosed with AF who have an estimated annual risk of stroke or thromboembolic events ≥2%, selection of therapy to reduce the risk of stroke should be based on the risk of thromboembolism, regardless of whether the AF pattern is paroxysmal, persistent, long-standing persistent, or permanent.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01176,2023,31,Class 1,B-NR,"In patients with AF at risk for stroke, reevaluation of the need for and choice of stroke risk reduction therapy at periodic intervals is recommended to reassess stroke and bleeding risk, net clinical benefit, and proper dosing.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01177,2023,33,Class 1,A,"For patients with AF and an estimated annual thromboembolic risk of ≥2% per year (eg, CHA2DS2-VASc score of ≥2 in men and ≥3 in women), anticoagulation is recommended to prevent stroke and systemic thromboembolism.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01178,2023,33,Class 1,A,"In patients with AF who do not have a history of moderate to severe rheumatic mitral stenosis or a mechanical heart valve, and who are candidates for anticoagulation, DOACs are recommended over warfarin to reduce the risk of mortality, stroke, systemic embolism, and ICH.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01179,2023,33,2A,A,"For patients with AF and an estimated annual thromboembolic risk of ≥1% but <2% per year (equivalent to CHA2DS2-VASc score of 1 in men and 2 in women), anticoagulation is reasonable to prevent stroke and systemic thromboembolism.1,3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01180,2023,33,Class 3: No Benefit,B-NR,"In patients with AF without risk factors for stroke, aspirin monotherapy for prevention of thromboem- bolic events is of no benefit.10,11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01181,2023,36,Class 1,C-LD,"For patients with AF receiving DOACs, optimal man- agement of drug interactions is recommended for those receiving concomitant therapy with interacting drugs, especially CYP3A4 and/or p-glycoprotein inhibitors or inducers (Table 13).1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01182,2023,36,Class 1,B-R,"For patients with AF receiving warfarin,* a target INR between 2 and 3 is recommended, as well as optimal management of drug-drug interactions, consistency in vitamin K dietary intake, and routine INR monitoring to improve time in therapeutic range and to minimize risks of preventable thromboembolism or major bleed- ing.8–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01183,2023,38,2A,B-R,"In patients with stroke or TIA of undetermined cause, initial cardiac monitoring and, if needed, extended monitoring with an implantable loop recorder are reasonable to improve detection of AF.1 Table 13.  Continued Class VKA Direct Thrombin Inhibitor Factor Xa Inhibitor Name Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Appropriate use based on liver function (Child-Pugh score)† Child-Pugh A (mild) Not mentioned in the labeling No dose adjustment needed No dose adjustment needed No dose adjustment needed No dose adjustment needed Child-Pugh B (moderate) Use with caution Avoid use Use with caution Use with caution Child-Pugh C (severe) Avoid use Avoid use Avoid use Avoid use Information obtained from manufacturer package inserts.13,14,20–22 Adapted with permission from pgs. 28-31 of Kido et al.23 Copyright 2021 American College of",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01184,2023,40,2A,B-NR,"For patients with a device-detected atrial high-rate episode (AHRE) lasting ≥24 hours1 and with a CHA2DS2-VASc score ≥2 or equivalent stroke risk,2 it is reasonable to initiate oral anticoagulation3 within a SDM framework that considers episode duration and individual patient risk.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01185,2023,40,2B,B-NR,"For patients with a device-detected AHRE last- ing between 5 minutes and 24 hours and with a CHA2DS2-VASc score ≥3 or equivalent stroke risk,2 it may be reasonable to initiate anticoagulation within a SDM framework that considers episode duration and individual patient risk.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01186,2023,40,Class 3: No Benefit,B-NR,"Patients with a device-detected AHRE lasting <5 minutes and without another indication for oral anticoagulation should not receive oral anticoagulation.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01187,2023,42,2A,B-NR,"In patients with AF, a moderate to high risk of stroke (CHA2DS2-VASc score ≥2), and a contraindication (Table 14) to long-term oral anticoagulation due to a nonreversible cause, percutaneous LAAO (pLAAO) is reasonable.1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01188,2023,42,2B,B-R,"In patients with AF and a moderate to high risk of stroke and a high risk of major bleeding on oral anti- coagulation, pLAAO may be a reasonable alternative to oral anticoagulation based on patient preference, with careful consideration of procedural risk and with the understanding that the evidence for oral antico- agulation is more extensive.1–3,5,6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01189,2023,43,Class 1,A,"In patients with AF undergoing cardiac surgery with a CHA2DS2-VASc score ≥2 or equivalent stroke risk, surgical LAA exclusion, in addition to continued anti- coagulation, is indicated to reduce the risk of stroke and systemic embolism.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01190,2023,43,Class 1,A,"In patients with AF undergoing cardiac surgery and LAA exclusion, a surgical technique resulting in absence of flow across the suture line and a stump of <1 cm as determined by intraoperative trans- esophageal echocardiography should be used.1,4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01191,2023,43,2B,A,"In patients with AF undergoing cardiac surgery with CHA2DS2-VASc score ≥2 or equivalent stroke risk, the benefit of surgical LAA exclusion in the absence of continued anticoagulation to reduce the risk of stroke and systemic embolism is uncertain.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01192,2023,44,Class 1,B-NR,"In patients with AF receiving dabigatran who develop life-threatening bleeding, treatment with idarucizumab is recommended to rapidly reverse dabigatran’s anticoagulation effect.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01193,2023,44,2A,C-LD,"In patients with AF receiving dabigatran who develop life-threatening bleeding, treatment with activated prothrombin complex concentrate (PCC) is reason- able to reverse dabigatran’s anticoagulation effect if idarucizumab is unavailable.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01194,2023,45,Class 1,A,"In patients with AF receiving warfarin who develop life-threatening bleeding, treatment with 4-factor prothrombin complex concentrate (if available) in addition to intravenous vitamin K is recommended to rapidly achieve INR correction over fresh frozen plasma and intravenous vitamin K treatment.8–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01195,2023,45,2B,B-NR,"In patients with AF who develop major gastrointestinal bleeding, resumption of oral anticoagulation therapy may be reasonable after correction of reversible causes of bleeding and reassessment of its long-term benefits and risks with a multidisciplinary team approach during SDM with patients.11,12 *B-NR LOE applies to data on apixaban or rivaroxaban. †C-LD LOE applies to data on edoxaban.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01196,2023,47,2A,C-LD,"In patients with AF and conditions associated with very high risk of thromboembolic events (>5%/year), such as rheumatic heart disease or a mechanical heart valve, early (1-2 weeks) resumption of antico- agulation after ICH is reasonable to reduce the risk of thromboembolic events.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01197,2023,47,2B,C-LD,"In patients with AF and ICH, delayed (4-8 weeks) resumption of anticoagulation may be considered to balance the risks of thromboembolic and hemorrhagic complications after careful risk benefit assessment.2–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01198,2023,47,2B,B-NR,"In patients with AF and conditions associated with high risk of recurrent ICH (eg, cerebral amyloid angiopathy) anticoagulation-sparing strategies (eg, LAAO) may be considered to reduce the risk of recurrent hemorrhage.6,7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01199,2023,50,Class 1,A,"In patients with AF on warfarin anticoagulation and an annual predicted risk of thromboembolism of ≥5% undergoing pacemaker or defibrillator implantation or generator change, continued anticoagulation is rec- ommended in preference to interruption of warfarin and bridging anticoagulation with heparin to reduce the risk of pocket hematoma.5–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01200,2023,50,2A,A,"In patients with AF with CHA2DS2-VASc score ≥2 or equivalent risk of stroke, on DOAC anticoagulation and undergoing pacemaker or defibrillator implanta- tion or generator change, either uninterrupted or interrupted DOAC is reasonable.8–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01201,2023,50,Class 1,B-NR,"In patients with AF on DOAC and scheduled to undergo an invasive procedure or surgery that cannot be performed safely on uninterrupted antico- agulation, the timing of interruption of DOAC should be guided by the specific agent, renal function, and the bleeding risk of the procedure (Table 18).4,11,12",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01202,2023,50,2A,B-NR,"In patients with AF on DOAC that has been inter- rupted for an invasive procedure or surgery, in gen- eral, resumption of anticoagulation the day after low bleeding risk surgery and between the evening of the second day and the evening of the third day after high bleeding risk surgery is reasonable, as long as hemostasis has been achieved and further bleeding is not anticipated.4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01203,2023,52,Class 1,A,"In patients with AF and an increased risk for stroke who undergo PCI, DOACs are preferred over VKAs in combination with APT to reduce the risk of clinically relevant bleeding.1–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01204,2023,52,Class 1,A,"In most patients with AF who take oral anticoagulation and undergo PCI, early discontinuation of aspirin (1-4 wk) and continuation of dual antithrombotic therapy with OAC and a P2Y12 inhibitor is preferred over triple therapy (OAC, P2Y12 inhibitor, and aspirin) to reduce the risk of clinically relevant bleeding.1–4,6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01205,2023,53,Class 1,B-R,"In patients with AF and CCD (beyond 1 year after revascularization or CAD not requiring coronary revascularization) without history of stent thrombosis, oral anticoagulation monotherapy is recommended over the combination therapy of OAC and single APT (aspirin or P2Y12 inhibitor) to decrease the risk of major bleeding.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01206,2023,54,2A,B-NR,"In patients with AF and concomitant stable PAD, monotherapy oral anticoagulation is reasonable over dual therapy (anticoagulation plus aspirin or P2Y12 inhibitors) to reduce the risk of bleeding.1–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01207,2023,55,Class 1,B-R,"For patients with AF at elevated risk for stroke and CKD stage 3, treatment with warfarin or, preferably, evidence-based doses of direct thrombin or factor Xa inhibitors (Table 19) is recommended to reduce the risk of stroke.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01208,2023,55,2A,B-NR,"For patients with AF at elevated risk for stroke and CKD stage 4, treatment with warfarin or labeled doses of DOACs is reasonable to reduce the risk of stroke.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01209,2023,55,2B,B-NR,"For patients with AF at elevated risk for stroke and who have end-stage CKD (CrCl <15 mL/min) or are on dialysis, it might be reasonable to prescribe warfarin (INR 2.0-3.0) or an evidence-based dose of apixaban for oral anticoagulation to reduce the risk of stroke.6,7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01210,2023,56,Class 1,B-R,"In patients with rheumatic mitral stenosis or mitral stenosis of moderate or greater severity and history of AF, long-term anticoagulation with warfarin is recommended over DOACs, independent of the CHA2DS2-VASc score to prevent cardiovascular events, including stroke or death.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01211,2023,56,Class 1,B-NR,"In patients with AF and valve disease other than moderate or greater mitral stenosis or a mechanical heart valve, DOACs are recommended over VKAs.2–8",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01212,2023,57,Class 1,B-NR,"For patients with AFL, anticoagulant therapy is recommended according to the same risk profile used for AF.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01213,2023,57,Class 1,C-LD,"In patients with AFL who undergo successful cardioversion or ablation resulting in restoration of sinus rhythm, anticoagulation should be continued for at least 4 weeks postprocedure.1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01214,2023,57,Class 1,A,"Patients with typical AFL who have undergone suc- cessful CTI ablation and have had AF previously detected before AFL ablation should receive ongoing oral anticoagulation postablation as indicated for AF.5,6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01215,2023,57,Class 1,B-NR,"Patients with typical AFL who have undergone suc- cessful CTI ablation and are deemed to be at high thromboembolic risk, without any known previous history of AF, should receive close follow-up and arrhythmia monitoring to detect silent AF if they are not receiving ongoing anticoagulation in view of significant risk of AF.7–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01216,2023,57,2B,B-NR,"In patients with typical AFL who have undergone successful CTI ablation without any known previous history of AF who are at high risk for development of AF (eg, LA enlargement, inducible AF, chronic obstructive pulmonary disease [COPD], HF), it may be reasonable to prescribe long-term anticoagulation if thromboembolic risk assessment suggests high risk (>2% annual risk) for stroke.5,10–13 *This section refers to typical right-sided (CTI-dependent) AFL. Left-sided AFLs or atrial tachycardias (ATs) that develop after ablation of AF should be anticoagulated and managed in a manner similar to AF. “Typical” AFL is defined as either typical counterclockwise AFL when the macroreentrant circuit is de- pendent on the CTI using the isthmus from the patient’s right to left or typical clockwise AFL when the macroreentrant circuit is dependent on the CTI and uses this isthmus from the patient’s left to right. “Atypical” AFL is not dependent on the CTI and may arise from a macroreentrant circuit in the LA, such as perimitral or",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01217,2023,59,Class 1,B-NR,"In patients with AF, SDM with the patient is recom- mended to discuss rhythm- versus rate-control strategies (taking into consideration clinical presen- tation, comorbidity burden, medication profile, and patient preferences), discuss therapeutic options, and for assessing long-term benefits.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01218,2023,59,2A,B-R,"In patients with AF without HF who are candidates for select rate-control strategies, heart rate target should be guided by underlying patient symptoms, in general aiming at a resting heart rate of <100 to 110 bpm.2,4–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01219,2023,60,Class 1,B-R,"In patients with AF with rapid ventricular response who are hemodynamically stable, beta blockers or nondihydropyridine calcium channel blockers (vera- pamil, diltiazem; provided that EF >40%) are recom- mended for acute rate control (Figure 17).1–4",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01220,2023,60,2A,B-R,"In patients with AF with rapid ventricular response in whom beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated, digoxin can be considered for acute rate control, either alone or in combination with the aforemen- tioned agents.5–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01221,2023,60,2A,A,"In patients with AF with rapid ventricular response, the addition of intravenous magnesium to standard rate-control measures is reasonable to achieve and maintain rate control.10,11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01222,2023,60,2B,B-NR,"In patients with AF with rapid ventricular response who are critically ill and/or in decompensated HF in whom beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated, intravenous amiodarone may be considered for acute rate control.*12,13",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01223,2023,63,Class 1,B-NR,"In patients with AF, beta blockers or nondihydropyri- dine calcium channel blockers (diltiazem, verapamil) are recommended for long-term rate control with the choice of agent according to underlying substrate and comorbid conditions.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01224,2023,63,2A,B-NR,"For patients with AF in whom measuring serum digoxin levels is indicated, it is reasonable to target levels <1.2 ng/mL.3–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01225,2023,63,2A,B-R,"In patients with AF and HF symptoms, digoxin is reasonable for long-term rate control in combination with other rate-controlling agents, or as monotherapy if other agents are not preferred, not tolerated, or contraindicated.7–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01226,2023,64,Class 1,C-LD,"In patients with AF and a persistently rapid ventricular response who undergo AVNA, initial pacemaker lower rate programming should be 80 to 90 bpm to reduce the risk of sudden death.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01227,2023,64,2A,B-R,"In patients with AF and uncontrolled rapid ventricular response refractory to rate-control medications (who are not candidates for or in whom rhythm control has been unsuccessful), AVNA can be useful to improve symptoms and QOL.3–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01228,2023,64,Class 1,B-NR,"In patients with AF who are planned to undergo AVNA, implantation of a pacemaker before the ablation (ie, before or same day of ablation) is recommended to ensure adequacy of the pacing leads before performing ablation.7–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01229,2023,64,2B,C-LD,"In patients with AF with normal EF undergoing AVNA, conduction system pacing of the His bundle10–13 or left bundle area12,13 may be reasonable.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01230,2023,66,Class 1,B-R,"In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function.1–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01231,2023,66,2A,B-R,"In patients with symptomatic AF, rhythm control can be useful to improve symptoms.7–11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01232,2023,66,2A,B-R,"In patients with a recent diagnosis of AF (<1 year), rhythm control can be useful to reduce hospitaliza- tions, stroke, and mortality.12–14",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01233,2023,66,2A,B-R,"In patients with AF and HF, rhythm control can be useful for improving symptoms and improving out- comes, such as mortality and hospitalizations for HF and ischemia.15–19",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01234,2023,66,2A,B-NR,"In patients with AF, rhythm-control strategies can be useful to reduce the likelihood of AF progression.20–27",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01235,2023,66,2B,C-LD,"In patients with AF where symptoms associated with AF are uncertain, a trial of rhythm control (eg, cardio- version or pharmacological therapy) may be useful to determine what if any symptoms are attributable to AF.28–32",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01236,2023,66,2B,B-NR,"In patients with AF, rhythm-control strategies may be useful to reduce the likelihood of development of dementia or worsening cardiac structural abnormali- ties.33–45",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01237,2023,69,Class 1,B-R,"In patients with AF duration of ≥48 hours, a",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01238,2023,69,Class 1,B-NR,"In patients with AF undergoing cardioversion, thera- peutic anticoagulation should be established before cardioversion and continued for at least 4 weeks afterwards without interruption to prevent thromboembolism.2–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01239,2023,69,Class 1,C-LD,"In patients with AF in whom cardioversion is deferred due to LAA thrombus detected on precardioversion imaging, therapeutic anticoagulation should be insti- tuted for at least 3 to 6 weeks, after which imaging should be repeated before cardioversion.1,8",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01240,2023,69,2B,B-NR,"In patients with AF and previous LAAO who are not on anticoagulation, imaging evaluation to assess the adequacy of LAAO and exclude device-related throm- bosis before cardioversion may be reasonable.9–19",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01241,2023,69,2B,C-LD,"In patients with AF and previous LAAO with residual leak, pericardioversion anticoagulation may be considered and continued thereafter.9–11,20",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01242,2023,69,2B,C-LD,"In patients with reported AF duration of <48 hours (not in the setting of cardiac surgery) and who are not on anticoagulation, precardioversion imaging to exclude intracardiac thrombus may be considered ins those who are at elevated thromboembolic risk (CHA2DS2-VASc score ≥2 or equivalent).21,22",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01243,2023,69,2B,C-LD,"In patients with low thromboembolic risks (CHA2DS2-VASc 0-1 or equivalent) and AF duration of <12 hours, the benefit of precardioversion imaging or pericardioversion anticoagulation is uncertain given the low incidence of pericardioversion thromboembolic events in this population.21,22",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01244,2023,72,Class 1,C-LD,"In patients with hemodynamic instability attributable to AF, immediate electrical cardioversion should be performed to restore sinus rhythm.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01245,2023,72,Class 1,B-R,"In patients with AF who are hemodynamically stable, electrical cardioversion can be performed as initial rhythm-control strategy or after unsuccessful pharmacological cardioversion.2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01246,2023,72,Class 1,C-LD,"In patients with AF undergoing electrical cardiover- sion, energy delivery should be confirmed to be syn- chronized to the QRS to reduce the risk of inducing VF.3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01247,2023,72,2A,B-R,"For patients with AF undergoing elective electrical cardioversion, the use of biphasic energy of at least 200 J as initial energy can be beneficial to improve success of initial electrical shock.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01248,2023,72,2A,B-NR,"In patients with AF undergoing elective cardiover- sion, with longer duration of AF or unsuccessful initial shock, optimization of electrode vector, use of higher energy, and pretreatment with antiarrhythmic drugs can facilitate success of electrical cardioversion.5–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01249,2023,72,2B,C-LD,"In patients with obesity and AF, use of manual pressure augmentation and/or further escalation of electrical energy may be beneficial to improve suc- cess of electrical cardioversion.10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01250,2023,73,2A,C-LD,"For patients with AF, pharmacological cardioversion is reasonable as an alternative to electrical cardiover- sion for those who are hemodynamically stable or in situations when electrical cardioversion is preferred but cannot be performed.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01251,2023,73,2A,A,"For patients with AF, ibutilide2,3 is reasonable for pharmacological cardioversion for patients without depressed LV function (LVEF <40%).",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01252,2023,73,2A,A,"For patients with AF, intravenous amiodarone is rea- sonable for pharmacological cardioversion, although time to conversion is generally longer than with other agents (8-12 hours).4–8",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01253,2023,73,2A,A,"For patients with recurrent AF occurring outside the setting of a hospital, the “pill-in-the-pocket” (PITP) approach with a single oral dose of flecainide9–11 or propafenone,10–14 with a concomitant atrioventricular nodal blocking agent,15 is reasonable for pharmaco- logical cardioversion if previously tested in a moni- tored setting.16–18",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01254,2023,73,2B,B-R,"For patients with AF, use of intravenous procainamide may be considered for pharmacological cardioversion when other intravenous agents are contraindicated or not preferred.19",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01255,2023,76,2A,A,"For patients with AF and no previous MI, or known or suspected significant structural heart disease, or ven- tricular scar or fibrosis, use of flecainide3–5 or propafe- none5–12 is reasonable for long-term maintenance of sinus rhythm.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01256,2023,76,2A,A,"For patients with AF without recent decompensated HF or severe LV dysfunction, use of dronedarone5,13–15 is reasonable for long-term maintenance of sinus rhythm.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01257,2023,76,2A,A,"For patients with AF without significant baseline QT interval prolongation or uncorrected hypokalemia or hypomagnesemia, use of dofetilide1,5,16 5–7,10,17,18 is reasonable for long-term maintenance of sinus rhythm, with proper dose selection based on kidney function and close monitoring of the QT interval, serum potassium and magnesium concentrations, and kidney function.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01258,2023,76,2A,A,"For patients with AF and normal LV function, use of low-dose amiodarone (100-200 mg/d) is rea- sonable for long-term maintenance of sinus rhy thm2,5,17–22 but, in view of its adverse effect pro- file,5,23,24 should be reserved for patients in whom other rhythm control strategies are ineffective, not preferred, or contraindicated.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01259,2023,76,2B,A,"For patients with AF without significant baseline QT interval prolongation, hypokalemia, hypomag- nesemia, or bradycardia, use of sotalol5–7,10,17,18 may be considered for long-term maintenance of sinus rhythm, with proper dose selection based on kidney function and close monitoring of the QT interval, heart rate, serum potassium and magnesium con- centrations, and kidney function.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01260,2023,79,Class 1,A,"Patients with AF who are initiating, increasing the dose of, or reinitiating dofetilide therapy should be admitted for a minimum of 3 days to a facility that can provide continuous electrocardiographic monitoring, calculations of CrCl, and cardiac resuscitation, given the potential for proarrhythmia.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01261,2023,79,2A,B-R,"In patients with AF, it is reasonable to initiate sotalol therapy in a facility that can provide continuous electrocardiographic monitoring, calculations of CrCl, and cardiac resuscitation, given the potential for proarrhythmia and bradycardia.4,8–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01262,2023,79,2A,B-NR,"In patients with AF who are initiating PITP dosing of flecainide and propafenone with concomitant atrioventricular nodal blocking drugs, it is reasonable to receive the first dose in a facility that can provide continuous electrocardiographic monitoring, given the potential for proarrhythmia.9–13",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01263,2023,84,Class 1,A,"In patients with symptomatic AF in whom anti- arrhythmic drugs have been ineffective, contra- indicated, not tolerated or not preferred, and continued rhythm control is desired, cath- eter ablation is useful to improve symptoms.1–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01264,2023,84,Class 1,A,"In selected patients (generally younger with few comorbidities) with symptomatic parox- ysmal AF in whom rhythm control is desired, catheter ablation is useful as first-line therapy to improve symptoms and reduce progression to persistent AF.11–16",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01265,2023,84,Class 1,A,"In patients with symptomatic or clinically significant AFL, catheter ablation is useful for improving symptoms.17–19",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01266,2023,84,2A,B-NR,"In patients who are undergoing ablation for AF, ablation of additional clinically significant supraventricular arrhythmias can be useful to reduce the likelihood of future arrhythmia.17,18,20–27",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01267,2023,84,2A,B-R,"In patients (other than younger with few comorbidities) with symptomatic paroxysmal or persistent AF who are being managed with a rhythm-control strategy, catheter ablation as first-line therapy can be useful to improve symptoms.11–13,28 Cost Value Statement: Intermediate B-R",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01268,2023,84,2B,B-NR,"In selected* patients with asymptomatic or minimally symptomatic AF, catheter ablation may be useful for reducing progression of AF and its associated complications.31–39 *Younger patients with few comorbidities and a moderate to high burden of AF or persistent AF and AFL.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01269,2023,86,Class 1,A,"In patients undergoing ablation for AF, PVI is recom- mended as the primary lesion set for all patients unless a different specific trigger is identified.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01270,2023,86,2B,B-R,"In patients undergoing ablation for AF, the value of other endpoints beyond PVI such as noninducibility and ablation of additional anatomic ablation targets (eg, posterior wall sites, low voltage areas, complex fractionated electrograms, rotors) is uncertain.8–18",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01271,2023,87,Class 1,B-NR,"In patients with recurrent symptomatic AF after catheter ablation, repeat catheter ablation or antiarrhythmic drug therapy is useful to improve symptoms and freedom from AF.1–11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01272,2023,87,2A,A,"In some patients who have undergone catheter ablation of AF, short-term antiarrhythmic drug therapy after ablation can be useful to reduce early recur- rences of atrial arrhythmia and hospitalization.12–16",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01273,2023,88,Class 1,B-NR,"In patients on warfarin who are undergoing catheter ablation of AF, catheter ablation should be performed on uninterrupted therapeutic anticoagula- tion with a goal INR of 2.0 to 3.0.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01274,2023,88,Class 1,A,"In patients on a DOAC who are undergoing catheter ablation of AF, catheter ablation should be performed with either continuous or minimally interrupted oral anticoagulation.2–10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01275,2023,88,Class 1,B-NR,"In patients who have undergone catheter ablation of AF, oral anticoagulation should be continued for at least 3 months after the procedure with a longer duration determined by underlying risk.11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01276,2023,88,Class 1,B-NR,"In patients who have undergone catheter ablation of AF, continuation of longer-term oral anticoagulation should be dictated according to the patients’ stroke risk (eg, CHA2DS2-VASc score ≥2).11–17",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01277,2023,89,Class 1,A,"In patients with bradycardia requiring cardiac- implanted electronic devices who have normal atrioventricular conduction, device selection and pro- gramming strategies to maintain atrioventricular syn- chrony and minimize ventricular pacing should be used to reduce the incidence and progression of AF. 1–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01278,2023,89,2B,B-NR,"In selected patients with a pacemaker and symptomatic atrial tachyarrhythmias, antitachycar- dia atrial pacing and ventricular pacing minimiza- tion may be useful for reducing symptoms.7–13 (Continued ) Downloaded from http://ahajournals.org by on June 19, 2025",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01279,2023,90,2B,C-LD,"In patients with AF who require significant ventricular pacing, conduction system pacing may be useful to reduce progression of AF.14,15",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01280,2023,90,Class 3: No Benefit,B-R,"In patients with AF, specialized atrial pacing algorithms designed to suppress AF are not useful for reducing the incidence or slowing the progression of AF.12,16–18",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01281,2023,90,2A,B-R,"For patients with AF who are undergoing cardiac surgery, concomitant surgical ablation can be beneficial to reduce the risk of recurrent AF.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01282,2023,90,2A,B-NR,"In patients undergoing surgical ablation, anticoagulation therapy is reasonable for at least",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01283,2023,90,2B,B-R,"For patients with symptomatic, persistent AF refractory to antiarrhythmic drug therapy, a hybrid epi- cardial and endocardial ablation might be reasonable to reduce the risk of recurrent atrial arrhythmia.5–7 Recommendations for the Role of Pacemakers and ICDs for the Prevention and Treatment of AF (Continued ) COR LOE Recommendations Downloaded from http://ahajournals.org by on June 19, 2025",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01284,2023,92,Class 1,B-NR,"In patients who present with a new diagnosis of HFrEF and AF, arrhythmia-induced cardiomyopathy should be suspected, and an early and aggressive approach to AF rhythm control is recommended.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01285,2023,92,Class 1,A,"In appropriate patients with AF and HFrEF who are on GDMT, and with reasonable expectation of proce- dural benefit (Figure 24), catheter ablation is benefi- cial to improve symptoms, QOL, ventricular function, and cardiovascular outcomes.3–13",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01286,2023,92,2A,B-NR,"In appropriate patients with symptomatic AF and HFpEF with reasonable expectation of benefit, catheter ablation can be useful to improve symptoms and improve QOL.14,15",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01287,2023,92,2A,B-R,"In patients with AF and HF, digoxin is reasonable for rate control, in combination with other rate-controlling agents or as monotherapy if other agents are not tolerated.16,17",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01288,2023,92,2A,B-NR,"In patients with AF and HF with rapid ventricular rates in whom beta blockers or calcium channel blockers are contraindicated or ineffective, intravenous amiodarone is reasonable for acute rate control.†18,19",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01289,2023,92,2A,B-R,"In patients with AF, HFrEF (LVEF <50%), and refractory rapid ventricular response who are not candidates for or in whom rhythm control has failed, AVNA and biventricular pacing therapy can be useful to improve symptoms, QOL, and EF.20–23",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01290,2023,92,2A,B-NR,"In patients with AF, HF, and implanted biventricular pacing therapy in whom an effective pacing percentage cannot be achieved with pharmacological therapy, AVNA can be beneficial to improve functional class,24,25 reduce the risk of ICD shock,26 and improve survival.24,25",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01291,2023,92,2A,B-NR,"In patients with AF-induced cardiomyopathy who have recovered LV function, long-term surveillance can be beneficial to detect recurrent AF in view of the high risk of recurrence of arrhythmia-induced cardiomyopathy.27,28",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01292,2023,92,2B,B-NR,"In patients with suspected AF-induced cardiomyopathy or refractory HF symptoms undergoing pharmacological rate-control therapy for AF, a stricter rate-control strategy (target heart rate <80 bpm at rest and <110 bpm during moderate exercise) may be reasonable.29–31",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01293,2023,92,2B,C-LD,"In patients with AF and HFrEF who undergo AVNA, conduction system pacing of the His bundle or left bundle branch area may be reasonable as an alterna- tive to biventricular pacing to improve symptoms, QOL, and LV function.32–35",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01294,2023,97,2B,B-NR,"In patients with an onset of unexplained AF before 30 years of age, electrophysiological study to evaluate and treat reentrant supraventricular tachyarrhythmias with a targeted ablation may be reasonable because of the high prevalence of reen- trant arrhythmias in this group.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01295,2023,97,2B,B-NR,"In patents with an onset of AF before 45 years of age without obvious risk factors for AF, referral for genetic counseling, genetic testing for rare patho- genic variants, and surveillance for cardiomyopathy or arrhythmia syndromes may be reasonable.4,5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01296,2023,98,2A,B-NR,"In athletes who develop AF, catheter ablation with PVI is a reasonable strategy for rhythm control because of its effectiveness and low risk of detrimental effect on exercise capacity.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01297,2023,98,2A,B-NR,"In patients with AF and class III obesity (BMI ≥ 40 kg/m2), DOACs are reasonable to choose over warfarin for stroke risk reduction.1–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01298,2023,98,2B,C-LD,"In patients with AF who have undergone bariatric surgery, warfarin may be reasonable to choose over DOACs for stroke risk reduction in view of concerns about DOAC drug absorption.6,7 Downloaded from http://ahajournals.org by on June 19, 2025",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01299,2023,99,Class 1,B-NR,"Patients with AF with rapid anterograde conduction (preexcited AF), and hemodynamic instability should be treated with electrical cardioversion.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01300,2023,99,Class 1,B-NR,"For patients with AF with rapid anterograde conduction (preexcited AF), catheter ablation of accessory pathways (APs) is recommended.3–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01301,2023,99,Class 1,C-LD,"In patients with AF with rapid anterograde conduction (preexcited AF) and hemodynamic stability, pharmacological cardioversion with intravenous ibutilide or intravenous procainamide is recommended as an alternative to elective cardioversion.1,8,9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01302,2023,100,Class 1,B-NR,"In adults with congenital heart disease and AF, it is recommended to evaluate for and treat precipitating factors and reversible causes of AF, recognizing that residual hemodynamic sequelae may contribute to the occurrence of the arrhythmia.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01303,2023,100,Class 1,C-LD,"In adults with AF and moderate or complex congeni- tal heart disease, electrophysiological procedures should be performed by operators with expertise in ACHD procedures and in collaboration with an ACHD cardiologist, ideally in specialized centers, when available.3–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01304,2023,100,Class 1,C-LD,"In adults with congenital heart disease and symp- tomatic or hemodynamically significant paroxysmal or persistent AF, an initial strategy of rhythm control is recommended regardless of lesion severity as AF in this population is often poorly tolerated.6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01305,2023,100,2A,B-NR,"In symptomatic patients with simple congenital heart disease with antiarrhythmic drug–refractory AF, it is reasonable to choose ablation over long-term antiar- rhythmic therapies.4,7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01306,2023,100,2B,C-LD,"In adults with congenital heart disease with AF undergoing PVI, it may be reasonable to include an ablative strategy in the right atrium directed at reentrant arrhythmia secondary to atriotomy scars and the CTI.8,9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01307,2023,100,2B,C-LD,"In adults with AF and moderate or severe forms of congenital heart disease, particularly those with low-flow states such as Fontan circulation, blind- ending cardiac chambers, and cyanosis, it may be reasonable to treat with anticoagulation independent of conventional risk score to reduce risk of thromboembolic events.10",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01308,2023,102,2A,B-R,"In patients undergoing cardiac surgery who are at high risk for postoperative AF, it is reasonable to administer short-term prophylactic beta blockers or amiodarone to reduce the incidence of postoperative AF.1–5",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01309,2023,102,2A,B-R,"In patients undergoing CABG, aortic valve, or ascend- ing aortic aneurysm operations, it is reasonable to perform concomitant posterior left pericardiotomy to reduce the incidence of postoperative AF.6,7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01310,2023,102,Class 1,B-R,"In hemodynamically stable cardiac surgery patients with postoperative AF, rate-control (target heart rate, <100 bpm) and/or rhythm-control medications are recommended as initial therapy, with the choice of strategy according to patient symptoms, hemody- namic consequences of the arrhythmia, and physician preference.5,6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01311,2023,102,Class 1,B-R,"In patients who develop poorly tolerated AF after cardiac surgery, direct current cardioversion in com- bination with antiarrhythmic drug therapy is recom- mended, with consideration of imaging to rule out left appendage thrombus before cardioversion in those patients in whom AF has been present >48 hours and who have not been on anticoagulation.5,6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01312,2023,102,2A,B-NR,"In patients who develop postoperative AF after cardiac surgery, it is reasonable to administer anti- coagulation when deemed safe in regard to surgical bleeding for 60 days after surgery unless complica- tions develop and to reevaluate the need for longer term anticoagulation at that time.5,7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01313,2023,102,2A,C-LD,"In patients who develop AF after cardiac surgery and who are treated with rate-control strategy, at 30- to 60-day follow-up it is reasonable to perform rhythm assessment and, if AF does not revert to sinus rhythm spontaneously, consider cardioversion after an adequate duration of anticoagulation.5,6 *A LOE applies to the data on beta blockers. †B-R LOE applies to the data on nondihydropyridine calcium channel blockers.",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01314,2023,104,Class 1,B-NR,Patients with AF who are identified in the setting of acute medical illness or surgery should be coun- seled about the significant risk of recurrent AF after the acute illness is resolved.1–6,joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01315,2023,104,2A,B-NR,"In patients with AF who are identified in the setting of acute medical illness or surgery, outpatient follow- up for thromboembolic risk stratification and decision-making on OAC initiation or continuation, as well as AF surveillance, can be beneficial given a high risk of AF recurrence.4–9",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01316,2023,104,2B,B-NR,"In patients with AF who are identified in the setting of critical illness due to sepsis, the benefits of anticoagulation during critical illness for stroke pre- vention are uncertain.10,11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01317,2023,106,Class 1,B-NR,"In patients with hyperthyroidism and AF who have an elevated risk of stroke based on a standard clinical risk score, anticoagulation is recommended until thyroid function has returned to normal and sinus rhythm can be maintained.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01318,2023,106,2A,B-R,"In patients with AF and COPD, it is reasonable to use cardioselective beta blockers for rate control of AF, especially where other indications exist (eg, MI and HF).1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01319,2023,106,2A,B-NR,"In patients with pulmonary hypertension (PH) with pulmonary vascular disease and AF or AFL, a rhythm-control strategy is reasonable to improve functional status and potentially prolong survival.4–12",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01320,2023,107,Class 1,B-NR,"In pregnant patients with AF, DCCV is safe to the patient and fetus and should be performed in the same manner as in patients who are not pregnant.1",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01321,2023,107,2B,C-LD,"In pregnant individuals with structurally normal hearts and hemodynamically stable AF, pharmacological cardioversion with agents with history of safe use in pregnancy, such as intravenous procainamide, may be considered.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01322,2023,107,2A,C-LD,"In pregnant individuals with AF and without structural heart disease, antiarrhythmic agents with history of safe use in pregnancy (eg, flecainide and sotalol) are reasonable for maintenance of sinus rhythm.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01323,2023,107,2A,B-NR,"In pregnant individuals with persistent AF, rate-control agents with a record of safety in pregnancy, such as beta blockers (eg, propranolol or metoprolol) and digoxin, either alone or in combination with beta blockers, are reasonable as first-line agents.1,2",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01324,2023,107,2B,C-LD,"Pregnant individuals with AF and elevated risk of stroke may be considered for anticoagulation with the recognition that no anticoagulation strategy is completely safe for both the mother and fetus, and an SDM discussion should take place regarding risks to both mother and fetus (Table 28).3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01325,2023,108,Class 1,C-LD,"In patients with cancer and AF, multidisciplinary com- munication including cardiology, oncology and other clinicians, and SDM with the patient is recommended to optimize cancer and AF treatment and to reduce the risk of drug-drug interactions, QTc prolongation, proarrhythmia, bleeding, and thromboembolism.1–3",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01326,2023,108,2A,C-LD,"In patients who are to be initiated on cancer therapies associated with an increased risk of developing AF, increased vigilance for incident AF and treatment of contributing factors is reasonable to decrease morbidity.1,4–6",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01327,2023,108,2A,B-NR,"In most patients with AF and cancer (remote history or receiving active cancer treatment), DOACs are reasonable to choose over VKAs for stroke risk reduction.7,8",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01328,2023,110,2A,B-NR,"For patients with AF who are at increased risk of systemic thromboembolism and mild or moderate liver disease (Child-Pugh* class A or B), OAC therapy is reasonable in the absence of clinically significant liver disease–induced coagulopathy or thrombocyto- penia.1–7",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01329,2023,110,2A,B-NR,"For patients with AF who are at increased risk of systemic thromboembolism and mild or moderate liver disease (Child-Pugh class A or B) and who are deemed to be candidates for anticoagulation, it is reasonable to prescribe DOACs (Child-Pugh class A: any DOAC; Child-Pugh class B: apixaban, dabigatran, or edoxaban) over warfarin.1,7–11",joglar-et-al-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the.pdf
id_01330,2023,8,2A,B-NR,"If combined opioid and benzodiazepine poisoning is suspected, it is reasonable to administer nal- oxone first (before other antidotes) for respiratory depression/respiratory arrest.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01331,2023,8,2A,B-NR,Flumazenil can be effective in select patients with respiratory depression/respiratory arrest caused by pure benzodiazepine poisoning who do not have ­contraindications to flumazenil.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01332,2023,8,Class 3: No Benefit,C-EO,Flumazenil has no role in cardiac arrest related to benzodiazepine poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01333,2023,8,Class 3: Harm,B-R,"Flumazenil administration is associated with harm in patients who are at increased risk for seizures or dysrhythmias. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01334,2023,9,Class 1,B-NR,We recommend that high-dose insulin be administered for hypotension due to β-blocker poisoning refractory to or in conjunction with vasopressor therapy.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01335,2023,9,Class 1,C-LD,We recommend that vasopressors be adminis- tered for hypotension due to β-blocker poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01336,2023,9,2A,C-LD,"It is reasonable to use a bolus of glucagon, fol- lowed by a continuous infusion, for bradycardia or hypotension due to β-blocker poisoning.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01337,2023,9,2A,C-LD,It is reasonable to utilize extracorporeal life sup- port techniques such as VA-ECMO for life-threat- ening β-blocker poisoning with cardiogenic shock refractory to pharmacological interventions.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01338,2023,9,2B,C-LD,It may be reasonable to administer atropine for β-blocker–induced bradycardia.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01339,2023,9,2B,C-LD,It may be reasonable to attempt electrical pacing for β-blocker–induced bradycardia.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01340,2023,9,2B,C-LD,It may be reasonable to use hemodialysis for life- threatening atenolol or sotalol poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01341,2023,9,Class 3: No Benefit,C-LD,"Intravenous lipid emulsion therapy is not likely to be beneficial for life-threatening β-blocker poisoning. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01342,2023,10,Class 1,B-NR,We recommend administering vasopressors for hypotension from calcium channel blocker (CCB) ­poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01343,2023,10,Class 1,B-NR,We recommend administering high-dose insulin for hypotension due to CCB poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01344,2023,10,2A,C-LD,It is reasonable to administer calcium for CCB ­poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01345,2023,10,2A,C-LD,It is reasonable to administer atropine for hemodynam- ically significant bradycardia from CCB poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01346,2023,10,2A,C-LD,It is reasonable to utilize extracorporeal life support techniques such as VA-ECMO for cardiogenic shock due to CCB poisoning that is refractory to pharma- cological interventions.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01347,2023,10,2B,C-LD,It might be reasonable to attempt electrical pacing for CCB poisoning with refractory bradycardia.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01348,2023,10,2B,C-LD,The usefulness of a glucagon bolus and infusion for,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01349,2023,10,2B,C-LD,The usefulness of administering methylene blue for refractory vasodilatory shock due to CCB poisoning is uncertain.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01350,2023,10,Class 3: No Benefit,C-LD,"The routine use of intravenous lipid emulsion (ILE) therapy for CCB poisoning is not recommended. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01351,2023,12,Class 1,C-LD,We recommend rapid external cooling for life-threatening hyperthermia from cocaine poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01352,2023,12,2A,C-LD,It is reasonable to administer sodium bicarbonate for wide-complex tachycardia or cardiac arrest from cocaine poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01353,2023,12,2A,C-LD,It is reasonable to administer lidocaine for wide- complex tachycardia from cocaine poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01354,2023,12,2A,C-LD,"It is reasonable to administer vasodilators (eg, nitrates, phentolamine, calcium channel blockers) for patients with cocaine-induced coronary vaso- spasm or hypertensive emergencies. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01355,2023,14,Class 1,C-LD,We recommend that hydroxocobalamin be administered for cyanide poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01356,2023,14,Class 1,C-LD,We recommend that sodium nitrite be administered for cyanide poisoning when hydroxocobalamin is unavailable.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01357,2023,14,2A,C-LD,"In addition to administering hydroxocobalamin or sodium nitrite, it is reasonable to administer sodium thiosulfate for cyanide poisoning.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01358,2023,14,2A,C-EO,"It is reasonable to administer 100% oxygen for cyanide poisoning. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01359,2023,15,Class 1,B-NR,We recommend administration of digoxin-specific antibody fragments (digoxin-Fab) for digoxin or digitoxin poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01360,2023,15,2A,C-LD,It is reasonable to administer digoxin-Fab for poisoning due to Bufo toad venom and yellow oleander.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01361,2023,15,2B,C-LD,"It may be reasonable to administer digoxin-Fab to treat poisoning from cardiac glycosides other than digoxin, digitoxin, Bufo toad venom, and yellow oleander.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01362,2023,15,2B,C-LD,It may be reasonable to administer atropine for bradydysrhythmias caused by digoxin and other cardiac glycoside poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01363,2023,15,2B,C-LD,It may be reasonable to attempt electrical pacing to treat bradydysrhythmias from digoxin and other cardiac glycoside poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01364,2023,15,2B,C-LD,"It may be reasonable to administer lidocaine, ­phenytoin, or bretylium to treat ventricular dys- rhythmias caused by digitalis and other cardiac glycoside poisoning until digoxin-Fab can be ad- ministered.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01365,2023,15,Class 3: No Benefit,B-NR,"We do not recommend the use of hemodialysis, hemofiltration, hemoperfusion, or plasmapheresis to treat digoxin poisoning. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01366,2023,18,Class 1,C-LD,We recommend the administration of intravenous lipid emulsion for local anesthetic poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01367,2023,18,Class 1,C-LD,We recommend the use of benzodiazepines to treat seizures associated with local anesthetic systemic toxicity.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01368,2023,18,2A,C-LD,It is reasonable to administer sodium bicarbonate for life-threatening wide-complex tachycardia associated with local anesthetic toxicity.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01369,2023,18,2A,C-EO,It is reasonable to administer atropine for life- threatening bradycardia associated with local anesthetic systemic toxicity.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01370,2023,18,2A,C-EO,"It is reasonable to utilize extracorporeal life support techniques such as VA-ECMO in local anesthetic toxicity with refractory cardiogenic shock. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01371,2023,19,Class 1,B-NR,We recommend administering methylene blue for methemoglobinemia.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01372,2023,19,2B,C-LD,Exchange transfusion may be reasonable as a treatment for methemoglobinemia that is not responsive to methylene blue.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01373,2023,19,2B,C-LD,Hyperbaric oxygen therapy may be reasonable as a treatment for methemoglobinemia that is not responsive to methylene blue.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01374,2023,19,Class 3: No Benefit,B-R,N-acetylcysteine is not recommended as a treatment for methemoglobinemia.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01375,2023,19,Class 3: No Benefit,C-LD,"Ascorbic acid is not recommended as a treatment for methemoglobinemia. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01376,2023,21,Class 1,C-LD,"For patients in respiratory arrest, rescue breath- ing or bag-mask ventilation should be maintained until spontaneous breathing returns, and standard BLS, ALS, and/or pediatric ALS measures should continue if return of spontaneous breathing does not occur.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01377,2023,21,Class 1,C-EO,"For patients known or suspected to be in cardiac arrest, in the absence of a proven benefit from the use of naloxone, standard resuscitative measures should take priority over naloxone administration, with a focus on high-quality CPR (compressions plus ventilation).",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01378,2023,21,Class 1,C-EO,Lay and trained responders should not delay acti- vating emergency response systems while await- ing the patient’s response to naloxone or other interventions.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01379,2023,21,2A,B-NR,"For a patient with suspected opioid overdose who has a definite pulse but no normal breathing or only gasping (ie, a respiratory arrest), in addition to providing standard BLS and/or ALS care, it is reasonable for responders to administer naloxone. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01380,2023,22,Class 1,C-LD,"After return of spontaneous breathing, patients should be observed in a healthcare setting until the risk of recurrent opioid toxicity is low and the patient’s level of consciousness and vital signs have normalized.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01381,2023,22,2A,C-LD,"If recurrent opioid toxicity develops, repeated small doses or an infusion of naloxone can be ben- eficial. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01382,2023,23,2A,B-R,"It is reasonable for lay rescuers to receive training in responding to opioid overdose, including provi- sion of naloxone.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01383,2023,26,Class 1,A,"We recommend giving atropine immediately for severe poisoning, such as bronchospasm, bron- chorrhea, seizures, or significant bradycardia, from organophosphate or carbamate poisoning.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01384,2023,26,Class 1,B-NR,We recommend early endotracheal intubation for life-threatening organophosphate or carbamate poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01385,2023,26,Class 1,C-LD,We recommend administration of benzodiazepines to treat seizures and agitation in the setting of organophosphate or carbamate poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01386,2023,26,Class 1,C-LD,We recommend use of appropriate personal pro- tective equipment when caring for patients with organophosphate or carbamate exposure.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01387,2023,26,Class 1,C-EO,We recommend dermal decontamination for exter- nal organophosphate or carbamate exposure.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01388,2023,26,2A,A,The use of pralidoxime is reasonable for organo- phosphate poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01389,2023,26,Class 3: No Benefit,C-LD,"Use of neuromuscular blockers metabolized by cholinesterase (ie, succinylcholine and mivacu- rium) is not recommended for patients with or- ganophosphate or carbamate poisoning. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01390,2023,28,Class 1,B-NR,We recommend using sodium bicarbonate to treat life-threatening cardiotoxicity from tricyclic and/or tetracyclic antidepressant poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01391,2023,28,2A,C-LD,It is reasonable to use sodium bicarbonate to treat life-threatening cardiotoxicity caused by poisoning from sodium channel blockers other than tricyclic or tetracyclic antidepressants.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01392,2023,28,2A,C-LD,"It is reasonable to use extracorporeal life sup- port, such as VA-ECMO, to treat refractory cardiogenic shock from sodium channel blocker poisoning.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01393,2023,28,2B,C-LD,"It may be reasonable to use Vaughan-Williams class Ib antidysrhythmics (eg, lidocaine) to treat life-threatening cardiotoxicity from class Ia or Ic sodium channel blockers.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01394,2023,28,2B,C-LD,It may be reasonable to use intravenous lipid emulsion to treat life-threatening sodium channel blocker poisoning refractory to other treatment modalities.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01395,2023,30,Class 1,B-NR,We recommend sedation for severe agitation from sympathomimetic poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01396,2023,30,Class 1,C-LD,We recommend rapid external cooling for life- threatening hyperthermia from sympathomimetic poisoning.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01397,2023,30,2A,C-EO,"Vasodilators, such as phentolamine and/or nitrates, are reasonable for coronary vasospasm from sympathomimetic poisoning.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01398,2023,30,2A,C-EO,"Mechanical circulatory support, such as intra- aortic balloon pump or VA-ECMO, is reasonable for cardiogenic shock from sympathomimetic poi- soning refractory to other treatment measures.",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01399,2023,30,Class 3: Harm,C-LD,"Prolonged use of physical restraint without sedation is potentially harmful. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01400,2023,32,2A,C-LD,It is reasonable to use VA-ECMO for persistent cardiogenic shock or cardiac arrest due to poison- ing that is not responsive to maximal treatment measures.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01401,2023,32,2A,C-LD,It is reasonable to use VA-ECMO for persistent dysrhythmias due to poisoning when other treat- ment measures fail.,lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01402,2023,32,2B,C-EO,"The effectiveness of VA-ECMO for poisoned patients with cardiovascular collapse from causes other than cardiogenic shock has not been estab- lished. Downloaded from http://ahajournals.org by on June 19, 2025",lavonas-et-al-2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life.pdf
id_01403,2023,12,Class 1,B-NR,"In patients with CCD and a change in symptoms or functional capacity that persists despite GDMT, stress positron emission tomography/single photon emission CT myocardial perfusion imaging (PET/ SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, or stress echocardiography is recommended to detect the presence and extent of myocardial ischemia, estimate risk of major adverse cardiovascular events (MACE), and guide therapeutic decision-making.*1–23",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01404,2023,12,Class 1,B-R,"In patients with CCD and a change in symptoms or functional capacity that persists despite GDMT, invasive coronary angiography (ICA) is recommended for guiding therapeutic decision-making with the goal of improving anginal symptoms.*24–28",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01405,2023,12,2A,B-R,"In patients with CCD and a change in symptoms or functional capacity that persists despite GDMT, when selected for rest/stress nuclear MPI, PET is reasonable in preference to SPECT, if available, to improve diagnostic accuracy and decrease the rate of nondiagnostic test results.*29",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01406,2023,12,2A,B-NR,"In patients with CCD and a change in symptoms or functional capacity that persists despite GDMT, exercise treadmill testing can be useful to determine whether the symptoms are consistent with angina pectoris, assess the severity of symptoms, evaluate functional capacity, and guide management.*26,30–32",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01407,2023,12,2A,B-NR,"In patients with CCD undergoing stress PET MPI or stress CMR imaging, the addition of myocardial blood flow reserve (MBFR) can be useful to improve diagnostic accuracy and enhance risk stratification.*18–23",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01408,2023,12,2A,B-NR,"In patients with CCD and a change in symptoms or functional capacity that persists despite GDMT, and who have had previous coronary revascularization, coronary CT angiography (CCTA) is reasonable to evaluate bypass graft or stent patency (for stents ≥3 mm).*33–37 *Modified from the 2021 AHA/ACC/Multisociety Guideline for the Evaluation and Diagnosis of Chest Pain.38",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01409,2023,13,Class 1,B-NR,"In patients with CCD, it is recommended that risk stratification incorporate all available information, including noninvasive, invasive, or both cardiovascular diagnostic testing results or use validated risk scores to classify patients as low (<1%), intermediate (1%-3%), or high (>3%) yearly risk for cardiovascular death or nonfatal MI.1–4 Relationship to Treatment",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01410,2023,13,Class 1,A,"In patients with CCD, optimization of GDMT is recommended to reduce MACE.*5–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01411,2023,13,Class 1,A,"In patients with CCD with newly reduced LV systolic function, clinical heart failure, or both, ICA is recommended to assess coronary anatomy and guide potential revascularization.8,9",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01412,2023,13,Class 3: No Benefit,A,"In patients with CCD, ICA for risk stratification is not routinely recommended in patients without LV systolic dysfunction, heart failure, stable chest pain refractory to GDMT, and/or noninvasive testing sug- gestive of significant (>50%) left main disease.5–7,10,11 *Modified from the 2021 AHA/ACC/Multisociety Guideline for the Evaluation and Diagnosis of Chest Pain.12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01413,2023,15,Class 1,C-LD,"In patients with CCD, clinical follow-up at least annually is recommended to assess for symptoms,1–12 change in functional status, adherence to and adequacy of lifestyle and medical interventions,13–15 and monitoring for complications of CCD and its treatments.16–18",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01414,2023,15,2B,B-NR,"In patients with CCD, use of a validated CCD-specific patient-reported health status measure may be reasonable to assess symptoms, functional status, and QOL.19–23",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01415,2023,16,Class 1,A,"In patients with CCD, a multidisciplinary team- based approach is recommended to improve health outcomes, facilitate modification of ASCVD risk factors, and improve health service utilization.*1–13 *Modified from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.14",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01416,2023,17,Class 1,C-LD,"Patients with CCD should receive ongoing individualized education on symptom management, lifestyle changes, and SDOH risk factors to improve knowledge and facilitate behavior change.1",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01417,2023,17,Class 1,C-LD,Patients with CCD should receive ongoing individualized education on medication adherence to improve knowledge and facilitate behavior change.2–4,virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01418,2023,18,Class 1,C-LD,"Patients with CCD and their clinicians should engage in shared decision-making particularly when evidence is unclear on the optimal diagnostic or treatment strategy, or when a significant risk or benefit tradeoff exists.1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01419,2023,18,2B,B-R,"For patients with CCD and angina on GDMT who are engaged in shared decision-making regarding revascularization, a validated decision aid may be considered to improve patient understanding and knowledge about treatment options.4",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01420,2023,19,Class 1,B-R,"In patients with CCD, routine assessment by clinicians and the care team for SDOH is recom- mended to inform patient-centered treatment deci- sions and lifestyle change recommendations.*1–8 *Modified from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.9",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01421,2023,21,Class 1,B-R,"In patients with CCD, a diet emphasizing vegetables, fruits, legumes, nuts, whole grains, and lean protein is recommended to reduce the risk of CVD events.*1–4",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01422,2023,21,2A,B-NR,"In patients with CCD, reducing the percentage of calories from saturated fat (<6% of total calories) and replacing with dietary monounsaturated and polyunsaturated fat, complex carbohydrates, and dietary fiber can be beneficial to reduce the risk of CVD events.*1–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01423,2023,21,2A,B-NR,"In patients with CCD, minimization of sodium (<2300 mg/d; optimally 1500 mg/d) and minimi- zation of processed meats (eg, cured bacon, hot dogs) can be beneficial to reduce the risk of CVD events.*2,3,6,7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01424,2023,21,2A,B-NR,"In patients with CCD, limiting refined carbohy- drates (eg, containing <25% whole grain by weight, including refined cold ready-to-eat break- fast cereal, white bread, white rice), and sugar- sweetened beverages (eg, soft drinks, energy drinks, fruit drinks with added sugars) can be beneficial to reduce the risk of CVD events.*2–4,6,8",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01425,2023,21,Class 3: Harm,B-NR,"In patients with CCD, the intake of trans fat should be avoided because trans fat is associated with increased morbidity and mortality rates.*9,10 Nutrition Supplements",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01426,2023,21,Class 3: No Benefit,B-NR,"In patients with CCD, the use of nonprescription or dietary supplements, including omega-3 fatty acid, vitamins C, D, E, beta-carotene, and calcium, is not beneficial to reduce the risk of acute CVD events.11–22 *Modified from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.23",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01427,2023,23,2A,B-R,"In patients with CCD, targeted discussions and screening for mental health is reasonable for clini- cians to assess and to refer for additional mental health evaluation and management.1–4",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01428,2023,23,2A,B-R,"In patients with CCD, treatment for mental health conditions with either pharmacologic or nonphar- macologic therapies, or both, is reasonable to improve cardiovascular outcomes.2,4–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01429,2023,25,Class 1,A,"In patients with CCD, tobacco use should be assessed at every health care visit to facilitate identification of those who may benefit from behavioral or pharmacologic interventions.*1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01430,2023,25,Class 1,A,Patients with CCD who regularly smoke tobacco should be advised to quit at every visit.*4,virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01431,2023,25,Class 1,A,"In patients with CCD who regularly smoke tobacco, behavioral interventions are recommended to maximize cessation rates in combination with pharmacotherapy, including bupropion, varenicline, or combination long- and short-acting nicotine replacement therapy (NRT).*5–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01432,2023,25,2B,B-R,"In patients with CCD who regularly smoke tobacco, varenicline may be considered versus bupropion or NRT to increase cessation rates.6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01433,2023,25,2B,B-R,"In patients with CCD who regularly smoke tobacco, the short-term use of nicotine-containing e-ciga- rettes may be considered to aid smoking cessation, although the risk of sustained use and unknown long-term safety may outweigh the benefits.8–10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01434,2023,25,Class 3: Harm,B-NR,"Patients with CCD should avoid secondhand smoke exposure to reduce risk of cardiovascular events.*11,12 *Modified from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.13",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01435,2023,26,Class 1,C-LD,Patients with CCD should be routinely asked and counseled about substance use to reduce ASCVD events.1–5,virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01436,2023,26,2A,B-NR,"In patients with CCD who consume alcohol, it is reasonable to limit alcohol intake (≤1 drink/d for women, ≤2 drinks/d for men) to reduce cardiovascular and all-cause death.6–8",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01437,2023,26,Class 3: No Benefit,B-NR,"Patients with CCD should not be advised to consume alcohol for the purpose of cardiovascular protection. 9,10 Downloaded from http://ahajournals.org by on June 19, 2025",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01438,2023,28,2A,B-NR,"In patients with CCD, it is reasonable to individual- ize resumption of sexual activity based on type of sexual activity, exercise capacity, and postproce- dural healing.*1,2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01439,2023,28,2A,B-NR,"In patients with CCD, cardiac rehabilitation and regular exercise can be useful to reduce the risk of cardiovascular complications with sexual activity.*3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01440,2023,28,Class 3: Harm,B-NR,"In patients with CCD, phosphodiesterase type 5 inhibi- tors should not be used concomitantly with nitrate medications because of risk for severe hypotension.*4 *Modified from the 2012 AHA Scientific Statement on Sexual Activity and Cardiovascular Disease.5",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01441,2023,29,Class 1,A,"In patients with CCD, high-intensity statin ther- apy is recommended with the aim of achieving a ≥50% reduction in LDL-C levels to reduce the risk of MACE.*1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01442,2023,29,Class 1,A,"In patients in whom high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy is recom- mended with the aim of achieving a 30% to 49% reduction in LDL-C levels to reduce the risk of MACE.*2,4–8",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01443,2023,29,Class 1,A,"In patients with CCD, adherence to changes in lifestyle and effects of lipid-lowering medication should be assessed by measurement of fasting lipids in 4 to 12 weeks after statin initiation or dose adjustment and then every 3 to 12 months thereafter based on need to assess response or adherence to therapy.*2,9–11 Cost Value Statement: High Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01444,2023,29,2A,B-R,"In patients with CCD who are judged to be at very high risk (Table 10) and on maximally tol- erated statin therapy with an LDL-C level ≥70 mg/dL (≥1.8 mmol/L), ezetimibe can be ben- eficial to further reduce the risk of MACE.*14–19 Cost Value Statement: High Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01445,2023,29,2A,A,"In patients with CCD who are judged to be at very high risk (Table 10) and who have an LDL-C level ≥70 mg/dL (≥1.8 mmol/L), or a non–high-density lipoprotein cholesterol (HDL-C) level ≥100 mg/dL (≥2.6 mmol/L), on maximally tolerated statin and ezetimibe, a PCSK9 monoclonal antibody can be beneficial to further reduce the risk of MACE.*22–29 Cost Value Statement: Uncertain B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01446,2023,29,2B,B-R,"In patients with CCD on maximally tolerated statin therapy with an LDL-C level <100 mg/ dL (<2.6 mmol/L) and a persistent fasting tri- glyceride level of 150 to 499 mg/dL (1.7–5.6 mmol/L) after addressing secondary causes, icosapent ethyl may be considered to further reduce the risk of MACE and cardiovascular death.32",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01447,2023,29,2B,B-R,"In patients with CCD who are not at very high risk and on maximally tolerated statin therapy with an LDL-C level ≥70 mg/dL (≥1.8 mmol/L), it may be reasonable to add ezetimibe to further reduce the risk of MACE.*14,15,18,19",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01448,2023,29,2B,B-R,"In patients with CCD on maximally tolerated statin therapy who have an LDL-C level ≥70 mg/dL (≥1.8 mmol/L), and in whom ezetimibe and PCSK9 monoclonal antibody are deemed insufficient or not tolerated, it may be reason- able to add bempedoic acid33,34 or inclisiran35 (in place of PCSK9 monoclonal antibody) to further reduce LDL-C levels.",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01449,2023,29,Class 3: No Benefit,B-R,"In patients with CCD receiving statin therapy, adding niacin,36,37 or fenofibrate38 or dietary supplements containing omega-3 fatty acids, are not beneficial in reducing cardiovascular risk.39–41 *Modified from the 2018 AHA/ACC/Multisociety Guideline on the Manage- ment of Blood Cholesterol.42",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01450,2023,34,Class 1,A,"In adults with CCD, nonpharmacologic strategies are recommended as first-line therapy to lower BP in those with elevated BP (120-129/<80 mm Hg) (see Table 12).*1–9",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01451,2023,34,Class 1,B-R,"In adults with CCD who have hypertension, a BP target of <130/<80 mm Hg is recommended to reduce CVD events and all-cause death.*10–14",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01452,2023,34,Class 1,B-R,"In adults with CCD and hypertension (systolic BP ≥130 and/or diastolic BP ≥80 mm Hg), in addition to nonpharmacological strategies, GDMT angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB), or beta blockers15–17 are recommended as first-line ther- apy for compelling indications (eg, recent MI or angina), with additional antihypertensive medica- tions (eg, dihydropyridine calcium channel block- ers [CCB], long-acting thiazide diuretics, and/or mineralocorticoid receptor antagonists) added as needed to optimize BP control.*13,18 *Modified from the 2017 ACC/AHA Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.19",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01453,2023,35,Class 1,A,"In patients with CCD who have type 2 diabetes, the use of either an SGLT2 inhibitor1–8 or a GLP-1 receptor agonist9–17 with proven cardio- vascular benefit is recommended to reduce the risk of MACE. Cost Value Statement: High Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01454,2023,36,Class 1,A,"In patients with CCD and heart failure with LVEF ≤40%, use of an SGLT2 inhibitor is rec- ommended to reduce the risk of cardiovascular death and heart failure hospitalization19–22 and to improve QOL,23,24 irrespective of diabetes status.* Cost Value Statement: Intermedi- ate Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01455,2023,36,2A,B-R,"In patients with CCD and heart failure with LVEF >40%, use of an SGLT2 inhibitor can be beneficial in decreasing heart failure hospitalizations27,28 and to improve QOL,4,29 irrespective of diabetes status. Cost Value Statement: Intermedi- ate Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01456,2023,37,Class 1,C-EO,"In patients with CCD, assessment of BMI with or without waist circumference is recommended dur- ing routine clinical follow-up.1–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01457,2023,37,Class 1,B-NR,"Patients with CCD and overweight or obesity should receive counseling on diet, lifestyle, and goals for weight loss.7–10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01458,2023,37,2A,B-R,"For patients with CCD and overweight or obesity in whom pharmacologic therapy is warranted for further weight reduction, a GLP-1 receptor agonist can be beneficial in addition to counseling for diet and physical activity,11,12 and it is reasonable to choose semaglutide over liraglutide.13,14 Downloaded from http://ahajournals.org by on June 19, 2025",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01459,2023,38,2A,B-NR,"In patients with CCD and severe obesity who have not met weight loss goals with lifestyle and pharmacologic intervention, and who have acceptable surgical risk, referral for consideration of a bariatric procedure is reasonable for weight loss and cardiovascular risk factor reduction.15–18",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01460,2023,38,Class 3: Harm,B-R,"In patients with CCD, use of sympathomimetic weight loss drugs is potentially harmful.19",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01461,2023,40,Class 1,A,"For patients with CCD who do not have contrain- dications, an exercise regimen is recommended, including ≥150 minutes/wk of moderate-intensity aerobic activities or ≥75 minutes/wk of higher- intensity aerobic activities to improve functional capacity and QOL, and to reduce hospital admis- sion and mortality rates.1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01462,2023,40,Class 1,B-R,"For patients with CCD who do not have contraindi- cations, resistance (strength) training exercises are recommended on ≥2 days/wk to improve muscle strength, functional capacity, and cardiovascular risk factor control.4–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01463,2023,40,2A,B-NR,"For patients with CCD who do not have contra- indications, lower-intensity lifestyle activities (eg, walking breaks at work) to reduce sedentary behavior (ie, sitting time) are reasonable to improve functional capacity and reduce cardiovascular risk, especially in individuals with low levels of habitual leisure time physical activity.7–9",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01464,2023,41,2A,B-NR,"In patients with CCD, minimization of exposure to ambient air pollution is reasonable to reduce the risk of cardiovascular events.1–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01465,2023,41,2B,B-NR,"In patients with CCD, minimization of climate-related exposures (eg, extreme temperatures, wildfire smoke) may be reasonable to reduce the risk of cardiovascular events.8–10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01466,2023,42,Class 1,A,"In patients with CCD and no indication for oral anticoagulant therapy, low-dose aspirin 81 mg (75-100 mg) is recommended to reduce atherosclerotic events.*1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01467,2023,42,Class 1,A,"In patients with CCD treated with PCI, dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel for 6 months post PCI followed by single antiplatelet therapy (SAPT) is indicated to reduce MACE and bleeding events.*4–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01468,2023,42,2A,A,"In select patients with CCD treated with PCI and a drug-eluting stent (DES) who have completed a 1- to 3-month course of DAPT, P2Y12 inhibitor monotherapy for at least 12 months is reasonable to reduce bleeding risk.8–12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01469,2023,42,2B,A,"In patients with CCD who have had a previous MI and are at low bleeding risk, extended DAPT beyond 12 months for a period of up to 3 years may be reasonable to reduce MACE.*13,14",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01470,2023,42,2B,B-R,"In patients with CCD and a previous history of MI without a history of stroke, transient ischemic attack (TIA), or ICH, vorapaxar may be added to aspirin therapy to reduce MACE.15–17",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01471,2023,42,2B,B-R,"In patients with CCD, the use of DAPT after CABG may be useful to reduce the incidence of saphenous vein graft occlusion.18",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01472,2023,42,Class 3: No Benefit,A,"In patients with CCD without recent ACS or a PCI-related indication for DAPT, the addition of clopidogrel to aspirin therapy is not useful to reduce MACE.*19",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01473,2023,42,Class 3: Harm,A,"In patients with CCD and previous stroke, TIA, or ICH, vorapaxar should not be added to DAPT because of increased risk of major bleeding and ICH.15,20",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01474,2023,42,Class 3: Harm,B-R,"In patients with CCD and previous stroke, TIA, or ICH, prasugrel should not be used because of risk of significant or fatal bleeding.21",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01475,2023,42,Class 3: Harm,B-R,"In patients with CCD, chronic nonsteroidal anti-inflammatory drugs should not be used because of increased cardiovascular and bleeding complications.*22 Antiplatelet Therapy With Direct Oral Anticoagulant (DOAC)",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01476,2023,42,Class 1,B-R,"In patients with CCD who have undergone elective PCI and who require oral anticoagulant therapy, DAPT for 1 to 4 weeks followed by clopidogrel alone for 6 months should be administered in addition to DOAC.†23",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01477,2023,42,2A,B-R,"In patients with CCD who have undergone PCI and who require oral anticoagulant therapy, continuing aspirin in addition to clopidogrel for up to 1 month is reasonable if the patient has a high thrombotic risk and low bleeding risk.*23–25",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01478,2023,42,2B,B-R,"In patients with CCD who require oral anticoagula- tion and have a low atherothrombotic risk, discon- tinuation of aspirin therapy with continuation of DOAC alone may be considered 1 year after PCI to reduce bleeding risk.*26",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01479,2023,42,2B,C-LD,"In patients with CCD who require oral anticoagula- tion, DOAC monotherapy may be considered if there is no acute indication for concomitant anti- platelet therapy.27–29 Antiplatelet Therapy and Low-Dose DOAC",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01480,2023,42,2A,B-R,"In patients with CCD without an indication for ther- apeutic DOAC or DAPT and who are at high risk of recurrent ischemic events but low-to-moderate bleeding risk, the addition of low-dose rivaroxaban 2.5 mg twice daily to aspirin 81 mg daily is reason- able for long-term reduction of risk for MACE.30–32 DAPT and Proton Pump Inhibitor (PPI)",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01481,2023,42,2A,B-R,"In patients with CCD on DAPT, the use of a PPI can be effective in reducing gastrointestinal bleed- ing risk.*33 *Modified from the 2016 ACC/AHA Guideline Focused Update on DAPT.34 †Modified from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.35",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01482,2023,47,Class 1,A,"In patients with CCD and LVEF ≤40% with or without previous MI, the use of beta-blocker ther- apy is recommended to reduce the risk of future MACE, including cardiovascular death.1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01483,2023,47,Class 1,A,"In patients with CCD and LVEF <50%, the use of sustained release metoprolol succinate, carvedilol, or bisoprolol with titration to target doses is recom- mended in preference to other beta blockers.*1,3–8",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01484,2023,47,2B,B-NR,"In patients with CCD who were initiated on beta- blocker therapy for previous MI without a history of or current LVEF ≤50%, angina, arrhythmias, or uncontrolled hypertension, it may be reasonable to reassess the indication for long-term (>1 year) use of beta-blocker therapy for reducing MACE.9–15",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01485,2023,47,Class 3: No Benefit,B-NR,"In patients with CCD without previous MI or LVEF ≤50%, the use of beta-blocker therapy is not ben- eficial in reducing MACE, in the absence of another primary indication for beta-blocker therapy.†16–19 *Modified from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.20 †Adapted from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.21",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01486,2023,48,Class 1,A,"In patients with CCD who also have hypertension, diabetes, LVEF ≤40%, or CKD, the use of ACE inhibitors, or ARBs if ACE inhibitor–intolerant, is recommended to reduce cardiovascular events.1–5",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01487,2023,48,2B,B-R,"In patients with CCD without hypertension, dia- betes, or CKD and LVEF >40%, the use of ACE inhibitors or ARBs may be considered to reduce cardiovascular events. 6–10 Downloaded from http://ahajournals.org by on June 19, 2025",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01488,2023,49,2B,B-R,"In patients with CCD, the addition of colchicine for secondary prevention may be considered to reduce recurrent ASCVD events.1,2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01489,2023,50,Class 1,A,"In patients with CCD, an annual influenza vaccina- tion is recommended to reduce cardiovascular mor- bidity, cardiovascular death, and all-cause death.1–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01490,2023,50,Class 1,C-EO,"In patients with CCD, coronavirus disease 2019 (COVID-19) vaccination is recommended per public health guidelines to reduce COVID-19 com- plications.8–10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01491,2023,50,2A,B-NR,"In patients with CCD, a pneumococcal vaccine is reasonable to reduce cardiovascular morbidity and mortality and all-cause death.11–13",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01492,2023,51,Class 1,B-R,"In patients with CCD and angina, antianginal therapy with either a beta blocker, CCB, or long- acting nitrate is recommended for relief of angina or equivalent symptoms.*1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01493,2023,51,Class 1,B-R,"In patients with CCD and angina who remain symptomatic after initial treatment, addition of a second antianginal agent from a different thera- peutic class (beta blockers, CCB, long-acting nitrates) is recommended for relief of angina or equivalent symptoms.*3–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01494,2023,51,Class 1,B-R,"In patients with CCD, ranolazine is recommended in patients who remain symptomatic despite treatment with beta blockers, CCB, or long- acting nitrate therapies.*7,8",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01495,2023,51,Class 1,B-NR,"In patients with CCD, sublingual nitroglycerin or nitroglycerin spray is recommended for immediate short-term relief of angina or equivalent symp- toms.*9,10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01496,2023,51,Class 3: Harm,B-R,"In patients with CCD and normal LV function, the addition of ivabradine to standard anti-anginal therapy is potentially harmful.*11 *Modified from the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD.12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01497,2023,52,2B,B-R,"In patients with CCD, refractory angina, and no other treatment options, enhanced external coun- terpulsation may be considered for relief of symp- toms.*1 *Modified from the 2012 ACC/AHA Multisociety Guideline for the Diagnosis and Management of Patients With SIHD.2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01498,2023,53,Class 1,A,"In patients with CCD and lifestyle-limiting angina despite GDMT and with significant coronary artery stenoses amenable to revascularization, revascularization is recom- mended to improve symptoms.*1–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01499,2023,53,Class 1,B-R,"In patients with CCD who have significant left main disease or multivessel disease with severe LV dysfunction (LVEF ≤ 35%), CABG in addition to medical therapy is rec- ommended over medical therapy alone to improve survival.*8–11 Cost Value Statement: Intermediate Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01500,2023,53,2A,B-R,"In patients with CCD and multivessel CAD appropriate for either CABG or PCI, revascu- larization in addition to GDMT is reasonable to lower the risk of cardiovascular events such as spontaneous MI, unplanned urgent revascularizations, or cardiac death.*13–20",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01501,2023,53,2A,B-NR,"In selected patients with CCD and significant left main stenosis for whom PCI can provide equivalent revascularization to that possible with CABG, PCI is reasonable to improve survival.*21 Decision-Making for Revascularization",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01502,2023,53,Class 1,A,"In patients with CCD who have angina or an anginal equivalent, no previous evaluation for ischemia, and angiographically intermediate stenoses, the use of FFR or other proven nonhyperemic pressure ratios (eg, iFR) is recommended before proceeding with PCI.*2,22,23 Cost Value Statement: High Value B-NR",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01503,2023,53,Class 1,B-NR,"In patients with CCD with complex 3-vessel disease or for whom the optimal treatment strategy is unclear, a Heart Team approach that includes representatives from interven- tional cardiology and cardiac surgery is recom- mended to improve patient outcomes.*26–29 *Modified from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.30",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01504,2023,56,Class 1,B-R,"In patients with CCD who require revascularization for significant left main involvement associated with high-complexity CAD, CABG is recommended in preference to PCI to improve survival.*1,2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01505,2023,56,2A,B-R,"In patients with CCD who require revasculariza- tion for multivessel CAD with complex and diffuse CAD (eg, SYNTAX score >33), it is reasonable to choose CABG over PCI to improve survival.*1,3–6 Patients With CCD at High Surgical Risk",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01506,2023,56,2A,B-NR,"In patients with CCD who are appropriate for revascularization but poor candidates for surgery, it is reasonable to choose PCI over CABG to improve symptoms and reduce MACE.7–9 Patients With CCD and Diabetes",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01507,2023,56,Class 1,A,"In patients with CCD, diabetes, and multivessel CAD with involvement of the left anterior descend- ing artery who are appropriate candidates for CABG, CABG (with a left internal mammary artery to the left anterior descending artery) is recom- mended in preference to PCI to reduce mortality and repeat revascularizations.*5,10–17",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01508,2023,56,2B,B-R,"In patients with CCD and diabetes who have left main stenosis and low- or intermediate-complexity CAD (eg, SYNTAX score ≤33), PCI may be considered as an alternative to CABG to reduce MACE.*10,18 *Modified from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.19",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01509,2023,57,Class 1,C-LD,"In patients with CCD who have experienced SCAD, counseling should be provided regard- ing potential triggers and risk of SCAD recur- rence.1–12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01510,2023,57,2A,C-LD,"In patients with CCD who have experienced SCAD, evaluation for underlying vasculopathies is reason- able to identify abnormalities in other vascular beds.1–4,7,10,13–15",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01511,2023,57,2B,C-LD,"In patients with CCD who have experienced SCAD, beta-blocker therapy may be reasonable to reduce the incidence of recurrent SCAD.1",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01512,2023,58,2A,B-R,"In symptomatic patients with nonobstructive CAD, a strategy of stratified medical therapy* guided by invasive coronary physiologic testing can be useful for improving angina severity and QOL.1,2 *See recommendation-specific supportive text for details. Table 14.  Screening Questions for SCAD-Associated Arteriopathies and Connective Tissue Disorders Personal history (Have you ever been diagnosed with or experienced any of the following?) Early-onset hypertension Stroke or transient ischemic attack Pulsatile tinnitus Migraine headaches Renal infarction Subarachnoid hemorrhage Aneurysm (aortic, peripheral, brain) Dissection (aortic, peripheral) Rupture of hollow organs (intestinal, bladder, uterine) Pneumothorax Tendon or muscle rupture Joint dislocation Talipes equinovarus (clubfoot) Umbilical or inguinal hernia Scoliosis or pectus deformity Pregnancy complications (cervical incompetence, hemorrhage, uterine prolapse, hypertension) Poor wound healing Ectopia lentis Myopia Detached retina, early glaucoma, or early cataracts Tall stature Abnormality of cardiac valve Systemic inflammatory disease Family history (Does anyone in your family have the following?) Dissection (coronary, aortic, peripheral) Inherited arteriopathy or connective tissue disorder (eg, vascular Ehlers-Danlos syndrome, Marfan syndrome, Loeys-Dietz syndrome) Early stroke, early myocardial infarction, sudden cardiac death Review of systems (Are you currently experiencing any of the following?) Headaches Pulsatile tinnitus Postprandial abdominal pain Flank pain Claudication Easy bruising Joint hypermobility or laxity",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01513,2023,61,2A,C-LD,"In young adults with CCD, after optimization of traditional cardiovascular risk factors, a compre- hensive evaluation and treatment of nontraditional cardiovascular risk factors can be beneficial in reducing the risk of cardiovascular events.1–3",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01514,2023,62,Class 1,C-LD,"In patients with CCD and cancer, a multidisciplinary team including cardiology and oncology expertise is recommended to improve long-term CVD out- comes.1,2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01515,2023,63,Class 1,C-LD,"Women with CCD who are contemplating preg- nancy or who are pregnant should be risk-stratified and counseled regarding risks of adverse maternal, obstetric, and fetal outcomes.1–4",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01516,2023,63,Class 1,C-LD,"Women with CCD who are contemplating preg- nancy or who are pregnant should receive care from a multidisciplinary cardio-obstetric care team beginning before conception and continuing throughout pregnancy, delivery, and postpartum to improve maternal and fetal outcomes.1,2,5",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01517,2023,63,2B,C-LD,"In women with CCD, continuation of statin use dur- ing pregnancy may be considered.6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01518,2023,63,Class 3: Harm,C-LD,"Women with CCD who are contemplating pregnancy or who are pregnant should not use ACE inhibitors, ARBs, direct renin inhibitors, angiotensin receptor- neprilysin inhibitors, or aldosterone antagonists dur- ing pregnancy to prevent harm to the fetus.2,7,8 Postmenopausal Hormone Therapy",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01519,2023,63,Class 3: Harm,A,"Women with CCD should not receive systemic postmenopausal hormone therapy because of a lack of benefit on MACE and mortality, and an increased risk of venous thromboembolism.9–11",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01520,2023,67,Class 1,C-LD,"In patients with CCD and CKD, measures should be taken to minimize the risk of treatment-related acute kidney injury.*1–3 *Modified from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.4",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01521,2023,67,Class 1,B-R,"In adults with CCD and HIV, antiretroviral therapy is beneficial to decrease the risk of cardiovascular events.1,2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01522,2023,67,2A,B-R,"In adults with CCD and HIV, it is reasonable to choose antiretroviral therapy regimens associated with more favorable lipid and cardiovascular risk pro- files with consideration of drug-drug interactions.3–5",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01523,2023,67,Class 3: Harm,C-LD,"In adults with CCD and HIV, lovastatin or simvastatin should not be administered with protease inhibitors as this may cause harm.6,7 Autoimmune Disorders in CCD",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01524,2023,67,2A,C-LD,"In adults with CCD and rheumatoid arthritis, initia- tion and maintenance of disease-modifying anti- rheumatoid drugs is beneficial to decrease the risk of cardiovascular events.8–11",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01525,2023,67,2B,C-LD,"In adults with CCD and autoimmune diseases, treatment with biologics and other immune modu- lating therapies that reduce disease activity may be considered to decrease the risk of cardiovascular events.10,11",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01526,2023,67,Class 3: Harm,C-LD,"In patients with CCD and rheumatoid arthritis, high- dose glucocorticoids should not be used long term if alternative therapies are available because of increased cardiovascular risk.11,12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01527,2023,69,Class 1,C-LD,"In patients with cardiac allograft vasculopathy, statins are recommended for secondary prevention to reduce MACE.1",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01528,2023,69,2A,C-LD,"In patients with cardiac allograft vasculopathy, aspirin can be beneficial for secondary prevention to reduce MACE.2",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01529,2023,69,2A,C-LD,"In patients with severe cardiac allograft vasculopathy, revascularization is reasonable in those with suitable anatomy to potentially mitigate the adverse long-term consequences of cardiac allograft vasculopathy.*3–6 *Modified from the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re- vascularization.7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01530,2023,71,2B,B-R,"In stable patients with CCD and with previous ACS or coronary revascularization, referral to telehealth programs, community-based programs, or both for lifestyle interventions may be reasonable as an adjunct to usual care to improve management of cardiovascular risk factors.1–7",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01531,2023,71,Class 3: No Benefit,B-R,"In patients with CCD without a change in clinical or functional status on optimized GDMT, routine periodic testing with coronary CTA or stress testing with or without imaging is not recommended to guide therapeutic decision-making.8–10",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01532,2023,71,Class 3: No Benefit,B-R,"In patients with CCD without a change in clinical or functional status, routine periodic reassessment of LV function is not recommended to guide thera- peutic decision-making.11,12",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01533,2023,71,Class 3: Harm,B-NR,"In patients with CCD without a change in clinical or functional status, routine periodic invasive coronary angiography should not be performed to guide therapeutic decision-making.13–17",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01534,2023,72,Class 1,B-NR,"When discussing treatment and prevention with patients who have CCD, it is recommended that the health care team discuss out-of-pocket costs for medications at the time of initiating a new med- ication and at least annually thereafter to preempt cost-related nonadherence.1–6",virani-et-al-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of-patients-with-chronic-coronary-disease-a.pdf
id_01535,2024,10,2A,B-NR,"In patients with known CVD being considered for NCS, a validated risk-prediction tool can be useful to estimate the risk of perioperative MACE.1–4",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01536,2024,12,2A,B-NR,"In patients undergoing elevated-risk NCS, a structured assessment of functional capac­ ity (such as the Duke Activity Status Index [DASI]) is reasonable to stratify the risk of perioperative adverse cardiovascular events.1–8",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01537,2024,13,2A,B-NR,"In all patients ≥65 years of age and in those <64 years with perceived frailty who are undergoing elevated-risk NCS, preoperative frailty assessment using a validated tool can be useful for evaluating perioperative risk and guiding management.1–5",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01538,2024,14,2A,B-NR,"In patients with known CVD, or age ≥65 years, or age ≥45 years with symptoms suggestive of CVD undergoing elevated-risk NCS, it is reasonable to measure B-type natriuretic peptide (BNP) or N- terminal pro–B-type natriuretic peptide (NT-proBNP) before surgery to supplement evaluation of perioperative risk.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01539,2024,14,2B,B-NR,"In patients with known CVD, or age ≥65 years, or age ≥45 years with symptoms suggestive of CVD undergoing elevated-risk NCS, it may be reasonable to measure cardiac troponin (cTn) before surgery to supplement evaluation of peri­ operative risk.4–6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01540,2024,15,2A,B-NR,"For patients with known coronary heart disease, signifi­ cant arrhythmia, peripheral arterial disease, cerebrovas­ cular disease, other significant structural heart disease, or symptoms* of CVD undergoing elevated-risk sur­ gery, a preoperative resting 12-lead electrocardiogram (ECG) is reasonable to establish a preoperative base­ line and guide perioperative management.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01541,2024,15,2A,B-NR,"In patients undergoing NCS with a preoperative ECG exhibiting new abnormalities,† further evalu­ ation is reasonable to refine assessment of cardio­ vascular risk.3–8",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01542,2024,15,2B,B-NR,"For asymptomatic patients undergoing elevated-risk surgeries without known CVD, a preoperative rest­ ing 12-lead ECG may be considered to establish a baseline and guide perioperative management.3,9,10",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01543,2024,15,Class 3: No Benefit,B-NR,"For asymptomatic patients undergoing low-risk surgi­ cal procedures, a routine preoperative resting 12-lead ECG is not recommended to improve outcomes.11 *Active symptoms and signs of CVD include chest pain, dyspnea, undiagnosed palpitations, tachycardia, syncope, or murmurs. †Abnormalities may include ST-segment elevation, ST depression, T-wave inversions, left ventricular (LV) hypertrophy, significant pathologic Q-waves, Mo­ bitz type II or higher atrioventricular block, bundle branch block, QT prolonga­ tion, or AF.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01544,2024,16,Class 1,B-NR,"In patients undergoing NCS with new dyspnea, physical examination findings of HF, or suspected new/worsening ventricular dysfunction, it is recom­ mended to perform preoperative evaluation of LV function to help guide perioperative management.1–8",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01545,2024,16,2A,C-LD,"In patients with a known diagnosis of HF with wors­ ening dyspnea or other change in clinical status undergoing NCS, preoperative assessment of LV function is reasonable to help guide perioperative management.1,4,7,9–11",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01546,2024,16,Class 3: No Benefit,B-NR,"In asymptomatic and clinically stable patients undergo­ ing NCS, routine preoperative evaluation of LV func­ tion is not recommended due to lack of benefit.12–15",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01547,2024,17,2B,B-NR,"For patients undergoing elevated-risk NCS with poor or unknown functional capacity and elevated risk for perioperative cardiovascular events based on a validated risk tool, stress testing may be consid­ ered to evaluate for inducible myocardial ischemia.1",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01548,2024,17,Class 3: No Benefit,B-R,"In patients who are at low risk for perioperative cardiovascular events, have adequate* functional capacity with stable symptoms, or who are undergo­ ing low-risk procedures, routine stress testing before NCS is not recommended due to lack of benefit.1–3 *Poor functional capacity is considered <4 METs or a DASI score of ≤34.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01549,2024,19,2B,B-NR,"For patients undergoing elevated-risk surgery with poor* or unknown functional capacity, and elevated risk for perioperative cardiovascular events based on a validated risk tool, coronary computed tomog­ raphy angiography (CCTA) for the detection of high-risk coronary anatomy† may be considered.1–4",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01550,2024,19,Class 3: No Benefit,B-NR,"In patients who are at low risk for perioperative cardiovascular events, have adequate* functional capacity with stable symptoms, or who are undergo­ ing low-risk procedures, routine CCTA before NCS is not recommended due to lack of benefit.1,5 *Poor functional capacity is considered <4 METs or a DASI score of ≤34. †High-risk coronary anatomy is defined as patients with obstructive stenosis who have ≥50% left main stenosis or anatomically significant 3-vessel disease (≥70% stenosis).6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01551,2024,20,Class 3: No Benefit,C-LD,"In patients undergoing NCS, routine preoperative invasive coronary angiography (ICA) is not recom­ mended to improve perioperative outcomes.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01552,2024,22,Class 1,C-LD,"In patients with ACS being considered for elective NCS, coronary revascularization as appropriate and deferral of surgery is recommended to reduce peri­ operative cardiovascular events.1–9",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01553,2024,22,2A,C-LD,"In patients with CCD and hemodynamically signifi­ cant left main coronary artery stenosis ≥50% who are planning elective NCS, coronary revasculariza­ tion and deferral of surgery is reasonable to reduce perioperative cardiovascular events.10,11",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01554,2024,22,Class 3: No Benefit,B-R,"In patients with non–left main CAD who are planned for NCS, routine preoperative coronary revascularization is not recommended to reduce perioperative cardiovascular events.*12–15 *Modified from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Re­ vascularization.”16",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01555,2024,23,2A,C-EO,"In most* patients with hypertension planned for elec­ tive NCS, it is reasonable to continue medical therapy for hypertension throughout the perioperative period.†",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01556,2024,23,2B,C-LD,"In patients undergoing elective elevated-risk surgery who have cardiovascular risk factors for periopera­ tive complications‡ and recent history of poorly con­ trolled hypertension (systolic blood pressure [SBP] ≥180 mm Hg or diastolic blood pressure [DBP] ≥110 mm Hg before the day of surgery), deferring surgery may be considered to reduce the risk of perioperative complications.†1,2 Intraoperative Blood Pressure Management",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01557,2024,23,Class 1,B-NR,"In patients undergoing NCS, maintaining an intraop­ erative mean arterial pressure (MAP) ≥60 to 65 mm Hg or SBP ≥90 mm Hg is recommended to reduce the risk of myocardial injury.3–9 Postoperative Blood Pressure Management",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01558,2024,23,Class 1,B-NR,"In patients undergoing NCS, treatment of hypoten­ sion (MAP <60-65 or SBP <90 mm Hg) in the postoperative period is recommended to limit the risk of cardiovascular, cerebrovascular, renal events, and mortality.6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01559,2024,23,Class 1,C-EO,"In patients with hypertension undergoing NCS, it is recommended that preoperative antihypertensive medications be restarted as soon as clinically rea­ sonable to avoid complications from postoperative hypertension. *Caution is advised when continuing antihypertensive therapy in patients with low or low-normal perioperative BPs, older adults (≥65 years),10 and patients in whom the risk for perioperative hypotension is high based on an evaluation of the patient’s overall clinical status, surgery type, and anesthetic plan. †Modified from the “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA High Blood Pressure Guideline.”11 ‡One or more components of the RCRI: CAD, congestive heart failure, cere­ brovascular accident, baseline serum creatinine >2.0 mg/dL, or preoperative in­ sulin treatment.12",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01560,2024,25,Class 1,C-LD,"In patients with HF undergoing elective NCS, sodium-glucose cotransporter-2 inhibitors (SGLT2i) should be withheld for 3 to 4 days* before surgery when feasible to reduce the risk of perioperative metabolic acidosis.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01561,2024,25,2A,C-LD,"In patients with compensated HF undergoing NCS, it is reasonable to continue GDMT (excluding SGLT2i) in the perioperative period, unless contraindicated, to reduce the risk of worsening HF.4–8 *Canagliflozin, dapagliflozin, and empagliflozin should be stopped ≥3 days and ertugliflozin ≥4 days before scheduled surgery.3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01562,2024,26,Class 1,C-LD,"In patients receiving stable doses of targeted medi­ cal therapies* for pulmonary arterial hypertension (PAH) undergoing NCS, it is recommended to con­ tinue these agents to reduce the risk for the devel­ opment of perioperative MACE.1",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01563,2024,26,2A,C-LD,"In patients with severe† PH undergoing elevated- risk NCS, referral to or consultation with a special­ ized PH center that can support risk assessment, optimization, and postoperative management (with consideration of intensive care after NCS) is reason­ able to reduce perioperative cardiopulmonary compli­ cations.2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01564,2024,26,2A,C-LD,"In patients with severe† PH undergoing elevated- risk NCS, invasive hemodynamic monitoring is reasonable to guide intraoperative and postoperative care.3–5 Table 9.  Preoperative and Intraoperative Management Considerations in Patients With Hypertrophic Cardiomyopathy Management Considerations Continue beta blockers and/or nondihydropyridine calcium channel blockers without interruption in the perioperative period Avoid hypovolemia and reduced preload (can worsen LVOT obstruction) Avoid hypotension and reduced afterload (can worsen LVOT obstruction) Avoid tachycardia to ensure adequate LV filling If hypotension develops: Prioritize intravenous fluid administration to correct hypovolemia Use alpha-agonists, such as phenylephrine or vasopressin,7 rather than beta-agonists, which can worsen LVOT obstruction Consider intraoperative echocardiography to evaluate LVOT obstruction in the setting of hypotension In selected cases, intravenous beta-blockade may be necessary to reduce LV myocardial contractility and relieve LVOT obstruction",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01565,2024,27,2B,C-EO,"In patients with precapillary PH undergoing elevated- risk NCS, perioperative administration of short-acting inhaled pulmonary vasodilators (eg, nitric oxide, aero­ solized prostacyclins) may be reasonable to reduce elevated RV afterload and prevent acute decompen­ sated right HF.6 *For example, nitric oxide pathway mediators, endothelin receptor antagonists, prostacyclin pathway agonists, or a combination of these. †Severe PH is defined according to hemodynamics (severe precapillary PH component by right heart catheterization and echocardiography) and additional data derived from clinical assessment, exercise tests, and laboratory biomarkers. Hemodynamically, severe PH displays a mean pulmonary artery (PA) pressure >40 mm Hg, pulmonary vascular resistance >5 Wood units, or echocardiographic evidence of significant RV dysfunction (eg, RV-to-LV diastolic diameter ratio >0.8 or RV dysfunction that is graded as moderate or severe). Although all 5 World Symposium on Pulmonary Hypertension group classifications display some de­ gree of risk for developing severe PH, Group 1 (PAH), Group 3 (PH due to lung disease), and Group 4 (chronic thromboembolic PH) are at high risk for devel­ oping severe PH if left untreated and may be best managed and followed at a center with PH specialists.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01566,2024,28,Class 1,B-NR,"In patients with intermediate- to elevated-risk congenital heart disease (CHD) lesions (Table 10) undergoing elective NCS, preoperative con­ sultation with an adult congenital heart disease (ACHD) specialist is recommended before the surgery.*1–4 *Modified from the “2018 AHA/ACC Guideline for Management of ACHD.”5 Table 10.  Adult Congenital Heart Disease Risk Stratification Before Noncardiac Surgery Risk Anatomy Functional/Hemodynamic Status Low Risk Patients with isolated small CHD lesions Patients with repaired CHD lesion with no residual shunt Patients with bicuspid aortic valve disease and aortopathy NYHA class I functional status, normal exercise capacity No chamber enlargement on imaging No residual shunt No PAH No arrhythmias Intermediate risk Unrepaired moderate-large shunts (ASD, VSD, PDA, AVSD) Repaired CHD with moderate to large residual shunt (ASD, VSD, PDA, AVSD) Obstructive left-sided lesions (congenital mitral stenosis, subaortic stenosis, supravalvular aortic stenosis, coarctation of aorta) except the ones described as low risk Obstructive right-sided lesion (pulmonary stenosis, branch pulmonary stenosis, repaired tetralogy of Fallot) Ebstein anomaly (disease spectrum includes mild, moderate, and severe variations) Anomalous coronary artery arising from the pulmonary artery Anomalous aortic origin of a coronary artery from the opposite sinus, especially with an interarterial or intramural course NYHA class II-IV functional status Limited exercise capacity Presence of residual shunt Presence of PAH Presence of cardiac chamber enlargement Significant valvular dysfunction (more than mild in severity) Arrhythmias requiring treatment Presence of HF Elevated risk Single-ventricle patients (palliated or status post Fontan procedure), unrepaired or palliated cyanotic CHD, double outlet right ventricle, pulmonary atresia, truncus arteriosus, TGA (classic or d-TGA; CCTGA or l-TGA), interrupted aortic arch NYHA class II-IV functional status Limited exercise capacity Significant valvular dysfunction (more than mild in severity) Arrhythmias requiring treatment Presence of PAH Presence of HF",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01567,2024,29,Class 1,C-EO,"In patients with a left ventricular assist device (LVAD), coordination with the LVAD care team on the appro­ priate timing and perioperative considerations of elective NCS is recommended to mitigate the risk of perioperative MACE.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01568,2024,30,Class 1,C-LD,"Patients with severe AS should be evaluated for the need for aortic valve intervention before elective NCS to reduce perioperative risk.*1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01569,2024,30,Class 1,C-EO,"In patients with suspected moderate or severe AS who are undergoing elevated-risk NCS, preoperative echocardiography is recommended before elective NCS to guide perioperative management.*",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01570,2024,30,2A,C-LD,"In asymptomatic patients with moderate or severe AS and normal LV systolic function as assessed by echocardiography within the past year, it is reason­ able to proceed with elective low-risk NCS.3–5 *Modified from the “2020 ACC/AHA Guideline for the Management of Pa­ tients With Valvular Heart Disease.”6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01571,2024,32,Class 1,B-NR,Patients with severe mitral stenosis (MS) should be evaluated for the need for mitral valve (MV) interven­ tion before elective NCS.1–17,thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01572,2024,32,2A,C-EO,"In patients with severe MS who cannot undergo MV intervention before NCS, perioperative invasive hemodynamic monitoring is reasonable to guide management to reduce the risk of cardiovascular complications.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01573,2024,32,2B,C-LD,"In patients with severe MS who cannot undergo MV intervention before NCS, perioperative heart-rate control (eg, beta blockers, calcium channel blockers [CCBs], ivabradine, digoxin) may be considered to prolong diastolic filling time and decrease periopera­ tive cardiovascular complications.18–21",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01574,2024,33,Class 1,C-EO,"In patients with suspected moderate or severe val­ vular regurgitation, preoperative echocardiography is recommended before elective NCS to guide periop­ erative management.*",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01575,2024,33,Class 1,C-EO,"In patients with VHD who meet indications for valvular intervention based on clinical presentation and severity of regurgitation, the need for valvular intervention should be considered before elective elevated-risk NCS to reduce perioperative risk.*1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01576,2024,33,2A,C-LD,"In asymptomatic patients with moderate or severe MR, normal LV systolic function, and estimated PA systolic pressure <50 mm Hg, it is reasonable to perform elective NCS.*45",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01577,2024,33,2A,C-LD,"In asymptomatic patients with moderate or severe aor­ tic regurgitation and normal LV systolic function (LVEF >55%), it is reasonable to perform elective NCS.*6 *Modified from the “2020 ACC/AHA Guideline for the Management of Pa­ tients With Valvular Heart Disease.”3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01578,2024,34,2A,B-NR,"For patients who undergo successful transcatheter aortic valve implantation (TAVI), it is reasonable to perform NCS early* as clinically indicated.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01579,2024,34,2A,C-EO,"For patients who undergo MV TEER, it is reasonable to perform NCS after the successful MV intervention as clinically indicated.4 *Evidence supports the safety of NCS within 30 days of TAVI, if indicated.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01580,2024,35,2A,C-LD,"In patients with rapid AF identified in the setting of NCS, it is reasonable to treat potential underlying triggers contributing to AF and rapid ventricular response (eg, sepsis, anemia, pain).*1–5",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01581,2024,35,2A,C-LD,"In patients with new-onset AF identified in the set­ ting of NCS, initiation of postoperative anticoagula­ tion therapy can be beneficial after considering the competing risks associated with thromboembolism and perioperative bleeding.*4,6 Postdischarge",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01582,2024,35,Class 1,C-LD,"In patients with new-onset AF identified in the set­ ting of NCS, outpatient follow-up for thromboembolic risk stratification and AF surveillance are recom­ mended given a high risk of AF recurrence.*7–11 *Adapted from the “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.”12",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01583,2024,36,Class 1,B-NR,"Patients with cardiovascular implantable electronic devices (CIED) having elective NCS should have a management plan developed before surgery if elec­ tromagnetic interference (EMI) is anticipated, includ­ ing identification of the type of CIED (eg, pacemaker, implantable cardioverter-defibrillator [ICD], implant­ able monitor), manufacturer, and model.1–6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01584,2024,36,Class 1,B-NR,"Patients who are pacemaker-dependent having surgeries above the umbilicus with anticipated EMI should have the pacemaker reprogrammed or have a magnet placed on the generator to provide an asyn­ chronous mode to avoid pacing inhibition.1,7",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01585,2024,36,Class 1,B-NR,"Pacemaker-dependent patients with a transvenous ICD undergoing surgery above the umbilicus with anticipated EMI should have the device repro­ grammed*; if the patient is not pacemaker- dependent, then either reprogramming or a magnet placed on the generator can be used to inhibit tachytherapies or inappropriate shocks.8,9",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01586,2024,36,Class 1,B-NR,Patients who have a pacemaker or ICD repro­ grammed to asynchronous pacing or have tachy­ therapies programmed off before surgery should have device functioning restored in the postoperative period before hospital discharge.10,thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01587,2024,36,Class 1,C-LD,Patients with leadless pacemakers who are pacemaker-dependent having surgeries with antici­ pated EMI above the umbilicus should have their pace­ makers reprogrammed to an asynchronous mode.11,thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01588,2024,36,2A,C-LD,"For patients with subcutaneous ICD having noncardiac or nonthoracic surgery with anticipated EMI above the groin, it is reasonable to reprogram the device or use a magnet to temporarily disable tachytherapies.12 *For pacemaker-dependent patients with an ICD, tachytherapies should be disabled and the device should be reprogrammed to an asynchronous mode to avoid pacing inhibition.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01589,2024,39,2A,B-NR,"In patients with a history of stroke or transient isch­ emic attack, it is reasonable to delay elective NCS for ≥3 months after the most recent cerebrovascular event to reduce the incidence of recurrent stroke, MACE, or both.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01590,2024,39,2A,B-NR,"In patients scheduled for NCS, obstructive sleep apnea (OSA) screening using validated question­ naires is reasonable to assess the risk of periopera­ tive complications.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01591,2024,40,Class 1,B-NR,"In patients currently on statins and scheduled for NCS, continuation of statin therapy is recommended to reduce the risk of MACE.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01592,2024,40,Class 1,B-R,"In statin-naïve adult patients who meet criteria for statin use based on ASCVD history or 10-year risk assessment and are scheduled for NCS, periopera­ tive initiation of statin is recommended with intention of long-term use.4,5",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01593,2024,41,2B,B-R,"In select* patients on chronic renin-angiotensin- aldosterone system inhibitors (RAASi) for hypertension undergoing elevated-risk NCS, omission 24 hours before surgery may be beneficial to limit intraoperative hypotension.1–6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01594,2024,41,2A,C-EO,"In patients on chronic RAASi for HFrEF, periopera­ tive continuation is reasonable.†1,2 *Patients with controlled BP and undergoing elevated-risk surgical procedures. †Modified from the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.”7",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01595,2024,42,Class 3: No Benefit,B-R,"In patients undergoing NCS, initiation of low-dose clonidine perioperatively is not recommended to reduce cardiovascular risk.1",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01596,2024,43,Class 1,B-NR,"For patients with CAD undergoing elective NCS, management of perioperative antiplatelet therapy and timing of surgery should be determined by a multidisciplinary team with shared decision-making to weigh the risks of bleeding, thrombosis, and con­ sequences of delayed surgery.1–7 Timing of NCS After PCI",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01597,2024,43,Class 1,C-LD,"In patients with recent coronary artery balloon angioplasty without stent placement, elective NCS should be delayed for a minimum of 14 days to minimize perioperative MACE.8,9",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01598,2024,43,Class 1,B-NR,"In patients with DES-PCI placed for ACS who require elective NCS with interruption of ≥1 anti­ platelet agents, surgery should ideally be delayed ≥12 months to minimize perioperative MACE.5,10–15",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01599,2024,43,2A,B-NR,"In patients with DES-PCI placed for CCD who require elective NCS with interruption of ≥1 anti­ platelet agents, it is reasonable to delay surgery for ≥6 months after PCI to minimize perioperative MACE.16–24",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01600,2024,43,2B,B-NR,"In patients with DES-PCI who require time-sensitive NCS with interruption of ≥1 antiplatelet agents, NCS may be considered ≥3 months after PCI if the risk of delaying surgery outweighs the risk of MACE.5,23,24",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01601,2024,43,Class 1,B-R,"In patients with prior PCI undergoing NCS, it is recommended to continue aspirin* (75-100 mg), if possible, to reduce the risk of cardiac events.27–30",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01602,2024,43,Class 1,B-NR,"In patients with CAD who require time-sensitive NCS within 30 days of PCI with BMS or <3 months of PCI with DES, DAPT should be con­ tinued unless the risk of bleeding outweighs the benefit of the prevention of stent thrombosis.23,31",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01603,2024,43,Class 1,B-NR,"In patients with prior PCI in whom OAC monotherapy must be discontinued before NCS, aspirin should be substituted when feasible in the perioperative period until OAC can be safely reinitiated.27–29",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01604,2024,43,2B,B-NR,"In select patients after PCI who have a high throm­ botic risk, perioperative bridging with intravenous antiplatelet therapy may be considered <6 months after DES or <30 days after BMS if NCS cannot be deferred.32,33 Perioperative Antiplatelet Management in Patients Without Prior PCI",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01605,2024,43,2B,B-R,"In patients with CCD without prior PCI undergoing elective NCS, it may be reasonable to continue aspirin in selected patients when the risk of cardiac events outweighs the risk of bleeding.27,34,35",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01606,2024,43,Class 3: No Benefit,B-R,"In patients with CAD but without prior PCI who are undergoing elective noncarotid NCS, routine initiation of aspirin is not beneficial.27,36 *Platelet adenosine diphosphate receptor (P2Y12) monotherapy may be con­ sidered if surgical bleeding risks are acceptable or if aspirin is not tolerated.",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01607,2024,46,Class 1,B-NR,"For patients with CVD receiving OAC who require elective NCS, a multidisciplinary team-based approach to time-based* interruption is recom­ mended to balance the competing risks of thromboembolism and perioperative bleeding (Tables 13 and 14).1–7 OAC Bridging",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01608,2024,46,2A,C-LD,"In patients with CVD and high thrombotic risk (Table 14) undergoing NCS where interruption of vitamin K antagonist (VKA) is required, preoperative bridging with parenteral heparin can be effective to reduce thromboembolic risk.8–10",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01609,2024,46,2A,C-LD,"In patients with preoperative OAC interruption, resumption of OAC is reasonable after hemostasis is achieved.9 *Timing of preoperative interruption is based on patient-specific factors (eg, thrombotic risk, age, sex, body weight, renal clearance), surgical bleeding risk, and drug factors (eg, pharmacokinetics, dosing, drug interactions).",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01610,2024,49,Class 1,B-NR,"In patients on stable doses of beta blockers under­ going NCS, beta blockers should be continued through the perioperative period as appropriate based on the clinical circumstances.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01611,2024,49,2B,B-NR,"In patients scheduled for elective NCS who have a new indication for beta blockade, beta blockers may be initiated far enough before surgery (optimally >7 days) to permit assessments of tolerability and drug titration if needed.3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01612,2024,50,2A,B-NR,"In patients with or at risk for diabetes who are scheduled for elective NCS, preoperative hemoglobin A1c (HbA1C) testing is reasonable if it has not been performed in ≤3 months.1–4",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01613,2024,50,Class 1,C-LD,"In patients scheduled for NCS, SGLT2i should be discontinued 3 to 4 days* days before surgery to reduce the risk of perioperative metabolic acidosis.5–7",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01614,2024,50,2A,C-LD,"In patients with diabetes or impaired glucose toler­ ance, continuation of metformin during the periop­ erative period is reasonable to maintain glycemic control.8–12 *Canagliflozin, dapagliflozin, and empagliflozin should be stopped ≥3 days and ertugliflozin ≥4 days before scheduled surgery.13",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01615,2024,51,2A,A,"In patients undergoing NCS, use of a volatile-based anesthetic agent or total intravenous anesthesia is reasonable for general anesthesia with no apparent difference in associated cardiovascular events (eg, MI, ischemia).1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01616,2024,51,2A,B-R,"In patients undergoing NCS where neuraxial is feasible, either neuraxial or general anesthesia is reasonable with no apparent difference in associated cardiovascular events.4–6",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01617,2024,52,2A,B-R,"For patients undergoing major abdominal surgery, the use of epidural analgesia for postoperative pain relief is reasonable to decrease the incidence of perioperative cardiac events.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01618,2024,52,2B,B-R,"For patients with a hip fracture waiting for surgi­ cal repair, epidural analgesia may be considered to decrease the incidence of preoperative cardiac events.3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01619,2024,54,2A,B-R,"In patients with CVD undergoing NCS, maintenance of normothermia is reasonable to avoid perioperative complications overall.1–5",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01620,2024,54,2B,C-LD,"In patients with acute, severe hemodynamic instabil­ ity and cardiopulmonary dysfunction undergoing urgent or emergency NCS, temporary MCS devices may be used preemptively or as rescue therapy.1–5",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01621,2024,54,2B,C-LD,"In patients with CVD undergoing NCS, the use of PA catheterization may be considered when under­ lying medical conditions that significantly affect hemodynamics (eg, decompensated HF, severe valvular disease, combined shock states, PH) cannot be corrected before surgery.1,2",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01622,2024,54,Class 3: No Benefit,A,"In patients with CVD undergoing NCS, routine use of PA catheterization is not recommended to reduce morbidity or mortality.3 Downloaded from http://ahajournals.org by on June 19, 2025",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01623,2024,55,2A,A,"In patients having NCS with expected blood loss, tranexamic acid is reasonable to reduce intraoperative blood loss, reduce transfusions, and avoid anemia.1–3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01624,2024,55,2A,B-R,"In patients with iron deficiency anemia having elec­ tive NCS, iron therapy (either oral or intravenous) administered preoperatively is reasonable to reduce blood transfusions and to increase hemoglobin.4–18",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01625,2024,56,2B,B-NR,"In patients with known CVD, symptoms of CVD, or age ≥65 years with cardiovascular risk factors undergoing elevated-risk NCS, it may be reasonable to measure cTn at 24 and 48 hours after surgery to identify myocardial injury.1–4",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01626,2024,56,Class 3: No Benefit,B-NR,"In patients undergoing low-risk NCS, routine post­ operative screening with cTn levels is not indicated without signs or symptoms suggestive of myocardial ischemia or MI.5,6 MINS Management",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01627,2024,56,2A,B-NR,"In patients who develop MINS, especially in those not previously known to have excess cardiovascular risk, outpatient follow-up is reasonable for optimiza­ tion of cardiovascular risk factors.4,7–10",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01628,2024,56,2B,C-LD,"In patients who develop MINS, antithrombotic ther­ apy may be considered to reduce thromboembolic events.4,11",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01629,2024,58,Class 1,B-NR,"Patients who develop STEMI after NCS should be considered for GDMT, including consideration of ICA, balancing bleeding and thrombotic risks with the severity of the clinical presentation.1–3 Downloaded from http://ahajournals.org by on June 19, 2025",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01630,2024,59,Class 1,C-EO,Patients who develop NSTEMI after NCS should receive medical therapy as recommended for patients with spontaneous MI but after consideration of postoperative bleeding risks and hemodynamic status.,thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01631,2024,59,2A,C-LD,"Patients who develop NSTEMI after NCS can be considered for ICA, balancing bleeding and throm­ botic risks with the severity of clinical presentation.2,3",thompson-et-al-2024-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-perioperative-cardiovascular-management-for.pdf
id_01632,2022,14,Class 1,B-NR,"In patients with HF, vital signs and evidence of clinical congestion should be assessed at each encounter to guide overall management, includ- ing adjustment of diuretics and other medica- tions.1–6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01633,2022,14,Class 1,B-NR,"In patients with symptomatic HF, clinical factors indicating the presence of advanced HF should be sought via the history and physical examina- tion.7–12",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01634,2022,14,Class 1,B-NR,"In patients with cardiomyopathy, a 3-generation family history should be obtained or updated when assessing the cause of the cardiomyopa- thy to identify possible inherited disease.13,14",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01635,2022,14,Class 1,B-NR,"In patients presenting with HF, a thorough history and physical examination should direct diagnos- tic strategies to uncover specific causes that may warrant disease-specific management.15,16",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01636,2022,14,Class 1,C-EO,"In patients presenting with HF, a thorough history and physical examination should be obtained and performed to identify cardiac and noncardiac disorders, lifestyle and behavioral factors, and social determinants of health that might cause or accelerate the development or progression of HF.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01637,2022,16,Class 1,B-NR,"For patients presenting with HF, the specific cause of HF should be explored using addi- tional laboratory testing for appropriate man- agement.1–8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01638,2022,16,Class 1,C-EO,"For patients who are diagnosed with HF, laboratory evaluation should include com- plete blood count, urinalysis, serum electro- lytes, blood urea nitrogen, serum creatinine, glucose, lipid profile, liver function tests, iron studies, and thyroid-stimulating hormone to optimize management.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01639,2022,16,Class 1,C-EO,"For all patients presenting with HF, a 12-lead ECG should be performed at the initial encoun- ter to optimize management.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01640,2022,17,Class 1,A,"In patients presenting with dyspnea, measure- ment of B-type natriuretic peptide (BNP) or N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is useful to support a diagnosis or exclusion of HF.1–12",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01641,2022,17,Class 1,A,"In patients with chronic HF, measurements of BNP or NT-proBNP levels are recommended for risk stratification.11,13–29",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01642,2022,17,Class 1,A,"In patients hospitalized for HF, measurement of BNP or NT-proBNP levels at admission is recommended to establish prognosis.11,13–19",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01643,2022,17,2A,B-R,"In patients at risk of developing HF, BNP or NT-proBNP–based screening followed by team-based care, including a cardiovascular specialist, can be useful to prevent the devel- opment of LV dysfunction or new-onset HF.30,31",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01644,2022,17,2A,B-NR,"In patients hospitalized for HF, a predischarge BNP or NT-proBNP level can be useful to inform the trajectory of the patient and estab- lish a postdischarge prognosis.14,17,20–29",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01645,2022,18,Class 1,B-NR,"In first-degree relatives of selected patients with genetic or inherited cardiomyopathies, genetic screening and counseling are recom- mended to detect cardiac disease and prompt consideration of treatments to decrease HF progression and sudden death.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01646,2022,18,2A,B-NR,"In select patients with nonischemic cardio- myopathy, referral for genetic counseling and testing is reasonable to identify conditions that could guide treatment for patients and family members.3,4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01647,2022,19,Class 1,C-LD,"In patients with suspected or new-onset HF, or those presenting with acute decompensated HF, a chest x-ray should be performed to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contrib- ute to the patient’s symptoms.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01648,2022,19,Class 1,C-LD,"In patients with suspected or newly diag- nosed HF, transthoracic echocardiography (TTE) should be performed during initial evaluation to assess cardiac structure and function.3",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01649,2022,19,Class 1,C-LD,"In patients with HF who have had a significant clinical change, or who have received GDMT and are being considered for invasive procedures or device therapy, repeat measurement of EF, degree of structural remodeling, and valvular function are useful to inform therapeutic interven- tions.4–7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01650,2022,19,Class 1,C-LD,"In patients for whom echocardiography is inadequate, alternative imaging (eg, cardiac magnetic resonance [CMR], cardiac computed tomography [CT], radionuclide imaging) is rec- ommended for assessment of LVEF.8–15",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01651,2022,19,2A,B-NR,"In patients with HF or cardiomyopathy, CMR can be useful for diagnosis or manage- ment.16–23",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01652,2022,19,2A,B-NR,"In patients with HF, an evaluation for possible ischemic heart disease can be useful to identify the cause and guide management.24–27",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01653,2022,19,2B,B-NR,"In patients with HF and coronary artery disease (CAD) who are candidates for coronary revas- cularization, noninvasive stress imaging (stress echocardiography, single-photon emission CT [SPECT], CMR, or positron emission tomog- raphy [PET]) may be considered for detection of myocardial ischemia to help guide coronary revascularization.28–32",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01654,2022,19,Class 3: No Benefit,C-EO,"In patients with HF in the absence of: 1) clinical status change, 2) treatment interventions that might have had a significant effect on cardiac function, or 3) candidacy for invasive proce- dures or device therapy, routine repeat assess- ment of LV function is not indicated.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01655,2022,21,2A,B-NR,"In patients with HF, endomyocardial biopsy may be useful when a specific diagnosis is sus- pected that would influence therapy.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01656,2022,21,2A,C-EO,"In selected patients with HF with persistent or worsening symptoms, signs, diagnostic param- eters, and in whom hemodynamics are uncer- tain, invasive hemodynamic monitoring can be useful to guide management.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01657,2022,21,Class 3: No Benefit,B-R,"In patients with HF, routine use of invasive hemodynamic monitoring is not recom- mended.3,4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01658,2022,21,Class 3: Harm,C-LD,"For patients undergoing routine evaluation of HF, endomyocardial biopsy should not be per- formed because of the risk of complications.5,6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01659,2022,22,2B,B-R,"In selected adult patients with NYHA class III HF and history of a HF hospitalization in the past year or elevated natriuretic peptide levels, on maximally tolerated stable doses of GDMT with optimal device therapy, the use- fulness of wireless monitoring of PA pressure by an implanted hemodynamic monitor to reduce the risk of subsequent HF hospitaliza- tions is uncertain.1–4 Value Statement: Uncertain Value (B-NR)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01660,2022,23,Class 1,C-LD,"In patients with HF, assessment and documen- tation of NYHA functional classification are recommended to determine eligibility for treat- ments.1–3",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01661,2022,23,Class 1,C-LD,"In selected ambulatory patients with HF, cardiopulmonary exercise testing (CPET) is recommended to determine appropriateness of advanced treatments (eg, LVAD, heart transplant).4–8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01662,2022,23,2A,C-LD,"In ambulatory patients with HF, performing a CPET or 6-minute walk test is reasonable to assess functional capacity.4,5,9–16",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01663,2022,23,2A,C-LD,"In ambulatory patients with unexplained dys- pnea, CPET is reasonable to evaluate the cause of dyspnea.17,18",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01664,2022,24,2A,B-NR,"In ambulatory or hospitalized patients with HF, validated multivariable risk scores can be useful to estimate subsequent risk of mortality.1–14",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01665,2022,25,Class 1,A,"In patients with hypertension, blood pressure should be controlled in accordance with GDMT for hypertension to prevent symptomatic HF.1–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01666,2022,25,Class 1,A,"In patients with type 2 diabetes and either established CVD or at high cardiovascular risk, SGLT2i should be used to prevent hospitaliza- tions for HF.10–12",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01667,2022,25,Class 1,B-NR,"In the general population, healthy lifestyle hab- its such as regular physical activity, maintaining normal weight, healthy dietary patterns, and avoiding smoking are helpful to reduce future risk of HF.13–21",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01668,2022,25,2A,B-R,"For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of LV dysfunction (systolic or diastolic) or new-onset HF.22,23",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01669,2022,25,2A,B-NR,"In the general population, validated multivari- able risk scores can be useful to estimate sub- sequent risk of incident HF.24–26",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01670,2022,27,Class 1,A,"In patients with LVEF ≤40%, ACEi should be used to prevent symptomatic HF and reduce mortality.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01671,2022,27,Class 1,A,"In patients with a recent or remote history of MI or ACS, statins should be used to prevent symptomatic HF and adverse cardiovascular events.5–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01672,2022,27,Class 1,B-R,"In patients with a recent MI and LVEF ≤40% who are intolerant to ACEi, ARB should be used to prevent symptomatic HF and reduce mortal- ity.10",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01673,2022,27,Class 1,B-R,"In patients with a recent or remote history of MI or acute coronary syndrome (ACS) and LVEF ≤40%, evidence-based beta blockers should be used to reduce mortality.11–13",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01674,2022,27,Class 1,B-R,"In patients who are at least 40 days post-MI with LVEF ≤30% and NYHA class I symptoms while receiving GDMT and have reasonable expectation of meaningful survival for >1 year, an ICD is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality.14",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01675,2022,27,Class 1,C-LD,"In patients with LVEF ≤40%, beta blockers should be used to prevent symptomatic HF.12,13",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01676,2022,27,Class 3: Harm,B-R,"In patients with LVEF <50%, thiazolidinediones should not be used because they increase the risk of HF, including hospitalizations.15",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01677,2022,27,Class 3: Harm,C-LD,"In patients with LVEF <50%, nondihydropyri- dine calcium channel blockers with negative inotropic effects may be harmful.16,17",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01678,2022,29,Class 1,A,"Patients with HF should receive care from multidisciplinary teams to facilitate the imple- mentation of GDMT, address potential barriers to self-care, reduce the risk of subsequent rehospitalization for HF, and improve survival.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01679,2022,29,Class 1,B-R,"Patients with HF should receive specific edu- cation and support to facilitate HF self-care in a multidisciplinary manner.2,5–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01680,2022,29,2A,B-NR,"In patients with HF, vaccinating against respi- ratory illnesses is reasonable to reduce mor- tality.10–16",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01681,2022,29,2A,B-NR,"In adults with HF, screening for depression,17,18 social isolation,19–22 frailty,23,24 and low health literacy25,26 as risk factors for poor self-care is reasonable to improve management.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01682,2022,31,2A,C-LD,"For patients with stage C HF, avoiding exces- sive sodium intake is reasonable to reduce congestive symptoms.1–6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01683,2022,32,Class 1,A,"For patients with HF who are able to par- ticipate, exercise training (or regular physical activity) is recommended to improve functional status, exercise performance, and QOL.1–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01684,2022,32,2A,B-NR,"In patients with HF, a cardiac rehabilitation program can be useful to improve functional capacity, exercise tolerance, and health-related QOL.1,2,5,6,8 Table 11.  Potential Barriers to Effective HF Self-Care and Example Interventions Potential Barrier Example Screening Tools Example Interventions Medical Barriers Cognitive impairment48–50 Mini-Cog Mini-Mental State Examination (MMSE) Montreal Cognitive Assessment (MoCA) Home health aide Home meal deliveries Adult day care Geriatric psychiatry referral Memory care support groups Depression51,52 Hamilton Depression Rating Scale (HAM-D) Beck Depression Inventory-II (BDI-II) Patient Health Questionnaire-9 (PHQ-9) Psychotherapy Selective serotonin reuptake inhibitors Nurse-led support Substance use disorders53 Tobacco, Alcohol, Prescription medication, and other Sub- stance use (TAPS) Referral to social work services and community support partners Referral for addiction psychiatry consultation Frailty54 Fried frailty phenotype Cardiac rehabilitation Registered dietitian nutritionist evaluation for malnutrition Social Barriers Financial burden of HF treatments55 COmprehensive Score for financial Toxicity–Functional As- sessment of Chronic Illness Therapy (COST-FACIT) PharmD referral to review prescription assistance eligibilities Food insecurity56,57 Hunger Vital Sign, 2 items US Household Food Security Survey Module, 6 items Determine eligibility for the Supplemental Nutrition Assistance Program (SNAP) Connect patients with community partners such as food pantries/ food banks Home meal deliveries Registered dietitian nutritionist evaluation for potential malnutrition Homelessness or housing insecurity58–60 Homelessness Screening Clinical Reminder (HSCR) Referral to local housing services Connect patients with community housing partners Intimate partner violence or elder abuse61,62 Humiliation, Afraid, Rape, Kick (HARK) questionnaire Partner Violence Screen (PVS) Woman Abuse Screening Tool (WAST) Referral to social work services and community support partners Limited English proficiency or other language barriers63 Routinely inquire in which language the patient is most comfortable conversing Access to interpreter services covering a wide range of languag- es, ideally in person or, alternatively, via video platform Printed educational materials in a range of appropriate languages Low health literacy64 Short Assessment of Health Literacy (SAHL) Rapid Estimate of Adult Literacy in Medicine–Short Form (REALM-SF) Brief Health Literacy Screen (BHLS), 3 items Agency for Healthcare Research and Quality (AHRQ) Health Lit- eracy Universal Precautions Toolkit Written education tools provided at sixth grade reading level or below Graphic educational documents Social isolation or low social support65 Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Short Form Determine eligibility for home care services Support group referral Transport limitations",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01685,2022,33,Class 1,B-NR,"In patients with HF who have fluid retention, diuretics are recommended to relieve conges- tion, improve symptoms, and prevent worsen- ing HF.1–5",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01686,2022,33,Class 1,B-NR,"For patients with HF and congestive symptoms, addition of a thiazide (eg, metolazone) to treat- ment with a loop diuretic should be reserved for patients who do not respond to moderate- or high-dose loop diuretics to minimize electro- lyte abnormalities.6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01687,2022,34,Class 1,A,"In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.1–5",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01688,2022,34,Class 1,A,"In patients with previous or current symptoms of chronic HFrEF, the use of ACEi is beneficial to reduce morbidity and mortality when the use of ARNi is not feasible.6–13",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01689,2022,34,Class 1,A,"In patients with previous or current symptoms of chronic HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARNi is not feasible, the use of ARB is rec- ommended to reduce morbidity and mortality.14–18 Value Statement: High Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01690,2022,34,Class 1,B-R,"In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACEi or ARB, replacement by an ARNi is recommended to further reduce morbidity and mortality.1–5 Value Statement: High Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01691,2022,34,Class 3: Harm,B-R,"ARNi should not be administered concomi- tantly with ACEi or within 36 hours of the last dose of an ACEi.30,31",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01692,2022,34,Class 3: Harm,C-LD,ARNi should not be administered to patients with any history of angioedema.32–35,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01693,2022,34,Class 3: Harm,C-LD,"ACEi should not be administered to patients with any history of angioedema.36–39 *See Section 7.2, “Diuretics and Decongestion Strategies in Patients with",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01694,2022,37,Class 1,A,"In patients with HFrEF, with current or previ- ous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (eg, bisoprolol, carvedilol, sustained-release metoprolol succi- nate) is recommended to reduce mortality and hospitalizations.1–3 Value Statement: High Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01695,2022,37,Class 1,A,"In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplere- none) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. Careful moni- toring of potassium, renal function, and diuretic dosing should be performed at initiation and closely monitored thereafter to minimize risk of hyperkalemia and renal insufficiency.1–3 Value Statement: High Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01696,2022,37,Class 3: Harm,B-NR,"In patients taking MRA whose serum potas- sium cannot be maintained at <5.5 mEq/L, MRA should be discontinued to avoid life- threatening hyperkalemia.8,9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01697,2022,38,Class 1,A,"In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospital- ization for HF and cardiovascular mortality, irre- spective of the presence of type 2 diabetes.1,2 Value Statement: Intermediate Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01698,2022,39,Class 1,A,"For patients self-identified as African American with NYHA class III-IV HFrEF who are receiv- ing optimal medical therapy, the combination of hydralazine and isosorbide dinitrate is rec- ommended to improve symptoms and reduce morbidity and mortality.1,2 Value Statement: High Value (B-NR)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01699,2022,39,2B,C-LD,"In patients with current or previous symp- tomatic HFrEF who cannot be given first-line agents, such as ARNi, ACEi, or ARB, because of drug intolerance or renal insufficiency, a combination of hydralazine and isosorbide dini- trate might be considered to reduce morbidity and mortality.4,5",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01700,2022,40,2B,B-R,"In patients with HF class II to IV symptoms, omega-3 polyunsaturated fatty acid (PUFA) supplementation may be reasonable to use as adjunctive therapy to reduce mortality and car- diovascular hospitalizations.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01701,2022,40,2B,B-R,"In patients with HF who experience hyperkale- mia (serum potassium level ≥5.5 mEq/L) while taking a renin-angiotensin-aldosterone system inhibitor (RAASi), the effectiveness of potas- sium binders (patiromer, sodium zirconium cyclosilicate) to improve outcomes by facilitat- ing continuation of RAASi therapy is uncer- tain.5,6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01702,2022,40,Class 3: No Benefit,B-R,"In patients with chronic HFrEF without a spe- cific indication (eg, venous thromboembolism [VTE], AF, a previous thromboembolic event, or a cardioembolic source), anticoagulation is not recommended.7–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01703,2022,41,Class 3: No Benefit,A,"In patients with HFrEF, dihydropyridine calcium channel-blocking drugs are not recommended treatment for HF.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01704,2022,41,Class 3: No Benefit,B-R,"In patients with HFrEF, vitamins, nutritional supplements, and hormonal therapy are not recommended other than to correct specific deficiencies.3–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01705,2022,41,Class 3: Harm,A,"In patients with HFrEF, nondihydropyridine calcium channel-blocking drugs are not recom- mended.10–13",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01706,2022,41,Class 3: Harm,A,"In patients with HFrEF, class IC antiarrhythmic medications and dronedarone may increase the risk of mortality.14–16",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01707,2022,41,Class 3: Harm,A,"In patients with HFrEF, thiazolidinediones increase the risk of worsening HF symptoms and hospitalizations.17–21",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01708,2022,41,Class 3: Harm,B-R,"In patients with type 2 diabetes and high cardiovascular risk, the dipeptidyl pepti- dase-4 (DPP-4) inhibitors saxagliptin and alogliptin increase the risk of HF hospitaliza- tion and should be avoided in patients with HF.22–24",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01709,2022,41,Class 3: Harm,B-NR,"In patients with HFrEF, NSAIDs worsen HF symptoms and should be avoided or withdrawn whenever possible.25–28",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01710,2022,43,Class 1,A,"In patients with HFrEF, titration of guideline- directed medication dosing to achieve target doses showed to be efficacious in RCTs is rec- ommended, to reduce cardiovascular mortality and HF hospitalizations, unless not well toler- ated.1–10",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01711,2022,43,2A,C-EO,"In patients with HFrEF, titration and optimiza- tion of guideline-directed medications as frequently as every 1 to 2 weeks depending on the patient’s symptoms, vital signs, and labora- tory findings can be useful to optimize manage- ment.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01712,2022,45,2A,B-R,"For patients with symptomatic (NYHA class II to III) stable chronic HFrEF (LVEF ≤35%) who are receiving GDMT, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ≥70 bpm at rest, ivabradine can be beneficial to reduce HF hospitalizations and cardiovascular death.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01713,2022,46,2B,B-R,"In patients with symptomatic HFrEF despite GDMT (or who are unable to tolerate GDMT), digoxin might be considered to decrease hospi- talizations for HF.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01714,2022,47,2B,B-R,"In selected high-risk patients with HFrEF and recent worsening of HF already on GDMT, an oral soluble guanylate cyclase stimulator (vericiguat) may be considered to reduce HF hospitalization and cardiovascular death.1",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01715,2022,47,Class 1,A,"In patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF ≤35% and NYHA class II or III symp- toms on chronic GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary pre- vention of SCD to reduce total mortality.1–9 Value Statement: High Value (A)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01716,2022,47,Class 1,B-R,"In patients at least 40 days post-MI with LVEF ≤30% and NYHA class I symptoms while receiving GDMT, who have reasonable expec- tation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality.6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01717,2022,47,Class 1,B-R,"For patients who have LVEF ≤35%, sinus rhythm, left bundle branch block (LBBB) with a QRS duration ≥150 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT, CRT is indicated to reduce total mortality, reduce hospi- talizations, and improve symptoms and QOL.16–21 Value Statement: High Value (B-NR)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01718,2022,47,2A,B-R,"For patients who have LVEF ≤35%, sinus rhythm, a non-LBBB pattern with a QRS duration ≥150 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT, CRT can be useful to reduce total mortality, reduce hospitalizations, and improve symp- toms and QOL.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01719,2022,47,2A,B-R,"In patients with high-degree or complete heart block and LVEF of 36% to 50%, CRT is reasonable to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL.34,35 Downloaded from http://ahajournals.org by on June 19, 2025",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01720,2022,48,2A,B-NR,"For patients who have LVEF ≤35%, sinus rhythm, LBBB with a QRS duration of 120 to 149 ms, and NYHA class II, III, or ambu- latory IV symptoms on GDMT, CRT can be useful to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01721,2022,48,2A,B-NR,"In patients with AF and LVEF ≤35% on GDMT, CRT can be useful to reduce total mortality, improve symptoms and QOL, and increase LVEF, if: a) the patient requires ventricular pac- ing or otherwise meets CRT criteria and b) atrioventricular nodal ablation or pharmacologi- cal rate control will allow near 100% ventricu- lar pacing with CRT.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01722,2022,48,2A,B-NR,"For patients on GDMT who have LVEF ≤35% and are undergoing placement of a new or replacement device implantation with anticipated requirement for significant (>40%) ventricular pacing, CRT can be useful to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01723,2022,48,2A,B-NR,"In patients with genetic arrhythmogenic car- diomyopathy with high-risk features of sudden death, with EF ≤45%, implantation of ICD is reasonable to decrease sudden death.36,37",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01724,2022,48,2B,B-NR,"For patients who have LVEF ≤35%, sinus rhythm, a non-LBBB pattern with QRS dura- tion of 120 to 149 ms, and NYHA class III or ambulatory class IV on GDMT, CRT may be considered to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01725,2022,48,2B,B-NR,"For patients who have LVEF ≤30%, ischemic cause of HF, sinus rhythm, LBBB with a QRS duration ≥150 ms, and NYHA class I symp- toms on GDMT, CRT may be considered to reduce hospitalizations and improve symptoms and QOL.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01726,2022,48,Class 3: No Benefit,B-R,"In patients with QRS duration <120 ms, CRT is not recommended.36–41",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01727,2022,48,Class 3: No Benefit,B-NR,"For patients with NYHA class I or II symptoms and non-LBBB pattern with QRS duration <150 ms, CRT is not recommended.16–21,28–33",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01728,2022,48,Class 3: No Benefit,C-LD,"For patients whose comorbidities or frailty limit survival with good functional capacity to <1 year, ICD and cardiac resynchronization therapy with defibrillation (CRT-D) are not indi- cated.1–9,16–21",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01729,2022,51,Class 1,B-R,"In selected patients with HF, reduced EF (EF ≤35%), and suitable coronary anatomy, surgical revascularization plus GDMT is beneficial to improve symptoms, cardiovascular hospitaliza- tions, and long-term all-cause mortality.1–8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01730,2022,52,Class 1,B-R,"In patients with HF, VHD should be managed in a multidisciplinary manner in accordance with clini- cal practice guidelines for VHD to prevent wors- ening of HF and adverse clinical outcomes.1–11",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01731,2022,52,Class 1,C-LD,"In patients with chronic severe secondary MR and HFrEF, optimization of GDMT is recom- mended before any intervention for secondary MR related to LV dysfunction.3–5,12–14",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01732,2022,54,2A,B-R,"In patients with HFmrEF, SGLT2i can be ben- eficial in decreasing HF hospitalizations and cardiovascular mortality.1",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01733,2022,54,2B,B-NR,"Among patients with current or previous symp- tomatic HFmrEF (LVEF, 41%–49%), use of evidence-based beta blockers for HFrEF, ARNi, ACEi, or ARB, and MRAs may be considered to reduce the risk of HF hospitalization and cardiovascular mortality, particularly among patients with LVEF on the lower end of this spectrum.2–9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01734,2022,55,Class 1,B-R,"In patients with HFimpEF after treatment, GDMT should be continued to prevent relapse of HF and LV dysfunction, even in patients who may become asymptomatic.1",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01735,2022,55,Class 1,C-LD,Patients with HFpEF and hypertension should have medication titrated to attain blood pres- sure targets in accordance with published clini- cal practice guidelines to prevent morbidity.1–3,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01736,2022,55,2A,B-R,"In patients with HFpEF, SGLT2i can be ben- eficial in decreasing HF hospitalizations and cardiovascular mortality.4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01737,2022,55,2A,C-EO,"In patients with HFpEF, management of AF can be useful to improve symptoms.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01738,2022,55,2B,B-R,"In selected patients with HFpEF, MRAs may be considered to decrease hospitalizations, par- ticularly among patients with LVEF on the lower end of this spectrum.5–7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01739,2022,55,2B,B-R,"In selected patients with HFpEF, the use of ARB may be considered to decrease hospital- izations, particularly among patients with LVEF on the lower end of this spectrum.8,9",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01740,2022,55,2B,B-R,"In selected patients with HFpEF, ARNi may be considered to decrease hospitalizations, par- ticularly among patients with LVEF on the lower end of this spectrum.10,11",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01741,2022,55,Class 3: No Benefit,B-R,"In patients with HFpEF, routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QOL is ineffective.12,13 *See Section 7.2, “Diuretics and Decongestion Strategies in Patients with HF,” and Section 10.2, “Management of Atrial Fibrillation (AF) in HF” for recom- mendations for use of diuretics and management of AF in HF. Downloaded from http://ahajournals.org by on June 19, 2025",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01742,2022,58,Class 1,B-NR,Patients for whom there is a clinical suspi- cion for cardiac amyloidosis*1–5 should have screening for serum and urine monoclonal light chains with serum and urine immuno- fixation electrophoresis and serum free light chains.6,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01743,2022,58,Class 1,B-NR,"In patients with high clinical suspicion for car- diac amyloidosis, without evidence of serum or urine monoclonal light chains, bone scintigra- phy should be performed to confirm the pres- ence of transthyretin cardiac amyloidosis.7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01744,2022,58,Class 1,B-NR,"In patients for whom a diagnosis of transthyre- tin cardiac amyloidosis is made, genetic testing with TTR gene sequencing is recommended to differentiate hereditary variant from wild-type transthyretin cardiac amyloidosis.8 *LV wall thickness ≥14 mm in conjunction with fatigue, dyspnea, or edema, especially in the context of discordance between wall thickness on echocardiogram and QRS voltage on ECG, and in the context of aortic ste- nosis, HFpEF, carpal tunnel syndrome, spinal stenosis, and autonomic or sensory polyneuropathy.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01745,2022,60,Class 1,B-R,"In select patients with wild-type or variant trans- thyretin cardiac amyloidosis and NYHA class I to III HF symptoms, transthyretin tetramer sta- bilizer therapy (tafamidis) is indicated to reduce cardiovascular morbidity and mortality.1 Value Statement: Low Value (B-NR)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01746,2022,60,2A,C-LD,"In patients with cardiac amyloidosis and AF, anticoagulation is reasonable to reduce the risk of stroke regardless of the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex category) score.3,4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01747,2022,61,Class 1,C-LD,"In patients with advanced HF, when consistent with the patient’s goals of care, timely refer- ral for HF specialty care is recommended to review HF management and assess suitability for advanced HF therapies (eg, LVAD, cardiac transplantation, palliative care, and palliative inotropes).1–6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01748,2022,62,2B,C-LD,"For patients with advanced HF and hypona- tremia, the benefit of fluid restriction to reduce congestive symptoms is uncertain.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01749,2022,63,2A,B-NR,"In patients with advanced (stage D) HF refrac- tory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac trans- plantation, continuous intravenous inotropic support is reasonable as “bridge therapy.”1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01750,2022,63,2B,B-NR,"In select patients with stage D HF, despite optimal GDMT and device therapy who are ineligible for either MCS or cardiac transplan- tation, continuous intravenous inotropic sup- port may be considered as palliative therapy for symptom control and improvement in func- tional status.5–7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01751,2022,63,Class 3: Harm,B-R,"In patients with HF, long-term use of either continuous or intermittent intravenous inotropic agents, for reasons other than palliative care or as a bridge to advanced therapies, is potentially harmful.5,6,8–11",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01752,2022,64,Class 1,A,"In select patients with advanced HFrEF with NYHA class IV symptoms who are deemed to be dependent on continuous intravenous inotropes or temporary MCS, durable LVAD implantation is effective to improve functional status, QOL, and survival.1–18",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01753,2022,64,2A,B-R,"In select patients with advanced HFrEF who have NYHA class IV symptoms despite GDMT, durable MCS can be beneficial to improve symptoms, improve functional class, and reduce mortality.2,4,7,10,12–17,19 Value Statement: Uncertain Value (B-NR)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01754,2022,64,2A,B-NR,"In patients with advanced HFrEF and hemody- namic compromise and shock, temporary MCS, including percutaneous and extracorporeal ventricular assist devices, are reasonable as a “bridge to recovery” or “bridge to decision.”25–29",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01755,2022,66,Class 1,C-LD,"For selected patients with advanced HF despite GDMT, cardiac transplantation is indi- cated to improve survival and QOL.1–3 Value Statement: Intermediate Value (C-LD)",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01756,2022,66,Class 1,C-LD,"In patients hospitalized with HF, severity of con- gestion and adequacy of perfusion should be assessed to guide triage and initial therapy.1–5",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01757,2022,66,Class 1,C-LD,"In patients hospitalized with HF, the common precipitating factors and the overall patient trajectory should be assessed to guide appro- priate therapy.5,6 Goals for Optimization and Continuation of GDMT",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01758,2022,66,Class 1,C-LD,"For patients admitted with HF, treatment should address reversible factors, establish optimal volume status, and advance GDMT toward targets for outpatient therapy.6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01759,2022,68,Class 1,B-NR,"In patients with HFrEF requiring hospitalization, preexisting GDMT should be continued and optimized to improve outcomes, unless contra- indicated.1–5",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01760,2022,68,Class 1,B-NR,"In patients experiencing mild decrease of renal function or asymptomatic reduction of blood pressure during HF hospitalization, diuresis and other GDMT should not routinely be discontin- ued.6–11",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01761,2022,68,Class 1,B-NR,"In patients with HFrEF, GDMT should be initi- ated during hospitalization after clinical stability is achieved.2,3,5,12–18",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01762,2022,68,Class 1,B-NR,"In patients with HFrEF, if discontinuation of GDMT is necessary during hospitalization, it should be reinitiated and further optimized as soon as possible.19–22",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01763,2022,69,Class 1,B-NR,Patients with HF admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to improve symptoms and reduce morbidity.1,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01764,2022,69,Class 1,B-NR,"For patients hospitalized with HF, therapy with diuretics and other guideline-directed medica- tions should be titrated with a goal to resolve clinical evidence of congestion to reduce symp- toms and rehospitalizations.1–6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01765,2022,69,Class 1,B-NR,"For patients requiring diuretic treatment during hospitalization for HF, the discharge regimen should include a plan for adjustment of diuret- ics to decrease rehospitalizations.7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01766,2022,69,2A,B-NR,"In patients hospitalized with HF when diuresis is inadequate to relieve symptoms and signs of congestion, it is reasonable to intensify the diuretic regimen using either: a. higher doses of intravenous loop diuretics.1,3); or b. addition of a second diuretic.3",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01767,2022,70,2B,B-NR,"In patients who are admitted with decompen- sated HF, in the absence of systemic hypoten- sion, intravenous nitroglycerin or nitroprusside may be considered as an adjuvant to diuretic therapy for relief of dyspnea.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01768,2022,71,Class 1,B-R,"In patients hospitalized with HF, prophylaxis for VTE is recommended to prevent venous throm- boembolic disease.1–3",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01769,2022,71,Class 1,B-NR,"In patients with cardiogenic shock, intravenous inotropic support should be used to maintain systemic perfusion and preserve end-organ performance.1–8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01770,2022,71,2A,B-NR,"In patients with cardiogenic shock, temporary MCS is reasonable when end-organ function cannot be maintained by pharmacologic means to support cardiac function.9–17",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01771,2022,71,2A,B-NR,"In patients with cardiogenic shock, manage- ment by a multidisciplinary team experienced in shock is reasonable.17–22",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01772,2022,71,2B,B-NR,"In patients presenting with cardiogenic shock, placement of a PA line may be considered to define hemodynamic subsets and appropriate management strategies.23–27",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01773,2022,71,2B,C-LD,"For patients who are not rapidly responding to initial shock measures, triage to centers that can provide temporary MCS may be consid- ered to optimize management.17–22",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01774,2022,73,Class 1,B-R,"In patients with high-risk HF, particularly those with recurrent hospitalizations for HFrEF, refer- ral to multidisciplinary HF disease management programs is recommended to reduce the risk of hospitalization.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01775,2022,73,Class 1,B-NR,"In patients hospitalized with worsening HF, patient-centered discharge instructions with a clear plan for transitional care should be pro- vided before hospital discharge.5,6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01776,2022,73,2A,B-NR,"In patients hospitalized with worsening HF, participation in systems that allow benchmark- ing to performance measures is reasonable to increase use of evidence-based therapy, and to improve quality of care.7–10",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01777,2022,73,2A,B-NR,"In patients being discharged after hospital- ization for worsening HF, an early follow-up, generally within 7 days of hospital discharge, is reasonable to optimize care and reduce rehos- pitalization.11,12",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01778,2022,75,2A,B-R,"In patients with HFrEF and iron deficiency with or without anemia, intravenous iron replace- ment is reasonable to improve functional status and QOL.1–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01779,2022,75,Class 3: Harm,B-R,"In patients with HF and anemia, erythropoietin- stimulating agents should not be used to improve morbidity and mortality.5,6 Management of Hypertension",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01780,2022,75,Class 1,C-LD,"In patients with HFrEF and hypertension, uptitration of GDMT to the maximally tolerated target dose is recommended.7,8 Management of Sleep Disorders",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01781,2022,75,2A,C-LD,"In patients with HF and suspicion of sleep-dis- ordered breathing, a formal sleep assessment is reasonable to confirm the diagnosis and differentiate between obstructive and central sleep apnea.9,10",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01782,2022,75,2A,B-R,"In patients with HF and obstructive sleep apnea, continuous positive airway pressure may be reasonable to improve sleep quality and decrease daytime sleepiness.9,11–13",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01783,2022,75,Class 3: Harm,B-R,"In patients with NYHA class II to IV HFrEF and central sleep apnea, adaptive servo-ventilation causes harm.11,12 Management of Diabetes",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01784,2022,75,Class 1,A,"In patients with HF and type 2 diabetes, the use of SGLT2i is recommended for the man- agement of hyperglycemia and to reduce HF- related morbidity and mortality.14–17",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01785,2022,78,Class 1,A,Patients with chronic HF with permanent-per- sistent-paroxysmal AF and a CHA2DS2-VASc score of ≥2 (for men) and ≥3 (for women) should receive chronic anticoagulant therapy.1–5,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01786,2022,78,Class 1,A,"For patients with chronic HF with permanent- persistent-paroxysmal AF, DOAC is recom- mended over warfarin in eligible patients.2–10",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01787,2022,78,2A,B-R,"For patients with HF and symptoms caused by AF, AF ablation is reasonable to improve symp- toms and QOL.11–14",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01788,2022,78,2A,B-R,"For patients with AF and LVEF ≤50%, if a rhythm control strategy fails or is not desired, and ventricular rates remain rapid despite medi- cal therapy, atrioventricular nodal ablation with implantation of a CRT device is reasonable.15–22",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01789,2022,78,2A,B-NR,"For patients with chronic HF and permanent- persistent-paroxysmal AF, chronic anticoagulant therapy is reasonable for men and women with- out additional risk factors.23–26",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01790,2022,79,Class 1,C-LD,"In vulnerable patient populations at risk for health disparities, HF risk assessments and multidisciplinary management strategies should target both known risks for CVD and social determinants of health, as a means toward elimination of disparate HF outcomes.1–6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01791,2022,79,Class 1,C-LD,"Evidence of health disparities should be moni- tored and addressed at the clinical practice and the health care system levels.7–13 *This section crosslinks to Section 7.1.1, “Stage C Nonpharmacological In- terventions and Self-Care Support in HF,” where screening and interventions for social determinants of health are now addressed.",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01792,2022,81,Class 1,B-NR,"In patients who develop cancer therapy–related cardiomyopathy or HF, a multidisciplinary discussion involving the patient about the risk- benefit ratio of cancer therapy interruption, dis- continuation, or continuation is recommended to improve management.1,2",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01793,2022,81,2A,B-NR,"In asymptomatic patients with cancer therapy– related cardiomyopathy (EF <50%), ARB, ACEi, and beta blockers are reasonable to prevent progression to HF and improve cardiac function.2–4",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01794,2022,81,2A,B-NR,"In patients with cardiovascular risk factors or known cardiac disease being considered for potentially cardiotoxic anticancer therapies, pretherapy evaluation of cardiac function is rea- sonable to establish baseline cardiac function and guide the choice of cancer therapy.2,5–16",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01795,2022,81,2A,B-NR,"In patients with cardiovascular risk factors or known cardiac disease receiving potentially cardiotoxic anticancer therapies, monitoring of cardiac function is reasonable for the early iden- tification of drug-induced cardiomyopathy.2,4,6,8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01796,2022,81,2B,B-R,"In patients at risk of cancer therapy–related cardiomyopathy, initiation of beta blockers and ACEi/ARB for the primary prevention of drug-induced cardiomyopathy is of uncertain benefit.17–28",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01797,2022,81,2B,C-LD,"In patients being considered for potentially car- diotoxic therapies, serial measurement of car- diac troponin might be reasonable for further risk stratification.29–32",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01798,2022,84,Class 1,C-LD,"In women with a history of HF or cardiomyopathy, including previous peripartum cardiomyopathy, patient-centered counseling regarding contra- ception and the risks of cardiovascular deteriora- tion during pregnancy should be provided.1–8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01799,2022,84,2B,C-LD,"In women with acute HF caused by peripartum cardiomyopathy and LVEF <30%, anticoagula- tion may be reasonable at diagnosis, until 6 to 8 weeks postpartum, although the efficacy and safety are uncertain.9–12",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01800,2022,84,Class 3: Harm,C-LD,"In women with HF or cardiomyopathy who are pregnant or currently planning for pregnancy, ACEi, ARB, ARNi, MRA, SGLT2i, ivabradine, and vericiguat should not be administered because of significant risks of fetal harm.13–15",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01801,2022,86,Class 1,B-NR,Performance measures based on professionally developed clinical practice guidelines should be used with the goal of improving quality of care for patients with HF.1–7,heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01802,2022,86,2A,B-NR,"Participation in quality improvement programs, including patient registries that provide bench- mark feedback on nationally endorsed, clinical practice guideline–based quality and perfor- mance measures can be beneficial in improving the quality of care for patients with HF.1,2,5,6",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01803,2022,86,Class 1,C-LD,"For all patients with HF, palliative and supportive care—including high-quality communication, conveyance of prognosis, clarifying goals of care, shared decision-making, symptom man- agement, and caregiver support—should be provided to improve QOL and relieve suffering.1",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01804,2022,86,Class 1,C-LD,"For patients with HF being considered for, or treated with, life-extending therapies, the option for discontinuation should be anticipated and dis- cussed through the continuum of care, including at the time of initiation, and reassessed with changing medical conditions and shifting goals of care.2,3",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01805,2022,86,2A,B-R,"For patients with HF—particularly stage D HF patients being evaluated for advanced therapies, patients requiring inotropic support or temporary mechanical support, patients experiencing uncontrolled symptoms, major medical decisions, or multimorbidity, frailty, and cognitive impairment—specialist palliative care consultation can be useful to improve QOL and relieve suffering.4–6 Downloaded from http://ahajournals.org by on June 19, 2025",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01806,2022,87,2A,C-LD,"For patients with HF, execution of advance care directives can be useful to improve docu- mentation of treatment preferences, delivery of patient-centered care, and dying in preferred place.7",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01807,2022,87,2A,C-LD,"In patients with advanced HF with expected survival <6 months, timely referral to hospice can be useful to improve QOL.8",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01808,2022,92,2A,C-LD,"In patients with HF, standardized assessment of patient-reported health status using a vali- dated questionnaire can be useful to provide incremental information for patient functional status, symptom burden, and prognosis.1–19",heidenreich-et-al-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of.pdf
id_01809,2024,9,Class 1,B-NR,"In patients at increased risk of PAD (Table 5), a comprehensive medical history and review of symptoms to assess for exertional leg symptoms, lower extremity rest pain, and lower extremity wounds or other ischemic skin changes should be performed.1–4",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01810,2024,9,Class 1,B-NR,"In patients at increased risk of PAD (Table 5), a comprehensive vascular examination and inspection of the legs and feet should be performed regularly (Table 6).2,5–8",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01811,2024,12,Class 1,B-NR,"In patients with history or physical examination find- ings suggestive of PAD (Table 6), the resting ABI, with or without ankle pulse volume recordings (PVR) and/or Doppler waveforms, is recommended to establish the diagnosis.1,2",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01812,2024,12,Class 1,B-NR,"The resting ABI should be reported as abnormal (ABI ≤0.90), borderline (ABI 0.91-0.99), normal (ABI",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01813,2024,12,2A,B-NR,"In patients at increased risk of PAD (Table 5), screening for PAD with the resting ABI, with or without ankle PVR and/or Doppler waveforms, is reasonable.4–9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01814,2024,12,Class 3: No Benefit,B-NR,"In patients not at increased risk of PAD (Table 5) and without history or physical examination findings suggestive of PAD (Table 6), screening for PAD with the ABI is not recommended.10,11 Exercise ABI and Additional Physiological Testing",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01815,2024,12,Class 1,B-NR,"In patients with suspected PAD, toe pressure/ toe-brachial index (TBI) with waveforms should be performed when the resting ABI is >1.40 (noncompressible).12–17",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01816,2024,12,Class 1,B-NR,"Patients with suspected chronic symptomatic PAD (ie, exertional nonjoint-related leg symptoms) and normal or borderline resting ABI (>0.90 and ≤1.40, respectively) should undergo exercise treadmill ABI testing to evaluate for PAD.18,19",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01817,2024,12,2A,B-NR,"In patients with PAD and an abnormal resting ABI (≤0.90), the exercise treadmill ABI test can be useful to objectively assess the functional status and walking performance.20–25",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01818,2024,12,2A,C-LD,"In patients with chronic symptomatic PAD, it is reasonable to perform segmental leg pressures with PVR and/or Doppler waveforms in addition to the resting ABI to help delineate the anatomic level of PAD.26,27",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01819,2024,12,2A,B-NR,"In patients with suspected CLTI, it is reasonable to use toe pressure/TBI with waveforms, transcutaneous oxygen pressure (TcPO2), and/or skin perfusion pressure (SPP) in addition to ABI for assessment of arterial perfusion and to establish the diagnosis of CLTI.13,28–37 Table 7.  Alternative Diagnosis for Leg Pain or Claudication Not Related to PAD (Normal Physiological Testing) Condition Location Characteristic Effect of Exercise Effect of Rest Effect of Position Other Characteristics Hip arthritis Lateral hip, thigh Aching discomfort After variable degree of exercise Not quickly relieved Improved when not bearing weight Symptoms variable; history of degenerative arthritis Foot/ankle arthritis Ankle, foot, arch Aching pain After variable degree of exercise; may also be present at rest Not quickly relieved May be relieved by not bearing weight Symptoms variable Nerve root compression Radiates down leg Sharp lancinating pain Induced by sitting, standing, or walking (variable) Often present at rest Improved by change in position History of back problems; worse with sitting; relief when supine or standing Spinal stenosis (eg, degenerative disc disease or tumor) Often bilateral buttocks, posterior leg Pain and weakness May mimic claudication Variable relief but can take a long time to recover Relief by lumbar spine flexion Worse with standing and extending spine Symptomatic popliteal (Baker’s) cyst Behind knee, down calf Swelling, tenderness With exercise Also present at rest None Not intermittent Venous claudication Entire leg, worse in calf Tight, bursting pain After walking Subsides slowly Relief speeded by leg elevation History of iliofemoral deep vein thrombosis; edema; signs of venous stasis Chronic compartment syndrome Calf muscles Tight, bursting pain After strenuous exercise (jogging) Subsides very slowly Relief with rest Typically heavy muscled athletes",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01820,2024,13,2A,B-NR,"In patients with CLTI with nonhealing wounds or gangrene, it can be useful to use toe pressure/ TBI with waveforms, TcPO2, SPP, and/or other local perfusion measures to determine the likelihood of wound healing without or after revascularization.13,14,28,33–36,38",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01821,2024,16,Class 1,B-NR,"In patients with functionally limiting claudication with inadequate response to GDMT (including structured exercise) for whom revascularization is being consid- ered, duplex ultrasound, computed tomography angiog- raphy (CTA), magnetic resonance angiography (MRA), or catheter angiography of the lower extremities is use- ful for assessment of anatomy and severity of disease and to determine potential revascularization strategy.1–4",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01822,2024,16,Class 1,B-NR,"In patients with CLTI, duplex ultrasound, CTA, MRA, or catheter angiography is useful to determine revascularization strategy.1–3,5,6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01823,2024,16,2B,C-EO,"In patients with suspected PAD (ie, potential signs and/or symptoms) with inconclusive ABI and physiological testing, noninvasive imaging with duplex ultrasound, CTA, or MRA may be considered to establish the diagnosis of PAD.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01824,2024,17,Class 1,C-EO,"In the evaluation of patients with PAD, clinicians should assess for and incorporate the presence of PAD-related risk amplifiers (Table 9) when developing patient-focused treatment recommendations. Downloaded from http://ahajournals.org by on June 19, 2025",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01825,2024,20,Class 1,C-EO,"Clinicians and health care systems should actively pursue evidence of health disparities in diagnosis, treatment, and outcomes for patients with PAD and use efforts to limit the impact of these disparities on clinical outcomes.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01826,2024,22,2A,B-NR,"In older patients (ie, ≥75 years of age) with PAD, assessment for geriatric syndromes (Table 10), such as frailty, sarcopenia, malnutrition, and mobil- ity impairment, can be useful to identify high-risk patients, including before revascularization, and to provide safe and goal-concordant care.1–15",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01827,2024,24,Class 1,A,"In patients with symptomatic PAD, single antiplatelet therapy is recommended to reduce the risk of MACE.1–4",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01828,2024,24,Class 1,B-R,"In patients with symptomatic PAD, single antiplatelet therapy with clopidogrel alone (75 mg daily) is recommended to reduce the risk of MACE.4",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01829,2024,24,Class 1,C-LD,"In patients with symptomatic PAD, single antiplatelet therapy with aspirin alone (range, 75-325 mg daily) is recommended to reduce the risk of MACE.1–3",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01830,2024,24,Class 1,A,"In patients with symptomatic PAD, low-dose rivaroxaban (2.5 mg twice daily) combined with low-dose aspirin is effective to reduce the risk of MACE and MALE.5,6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01831,2024,24,Class 1,B-R,"After endovascular or surgical revascularization for PAD, antiplatelet therapy is recommended.1,7–9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01832,2024,24,Class 1,A,"After endovascular or surgical revascularization for PAD, low-dose rivaroxaban (2.5 mg twice daily) combined with low-dose aspirin is recommended to reduce the risk of MACE and MALE.7",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01833,2024,24,2A,C-LD,"After endovascular revascularization for PAD, dual antiplatelet therapy with a P2Y12 antagonist and low-dose aspirin is reasonable for at least 1 to 6 months.8–11",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01834,2024,24,2A,C-LD,"After endovascular or surgical revascularization in patients with PAD who require full-intensity anticoagulation for another indication and are not at high risk of bleeding, adding single antiplatelet therapy is reasonable.12,13",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01835,2024,24,2A,C-EO,"In patients with asymptomatic PAD, single antiplatelet therapy is reasonable to reduce the risk of MACE.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01836,2024,24,2B,B-R,"In patients with symptomatic PAD without recent revascularization, the benefit of dual antiplatelet therapy is uncertain.14,15",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01837,2024,24,2B,B-R,"In patients with symptomatic PAD, the benefit of vorapaxar added to existing antiplatelet therapy is uncertain.16",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01838,2024,24,2B,B-R,"After surgical revascularization for PAD with a prosthetic graft, dual antiplatelet therapy with a P2Y12 antagonist and low-dose aspirin may be reasonable for at least 1 month.17",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01839,2024,27,Class 1,A,"In patients with PAD, treatment with high-intensity statin therapy is indicated, with an aim of achieving a ≥50% reduction in low-density lipoprotein cholesterol (LDL-C) level.1–3",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01840,2024,27,2A,B-R,"In patients with PAD who are on maximally tolerated statin therapy and have an LDL-C level of ≥70 mg/dL, it is reasonable to add PCSK9 inhibitor therapy.1,4–6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01841,2024,27,2A,B-R,"In patients with PAD who are on maximally tolerated statin therapy and have an LDL-C level of ≥70 mg/dL, it is reasonable to add ezetimibe therapy.1,7",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01842,2024,29,Class 1,A,"In patients with PAD and hypertension, antihypertensive therapy should be administered to reduce the risk of MACE.1–5",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01843,2024,29,Class 1,B-R,"In patients with PAD and hypertension, a systolic blood pressure (SBP) goal of <130 mm Hg and a diastolic blood pressure target of <80 mm Hg is recommended.5–9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01844,2024,29,Class 1,B-R,"In patients with PAD and hypertension, the selective use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers is recommended to reduce the risk of MACE.10–12",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01845,2024,30,Class 1,A,Patients with PAD who smoke cigarettes or use any other forms of tobacco should be advised at every visit to quit or encouraged to maintain cessation.1–3,gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01846,2024,30,Class 1,A,"Patients with PAD who smoke cigarettes or use any other forms of tobacco should be assisted in developing a plan for quitting that includes pharma- cotherapy (ie, varenicline, bupropion, and/or nicotine replacement therapies) combined with counseling, and/or referral to a smoking cessation program.4–9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01847,2024,30,Class 1,B-NR,"Patients with PAD should be advised to avoid exposure to secondhand tobacco smoke in all indoor or enclosed spaces, including work, home, transportation vehicles, and public places.10–14",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01848,2024,31,Class 1,A,"In patients with PAD and type 2 diabetes, use of glucagon-like peptide–1 agonists (liraglutide and semaglutide) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (canagliflozin, dapagliflozin, and empagliflozin) are effective to reduce the risk of MACE.1–12",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01849,2024,31,Class 1,C-EO,"In patients with PAD, management of diabetes should be coordinated among members of the health care team.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01850,2024,31,2B,B-NR,"In patients with PAD and diabetes, glycemic control may be beneficial to improve limb outcomes.13–16",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01851,2024,32,Class 1,C-LD,Patients with PAD should receive an annual influenza vaccination.1–5,gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01852,2024,32,Class 1,C-EO,"Patients with PAD should receive the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccination sequence, including the booster(s).",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01853,2024,32,2A,B-R,"In patients at high cardiovascular risk, a diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, and fish can be beneficial for reducing the risk of developing PAD and the risk of MACE.6–15",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01854,2024,32,Class 3: No Benefit,B-R,"In patients with PAD, B-complex vitamin supple- mentation to lower homocysteine levels is not ben- eficial for prevention of MACE.16–18",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01855,2024,32,Class 3: No Benefit,B-R,"In patients with PAD, chelation therapy (eg, EDTA) is not beneficial for prevention of MACE.19,20",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01856,2024,32,Class 3: No Benefit,B-R,"In patients with PAD, vitamin D supplementation is not beneficial for prevention of MACE.21–25 Downloaded from http://ahajournals.org by on June 19, 2025",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01857,2024,34,Class 1,A,"In patients with claudication, cilostazol is recommended to improve leg symptoms and increase walking distance.1–4",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01858,2024,34,2B,B-R,"In patients with PAD, cilostazol may be useful to reduce restenosis after endovascular therapy for femoropopliteal disease.5–7",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01859,2024,34,Class 3: No Benefit,B-R,"In patients with chronic symptomatic PAD, pentoxifylline is not recommended for treatment of claudication.11,12 Chelation Therapy",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01860,2024,34,Class 3: No Benefit,B-R,"In patients with chronic symptomatic PAD, chelation therapy is not recommended for treatment of claudication.13",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01861,2024,35,Class 1,C-LD,"In patients with PAD, providing general preventive foot self-care education to patients and their family members and support persons is recommended.1–7",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01862,2024,35,Class 1,C-EO,"In patients with PAD, foot inspection by a clinician at every visit is recommended.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01863,2024,35,Class 1,C-LD,"In patients with PAD at high risk for ulcers and amputation (Table 12), therapeutic footwear is recommended.8,9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01864,2024,35,Class 1,C-EO,"In patients with PAD, a comprehensive foot evaluation (Table 13) should be performed at least annually to identify risk factors for ulcers and amputation.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01865,2024,35,2A,B-NR,"In patients with PAD, referral to a footcare specialist, when available, is reasonable for ongoing preventive care and longitudinal surveillance.10–16",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01866,2024,37,Class 1,A,"In patients with chronic symptomatic PAD, SET is recommended to improve walking performance, functional status, and QOL.7,16–28",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01867,2024,37,Class 1,A,"In patients with chronic symptomatic PAD, a structured community-based exercise program with behavioral change techniques is effective to improve walking performance, functional status, and QOL.5–15",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01868,2024,37,Class 1,A,"In patients who have undergone revascularization for chronic symptomatic PAD, SET after revascularization is effective to improve walking performance, functional status, and QOL.29–39",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01869,2024,37,Class 1,B-R,"In patients with functionally limiting claudication, SET or a structured community-based exercise program should be offered as an initial treatment option.17,18,25,40",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01870,2024,37,2A,A,"In patients with chronic symptomatic PAD, alterna- tive programs of nonwalking structured exercise therapy (eg, arm ergometry, recumbent stepping) can be beneficial to improve walking performance, functional status, and QOL.19,20,41–47",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01871,2024,37,2B,B-R,"In patients with chronic symptomatic PAD, the use- fulness of structured walking exercise therapy that avoids moderate to severe ischemic symptoms is uncertain.5,45,46",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01872,2024,37,2B,B-R,"In patients with chronic symptomatic PAD, the usefulness of unstructured exercise to improve walking performance, functional status, and QOL is uncertain.10,12,28 Table 14.  Structured Exercise Programs for PAD Supervised Exercise Therapy5,7,16–28,42,52,53",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01873,2024,40,2A,B-NR,"In patients with asymptomatic PAD, it is reasonable to perform revascularization procedures (endovas- cular or surgical) to reconstruct diseased arteries if needed for the safety, feasibility, or effectiveness of other procedures (eg, transfemoral aortic valve replacement, mechanical circulatory support, endovascular aortic aneurysm repair).1–8",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01874,2024,42,Class 1,B-NR,"In patients with functionally limiting claudication who are being considered for revascularization, potential benefits with respect to QOL, walking performance, and overall functional status should be weighed against the risks and durability of intervention and possible need for repeated procedures.1–6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01875,2024,42,2A,B-R,"In patients with functionally limiting claudication and an inadequate response to GDMT (including structured exercise), revascularization is a reasonable treatment option to improve walking function and QOL.7–14",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01876,2024,42,Class 3: No Benefit,C-EO,"In patients with claudication who have had an adequate clinical response to GDMT (including structured exercise), revascularization is not recommended. Revascularization for Claudication: Aortoiliac Disease and Femoro- popliteal Disease (Excluding Common Femoral Artery Disease)",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01877,2024,42,Class 1,A,"In patients with functionally limiting claudication and hemodynamically significant aortoiliac or femoropopliteal disease with inadequate response to GDMT (including structured exercise), endovascular revascularization is effective to improve walking performance and QOL.7–28",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01878,2024,42,2A,B-NR,"In patients with functionally limiting claudication and hemodynamically significant aortoiliac or femoropopliteal disease with inadequate response to GDMT (including structured exercise), surgical revascularization is reasonable if perioperative risk is acceptable and technical factors suggest advantages over endovascular approaches.29–31 Revascularization for Claudication: Common Femoral Artery Disease",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01879,2024,42,2A,B-R,"In patients with functionally limiting claudication and hemodynamically significant common femoral artery disease with inadequate response to GDMT (including structured exercise), surgical endarterectomy is reasonable, especially if endovascular approaches adversely affect profunda femoris artery pathways.32,33",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01880,2024,42,2B,B-R,"In patients with functionally limiting claudication and hemodynamically significant common femoral artery disease with inadequate response to GDMT (including structured exercise), endovascular approaches may be considered in those at high risk for surgical revascularization and/or if anatomical factors are favorable (ie, no adverse effect on profunda femoris artery pathways).33–40 Revascularization for Claudication: Infrapopliteal Disease",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01881,2024,42,2B,C-LD,"In patients with functionally limiting claudication and isolated hemodynamically significant infrapopliteal disease with inadequate response to GDMT (including structured exercise), the effectiveness of endovascular revascularization is unknown.41",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01882,2024,42,2B,C-LD,"In patients with functionally limiting claudication and isolated hemodynamically significant infrapop- liteal disease with inadequate response to GDMT (including structured exercise), the effectiveness of surgical revascularization is unknown.42",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01883,2024,45,Class 1,A,"In patients who are undergoing surgical revascu- larization for functionally limiting claudication and hemodynamically significant femoropopliteal disease, bypass to the popliteal artery with autogenous vein is recommended in preference to prosthetic graft material.1–5",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01884,2024,46,Class 1,B-NR,"In patients with CLTI, a multispecialty care team should evaluate and provide comprehensive care with goals of complete wound healing, minimizing tissue loss, and preservation of ambulatory status.1,2",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01885,2024,47,Class 1,B-R,"In patients with CLTI, surgical, endovascular, or hybrid revascularization techniques are recommended, when feasible, to minimize tissue loss, heal wounds, relieve pain, and preserve a functional limb.1–14",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01886,2024,47,Class 1,C-EO,"In patients with CLTI, an evaluation for revasculariza- tion options by a multispecialty care team is recom- mended before amputation (Table 15). Revascularization Strategy for CLTI",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01887,2024,47,Class 1,A,"In patients undergoing surgical revascularization for CLTI, bypass to the popliteal or infrapopliteal arteries (ie, tibial, pedal) should be constructed with autog- enous vein if available.14–20",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01888,2024,47,Class 1,B-R,"In patients with CLTI due to infrainguinal disease, anatomy, available conduit, patient comorbidities, and patient preferences should be considered in selecting the optimal first revascularization strategy (surgical bypass or endovascular revascularization) (Table 16).3,13",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01889,2024,47,Class 1,B-R,"In patients with CLTI who are candidates for surgical bypass and endovascular revascularization, ultrasound mapping of the great saphenous vein is recom- mended.3,13",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01890,2024,47,2A,B-NR,"In patients with CLTI for whom a surgical approach is selected and a suitable autogenous vein is unavailable, alternative conduits such as prosthetic or cadaveric grafts can be effective for bypass to the popliteal and tibial arteries.21–26",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01891,2024,47,2A,B-NR,"In patients with CLTI and nonhealing wounds or gangrene, revascularization in a manner that achieves in-line blood flow or maximizes perfusion to the wound bed can be beneficial.27–33",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01892,2024,47,2A,C-LD,"In patients with CLTI with ischemic rest pain (ie, with- out nonhealing wounds or gangrene) attributable to multilevel arterial disease, a revascularization strategy addressing inflow disease first is reasonable.34,35",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01893,2024,50,Class 1,A,"Patients with CLTI and diabetic foot ulcers should receive pressure offloading, when possible, to promote tissue growth and wound healing.1–9",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01894,2024,50,Class 1,B-R,"Patients with PAD and previous diabetic foot ulcers should be referred for customized footwear that accommodates, protects, and fits the shape of their feet.10–12",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01895,2024,50,2B,C-EO,Patients with CLTI and foot ulcers who do not have diabetes may be considered for pressure offloading to promote tissue growth and wound healing.,gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01896,2024,51,Class 1,B-NR,"In patients with CLTI, prompt management of foot infection with antibiotics, debridement, and other surgical management is recommended.1–5",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01897,2024,51,Class 1,C-LD,"In patients with CLTI with nonhealing wounds, wound care should be provided to optimize the wound-healing environment after revascularization with the goal of complete wound healing.6–10",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01898,2024,51,2B,B-NR,"In patients with CLTI with nonhealing diabetic foot ulcers, hyperbaric oxygen therapy may be considered to assist in wound healing after revascularization.11–14",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01899,2024,52,2B,B-R,"In patients with CLTI for whom revascularization is not an option and a lack of outflow to the foot is observed, the usefulness of prostanoids is uncertain.1–3",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01900,2024,52,2B,B-NR,"In patients with CLTI for whom revascularization is not an option, arterial intermittent pneumatic compression devices may be considered to augment wound healing or ameliorate ischemic rest pain.4–7",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01901,2024,52,2B,B-NR,"In patients with CLTI for whom arterial revascularization is not an option and a lack of outflow to the foot is observed, venous arterialization may be considered for limb preservation.8–12",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01902,2024,54,Class 1,B-NR,"In patients with CLTI who require amputation, evaluation should be performed by a multispecialty care team (Table 15) to assess for the most distal level of amputation that facilitates healing and provides maximal functional ability.1–6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01903,2024,54,Class 1,C-EO,"In patients with CLTI, primary amputation is indicated when life over limb is the prevailing consideration and clinical factors suggest the threatened limb to be the cause of the patient’s instability (eg, ischemia, meta- bolic derangement, or advanced infection).",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01904,2024,54,Class 1,C-EO,"In patients with CLTI, a patient-centered approach using objective classification of the threatened limb, patient risk, and anatomic pattern of disease combined with patient and family goals is recom- mended to identify those patients in whom primary amputation or palliative management is appropriate.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01905,2024,54,Class 1,C-EO,"In patients with CLTI undergoing minor amputation (ie, inframalleolar level), a customized program of follow-up care that can include local wound care, pressure offloading, serial evaluation of foot biome- chanics, and use of therapeutic footwear is recommended to prevent wound recurrence.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01906,2024,54,2A,C-EO,"For patients with CLTI, retrospective assessment of institutional outcomes (including amputation) with objective limb threat classification tools can be useful for quality improvement.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01907,2024,56,Class 1,C-EO,Patients with ALI should be evaluated on an emergency basis by a clinician with sufficient experience to assess limb viability and implement appropriate therapy.,gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01908,2024,56,Class 1,C-LD,"In patients with suspected ALI, the initial clinical evaluation should rapidly assess limb viability and potential for salvage and can be achieved without noninvasive imaging (ie, duplex ultrasound, CTA, or MRA).1–6",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01909,2024,56,2B,C-EO,"In patients with ALI who have a complicated history of revascularization procedures, it may be reason- able to obtain noninvasive imaging (ie, duplex ultra- sound, CTA, or MRA) before deciding to proceed with revascularization.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01910,2024,58,Class 1,A,"In patients with ALI and a salvageable limb, revascularization (endovascular or surgical, including catheter-directed thrombolysis) is indicated to prevent amputation.1–5",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01911,2024,58,2A,C-EO,"In patients with ALI and a salvageable limb who are treated with catheter-directed thrombolysis, adjunctive revascularization (ie, endovascular or surgical) procedures can be useful.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01912,2024,58,2B,C-LD,"In patients presenting with ALI from chemotherapeutic or prothrombotic viral states, it may be reasonable to take a more deliberate planning strategy before engaging in a definitive revascularization or medical treatment plan.6–14",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01913,2024,59,Class 1,C-EO,"Patients with ALI should be monitored and treated for compartment syndrome with fasciotomy after revascularization (endovascular or surgical, including catheter-directed thrombolysis) to prevent the sequelae of reperfusion injury and need for amputation.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01914,2024,59,2A,B-NR,"In patients with ALI with a threatened but salvageable limb (ie, category IIa or IIb), prophylactic fasciotomy is reasonable based on the clinical findings.1,2",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01915,2024,59,2A,C-EO,"In patients with ALI and prolonged ischemia in whom revascularization (endovascular or surgical, including catheter-directed thrombolysis) is performed, concur- rent and early amputation can be beneficial to avoid the morbidity of reperfusion.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01916,2024,60,Class 1,C-EO,"In patients with ALI, regardless of cause or anatomic level of occlusion, systemic anticoagulation with unfractionated heparin should be administered on diagnosis unless contraindicated.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01917,2024,60,Class 1,C-EO,"In patients with ALI, a comprehensive medical history and physical examination should be performed to determine the cause of thrombosis or embolization.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01918,2024,60,2A,C-LD,"In patients with ALI, testing for a cardiovascular cause of thromboembolism can be useful.1–4 Downloaded from http://ahajournals.org by on June 19, 2025",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01919,2024,62,Class 1,C-EO,"In patients with PAD, with or without revascularization, longitudinal follow-up with routine clinical evaluation, including assessment of limb symptoms and functional status, lower extremity pulse and foot assessment, and progress of risk factor management, is recommended.",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01920,2024,62,Class 1,C-EO,"In patients with PAD, coordination of care among clinicians to improve the management of PAD and comorbid conditions and to optimize patient outcomes is recommended. Functional Status and QOL",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01921,2024,62,Class 1,B-NR,"In patients with PAD, with or without revascularization, periodic assessment of functional status as well as overall health-related QOL as a component of longitudinal follow-up is recommended.1–6 Medical Therapy",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01922,2024,62,Class 1,A,"In patients with PAD, long-term use of GDMT to prevent MACE and MALE is recommended.7–12 Postrevascularization Follow-Up",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01923,2024,62,Class 1,C-LD,"In patients with PAD who have undergone lower extremity revascularization (ie, surgical and/or endo- vascular), longitudinal follow-up that includes periodic clinical evaluation of lower extremity symptoms and pulse and foot assessment is recommended.13–16",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01924,2024,62,Class 1,C-LD,"In patients with PAD who have undergone lower extremity revascularization (ie, surgical, endovascular, or both) with new lower extremity signs or symptoms, ABI and arterial duplex ultrasound is recommended.14,17–20",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01925,2024,62,2A,B-R,"In patients with PAD who have undergone infrain- guinal, autogenous vein bypass graft(s) without new lower extremity signs or symptoms, it is reasonable to perform ABI and arterial duplex ultrasound surveillance within the first 1 to 3 months postprocedure, then repeat at 6 and 12 months, and then annually.13,14,20–22",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01926,2024,62,2A,C-LD,"In patients with PAD who have undergone endovascular procedures without new lower extremity signs or symptoms, it is reasonable to per- form ABI and arterial duplex ultrasound surveillance within the first 1 to 3 months postprocedure, then repeat at 6 and 12 months, and then annually.17,19,20",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01927,2024,62,2B,B-NR,"In patients with PAD who have undergone infrain- guinal, prosthetic bypass graft(s) without new lower extremity signs or symptoms, the effectiveness of ABI and arterial duplex ultrasound surveillance is uncertain.14,20,23,24 Telehealth",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01928,2024,62,2A,C-LD,"For patients with PAD, telehealth can be an alterna- tive mode for vascular evaluation and management and longitudinal follow-up, but the use of these visits should be consistent with the urgency of presenting symptoms.25–28",gornik-et-al-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for-the-management-of-lower-extremity.pdf
id_01929,2024,8,2B,C-LD,It may be reasonable for appropriately trained rescuers to provide in-water rescue breathing to an unresponsive person who has drowned if it does not compromise their own safety. Recommendation-Specific Supportive Text,dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01930,2024,9,Class 1,C-EO,Trained rescuers should provide supplemental oxygen if available to persons with cardiac arrest following drowning. Recommendation-Specific Supportive Text,dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01931,2024,10,Class 1,B-NR,"In cardiac arrest following drowning, CPR with rescue breaths should be started before AED application.",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01932,2024,10,2A,B-NR,AED use is reasonable in cardiac arrest following drowning.,dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01933,2024,10,Class 3: Harm,C-LD,The initiation of CPR should not be delayed to obtain or apply an AED in cardiac arrest following drowning. Recommendation-Specific Supportive Text,dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01934,2024,11,Class 1,B-NR,"In cardiac arrest following drowning and after removal from the water, CPR with rescue breaths and chest compressions should be provided to all persons.",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01935,2024,11,2A,B-NR,"In cardiac arrest following drowning, if the rescuer is unwilling, untrained, or unable to provide rescue breaths, it is reasonable to provide chest compressions only, until help arrives.",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01936,2024,11,2B,C-EO,"In cardiac arrest following drowning, it may be reasonable for trained rescuers to initiate CPR with rescue breaths followed by chest compressions. Recommendation-Specific Supportive Text",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01937,2024,12,2A,C-EO,"Implementation of PAD programs is reasonable in areas where there is a high risk of cardiac arrest, including aquatic environments (eg, areas with high population density, frequent utilization, other forms of exercise, long distances or response times to nearest AED). Recommendation-Specific Supportive Text",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01938,2024,13,2A,C-EO,"It is reasonable for trained rescuers to provide rescue breaths by the first means available (mouth- to-mouth, pocket mask, or bag-mask ventilation) for persons in cardiac arrest following drowning to avoid any delay in ventilation.",dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01939,2024,13,2A,C-EO,Provision of rescue breathing using equipment (bag-mask or advanced airways) should be optimized by providing rescuers a competency- based training program with regular retraining and maintenance of equipment. Recommendation-Specific Supportive Text,dezfulian-et-al-2024-american-heart-association-and-american-academy-of-pediatrics-focused-update-on-special.pdf
id_01940,2020,11,Class 1,C-EO,"In patients with rheumatic heart disease, secondary prevention of rheumatic fever is indicated (Tables 6 and 7).1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01941,2020,11,2A,C-LD,"Antibiotic prophylaxis is reasonable before dental procedures that involve manipulation of gingival tissue, manipulation of the periapical region of teeth, or perforation of the oral mucosa in patients with VHD who have any of the following1–9: a.   Prosthetic cardiac valves, including transcatheter-implanted prostheses and homografts. b.   Prosthetic material used for cardiac valve repair, such as annuloplasty rings, chords, or clips. c.   Previous IE. d.   Unrepaired cyanotic congenital heart disease or repaired congenital heart disease, with residual shunts or valvular regurgitation at the site of or adjacent to the site of a prosthetic patch or prosthetic device. e.   Cardiac transplant with valve regurgitation attributable to a structurally abnormal valve.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01942,2020,11,Class 3: No Benefit,B-NR,"In patients with VHD who are at high risk of IE, antibiotic prophylaxis is not recommended for nondental procedures (eg, TEE, esophagogastroduodenoscopy, colonoscopy, or cystoscopy) in the absence of active infection.10,11 Table 6.  Secondary Prevention of Rheumatic Fever Antibiotics for Prevention Dosage* Penicillin G benzathine",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01943,2020,12,Class 1,A,"For patients with AF and native valve heart disease (except rheumatic mitral stenosis [MS]) or who received a bioprosthetic valve >3 months ago, a non–vitamin K oral anticoagulant (NOAC) is an effective alternative to VKA anticoagulation and should be administered on the basis of the patient’s CHA2DS2-VASc score.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01944,2020,12,Class 1,C-EO,"For patients with AF and rheumatic MS, long-term VKA oral anticoagulation is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01945,2020,12,2A,B-NR,"For patients with new-onset AF ≤3 months after surgical or transcatheter bioprosthetic valve replacement, anticoagulation with a VKA is reasonable.3–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01946,2020,12,Class 3: Harm,B-R,"In patients with mechanical heart valves with or without AF who require long-term anticoagulation with VKA to prevent valve thrombosis, NOACs are not recommended.7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01947,2020,14,Class 1,C-EO,"For patients with VHD for whom intervention is contemplated, individual risks should be calculated for specific surgical and/or transcatheter procedures, using online tools when available, and discussed before the procedure as a part of a shared decision-making process.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01948,2020,15,Class 1,C-EO,Patients with severe VHD should be evaluated by a Multidisciplinary Heart Valve Team (MDT) when intervention is considered.,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01949,2020,15,2A,C-LD,"Consultation with or referral to a Primary or Comprehensive Heart Valve Center is reasonable when treatment options are being discussed for 1) asymptomatic patients with severe VHD, 2) patients who may benefit from valve repair versus valve replacement, or 3) patients with multiple comorbidities for whom valve intervention is considered.1–19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01950,2020,18,Class 1,C-EO,"In asymptomatic patients with any type of valve intervention, a baseline postprocedural TTE followed by periodic monitoring with TTE is recommended, depending on type of intervention, length of time after intervention, ventricular function, and concurrent cardiac conditions.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01951,2020,19,Class 1,A,"In patients with signs or symptoms of AS or a BAV, TTE is indicated for accurate diagnosis of the cause of AS, assessment of hemodynamic severity, measurement of LV size and systolic function, and determination of prognosis and timing of valve intervention.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01952,2020,19,Class 1,B-NR,"In patients with suspected low-flow, low- gradient severe AS with normal LVEF (Stage D3), optimization of blood pressure control is recommended before measurement of AS severity by TTE, TEE, cardiac catheterization, or CMR.3–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01953,2020,19,2A,B-NR,"In patients with suspected low-flow, low- gradient severe AS with reduced LVEF (Stage D2), low-dose dobutamine stress testing with echocardiographic or invasive hemodynamic measurements is reasonable to further define severity and assess contractile reserve.8–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01954,2020,19,2A,B-NR,"In patients with suspected low-flow, low- gradient severe AS with normal or reduced LVEF (Stages D2 and D3), calculation of the ratio of the outflow tract to aortic velocity is reasonable to further define severity.1,11–13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01955,2020,19,2A,B-NR,"In patients with suspected low-flow, low- gradient severe AS with normal or reduced LVEF (Stages D2 and D3), measurement of aortic valve calcium score by CT imaging is reasonable to further define severity.14–18",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01956,2020,22,2A,B-NR,"In asymptomatic patients with severe AS (Stage C1), exercise testing is reasonable to assess physiological changes with exercise and to confirm the absence of symptoms.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01957,2020,22,Class 3: Harm,B-NR,"In symptomatic patients with severe AS (Stage D1, aortic velocity ≥4.0 m/s or mean pressure gradient ≥40 mm Hg), exercise testing should not be performed because of the risk of severe hemodynamic compromise.5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01958,2020,22,Class 1,B-NR,"In patients at risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), hypertension should be treated according to standard GDMT, started at a low dose, and gradually titrated upward as needed, with appropriate clinical monitoring.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01959,2020,22,Class 1,A,"In all patients with calcific AS, statin therapy is indicated for primary and secondary prevention of atherosclerosis on the basis of standard risk scores.4–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01960,2020,22,2B,B-NR,"In patients who have undergone TAVI, renin–angiotensin system blocker therapy (ACE inhibitor or ARB) may be considered to reduce the long-term risk of all-cause mortality.7,8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01961,2020,22,Class 3: No Benefit,A,"In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention of hemodynamic progression of AS.4–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01962,2020,23,Class 1,A,"In adults with severe high-gradient AS (Stage D1) and symptoms of exertional dyspnea, HF, angina, syncope, or presyncope by history or on exercise testing, AVR is indicated.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01963,2020,23,Class 1,B-NR,"In asymptomatic patients with severe AS and an LVEF <50% (Stage C2), AVR is indicated.8–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01964,2020,23,Class 1,B-NR,"In asymptomatic patients with severe AS (Stage C1) who are undergoing cardiac surgery for other indications, AVR is indicated.12–16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01965,2020,23,Class 1,B-NR,"In symptomatic patients with low-flow, low- gradient severe AS with reduced LVEF (Stage D2), AVR is recommended.17–24",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01966,2020,23,Class 1,B-NR,"In symptomatic patients with low-flow, low- gradient severe AS with normal LVEF (Stage D3), AVR is recommended if AS is the most likely cause of symptoms.25–27",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01967,2020,23,2A,B-NR,"In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when an exercise test demonstrates decreased exercise tolerance (normalized for age and sex) or a fall in systolic blood pressure of ≥10 mm Hg from baseline to peak exercise.13,28–30",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01968,2020,23,2A,B-R,"In asymptomatic patients with very severe AS (defined as an aortic velocity of ≥5 m/s) and low surgical risk, AVR is reasonable.15,31–35",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01969,2020,23,2A,B-NR,"In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when the serum B-type natriuretic peptide (BNP) level is >3 times normal.32,36–38",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01970,2020,23,2A,B-NR,"In asymptomatic patients with high-gradient severe AS (Stage C1) and low surgical risk, AVR is reasonable when serial testing shows an increase in aortic velocity ≥0.3 m/s per year.39,40",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01971,2020,23,2B,B-NR,"In asymptomatic patients with severe high- gradient AS (Stage C1) and a progressive decrease in LVEF on at least 3 serial imaging studies to <60%, AVR may be considered.8–11,33",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01972,2020,23,2B,C-EO,"In patients with moderate AS (Stage B) who are undergoing cardiac surgery for other indications, AVR may be considered.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01973,2020,26,Class 1,C-EO,"In patients with an indication for AVR, the choice of prosthetic valve should be based on a shared decision-making process that accounts for the patient’s values and preferences and includes discussion of the indications for and risks of anticoagulant therapy and the potential need for and risks associated with valve reintervention.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01974,2020,26,Class 1,C-EO,"For patients of any age requiring AVR for whom VKA anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired, a bioprosthetic",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01975,2020,26,2A,B-R,"For patients <50 years of age who do not have a contraindication to anticoagulation and require AVR, it is reasonable to choose a mechanical aortic prosthesis over a bioprosthetic valve.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01976,2020,26,2A,B-NR,"For patients 50 to 65 years of age who require AVR and who do not have a contraindication to anticoagulation, it is reasonable to individualize the choice of either a mechanical or bioprosthetic AVR with consideration of individual patient factors and after informed shared decision-making.1–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01977,2020,26,2A,B-R,"In patients >65 years of age who require AVR, it is reasonable to choose a bioprosthesis over a mechanical valve.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01978,2020,26,2B,B-NR,"In patients <50 years of age who prefer a bioprosthetic AVR and have appropriate anatomy, replacement of the aortic valve by a pulmonic autograft (the Ross procedure) may be considered at a Comprehensive Valve Center.11–13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01979,2020,28,Class 1,A,"For symptomatic and asymptomatic patients with severe AS and any indication for AVR who are <65 years of age or have a life expectancy >20 years, SAVR is recommended.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01980,2020,28,Class 1,A,"For symptomatic patients with severe AS who are 65 to 80 years of age and have no anatomic contraindication to transfemoral TAVI, either SAVR or transfemoral TAVI is recommended after shared decision-making about the balance between expected patient longevity and valve durability.1,4–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01981,2020,28,Class 1,A,"For symptomatic patients with severe AS who are >80 years of age or for younger patients with a life expectancy <10 years and no anatomic contraindication to transfemoral TAVI, transfemoral TAVI is recommended in preference to SAVR.1,4–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01982,2020,28,Class 1,B-NR,"In asymptomatic patients with severe AS and an LVEF <50% who are ≤80 years of age and have no anatomic contraindication to transfemoral TAVI, the decision between TAVI and SAVR should follow the same recommendations as for symptomatic patients in Recommendations 1, 2, and 3 above.1,2,4–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01983,2020,28,Class 1,B-NR,"For asymptomatic patients with severe AS and an abnormal exercise test, very severe AS, rapid progression, or an elevated BNP (COR 2a indications for AVR), SAVR is recommended in preference to TAVI.1–3,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01984,2020,28,Class 1,A,"For patients with an indication for AVR for whom a bioprosthetic valve is preferred but valve or vascular anatomy or other factors are not suitable for transfemoral TAVI, SAVR is recommended. 1–3,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01985,2020,28,Class 1,A,"For symptomatic patients of any age with severe AS and a high or prohibitive surgical risk, TAVI is recommended if predicted post- TAVI survival is >12 months with an acceptable quality of life.12,13,14,15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01986,2020,28,Class 1,C-EO,"For symptomatic patients with severe AS for whom predicted post-TAVI or post-SAVR survival is <12 months or for whom minimal improvement in quality of life is expected, palliative care is recommended after shared decision-making, including discussion of patient preferences and values.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01987,2020,28,2B,C-EO,"In critically ill patients with severe AS, percutaneous aortic balloon dilation may be considered as a bridge to SAVR or TAVI.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01988,2020,35,Class 1,B-NR,"In patients with signs or symptoms of AR, TTE is indicated for assessment of the cause and severity of regurgitation, LV size and systolic function, prognosis, and timing of valve intervention.1–19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01989,2020,35,Class 1,B-NR,"In patients with a BAV or with known dilation of the aortic sinuses or ascending aorta, TTE is indicated to evaluate the presence and severity of AR.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01990,2020,35,Class 1,B-NR,"In patients with moderate or severe AR and suboptimal TTE images or a discrepancy between clinical and TTE findings, TEE, CMR, or cardiac catheterization is indicated for the assessment of LV systolic function, systolic and diastolic volumes, aortic size, and AR severity.20–25",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01991,2020,35,Class 1,B-NR,"In asymptomatic patients with chronic AR (Stages B and C), treatment of hypertension (systolic blood pressure >140 mm Hg) is recommended.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01992,2020,35,Class 1,B-NR,"In patients with severe AR who have symptoms and/or LV systolic dysfunction (Stages C2 and D) but a prohibitive surgical risk, GDMT for reduced LVEF with ACE inhibitors, ARBs, and/or sacubitril/valsartan is recommended.4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01993,2020,36,Class 1,B-NR,"In symptomatic patients with severe AR (Stage D), aortic valve surgery is indicated regardless of LV systolic function.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01994,2020,36,Class 1,B-NR,"In asymptomatic patients with chronic severe AR and LV systolic dysfunction (LVEF ≤55%) (Stage C2), aortic valve surgery is indicated if no other cause for systolic dysfunction is identified.3,5,8–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01995,2020,36,Class 1,C-EO,"In patients with severe AR (Stage C or D) who are undergoing cardiac surgery for other indications, aortic valve surgery is indicated.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01996,2020,36,2A,B-NR,"In asymptomatic patients with severe AR and normal LV systolic function (LVEF >55%), aortic valve surgery is reasonable when the LV is severely enlarged (LVESD >50 mm or indexed LVESD >25 mm/m2) (Stage C2).10,11,13–24",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01997,2020,36,2A,C-EO,"In patients with moderate AR (Stage B) who are undergoing cardiac or aortic surgery for other indications, aortic valve surgery is reasonable.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01998,2020,36,2B,B-NR,"In asymptomatic patients with severe AR and normal LV systolic function at rest (LVEF >55%; Stage C1) and low surgical risk, aortic valve surgery may be considered when there is a progressive decline in LVEF on at least 3 serial studies to the low–normal range (LVEF 55% to 60%) or a progressive increase in LV dilation into the severe range (LV end- diastolic dimension [LVEDD] >65 mm).12,16,17,20,25–28",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_01999,2020,36,Class 3: Harm,B-NR,"In patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed.29–32",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02000,2020,38,Class 1,B-NR,"In patients with a known BAV, TTE is indicated to evaluate valve morphology, measure severity of AS and AR, assess the shape and diameter of the aortic sinuses and ascending aorta, and evaluate for the presence of aortic coarctation for prediction of clinical outcome and to determine timing of intervention.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02001,2020,38,Class 1,C-LD,"In patients with BAV, CMR angiography or CT angiography is indicated when morphology of the aortic sinuses, sinotubular junction, or ascending aorta cannot be assessed accurately or fully by echocardiography.4,5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02002,2020,38,2B,B-NR,"In first-degree relatives of patients with a known BAV, a screening TTE might be considered to look for the presence of a BAV or asymptomatic dilation of the aortic sinuses and ascending aorta.6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02003,2020,38,2A,C-LD,"In patients with BAV and a diameter of the aortic sinuses or ascending aorta of ≥4.0 cm, lifelong serial evaluation of the size and morphology of the aortic sinuses and ascending aorta by echocardiography, CMR, or CT angiography is reasonable, with the examination interval determined by the degree and rate of progression of aortic dilation and by family history.1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02004,2020,38,2A,B-NR,"In patients with a BAV who have undergone AVR, continued lifelong serial interval imaging of the aorta is reasonable if the diameter of the aortic sinuses or ascending aorta is ≥4.0 cm.6,7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02005,2020,39,Class 1,B-NR,"In asymptomatic or symptomatic patients with a BAV and a diameter of the aortic sinuses or ascending aorta >5.5 cm, operative intervention to replace the aortic sinuses and/ or the ascending aorta is recommended.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02006,2020,39,2A,B-NR,"In asymptomatic patients with a BAV, a diameter of the aortic sinuses or ascending aorta of 5.0 to 5.5 cm, and an additional risk factor for dissection (eg, family history of aortic dissection, aortic growth rate >0.5 cm per year, aortic coarctation), operative intervention to replace the aortic sinuses and/or the ascending aorta is reasonable if the surgery is performed at a Comprehensive Valve Center.3,4 Figure 5. Intervals for imaging the aorta in patients with a BAV. Colors correspond to Table 2. BAV indicates bicuspid aortic valve; CTA, computed tomographic angiography; CMR, cardiac magnetic resonance;",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02007,2020,40,2A,B-NR,"In patients with a BAV with indications for SAVR and a diameter of the aortic sinuses or ascending aorta ≥4.5 cm, replacement of the aortic sinuses and/or ascending aorta is reasonable if the surgery is performed at a Comprehensive Valve Center.4–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02008,2020,40,2B,C-LD,"In patients with a BAV who meet criteria for replacement of the aortic sinuses, valve-sparing surgery may be considered if the surgery is performed at a Comprehensive Valve Center.8,9",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02009,2020,40,2B,B-NR,"In asymptomatic patients with a BAV who are at low surgical risk, have a diameter of the aortic sinuses or ascending aorta of 5.0 to 5.5 cm, and have no additional risk factors for dissection, operative intervention to replace the aortic sinuses and/or the ascending aorta may be considered if the surgery is performed at a Comprehensive Valve Center.4–7,10–14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02010,2020,40,2B,C-LD,"In patients with BAV and severe AR who meet criteria for AVR, aortic valve repair may be considered in selected patients if the surgery is performed at a Comprehensive Valve Center.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02011,2020,40,2B,B-NR,"In patients with BAV and symptomatic, severe AS, TAVI may be considered as an alternative to SAVR after consideration of patient- specific procedural risks, values, trade-offs, and preferences, and when the surgery is performed at a Comprehensive Valve Center.4–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02012,2020,42,Class 1,B-NR,"In patients with signs or symptoms of rheumatic MS, TTE is indicated to establish the diagnosis, quantify hemodynamic severity, assess concomitant valvular lesions, and demonstrate valve morphology (to determine suitability for mitral commissurotomy).1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02013,2020,42,Class 1,C-LD,"In patients considered for percutaneous mitral balloon commissurotomy (PMBC), TEE should be performed to assess the presence or absence of LA thrombus and to evaluate the severity of MR.4–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02014,2020,44,Class 1,C-LD,"In patients with rheumatic MS and a discrepancy between resting echocardiographic findings and clinical symptoms, exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate symptomatic response, exercise capacity, and the response of the mean mitral gradient and pulmonary artery pressure.1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02015,2020,44,Class 1,C-LD,"In patients with rheumatic MS and 1) AF, 2) a prior embolic event, or 3) an LA thrombus, anticoagulation with a VKA is indicated.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02016,2020,44,2A,C-LD,"In patients with rheumatic MS and AF with a rapid ventricular response, heart rate control can be beneficial.8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02017,2020,44,2A,A,"In patients with rheumatic MS in normal sinus rhythm with symptomatic resting or exertional sinus tachycardia, heart rate control can be beneficial to manage symptoms.9–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02018,2020,45,Class 1,A,"In symptomatic patients (NYHA class II, III, or IV) with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage D) and favorable valve morphology with less than moderate (2+) MR* in the absence of LA thrombus, PMBC is recommended if it can be performed at a Comprehensive Valve Center.1–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02019,2020,45,Class 1,B-NR,"In severely symptomatic patients (NYHA class III or IV) with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage D) who 1) are not candidates for PMBC, 2) have failed a previous PMBC, 3) require other cardiac procedures, or 4) do not have access to PMBC, mitral valve surgery (repair, commissurotomy, or valve replacement) is indicated.6,7,13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02020,2020,45,2A,B-NR,"In asymptomatic patients with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage C) and favorable valve morphology with less than 2+ MR in the absence of LA thrombus who have elevated pulmonary pressures (pulmonary artery systolic pressure >50 mm Hg), PMBC is reasonable if it can be performed at a Comprehensive Valve Center.14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02021,2020,45,2B,C-LD,"In asymptomatic patients with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage C) and favorable valve morphology with less than 2+/ MR* in the absence of LA thrombus who have new onset of AF, PMBC may be considered if it can be performed at a Comprehensive Valve Center.15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02022,2020,45,2B,C-LD,"In symptomatic patients (NYHA class II, III, or IV) with rheumatic MS and an mitral valve area >1.5 cm2, if there is evidence of hemodynamically significant rheumatic MS on the basis of a pulmonary artery wedge pressure >25 mm Hg or a mean mitral valve gradient >15 mm Hg during exercise, PMBC may be considered if it can be performed at a Comprehensive Valve Center.16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02023,2020,45,2B,B-NR,"In severely symptomatic patients (NYHA class III or IV) with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage D) who have a suboptimal valve anatomy and who are not candidates for surgery or are at high risk for surgery, PMBC may be considered if it can be performed at a Comprehensive Valve Center.17–19 *2+ on a 0 to 4+ scale according to Sellar’s criteria or less than moderate by Doppler echocardiography.20",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02024,2020,47,2B,C-LD,"In severely symptomatic patients (NYHA class III or IV) with severe MS (mitral valve area ≤1.5 cm2, Stage D) attributable to extensive mitral annular calcification, valve intervention may be considered only after discussion of the high procedural risk and the individual patient’s preferences and values.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02025,2020,49,Class 1,B-NR,"In patients with known or suspected primary MR, TTE is indicated for baseline evaluation of LV size and function, RV function, LA size, pulmonary artery pressure, and the mechanism and severity of primary MR (Stages A to D).1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02026,2020,49,Class 1,C-EO,"In patients with primary MR, when TTE provides insufficient or discordant information, TEE is indicated for evaluation of the severity of MR, mechanism of MR, and status of LV function (Stages B to D).",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02027,2020,49,Class 1,B-NR,"In patients with primary MR, CMR is indicated to assess LV and RV volumes and function and may help with assessing MR severity when there is a discrepancy between the findings on clinical assessment and echocardiography.6–9",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02028,2020,49,Class 1,B-NR,"In patients with severe primary MR undergoing mitral intervention, intraoperative TEE is indicated to establish the anatomic basis for primary MR (Stages C and D) and to guide repair.10,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02029,2020,50,Class 1,B-NR,"In patients with primary MR (Stages B to D) and new-onset or changing symptoms, TTE is indicated to evaluate the mitral valve apparatus and LV function.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02030,2020,51,Class 1,B-NR,"For asymptomatic patients with severe primary MR (Stages B and C1), TTE is indicated every 6 to 12 months for surveillance of LV function (estimated by LVEF, LVEDD, and LVESD) and assessment of pulmonary artery pressure.1–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02031,2020,51,2B,B-NR,"In asymptomatic patients with severe primary MR (Stages B and C1), use of serum biomarkers and novel measurements of LV function, such as global longitudinal strain, may be considered as an adjunct to guide timing of intervention.12–21",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02032,2020,52,2A,B-NR,"In patients with primary MR (Stages B and C) and symptoms that might be attributable to MR, hemodynamic exercise testing using Doppler echocardiography or cardiac catheterization or cardiopulmonary exercise testing is reasonable.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02033,2020,52,2A,B-NR,"In symptomatic or asymptomatic patients with severe primary MR and LV systolic dysfunction (Stages C2 and D) in whom surgery is not possible or must be delayed, GDMT for systolic dysfunction is reasonable.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02034,2020,52,Class 3: No Benefit,B-NR,"In asymptomatic patients with primary MR and normal LV systolic function (Stages B and C1), vasodilator therapy is not indicated if the patient is normotensive.4–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02035,2020,53,Class 1,B-NR,"In symptomatic patients with severe primary MR (Stage D), mitral valve intervention is recommended irrespective of LV systolic function.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02036,2020,53,Class 1,B-NR,"In asymptomatic patients with severe primary MR and LV systolic dysfunction (LVEF ≤60%, LVESD ≥40 mm) (Stage C2), mitral valve surgery is recommended.3–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02037,2020,53,Class 1,B-NR,"In patients with severe primary MR for whom surgery is indicated, mitral valve repair is recommended in preference to mitral valve replacement when the anatomic cause of MR is degenerative disease, if a successful and durable repair is possible.11–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02038,2020,53,2A,B-NR,"In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF ≥60% and LVESD ≤40 mm) (Stage C1), mitral valve repair is reasonable when the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1%, when it can be performed at a Primary or Comprehensive Valve Center.4,13,16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02039,2020,53,2B,C-LD,"In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF >60% and LVESD <40 mm) (Stage C1) but with a progressive increase in LV size or decrease in EF on ≥3 serial imaging studies, mitral valve surgery may be considered irrespective of the probability of a successful and durable repair.16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02040,2020,53,2A,B-NR,"In severely symptomatic patients (NYHA class III or IV) with primary severe MR and high or prohibitive surgical risk, transcatheter edge-to- edge repair (TEER) is reasonable if mitral valve anatomy is favorable for the repair procedure and patient life expectancy is at least 1 year.17,18",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02041,2020,53,2B,B-NR,"In symptomatic patients with severe primary MR attributable to rheumatic valve disease, mitral valve repair may be considered at a Comprehensive Valve Center by an experienced team when surgical treatment is indicated, if a durable and successful repair is likely.19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02042,2020,53,Class 3: Harm,B-NR,"In patients with severe primary MR where leaflet pathology is limited to less than one half the posterior leaflet, mitral valve replacement should not be performed unless mitral valve repair has been attempted at a Primary or Comprehensive Valve Center and was unsuccessful.11–14,20–22",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02043,2020,56,Class 1,B-NR,"In patients with chronic secondary MR (Stages B to D), TTE is useful to establish the etiology and to assess the extent of regional and global LV remodeling and systolic dysfunction, severity of MR, and magnitude of pulmonary hypertension.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02044,2020,56,Class 1,C-EO,"In patients with chronic secondary MR (Stages B to D), noninvasive imaging (stress nuclear/ PET, CMR, or stress echocardiography), coronary CT angiography, or coronary arteriography is useful to establish etiology of",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02045,2020,56,Class 1,B-NR,"In patients with chronic secondary MR with severe symptoms (Stage D) that are unresponsive to GDMT who are being considered for transcatheter mitral valve interventions, TEE is indicated to determine suitability for the procedure.3–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02046,2020,56,Class 1,C-EO,"In patients with chronic secondary MR undergoing transcatheter mitral valve intervention, intraprocedural guidance with TEE is recommended.4,7,9–13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02047,2020,57,Class 1,A,"Patients with chronic severe secondary MR (Stages C and D) and HF with reduced LVEF should receive standard GDMT for HF, including ACE inhibitors, ARBs, beta blockers, aldosterone antagonists, and/or sacubitril/valsartan, and biventricular pacing as indicated.1–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02048,2020,57,Class 1,C-EO,"In patients with chronic severe secondary MR and HF with reduced LVEF, a cardiologist expert in the management of patients with HF and LV systolic dysfunction should be the primary MDT member responsible for implementing and monitoring optimal GDMT.9,12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02049,2020,58,2A,B-R,"In patients with chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) who have persistent symptoms (NYHA class II, III, or IV) while on optimal GDMT for HF (Stage D), TEER is reasonable in patients with appropriate anatomy as defined on TEE and with LVEF between 20% and 50%, LVESD ≤70 mm, and pulmonary artery systolic pressure ≤70 mm Hg.1–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02050,2020,58,2A,B-NR,"In patients with severe secondary MR (Stages C and D), mitral valve surgery is reasonable when CABG is undertaken for the treatment of myocardial ischemia.9–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02051,2020,58,2B,B-NR,"In patients with chronic severe secondary MR from atrial annular dilation with preserved LV systolic function (LVEF ≥50%) who have severe persistent symptoms (NYHA class III or IV) despite therapy for HF and therapy for associated AF or other comorbidities (Stage D), mitral valve surgery may be considered.16–20",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02052,2020,58,2B,B-NR,"In patients with chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) who have persistent severe symptoms (NYHA class III or IV) while on optimal GDMT for HF (Stage D), mitral valve surgery may be considered.9,12,21–43",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02053,2020,58,2B,B-R,"In patients with CAD and chronic severe secondary MR related to LV systolic dysfunction (LVEF <50%) (Stage D) who are undergoing mitral valve surgery because of severe symptoms (NYHA class III or IV) that persist despite GDMT for HF, chordal-sparing mitral valve replacement may be reasonable to choose over downsized annuloplasty repair.9,12,21–32,44–47",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02054,2020,60,Class 1,C-LD,"In patients with TR, TTE is indicated to evaluate the presence and severity of TR, determine the etiology, measure the sizes of the right- sided chambers and inferior vena cava, assess RV systolic function, estimate pulmonary artery systolic pressure, and characterize any associated left-sided heart disease.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02055,2020,60,2A,C-LD,"In patients with TR, invasive measurement of the cardiac index, right-sided diastolic pressures, pulmonary artery pressures, and pulmonary vascular resistance, as well as right ventriculography, can be useful when clinical and noninvasive data are discordant or inadequate.3–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02056,2020,61,2A,C-EO,"In patients with signs and symptoms of right-sided HF attributable to severe TR (Stages C and D), diuretics can be useful.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02057,2020,61,2A,C-EO,"In patients with signs and symptoms of right-sided HF attributable to severe secondary TR (Stages C and D), therapies to treat the primary cause of HF (eg, pulmonary vasodilators to reduce elevated pulmonary artery pressures, GDMT for HF with reduced LVEF, or rhythm control of AF) can be useful1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02058,2020,62,Class 1,B-NR,"In patients with severe TR (Stages C and D) undergoing left-sided valve surgery, tricuspid valve surgery is recommended.1–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02059,2020,62,2A,B-NR,"In patients with progressive TR (Stage B) undergoing left-sided valve surgery, tricuspid valve surgery can be beneficial in the context of either 1) tricuspid annular dilation (tricuspid annulus end diastolic diameter >4.0 cm) or 2) prior signs and symptoms of right-sided HF.3–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02060,2020,62,2A,B-NR,"In patients with signs and symptoms of right-sided HF and severe primary TR (Stage D), isolated tricuspid valve surgery can be beneficial to reduce symptoms and recurrent hospitalizations.11–14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02061,2020,62,2A,B-NR,"In patients with signs and symptoms of right- sided HF and severe isolated secondary TR attributable to annular dilation (in the absence of pulmonary hypertension or left-sided disease) who are poorly responsive to medical therapy (Stage D), isolated tricuspid valve surgery can be beneficial to reduce symptoms and recurrent hospitalizations.11,12,15–19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02062,2020,62,2B,C-LD,"In asymptomatic patients with severe primary TR (Stage C) and progressive RV dilation or systolic dysfunction, isolated tricuspid valve surgery may be considered.12,20",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02063,2020,62,2B,B-NR,"In patients with signs and symptoms of right- sided HF and severe TR (Stage D) who have undergone previous left-sided valve surgery, reoperation with isolated tricuspid valve surgery may be considered in the absence of severe pulmonary hypertension or severe RV systolic dysfunction.1,2,11,18",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02064,2020,64,Class 1,C-EO,"For patients with mixed valve disease, TTE is recommended to assess the etiology, severity, and pathophysiological impact.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02065,2020,64,2A,C-EO,"In patients with ambiguous symptoms that are suspected to be attributable to mixed mitral valve disease, further assessment of filling pressure by using biomarkers or invasive hemodynamic measurements at rest or with exercise is reasonable.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02066,2020,65,Class 1,B-NR,"In symptomatic patients with combined AS and AR and a peak transvalvular jet velocity of at least 4.0 m/s or a mean transvalvular gradient of at least 40 mm Hg, AVR is recommended.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02067,2020,65,Class 1,C-EO,"In asymptomatic patients with combined AS and AR who have a jet velocity of ≥4.0 m/s with an LVEF <50%, SAVR is recommended.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02068,2020,66,Class 1,B-NR,"In patients with a surgical or transcatheter prosthetic valve and in patients who have had valve repair, an initial postprocedural TTE study is recommended for evaluation of valve hemodynamics and ventricular function.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02069,2020,66,Class 1,C-EO,"In patients with a prosthetic valve or prior valve repair and a change in clinical symptoms or signs suggesting valve dysfunction, repeat TTE is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02070,2020,66,Class 1,C-LD,"In patients with a prosthetic valve replacement or prior valve repair and clinical symptoms or signs that suggest prosthetic valve dysfunction, additional imaging with TEE, gated cardiac CT, or fluoroscopy is recommended, even if TTE does not show valve dysfunction.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02071,2020,66,2A,C-LD,"In patients with a bioprosthetic surgical valve, TTE at 5 and 10 years and then annually after implantation is reasonable, even in the absence of a change in clinical status.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02072,2020,66,2A,C-LD,"In patients with a bioprosthetic TAVI, TTE annually is reasonable. Table 21.  AS/MR Mixed Valve Disease Severe AS Severe MR Surgical Risk Procedure SAVR candidate Primary MR Repairable valve Low intermediate SAVR Surgical mitral valve repair SAVR candidate Primary MR Valve not repairable Low intermediate SAVR Surgical mitral valve replacement TAVI candidate Primary Repairable valve High prohibitive TAVI Mitral TEER* SAVR candidate TAVI candidate Secondary MR Low intermediate SAVR Surgical mitral valve repair/mitral valve replacement or TAVI Mitral TEER* TAVI candidate Secondary MR High prohibitive TAVI Mitral TEER* *Consider TEER as a later staged procedure if symptoms and severe MR persist after treatment of the AS. AS indicates aortic stenosis; MR, mitral regurgitation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; and TEER, transcatheter edge-to-edge repair. Downloaded from http://ahajournals.org by on June 19, 2025",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02073,2020,68,Class 1,C-LD,"For patients who require heart valve replacement, the choice of prosthetic valve should be based on a shared decision-making process that accounts for the patient’s values and preferences and includes discussion of the indications for and risks of anticoagulant therapy and the potential need for and risks associated with valve reintervention.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02074,2020,68,Class 1,C-EO,"For patients of any age requiring valve replacement for whom anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired, a bioprosthetic valve is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02075,2020,68,2A,B-NR,"For patients <50 years of age who do not have a contraindication to anticoagulation and require AVR, it is reasonable to choose a mechanical aortic prosthesis over a bioprosthetic valve.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02076,2020,68,2A,B-NR,"For patients 50 to 65 years of age who require AVR and who do not have a contraindication to anticoagulation, it is reasonable to individualize the choice of either a mechanical or bioprosthetic AVR, with consideration of individual patient factors and after informed shared decision-making.1–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02077,2020,68,2A,B-NR,"In patients >65 years of age who require AVR, it is reasonable to choose a bioprosthesis over a mechanical valve.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02078,2020,68,2A,B-NR,"For patients <65 years of age who have an indication for mitral valve replacement, do not have a contraindication to anticoagulation, and are unable to undergo mitral valve repair, it is reasonable to choose a mechanical mitral prosthesis over a bioprosthetic valve.1,7,10,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02079,2020,68,2A,B-NR,"For patients ≥65 years of age who require mitral valve replacement and are unable to undergo mitral valve repair, it is reasonable to choose a bioprosthesis over a mechanical valve.1,7,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02080,2020,68,2B,B-NR,"In patients <50 years of age who prefer a bioprosthetic AVR and have appropriate anatomy, replacement of the aortic valve by a pulmonic autograft (the Ross procedure) may be considered at a Comprehensive Valve Center.12–14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02081,2020,71,Class 1,A,"In patients with a mechanical prosthetic valve, anticoagulation with a VKA is recommended.1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02082,2020,71,Class 1,B-NR,"For patients with a mechanical bileaflet or current-generation single-tilting disk AVR and no risk factors for thromboembolism, anticoagulation with a VKA to achieve an INR of 2.5 is recommended.6–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02083,2020,71,Class 1,B-NR,"For patients with a mechanical AVR and additional risk factors for thromboembolism (eg, AF, previous thromboembolism, LV dysfunction, hypercoagulable state) or an older-generation prosthesis (eg, ball-in-cage), anticoagulation with a VKA is indicated to achieve an INR of 3.0.9,10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02084,2020,71,Class 1,B-NR,"For patients with a mechanical mitral valve replacement, anticoagulation with a VKA is indicated to achieve an INR of 3.0.9,11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02085,2020,71,2A,B-R,"For patients with a bioprosthetic TAVI, aspirin 75 to 100 mg daily is reasonable in the absence of other indications for oral anticoagulants.12–14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02086,2020,71,2A,B-NR,"For all patients with a bioprosthetic SAVR or mitral valve replacement, aspirin 75 to 100 mg daily is reasonable in the absence of other indications for oral anticoagulants.9,15–18",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02087,2020,71,2A,B-NR,"For patients with a bioprosthetic SAVR or mitral valve replacement who are at low risk of bleeding, anticoagulation with a VKA to achieve an INR of 2.5 is reasonable for at least 3 months and for as long as 6 months after surgical replacement.15,19–25",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02088,2020,71,2B,B-R,"For patients with a mechanical SAVR or mitral valve replacement who are managed with a VKA and have an indication for antiplatelet therapy, addition of aspirin 75 to 100 mg daily may be considered when the risk of bleeding is low.26",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02089,2020,71,2B,B-R,"For patients with a mechanical On-X AVR and no thromboembolic risk factors, use of a VKA targeted to a lower INR (1.5–2.0) may be reasonable starting ≥3 months after surgery, with continuation of aspirin 75 to 100 mg daily.27,28",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02090,2020,71,2B,B-NR,"For patients with a bioprosthetic TAVI who are at low risk of bleeding, dual- antiplatelet therapy with aspirin 75 to 100 mg and clopidogrel 75 mg may be reasonable for 3 to 6 months after valve implantation.12,13,29",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02091,2020,71,2B,B-NR,"For patients with a bioprosthetic TAVI who are at low risk of bleeding, anticoagulation with a VKA to achieve an INR of 2.5 may be reasonable for at least 3 months after valve implantation.23,31–33",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02092,2020,71,Class 3: Harm,B-R,"For patients with bioprosthetic TAVI, treatment with low-dose rivaroxaban (10 mg daily) plus aspirin (75–100 mg) is contraindicated in the absence of other indications for oral anticoagulants.30",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02093,2020,71,Class 3: Harm,B-R,"For patients with a mechanical valve prosthesis, anticoagulation with the direct thrombin inhibitor, dabigatran, is contraindicated.4,5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02094,2020,71,Class 3: Harm,C-EO,"For patients with a mechanical valve prosthesis, the use of anti-Xa direct oral anticoagulants has not been assessed and is not recommended.34–37",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02095,2020,75,Class 1,C-EO,"For patients with mechanical heart valves who are undergoing minor procedures (eg, dental extractions or cataract removal) where bleeding is easily controlled, continuation of VKA anticoagulation with a therapeutic INR is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02096,2020,75,Class 1,C-LD,"For patients with a bileaflet mechanical AVR and no other risk factors for thromboembolism who are undergoing invasive procedures, temporary interruption of VKA anticoagulation, without bridging agents while the INR is subtherapeutic, is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02097,2020,75,2A,C-LD,"For patients with a mechanical valve prosthesis receiving VKA therapy who require immediate/ emergency noncardiac surgery or an invasive procedure, administration of 4-factor prothrombin complex concentrate (or its activated form) is reasonable.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02098,2020,76,2A,C-LD,"For patients with bioprosthetic heart valves or annuloplasty rings who are receiving anticoagulation for AF, it is reasonable to consider the need for bridging anticoagulant therapy around the time of invasive procedures on the basis of the CHA2DS2-VASc score weighed against the risk of bleeding.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02099,2020,76,2A,C-LD,"For patients who are undergoing invasive procedures and have 1) a mechanical AVR and any thromboembolic risk factor, 2) an older-generation mechanical AVR, or 3) a mechanical mitral valve replacement, bridging anticoagulation therapy during the preoperative time interval when the INR is subtherapeutic is reasonable on an individualized basis, with the risks of bleeding weighed against the benefits of thromboembolism prevention.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02100,2020,77,2A,C-LD,"For patients with mechanical valves and uncontrollable bleeding who require immediate reversal of anticoagulation, administration of 4-factor prothrombin complex (or its activated form) is reasonable.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02101,2020,77,2A,C-LD,"For patients with mechanical valves and uncontrollable bleeding who have received 4-factor prothrombin concentrate complex, adjunctive use of intravenous vitamin K is reasonable if resumption of VKA therapy is not anticipated for 7 days.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02102,2020,77,2A,B-NR,"For patients with bioprosthetic valves or annuloplasty rings who are receiving a direct oral anticoagulant and who require immediate reversal of anticoagulation because of uncontrollable bleeding, treatment with idarucizumab (for dabigatran) or andexanet alfa (for anti-Xa agents) is reasonable.1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02103,2020,77,2B,C-LD,"For patients with a mechanical prosthetic valve and supratherapeutic INR (>5.0) who are not actively bleeding, the benefit of individualized treatment with oral vitamin K, in addition to temporary withdrawal of the VKA, is uncertain.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02104,2020,77,2A,C-EO,"In patients with a mechanical AVR who experience a stroke or systemic embolic event while in therapeutic range on VKA anticoagulation, it is reasonable to increase the INR goal from 2.5 (range, 2.0–3.0) to 3.0 (range, 2.5–3.5) or to add daily low-dose aspirin (75– 100 mg), with assessment of bleeding risk.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02105,2020,77,2A,C-EO,"In patients with a mechanical mitral valve replacement who experience a stroke or systemic embolic event while in therapeutic range on VKA anticoagulation, it is reasonable to increase the INR goal from 3.0 (range, 2.5–3.5) to 4.0 (range, 3.5–4.0) or to add daily low-dose aspirin (75–100 mg), with assessment of bleeding risk.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02106,2020,77,2B,C-EO,"In patients with a bioprosthetic surgical or transcatheter aortic valve or bioprosthetic mitral valve who experience a stroke or systemic embolic event while on antiplatelet therapy, VKA anticoagulation, instead of antiplatelet therapy may be considered after assessment of bleeding risk.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02107,2020,78,Class 1,B-NR,"In patients with suspected mechanical prosthetic valve thrombosis, urgent evaluation with TTE, TEE, fluoroscopy, and/ or multidetector CT imaging is indicated to assess valve function, leaflet motion, and the presence and extent of thrombus.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02108,2020,79,Class 1,B-NR,"For patients with a thrombosed left-sided mechanical prosthetic heart valve who present with symptoms of valve obstruction, urgent initial treatment with either slow-infusion, low- dose fibrinolytic therapy or emergency surgery is recommended.1–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02109,2020,79,2A,C-LD,"In patients with suspected bioprosthetic valve thrombosis, 3D TEE or 4D CT imaging can be useful to rule out leaflet thrombosis.1–5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02110,2020,79,2A,B-NR,"In patients with suspected or confirmed bioprosthetic valve thrombosis who are hemodynamically stable and have no contraindications to anticoagulation, initial treatment with a VKA is reasonable.1–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02111,2020,80,Class 1,B-NR,"In patients with suspected mechanical or bioprosthetic valve stenosis, TTE and TEE are recommended to diagnosis the cause and severity of valve obstruction, assess ventricular function, and estimate pulmonary artery systolic pressure.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02112,2020,80,Class 1,C-EO,"In patients with mechanical valve stenosis, fluoroscopy or cine-CT is recommended to assess motion of the mechanical valve leaflets.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02113,2020,80,2A,C-LD,"In patients with bioprosthetic valve stenosis, 3D TEE or 4D CT imaging can be useful to rule out leaflet thrombosis.3–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02114,2020,81,Class 1,B-NR,"In patients with symptomatic severe stenosis of a bioprosthetic or mechanical prosthetic valve, repeat surgical intervention is indicated unless surgical risk is high or prohibitive.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02115,2020,81,2A,B-NR,"For severely symptomatic patients with bioprosthetic aortic valve stenosis and high or prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center.4,5",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02116,2020,81,2A,B-NR,"For patients with significant bioprosthetic valve stenosis attributable to suspected or documented valve thrombosis, oral anticoagulation with a VKA is reasonable.6–13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02117,2020,82,Class 1,B-NR,"In patients with suspected mechanical or bioprosthetic valve regurgitation, TTE and TEE are recommended to determine the cause and severity of the leak, assess ventricular function, and estimate pulmonary artery systolic pressure.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02118,2020,82,Class 1,C-EO,"In patients undergoing a transcatheter procedure for paravalvular prosthetic regurgitation, 3D TEE is recommended for intraprocedural guidance.4–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02119,2020,83,Class 1,B-NR,"In patients with intractable hemolysis or HF attributable to prosthetic transvalvular or paravalvular leak, surgery is recommended unless surgical risk is high or prohibitive.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02120,2020,83,2A,B-NR,"In asymptomatic patients with severe prosthetic regurgitation and low operative risk, surgery is reasonable.1–4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02121,2020,83,2A,B-NR,"In patients with prosthetic paravalvular regurgitation with the following: 1) either intractable hemolysis or NYHA class III or IV symptoms and 2) who are at high or prohibitive surgical risk and 3) have anatomic features suitable for catheter-based therapy, percutaneous repair of paravalvular leak is reasonable when performed at a Comprehensive Valve Center.5–9",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02122,2020,83,2A,B-NR,"For patients with severe HF symptoms caused by bioprosthetic valve regurgitation who are at high to prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center.10–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02123,2020,85,Class 1,B-NR,"In patients at risk of IE (eg, those with congenital or acquired VHD, previous IE, prosthetic heart valves, certain congenital or heritable heart malformations, immunodeficiency states, or injection drug use) who have unexplained fever blood, culture samples should be obtained.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02124,2020,85,Class 1,B-NR,"In patients with the recent onset of left-sided valve regurgitation, at least 2 sets of blood culture samples should be obtained.1–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02125,2020,85,Class 1,B-NR,"In patients with suspected IE, the Modified Duke Criteria should be used for diagnosis (Tables 24 and 25).2–10",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02126,2020,85,Class 1,B-NR,"Patients with IE should be evaluated and managed with consultation with a multispecialty Heart Valve Team, which includes an infectious disease specialist, cardiologist, and cardiac surgeon; a cardiac anesthesiologist for surgically managed patients11; and a neurologist for patients with neurological events.11–13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02127,2020,85,Class 1,B-NR,"In patients with suspected IE, TTE is recommended to identify vegetations, characterize the hemodynamic severity of valvular lesions, assess ventricular function and pulmonary pressures, and detect complications.14–23",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02128,2020,85,Class 1,B-NR,"In all patients with known or suspected IE and nondiagnostic TTE results, when complications have developed or are clinically suspected or when intracardiac device leads are present, TEE is recommended.21,23–40",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02129,2020,85,Class 1,B-NR,"In patients with IE who have a change in clinical signs or symptoms (eg, new murmur, embolism, persistent fever, HF, abscess, or atrioventricular heart block) and in patients at high risk of complications (eg, extensive infected tissue, large vegetation on initial echocardiogram, or staphylococcal, enterococcal, or fungal infections), TTE and/or TEE are recommended for reevaluation.24,31,41–46",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02130,2020,85,Class 1,B-NR,"In patients undergoing valve surgery for IE, intraoperative TEE is recommended.47–50",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02131,2020,85,Class 1,B-NR,"In patients being considered for an early change to oral antibiotic therapy for the treatment of stable IE, a baseline TEE before switching to oral therapy and a repeat TEE",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02132,2020,85,2A,B-NR,"In patients with Staphylococcus aureus bacteremia without a known source, TEE is reasonable to diagnose possible IE.11,36,52–56",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02133,2020,85,2A,B-NR,"In patients with a prosthetic valve in the presence of persistent fever without bacteremia or a new murmur, a TEE is reasonable to aid in the diagnosis of IE.57–60",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02134,2020,85,2A,B-NR,"In patients in whom the anatomy cannot be clearly delineated by echocardiography in the setting of suspected paravalvular infections, CT imaging is reasonable.37,61–68",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02135,2020,85,2A,B-NR,"In patients classified by Modified Duke Criteria as having “possible IE,” 18F-fluorodeoxyglucose PET/CT is reasonable as adjunct diagnostic imaging.69–71",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02136,2020,85,2B,B-NR,"In patients with nosocomial S. aureus bacteremia with a known portal of entry from an extracardiac source, TEE might be considered to detect concomitant staphylococcal IE.22,53,54,72–74",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02137,2020,89,Class 1,B-NR,"In patients with IE, appropriate antibiotic therapy should be initiated and continued after blood cultures are obtained, with guidance from antibiotic sensitivity data and the infectious disease experts on the MDT.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02138,2020,89,Class 1,B-R,Patients with suspected or confirmed IE associated with drug use should be referred to addiction treatment for opioid substitution therapy.8–10,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02139,2020,89,2A,B-NR,"In patients with IE and with evidence of cerebral embolism or stroke, regardless of the other indications for anticoagulation, it is reasonable to temporarily discontinue anticoagulation.11–24",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02140,2020,89,2B,B-R,"In patients with left-sided IE caused by streptococcus, Enterococcus faecalis, S. aureus, or coagulase-negative staphylococci deemed stable by the MDT after initial intravenous antibiotics, a change to oral antibiotic therapy may be considered if TEE before the switch to oral therapy shows no paravalvular infection, if frequent and appropriate follow-up can be assured by the care team, and if a follow-up TEE can be performed 1 to 3 days before the completion of the antibiotic course.25",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02141,2020,89,2B,B-NR,"In patients receiving VKA anticoagulation at the time of IE diagnosis, temporary discontinuation of VKA anticoagulation may be considered.13,26–34",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02142,2020,89,Class 3: Harm,C-LD,"Patients with known VHD should not receive antibiotics before blood cultures are obtained for unexplained fever.22,35,36",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02143,2020,91,Class 1,B-NR,Decisions about the timing of surgical intervention for IE should be made by a Heart Valve Team.1–6,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02144,2020,91,Class 1,B-NR,"In patients with IE who present with valve dysfunction resulting in symptoms of HF, early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) is indicated.7–19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02145,2020,91,Class 1,B-NR,"In patients with left-sided IE caused by S. aureus, a fungal organism, or other highly resistant organisms, early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) is indicated.7,9,15,20–35",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02146,2020,91,Class 1,B-NR,"In patients with IE complicated by heart block, annular or aortic abscess, or destructive penetrating lesions, early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) is indicated.7,9,36–44",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02147,2020,91,Class 1,B-NR,"In patients with IE and evidence of persistent infection as manifested by persistent bacteremia or fevers lasting >5 days after onset of appropriate antimicrobial therapy, early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) for IE is indicated.7,9,15,25,26,45–48",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02148,2020,91,Class 1,B-NR,"In all patients with definite endocarditis and an implanted cardiac electronic device, complete removal of the pacemaker or defibrillator systems, including all leads and the generator, is indicated.49–55",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02149,2020,91,Class 1,C-LD,"For patients with prosthetic valve endocarditis and relapsing infection (defined as recurrence of bacteremia after a complete course of appropriate antibiotics and subsequent negative blood culture results) without other identifiable source of infection, surgery is recommended.7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02150,2020,91,Class 1,C-LD,"In patients with recurrent endocarditis and continued intravenous drug use, consultation with addiction medicine is recommended to discuss the long-term prognosis for the patient’s refraining from actions that risk reinfection before repeat surgical intervention is considered.56–60",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02151,2020,91,2A,B-NR,"In patients with IE who present with recurrent emboli and persistent vegetations despite appropriate antibiotic therapy, early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) is reasonable.53,61–66",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02152,2020,91,2B,B-NR,"In patients with native left-sided valve endocarditis who exhibit mobile vegetations >10 mm in length (with or without clinical evidence of embolic phenomenon), early surgery (during initial hospitalization and before completion of a full therapeutic course of antibiotics) may be considered.20,61–63,67",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02153,2020,91,2B,B-NR,"In patients with IE and an indication for surgery who have suffered a stroke but have no evidence of intracranial hemorrhage or extensive neurological damage, operation without delay may be considered.68–70",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02154,2020,91,2B,B-NR,"For patients with IE and major ischemic stroke with extensive neurological damage or intracranial hemorrhage, if the patient is hemodynamically stable, delaying valve surgery for at least 4 weeks may be considered.68,71",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02155,2020,94,Class 1,B-NR,Women with suspected valve disease who are considering pregnancy should undergo a clinical evaluation and TTE before pregnancy.1–5,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02156,2020,94,Class 1,B-NR,Women with severe valve disease (Stages C and D) who are considering pregnancy should undergo pre-pregnancy counseling by a cardiologist with expertise in managing women with VHD during pregnancy.1–5,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02157,2020,94,Class 1,B-NR,"Pregnant women with severe valve disease (Stages C and D) should be monitored in a tertiary-care center with a dedicated Heart Valve Team of cardiologists, surgeons, anesthesiologists, and maternal-fetal medicine obstetricians with expertise in the management of high-risk cardiac conditions during pregnancy.1–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02158,2020,94,2A,B-NR,"In asymptomatic women with severe valve disease (Stage C1) who are considering pregnancy, exercise testing is reasonable before pregnancy for risk assessment.3–5,11,13–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02159,2020,95,2A,C-LD,"In pregnant women with VHD, beta-blocker medications are reasonable as required for heart rate control or treatment of arrhythmias.1–6",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02160,2020,95,2A,C-LD,"In pregnant women with VHD and HF symptoms (Stage D), diuretic medications are reasonable if needed for volume overload.7,8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02161,2020,95,Class 3: Harm,B-NR,"In pregnant women with VHD, ACE inhibitors and ARBs should not be given because of fetal risk.6,9–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02162,2020,95,Class 1,B-NR,"In symptomatic women with severe VHD who are considering pregnancy, intervention before pregnancy is recommended on the basis of standard indications.1–11 Downloaded from http://ahajournals.org by on June 19, 2025",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02163,2020,96,Class 1,C-EO,"In women who require a valve intervention before pregnancy, the choice of prosthetic valve should be based on a shared decision- making process that accounts for the patient’s values and preferences, including discussion of the risks of mechanical valves during pregnancy and the reduced durability of bioprosthetic valves in young women.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02164,2020,96,2A,C-LD,"In asymptomatic women with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage C1) who are considering pregnancy, PMBC at a Comprehensive Valve Center is reasonable before pregnancy for those who have favorable valve morphology.1–5,12,13",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02165,2020,96,2A,B-NR,"In women of childbearing age who require valve replacement, bioprosthetic valves are preferred over mechanical valves because of the increased maternal and fetal risks of mechanical heart valves in pregnancy.14",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02166,2020,96,2A,C-EO,"In asymptomatic women with severe AS (aortic velocity ≥4.0 m/s or mean pressure gradient ≥40 mm Hg, Stage C) who are considering pregnancy, valve intervention before pregnancy is reasonable.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02167,2020,96,2B,C-EO,"In asymptomatic women with severe AS (aortic velocity ≥4.0 m/s or mean pressure gradient ≥40 mm Hg, Stage C1) who are considering pregnancy, do not meet COR 1 criteria for intervention, and have a preconception evaluation confirming the absence of symptoms (including normal exercise stress testing and serum BNP measurements), medical management during pregnancy may be considered to avoid prosthetic valve replacement.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02168,2020,96,2B,C-EO,"In asymptomatic women with severe MR (Stage C1) and a valve suitable for repair who are considering pregnancy, valve repair before pregnancy at a Comprehensive Valve Center may be considered but only after detailed discussion with the patient about the risks and benefits of the surgery and its effect on future pregnancies.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02169,2020,98,2A,B-NR,"In pregnant women with severe AS (mean pressure gradient ≥40 mm Hg, Stage D), valve intervention during pregnancy is reasonable if there is hemodynamic deterioration or if there are NYHA class III or IV HF symptoms.1–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02170,2020,98,2A,B-NR,"In pregnant women with severe rheumatic MS (mitral valve area ≤1.5 cm2, Stage D) and with valve morphology favorable for PMBC who remain symptomatic with NYHA class III or IV HF symptoms despite medical therapy, PMBC is reasonable during pregnancy if it is performed at a Comprehensive Valve Center.8–12",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02171,2020,98,2A,C-LD,"In pregnant women with severe valve regurgitation and with NYHA class IV HF symptoms (Stage D) refractory to medical therapy, valve surgery is reasonable during pregnancy.13–16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02172,2020,98,Class 3: Harm,C-LD,"In pregnant women with VHD, valve surgeries should not be performed in the absence of severe HF symptoms refractory to medical therapy.13–16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02173,2020,98,Class 1,C-EO,"Women with a prosthetic valve should undergo pre-pregnancy assessment, including echocardiography, by a cardiologist with expertise in managing women with VHD during pregnancy.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02174,2020,98,Class 1,C-EO,"Pregnant women with a mechanical prosthesis should be monitored in a tertiary-care center with a dedicated MDT of cardiologists, surgeons, anesthesiologists, and maternal-fetal medicine obstetricians with expertise in the management of high-risk cardiac conditions during pregnancy.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02175,2020,98,Class 1,B-NR,Women with mechanical heart valves considering pregnancy should be counselled that pregnancy is high risk and that there is no anticoagulation strategy that is consistently safe for the mother and baby.3–6,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02176,2020,98,Class 1,B-NR,Pregnant women with a mechanical prosthetic valve who have prosthetic valve obstruction or experience an embolic event should undergo a TEE.7–9,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02177,2020,99,Class 1,B-NR,Pregnant women with mechanical prostheses should receive therapeutic anticoagulation with frequent monitoring during pregnancy.1–10,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02178,2020,99,Class 1,B-NR,"Women with mechanical heart valves who cannot maintain therapeutic anticoagulation with frequent monitoring should be counseled against pregnancy.7,8,10–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02179,2020,99,Class 1,B-NR,"Women with mechanical heart valves and their providers should use shared decision- making to choose an anticoagulation strategy for pregnancy. Women should be informed that VKA during pregnancy is associated with the lowest likelihood of maternal complications but the highest likelihood of miscarriage, fetal death, and congenital abnormalities, particularly if taken during the first trimester and if the warfarin dose exceeds 5 mg/d.3–6,11,14,16",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02180,2020,99,Class 1,C-LD,"Pregnant women with mechanical valve prostheses who are on warfarin should switch to twice-daily LMWH (with a target anti-Xa level of 0.8 U/mL to 1.2 U/mL at 4 to 6 hours after dose) or intravenous UFH (with an activated partial thromboplastin time [aPTT] 2 times control) at least 1 week before planned delivery.5,8,13,17–20",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02181,2020,99,Class 1,C-LD,Pregnant women with mechanical valve prostheses who are on LMWH should switch to UFH (with an aPTT 2 times control) at least 36 hours before planned delivery.19–21,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02182,2020,99,Class 1,C-LD,Pregnant women with valve prostheses should stop UFH at least 6 hours before planned vaginal delivery.19–21,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02183,2020,99,Class 1,C-LD,"If labor begins or urgent delivery is required in a woman therapeutically anticoagulated with a VKA, cesarean section should be performed after reversal of anticoagulation.3,22,23",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02184,2020,99,2A,B-NR,"For pregnant women with mechanical prostheses who require a dose of warfarin ≤5 mg/d to maintain a therapeutic INR, continuation of warfarin for all 3 trimesters is reasonable after full discussion with the patient about risks and benefits.3,6,16,18,22,24,25",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02185,2020,99,2A,B-NR,"For pregnant women with mechanical prostheses who require >5 mg/d of warfarin to achieve a therapeutic INR, dose-adjusted LMWH (with a target anti-Xa level of 0.8 to",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02186,2020,99,2A,B-NR,"For pregnant women with mechanical prostheses who require a dose of warfarin >5 mg/d to achieve a therapeutic INR, and for whom dose-adjusted LMWH is unavailable, dose-adjusted continuous intravenous UFH during the first trimester (with aPTT 2 times control), followed by warfarin for the second and third trimesters, is reasonable.3,6,11,16 Downloaded from http://ahajournals.org by on June 19, 2025",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02187,2020,100,2A,B-NR,"For hemodynamically stable pregnant women with obstructive left-sided mechanical valve thrombosis, it is reasonable to manage with slow-infusion, low-dose fibrinolytic therapy.26",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02188,2020,100,2B,B-NR,"For pregnant women with mechanical prostheses who require a warfarin dose >5 mg/d to achieve a therapeutic INR, dose- adjusted LMWH (with a target anti-Xa level of 0.8 to 1.2 U/mL at 4 to 6 hours after dose) at least 2 times per day for all 3 trimesters may be considered.3,6,14–16,27",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02189,2020,100,2B,B-NR,"For pregnant women with mechanical prostheses who require a dose of warfarin ≤5 mg/d to maintain a therapeutic INR, dose-adjusted LMWH at least 2 times per day during the first trimester, followed by warfarin for the second and third trimesters, may be considered.1–3,6,12,16,22",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02190,2020,100,2B,B-NR,"For pregnant women with mechanical prostheses, aspirin 75 to 100 mg daily may be considered, in addition to anticoagulation, if needed for other indications.28",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02191,2020,100,Class 3: Harm,B-NR,"For pregnant women with mechanical prostheses, LMWH should not be administered unless anti-Xa levels are monitored 4 to 6 hours after administration and dose is adjusted according to levels.8–10,15,27",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02192,2020,100,Class 3: Harm,B-R,"For patients with mechanical valve prostheses, anticoagulation with the direct thrombin inhibitor, dabigatran, should not be administered.29",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02193,2020,100,Class 3: Harm,C-EO,The use of anti-Xa direct oral anticoagulants with mechanical heart valves in pregnancy has not been assessed and is not recommended.30–32,otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02194,2020,103,Class 1,C-EO,"In patients undergoing TAVI, 1) contrast- enhanced coronary CT angiography (in patients with a low pretest probability for CAD) or 2) an invasive coronary angiogram is recommended to assess coronary anatomy and guide revascularization.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02195,2020,103,2A,C-LD,"In patients undergoing TAVI with significant left main or proximal CAD with or without angina, revascularization by PCI before TAVI is reasonable.1,2",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02196,2020,103,2A,C-LD,"In patients with significant AS and significant CAD (luminal reduction >70% diameter, fractional flow reserve <0.8, instantaneous wave-free ratio <0.89) consisting of complex bifurcation left main and/or multivessel CAD with a SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score >33, SAVR and CABG are reasonable and preferred over TAVI and PCI.3,4",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02197,2020,105,Class 1,C-LD,"In patients with symptoms of angina, objective evidence of ischemia, decreased LV systolic function, history of CAD, or coronary risk factors (including men >40 years of age and postmenopausal women), invasive coronary angiography is indicated before valve intervention.1–8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02198,2020,105,Class 1,C-LD,"In patients with chronic severe secondary MR, invasive coronary angiography should be performed as part of the evaluation.9–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02199,2020,105,2A,B-NR,"In selected patients with a low to intermediate pretest probability of CAD, contrast-enhanced coronary CT angiography is reasonable to exclude the presence of significant obstructive CAD.12–18",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02200,2020,105,2A,C-LD,"In patients undergoing valve repair or replacement with significant proximal CAD (≥70% reduction in luminal diameter in major coronary arteries or ≥50% reduction in luminal diameter in the left main coronary artery and/or physiologically significance), CABG is reasonable for selective patients.19,20",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02201,2020,106,Class 1,C-LD,"In patients with VHD and AF for whom surgical intervention is planned, the potential symptomatic benefits and additional procedural risks of adjunctive arrhythmia surgery at the time of cardiac valvular surgery should be discussed with the patient.1–11",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02202,2020,106,2A,B-R,"For symptomatic patients with paroxysmal or persistent AF who are undergoing valvular surgery, surgical pulmonary vein isolation or a maze procedure can be beneficial to reduce symptoms and prevent recurrent arrhythmias.1,2,12–15",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02203,2020,106,2A,B-NR,"For patients with AF or atrial flutter who are undergoing valve surgery, LA appendage ligation/excision is reasonable to reduce the risk of thromboembolic events.16–19",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02204,2020,106,2A,B-NR,"In patients undergoing LA surgical ablation of atrial arrhythmias and/or LA appendage ligation/excision, anticoagulation therapy is reasonable for at least 3 months after the procedure.20–22",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02205,2020,106,Class 3: Harm,B-NR,"For patients without atrial arrhythmias who are undergoing valvular surgery, LA appendage occlusion/exclusion/amputation is potentially harmful.23",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02206,2020,107,Class 1,C-EO,"In patients with clinically suspected moderate or greater degrees of valvular stenosis or regurgitation who are undergoing noncardiac surgery, preoperative echocardiography is recommended.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02207,2020,108,Class 1,C-EO,"In patients who meet standard indications for intervention for VHD (replacement and repair) on the basis of symptoms and disease severity, intervention should be performed before elective noncardiac surgery to reduce perioperative risk if possible, depending on the urgency and risk of the noncardiac procedure.1",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02208,2020,109,2A,B-R,"In asymptomatic patients with moderate or greater degrees of AS and normal LV systolic function, it is reasonable to perform elective noncardiac surgery.1–3",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02209,2020,109,2A,C-EO,"In asymptomatic patients with moderate or greater degrees of rheumatic MS with less than severe pulmonary hypertension (pulmonary artery systolic pressure <50 mm Hg), it is reasonable to perform elective noncardiac surgery.",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02210,2020,109,2A,C-LD,"In asymptomatic patients with moderate or greater degrees of MR and normal LV systolic function with less than severe pulmonary hypertension (pulmonary artery systolic pressure <50 mm Hg), it is reasonable to perform elective noncardiac surgery.4–7",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02211,2020,109,2A,C-LD,"In asymptomatic patients with moderate or greater degrees of AR and normal LV systolic function, it is reasonable to perform elective noncardiac surgery.8",otto-et-al-2020-acc-aha-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american.pdf
id_02212,2022,16,Class 1,B-NR,"In patients with known or suspected aortic disease, aortic diameters should be mea- sured at reproducible anatomic landmarks perpendicular to axis of blood flow, and these measurement methods should be reported in a clear and consistent manner. In cases of asymmetric or oval contour, the longest diam- eter and its perpendicular diameter should be reported.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02213,2022,17,Class 1,C-LD,"In patients with known or suspected aortic disease, episodic and cumulative ionizing radi- ation doses should be kept as low as feasible while maintaining diagnostic image quality.5-7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02214,2022,17,Class 1,C-EO,"In patients with known or suspected aortic disease, when performing CT or MR imaging, it is recommended that the root and ascending aortic diameters be measured from inner-edge to inner-edge, using an electrocardiographic- synchronized technique. If there are aortic wall abnormalities, such as atherosclerosis or discrete wall thickening (more common in the distal aorta), the outer-edge to outer-edge diameter should be reported (Table 4).",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02215,2022,17,Class 1,C-EO,"In patients with known or suspected aortic disease, the aortic root diameter should be recorded as maximum sinus to sinus mea- surement. In the setting of known asymmetry, multiple measurements should be reported, and both short- and long-axis images of the root should be obtained to avoid underestima- tion of the diameter.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02216,2022,17,2A,C-LD,"In patients with known or suspected aortic disease, it is reasonable that a dilated root or ascending aorta be indexed to patient height or BSA in the report, to aid in clinical risk assessment.8-11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02217,2022,17,2A,C-EO,"In patients with known or suspected aortic disease, when performing echocardiography, it is reasonable to measure the aorta from leading-edge to leading-edge, perpendicular to the axis of blood flow.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02218,2022,22,Class 1,C-EO,"For patients with acute aortic disease that requires urgent repair, a multidisciplinary team should determine the most suitable interven- tion.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02219,2022,22,2A,C-LD,"For patients who are asymptomatic with extensive aortic disease, or who may benefit from complex open and endovascular aortic repairs, or with multiple comorbidities for whom intervention is considered, referral to a high-volume center (performing at least 30-40 aortic procedures annually) with expe- rienced surgeons in a Multidisciplinary Aortic Team is reasonable to optimize treatment outcomes.1-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02220,2022,24,Class 1,C-LD,"In patients with aortic disease, shared deci- sion-making is recommended when determin- ing the appropriate thresholds for intervention, deciding on the type of surgical repair, choos- ing between open surgical versus endovascu- lar approaches; and in medical management and surveillance.1-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02221,2022,24,Class 1,C-EO,"In patients with aortic disease who are contem- plating pregnancy or who are pregnant, shared decision-making is recommended when con- sidering the cardiovascular risks of pregnancy, the diameter thresholds for prophylactic aortic surgery, and the mode of delivery.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02222,2022,28,Class 1,B-NR,"In patients with aortic root/ascending aortic aneurysms or aortic dissection, obtaining a multigenerational family history of TAD, unex- plained sudden deaths, and peripheral and intracranial aneurysms is ­recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02223,2022,28,Class 1,B-NR,"In patients with aortic root/ascending aortic aneurysms or aortic dissection and risk factors for HTAD (Table 8, Figure 17), genetic testing to identify pathogenic/ likely pathogenic variants (ie, mutations) is ­recommended.4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02224,2022,28,Class 1,B-NR,"In patients with an established pathogenic or likely pathogenic variant in a gene predispos- ing to HTAD, it is recommended that genetic counseling be provided and the patient’s clini- cal management be informed by the specific gene and variant in the gene.7-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02225,2022,28,Class 1,B-NR,"In patients with TAD who have a pathogenic/ likely pathogenic variant, genetic testing of at- risk biological relatives (ie, cascade testing) is recommended.6,10,11 In family members who are found by genetic screening to have inherited the pathogenic/likely pathogenic variant, aortic imaging with TTE (if aortic root and ascending aorta are adequately visualized, otherwise with CT or MRI) is recommended.4,5,12",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02226,2022,28,Class 1,B-NR,"In a family with aortic root/ascending aor- tic aneurysms or aortic dissection, if the disease-causing variant is not identified with genetic testing, screening aortic imag- ing (as per recommendation 4) of at-risk biological relatives (ie, cascade testing) is ­recommended.13-15",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02227,2022,28,Class 1,C-LD,"In patients with aortic root/ascending aor- tic aneurysms or aortic dissection, in the absence of either a known family history of TAD or pathogenic/likely pathogenic variant, screening aortic imaging (as per recommen- dation 4) of first-degree relatives is recom- mended.13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02228,2022,30,Class 1,C-LD,"In asymptomatic patients with aneurysms of the aortic root or ascending aorta with nonsyndromic heritable thoracic aortic dis- ease (nsHTAD) and no identified genetic cause, determining the timing of surgical repair requires shared decision-making and is informed by known aortic diameters at the time of aortic dissection, TAA repair, or both in affected family members.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02229,2022,30,Class 1,C-LD,In asymptomatic patients with aneurysms of the aortic root or ascending aorta with nsHTAD and no identified genetic cause but no information on aortic diameters at the time of dissection or aneurysm repair in affected family members and who have no high-risk features for adverse aortic events (Table 9) it is recommended to repair the aorta when the maximal diameter reaches ≥5.0 cm.1,isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02230,2022,30,2A,C-LD,"In patients with aneurysms of the aortic root or ascending aorta with nsHTAD and no identified genetic cause and a maximal aortic diameter of ≥4.5 cm, who have high-risk fea- tures for adverse aortic events (Table 9), or who are undergoing cardiac surgery for other indications, aortic repair is reasonable when performed by experienced surgeons in a Mul- tidisciplinary Aortic Team.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02231,2022,31,Class 1,C-EO,"In patients with Marfan syndrome, a TTE is recommended at the time of initial diagnosis, to determine the diameters of the aortic root and ascending aorta, and 6 months thereafter, to determine the rate of aortic growth; if the aortic diameters are stable, an annual surveillance TTE is recommended.1 If the aortic root, ascending aorta, or both are not adequately visualized on TTE, a CT or MRI of the thoracic aorta is recommended.2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02232,2022,31,2A,C-EO,"In adults with Marfan syndrome, after the initial TTE, a CT or MRI of the thoracic aorta is reasonable to confirm the aortic diameters and assess the remainder of the thoracic aorta. Downloaded from http://ahajournals.org by on June 19, 2025",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02233,2022,32,Class 1,C-LD,"In patients with Marfan syndrome who have undergone aortic root replacement, surveil- lance imaging of the thoracic aorta by MRI (or CT) is recommended to evaluate for distal TAD, initially annually and then, if normal in diameter and unchanged after 2 years, every other year.3-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02234,2022,32,2A,C-LD,"In patients with Marfan syndrome who have undergone aortic root replacement, surveil- lance imaging every 3 to 5 years for potential AAA is reasonable.2,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02235,2022,32,Class 1,A,"In patients with Marfan syndrome, treatment with either a beta blocker or an ARB, in maxi- mally tolerated doses (unless contraindicated), is recommended to reduce the rate of aortic dilation.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02236,2022,32,2A,C-LD,"In patients with Marfan syndrome, the use of both a beta blocker and an ARB, in maximally tolerated doses (unless contraindicated), is reasonable to reduce the rate of aortic dila- tion.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02237,2022,33,Class 1,B-NR,"In patients with Marfan syndrome and an aortic root diameter of ≥5.0 cm, surgery to replace the aortic root and ascending aorta is recommended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02238,2022,33,2A,B-NR,"In patients with Marfan syndrome, an aortic root diameter of ≥4.5 cm, and features associ- ated with an increased risk of aortic dissection (see Table 10), surgery to replace the aortic root and ascending aorta is reasonable, when performed by experienced surgeons in a Mul- tidisciplinary Aortic Team.1,3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02239,2022,33,2A,C-LD,"In patients with Marfan syndrome and a maxi- mal cross-sectional aortic root area (cm2) to patient height (m) ratio of ≥10, surgery to replace the aortic root and ascending aorta is reasonable, when performed by experienced surgeons in a Multidisciplinary Aortic Team.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02240,2022,33,2B,C-LD,"In patients with Marfan syndrome and an aor- tic diameter approaching surgical threshold, who are candidates for valve-sparing root replacement (VSRR) and have a very low surgical risk, surgery to replace the aortic root and ascending aorta may be reasonable when performed by experienced surgeons in a Mul- tidisciplinary Aortic Team.2-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02241,2022,34,2A,C-EO,"In patients with Marfan syndrome and a nondissected aneurysm of the aortic arch, descending thoracic aorta, or abdominal aorta of ≥5.0 cm, surgical intervention to replace the aneurysmal segment is ­reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02242,2022,34,Class 1,C-EO,"In patients with Loeys-Dietz syndrome, a baseline TTE is recommended to determine the diameters of the aortic root and ascending aorta, and 6 months thereafter to determine the rate of aortic growth; if the aortic diam- eters are stable, annual surveillance TTE is recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02243,2022,34,Class 1,C-EO,"In patients with Loeys-Dietz syndrome and a dilated or dissected aorta and/or arterial branches at baseline, annual surveillance imaging of the affected aorta and arteries with MRI or CT is recommended.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02244,2022,34,Class 1,C-LD,"In patients with Loeys-Dietz syndrome, a baseline MRI or CT from head to pelvis is recommended to evaluate the entire aorta and its branches for aneurysm, dissection, and tortuosity.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02245,2022,34,2A,C-EO,"In patients with Loeys-Dietz syndrome with- out dilation of the aorta distal to the aortic root or ascending aorta and without dilated or dissected arterial branches, surveillance imaging from chest to pelvis with MRI (or CT) every 2 years is reasonable, but imaging may be more frequent depending on family ­history.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02246,2022,34,2A,C-EO,"In patients with Loeys-Dietz syndrome with- out dilation of the cerebral arteries on initial screening, periodic imaging surveillance for cerebral aneurysms with MRI or CT every 2 to",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02247,2022,35,2A,C-EO,"In patients with Loeys-Dietz syndrome, treat- ment with a beta blocker or an ARB (unless contraindicated), or both, in maximally toler- ated doses, is reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02248,2022,36,Class 1,C-LD,"In patients with Loeys-Dietz syndrome and aortic dilation, the surgical threshold for prophylactic aortic root and ascending aortic replacement should be informed by the spe- cific genetic variant, aortic diameter, aortic growth rate, extra-aortic features, family his- tory, patient age and sex, and physician and patient preferences (Table 11).1-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02249,2022,36,2B,C-EO,"In patients with Loeys-Dietz syndrome attrib- utable to a pathogenic variant in TGFBR1, TGFBR2, or SMAD3, surgery to replace the intact aortic arch, descending aorta, or abdominal aorta at a diameter of ≥4.5 cm may be considered, with the specific genetic variant, patient age, aortic growth rate, family history, presence of high-risk features (Table 11), and surgical risk informing the decision.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02250,2022,37,Class 1,B-NR,"In patients with Turner syndrome, TTE and cardiac MRI are recommended at the time of diagnosis to evaluate for BAV, aortic root and ascending aortic dilation, aortic coarctation, and other congenital heart defects.1-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02251,2022,37,Class 1,B-NR,"In patients with Turner syndrome who are ≥15 years old, the use of the ASI (ratio of aortic diameter [cm] to BSA [m2]) is recommended to define the degree of aortic dilation and assess the risk of aortic ­dissection.9,10,11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02252,2022,37,Class 1,C-LD,"In patients with Turner syndrome without risk factors for aortic dissection (Table 12), sur- veillance imaging with TTE or MRI to evalu- ate the aorta is recommended every 5 years in children and every 10 years in adults, as well as before planning a ­pregnancy.9,10,11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02253,2022,37,Class 1,C-EO,"In patients with Turner syndrome and an ASI >2.3 cm/m2, surveillance imaging of the aorta is recommended at least ­annually.9 Downloaded from http://ahajournals.org by on June 19, 2025",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02254,2022,38,Class 1,C-EO,"In patients with Turner syndrome and risk factors for aortic dissection (Table 12), surveil- lance aortic imaging at an interval depending on the aortic diameter, ASI, and aortic growth rate is recommended (­Figure 18).9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02255,2022,38,2A,C-LD,"In patients with Turnery syndrome who are ≥15 years old and have an ASI of ≥2.5 cm/m2 plus risk factors for aortic dissection (Table 12), surgical intervention to replace the aortic root, ascending aorta, or both is reasonable.9,10",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02256,2022,40,Class 1,B-NR,"In patients with a BAV, TTE is indicated to evaluate valve morphology and function, to evaluate the diameter of the aortic root and ascending aorta, and to evaluate for aortic coarctation and other associated cardiovascu- lar defects.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02257,2022,40,Class 1,C-LD,"In patients with a BAV, CT or MRI of the tho- racic aorta is indicated when the diameter and morphology of the aortic root, ascending aorta, or both cannot be assessed accurately or completely by TTE.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02258,2022,40,Class 1,C-LD,"In patients with a BAV and either HTAD or phenotypic features concerning for Loeys- Dietz syndrome, a medical genetics evaluation is recommended.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02259,2022,40,Class 1,C-LD,"In patients with a BAV and a dilated aortic root or ascending aorta, screening of all first- degree relatives by TTE is recommended to evaluate for the presence of a BAV, dilation of the aortic root and ascending aorta, or both; if the diameter and morphology of the aortic root, ascending aorta, or both cannot be assessed accurately or completely by TTE, a cardiac-gated CT or MRI of the thoracic aorta is indicated.7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02260,2022,40,2A,B-NR,"In patients with a BAV, screening of all first- degree relatives by TTE is reasonable to evaluate for the presence of a BAV, dilation of the aortic root and ascending aorta, or both.7-10",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02261,2022,41,Class 1,B-NR,"In patients with a BAV who have undergone previous aortic valve repair or replacement and have a diameter of the aortic root, ascending aortic, or both of ≥4.0 cm, lifelong surveillance imaging of the aortic root and ascending aorta by TTE, CT, or MRI is recom- mended at an interval dependent on aortic diameter and rate of growth.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02262,2022,41,Class 1,C-LD,"In patients with a BAV and a diameter of the aortic root, ascending aorta, or both of ≥4.0 cm, lifelong surveillance imaging of the aortic root and ascending aorta by TTE, CT, or MRI is recommended at an interval dependent on aortic diameter and rate of growth.4,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02263,2022,42,Class 1,B-NR,"In patients with a BAV and a diameter of the aortic root, ascending aorta, or both of ≥5.5 cm, surgery to replace the aortic root, ascending aorta, or both is recom- mended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02264,2022,42,2A,B-NR,"In patients with a BAV and a cross-­sectional aortic root or ascending aortic area (cm2) to height (m) ratio of ≥10 cm2/m, surgery to replace the aortic root, ascending aorta, or both is reasonable, when performed by expe- rienced surgeons in a Multidisciplinary Aortic Team.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02265,2022,42,2A,B-NR,"In patients with a BAV, a diameter of the aortic root or ascending aorta of 5.0 cm to 5.4 cm, and an additional risk factor for aortic dissec- tion (Table 14), surgery to replace the aortic root, ascending aorta, or both is reasonable, when performed by experienced surgeons in a Multidisciplinary Aortic Team.1,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02266,2022,42,2A,B-NR,"In patients with a BAV who are undergoing surgical aortic valve repair or replacement, and who have a diameter of the aortic root or ascending aorta of ≥4.5 cm, concomitant replacement of the aortic root, ascending aorta, or both is reasonable, when performed by experienced surgeons in a Multidisciplinary Aortic Team.1,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02267,2022,42,2B,B-NR,"In patients with a BAV, a diameter of the aortic root or ascending aorta of 5.0 cm to 5.4 cm, no other risk factors for aortic dissection (Table 14), and at low surgical risk, surgery to replace the aortic root, ascending aorta, or both may be reasonable, when performed by experienced surgeons in a Multidisciplinary Aortic Team.1,2,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02268,2022,43,Class 1,B-R,"In men who are ≥65 years of age who have ever smoked, ultrasound screening for detection of AAA is recommended.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02269,2022,43,Class 1,C-LD,"In men or women who are ≥65 years of age and who are first-degree relatives of patients with AAA, ultrasound screening for detection of AAA is recommended.2,3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02270,2022,43,2A,C-EO,"In women who are ≥65 years of age who have ever smoked, ultrasound screening for detection of AAA is reasonable.4,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02271,2022,43,2B,C-LD,"In men or women <65 years of age and who have multiple risk factors (Table 15) or a first-degree relative with AAA, ultrasound screening for AAA may be considered.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02272,2022,43,Class 3: No Benefit,B-NR,"In asymptomatic men or women >75 years who have had a negative initial ultrasound screen, repeat screening for detection of AAA is not recommended.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02273,2022,45,Class 1,B-NR,"In patients with TAA and an average systolic BP (SBP) of ≥130 mm Hg or an average diastolic BP (DBP) of ≥80 mm Hg, the use of antihypertensive medications is recommended to reduce risk of cardiovascular events.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02274,2022,45,2A,C-LD,"In patients with TAA, regardless of cause and in the absence of contraindications, use of beta blockers to achieve target BP goals is reasonable.1,4,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02275,2022,45,2A,C-EO,"In patients with TAA, regardless of etiology and in the absence of contraindications, ARB therapy is a reasonable adjunct to beta- blocker therapy to achieve target BP goals.6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02276,2022,46,2A,C-LD,"In patients with TAA and imaging or clinical evidence of atherosclerosis, statin therapy at moderate or high intensity is ­reasonable.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02277,2022,46,2B,C-LD,"In patients with TAA who have no evidence of atherosclerosis, the use of statin therapy may be considered.3-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02278,2022,47,Class 1,C-LD,"In patients with TAA who smoke cigarettes, smoking cessation efforts are recommended.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02279,2022,47,2A,C-EO,"In patients with atherosclerotic TAA and con- comitant aortic atheroma or PAU, the use of low-dose aspirin is reasonable, unless contra- indicated.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02280,2022,47,Class 1,B-NR,"In patients with AAA and an average SBP of ≥130 mm Hg, or an average DBP of ≥80 mm Hg, the use of antihypertensive medication is recommended to reduce risk of cardiovascular events.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02281,2022,48,Class 1,B-NR,"In patients with AAA and evidence of aortic atherosclerosis, statin therapy at moderate or high intensity is recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02282,2022,48,2B,C-LD,"In patients with AAA but no evidence of atherosclerosis, statin therapy may be ­considered.4,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02283,2022,48,Class 1,C-LD,"In patients with AAA who smoke cigarettes, smoking cessation efforts are recom- mended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02284,2022,49,2B,C-LD,"In patients with AAA with concomitant ather- oma and/or PAU, the use of low-dose aspirin may be considered, unless contraindicated.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02285,2022,49,Class 1,C-LD,"In patients with a dilated thoracic aorta, a TTE is recommended at the time of diag- nosis to assess aortic valve anatomy, aortic valve function, and thoracic aortic diam- eters.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02286,2022,49,2A,C-LD,"In patients with a dilated thoracic aorta, a CT or MRI at the time of diagnosis is reasonable to assess thoracic aortic anatomy and diam- eters.1,3,5-7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02287,2022,49,2A,C-LD,"In patients with a dilated thoracic aorta, follow-up imaging (with TTE, CT, or MRI, as appropriate based on individual anatomy) in 6 to 12 months is reasonable to determine the rate of aortic enlargement; if stable, surveillance imaging every 6 to 24 months (depending on aortic diameter) is reason- able.1,3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02288,2022,50,Class 1,B-NR,"In patients with an AAA of 3.0 cm to 3.9 cm, surveillance ultrasound is ­recommended every 3 years to assess for interval change.1-8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02289,2022,50,Class 1,B-NR,"In men with an AAA of 4.0 cm to 4.9 cm and in women with an AAA of 4.0 cm to 4.4 cm, surveillance ultrasound is recommended annually to assess for interval change.1-8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02290,2022,50,Class 1,B-NR,"In men with an AAA of ≥5.0 cm and women with an AAA of ≥4.5 cm, surveillance ultra- sound is recommended every 6 months to assess for interval change.1-8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02291,2022,50,Class 1,C-EO,"In patients with an AAA that is inadequately defined with ultrasound, surveillance CT is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02292,2022,50,Class 1,C-EO,"In patients with an AAA that meets criteria for repair, CT is recommended for preoperative planning.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02293,2022,51,Class 1,C-LD,"In patients with aneurysms of the aortic root and ascending aorta who have symptoms attrib- utable to the aneurysm, surgery is ­indicated.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02294,2022,51,Class 1,B-NR,"In asymptomatic patients with aneurysms of the aortic root or ascending aorta who have a maxi- mum diameter of ≥5.5 cm, surgery is indicated.3-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02295,2022,51,Class 1,C-LD,"In patients with an aneurysm of the aortic root or ascending aorta of <5.5 cm, whose growth rate confirmed by tomographic imaging is ≥0.3 cm/y in 2 consecutive years, or ≥0.5 cm in 1 year, surgery is ­indicated.10-13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02296,2022,51,2A,B-NR,"In asymptomatic patients with aneurysms of the aortic root or ascending aorta who have a maximum diameter of ≥5.0 cm, surgery is reasonable when performed by experienced surgeons in a Multidisciplinary Aortic Team.14-17",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02297,2022,51,2A,B-NR,"In patients undergoing repair or replace- ment of a tricuspid aortic valve who have a concomitant aneurysm of the ascending aorta with a maximum diameter of ≥4.5 cm, ascending aortic replacement is reasonable when performed by experienced surgeons in a Multidisciplinary Aortic Team.18-21",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02298,2022,51,2A,C-LD,"In patients with a height >1 standard devia- tion above or below the mean who have an asymptomatic aneurysm of the aortic root or ascending aorta and a maximal cross- sectional aortic area/height ratio of ≥10 cm2/m, surgery is reasonable when performed by experienced surgeons in a Multidisciplinary Aortic Team.14,15,22",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02299,2022,53,Class 1,B-NR,"In patients with an aneurysm isolated to the ascending aorta who meet criteria for surgery, aneurysm resection and replacement with an interposition graft should be performed.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02300,2022,53,Class 1,B-NR,"In patients undergoing aortic valve repair or replacement with a concomitant ascending aortic aneurysm, a separate aortic valve inter- vention and ascending aortic graft is recom- mended.3-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02301,2022,53,Class 1,B-NR,"In patients undergoing aortic root replace- ment with an aortic valve that is unsuitable for sparing or repair, a mechanical or biological valved conduit aortic root replacement is indi- cated.1,2,7,8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02302,2022,53,2A,B-NR,"In patients undergoing aortic root replace- ment, valve-sparing aortic root replacement is reasonable if the aortic valve is suitable for sparing or repair and when performed by experienced surgeons in a Multidisciplinary Aortic Team.9-21",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02303,2022,54,Class 1,C-EO,"In patients with an aortic arch aneurysm who have symptoms attributable to the aneurysm and are at low or intermediate operative risk, open surgical replacement is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02304,2022,54,2A,B-NR,"In patients with an isolated aortic arch aneurysm who are asymptomatic and have a low operative risk, open surgical replace- ment at an arch diameter of ≥5.5 cm is ­reasonable.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02305,2022,54,2A,C-LD,"In patients undergoing open surgical repair of an ascending aortic aneurysm, if the aneurys- mal disease extends into the proximal aortic arch, it is reasonable to extend the repair with a hemiarch replacement.4,5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02306,2022,54,2B,C-LD,"In patients undergoing open surgical repair of an aortic arch aneurysm, if the aneurysmal disease extends into the proximal descending thoracic aorta, an elephant trunk procedure may be considered.6,7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02307,2022,54,2B,C-EO,"In patients with an aortic arch aneurysm who are asymptomatic but meet criteria for inter- vention, but have a high risk from open surgi- cal repair, a hybrid or endovascular approach may be reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02308,2022,55,Class 1,B-NR,"In patients with intact descending TAA, repair is recommended when the diameter is ≥5.5 cm.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02309,2022,55,2B,B-NR,"In patients with intact descending TAA and risk factors for rupture (Table 17), repair may be considered at a diameter of <5.5 cm.2-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02310,2022,55,2B,B-NR,"In patients at increased risk for perioperative morbidity and mortality (Table 18), it may be reasonable to increase the size threshold for surgery accordingly.7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02311,2022,56,Class 1,B-NR,"In patients without Marfan syndrome, Loeys- Dietz syndrome, or vascular Ehlers-Danlos syndrome, who have a descending TAA that meets criteria for intervention and anatomy suitable for endovascular repair, TEVAR is recommended over open ­surgery.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02312,2022,56,Class 1,B-NR,"In patients with a descending TAA that meets criteria for repair with TEVAR, who have smaller or diseased access vessels, consid- erations for alternative vascular access are recommended.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02313,2022,56,2A,B-NR,"In patients with a descending TAA that meets criteria for intervention, who have anatomy unsuitable for endovascular repair, and who are without significant comorbidities and have a life expectancy of at least 10 years, open surgical repair is reasonable.6-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02314,2022,57,Class 1,B-NR,"In patients with descending TAA who undergo TEVAR with planned left subclavian artery coverage, revascularization of the left subcla- vian artery before TEVAR is recommended to prevent spinal cord injury (SCI)1,2 and poten- tially to reduce stroke risk2 and prevent other ischemic ­complications.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02315,2022,57,2B,C-LD,"In patients with descending TAA who have undergone TEVAR with left subclavian cover- age and develop SCI that is unresponsive to an increase in BP or a cerebrospinal fluid drain, left subclavian artery revascularization may be considered.3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02316,2022,58,2A,B-NR,"In patients with descending TAA undergoing TEVAR in whom celiac artery coverage is being considered, it is reasonable to first con- firm adequate collateralization.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02317,2022,58,Class 1,B-NR,"In patients with ruptured descending TAA who are anatomic candidates for endovascular repair, TEVAR is recommended over open repair because of decreased perioperative death and morbidity.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02318,2022,58,2B,B-NR,"In patients with ruptured descending TAA undergoing TEVAR, intentional coverage of the left subclavian artery, celiac artery, or both may be considered to increase the landing zone for endovascular repair.5-7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02319,2022,59,Class 1,B-NR,"In patients with descending TAA undergoing TEVAR, review of preoperative CTA of the iliofemoral vessels should be performed to evaluate access.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02320,2022,59,Class 1,B-NR,"In patients with descending TAA undergoing TEVAR, if iliac access is marginal or inade- quate to prevent access-related complications, the use of alternative conduits is recom- mended.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02321,2022,59,2A,B-NR,"In patients with descending TAA undergo- ing TEVAR who have suitable anatomy, total percutaneous femoral access is a reasonable alternative to open surgi- cal cutdown to avoid access-related ­complications.3-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02322,2022,59,Class 1,B-NR,"In patients with intact degenerative TAAA, repair is recommended when the diameter is ≥6.0 cm.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02323,2022,59,2A,B-NR,"In patients with intact degenerative TAAA, repair is reasonable when the diameter is ≥5.5 cm and the repair is performed by expe- rienced surgeons in a Multidisciplinary Aortic Team.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02324,2022,59,2A,B-NR,"In patients with intact degenerative TAAA who have features associated with an increased risk of rupture (Table 19), repair is reasonable when the diameter is <5.5 cm.4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02325,2022,60,Class 1,B-NR,"In patients with ruptured TAAA requiring inter- vention, open repair is recommended.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02326,2022,60,2B,C-LD,"In patients with ruptured TAAA requiring inter- vention, provided that the patient is hemo- dynamically stable, endovascular repair may be reasonable in centers with endovascular expertise and access to appropriate endovas- cular stent grafts.6 Intact TAAA",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02327,2022,60,Class 1,C-LD,"In patients with Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syn- drome and intact TAAA requiring intervention, open repair is recommended over endovascu- lar repair.7-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02328,2022,60,2B,B-NR,"In patients with intact degenerative TAAA and suitable anatomy, endovascular repair with fenestrated stent grafts, branched stent grafts, or both may be considered in centers with endovascular expertise and access to appropriate endovascular stent grafts.10-13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02329,2022,61,Class 1,A,"In patients undergoing open TAAA repair who are at high risk for SCI, cerebrospinal fluid drainage is recommended to reduce the inci- dence of temporary SCI, permanent SCI, or both.1-7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02330,2022,61,Class 1,B-NR,"In patients who experience delayed spinal cord dysfunction after either open or endo- vascular TAAA repair, timely measures to optimize spinal cord perfusion and decrease intrathecal pressure are recommended (Table 20).1-4,8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02331,2022,62,Class 1,A,"In patients undergoing open repair of TAAA involving the renal arteries, cold blood or crys- talloid renal perfusion is recommended to pro- vide effective protection against renal injury.1-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02332,2022,62,Class 1,B-NR,"In patients undergoing open or endovascular TAAA repair who have end-organ ischemia or significant stenoses from atherosclerotic vis- ceral or renal artery disease, additional revas- cularization procedures are recommended.7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02333,2022,63,Class 1,B-R,"In patients undergoing endovascular repair of AAA who have suitable common femoral artery anatomy, ultrasound-guided percutane- ous access and closure is recommended over open cutdown to reduce operative time, blood loss, length of stay, time to wound healing, and pain.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02334,2022,63,Class 1,B-R,"In patients presenting with ruptured AAA who are hemodynamically stable, CT imag- ing is recommended to evaluate whether the AAA is amenable to endovascular repair.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02335,2022,63,Class 1,B-R,"In patients presenting with ruptured AAA who have suitable anatomy, endovas- cular repair is recommended over open repair to reduce the risk of morbidity and ­mortality.1,4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02336,2022,63,2A,B-NR,"In patients undergoing endovascular repair for ruptured AAA, local anesthesia is preferred to general anesthesia to reduce risk of periop- erative mortality.7-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02337,2022,63,2A,C-LD,"In patients with ruptured AAA, permissive hypotension can be beneficial to decrease the rate of bleeding.1,3,10-12",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02338,2022,64,Class 1,A,"In patients with unruptured AAA, repair is rec- ommended in those with a maximal aneurysm diameter of ≥5.5 cm in men or ≥5.0 cm in women.1-6 Downloaded from http://ahajournals.org by on June 19, 2025",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02339,2022,65,Class 1,B-NR,"In patients with unruptured AAA who have symptoms that are attributable to the aneu- rysm, repair is recommended to reduce the risk of rupture.7,8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02340,2022,65,2B,C-LD,"In patients with unruptured saccular AAA, intervention to reduce the risk of rupture may be reasonable.9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02341,2022,65,2B,C-LD,"In patients with unruptured AAA and aneu- rysm growth of ≥0.5 cm in 6 months, repair to reduce the risk of rupture may be reason- able.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02342,2022,66,Class 1,A,"In patients with nonruptured AAA with low to moderate operative risk and who have anatomy suitable for either open or EVAR, a shared decision-making process weighing the risks and benefits of each approach is recom- mended.1-11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02343,2022,66,Class 1,B-NR,"In patients undergoing elective endovascular repair for nonruptured AAA, adherence to manufacturer’s instructions for use is recom- mended.12-16",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02344,2022,66,2A,B-NR,"In patients with nonruptured AAA and a high perioperative risk, EVAR is reasonable to reduce the risk of 30-day morbidity, mortality, or both.9,10",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02345,2022,66,2A,B-NR,"For patients with nonruptured AAA, a moderate to high perioperative risk, and anatomy suitable for an FDA-approved fenestrated endovascular device, endovas- cular repair is reasonable over open repair to reduce the risk of perioperative compli- cations.10,11,17,18",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02346,2022,67,Class 1,C-LD,"For patients with asymptomatic small AAA and concomitant common iliac artery aneurysm(s) ≥3.5 cm, elective repair of both abdominal and iliac aneurysms is recom- mended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02347,2022,67,Class 1,B-NR,"When treating common iliac artery aneu- rysms or ectasia as part of AAA repair, preservation of at least 1 hypogastric artery is recommended, if anatomically feasible, to decrease the risk of pelvic ­ischemia.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02348,2022,68,Class 1,B-NR,"In patients treated with TEVAR, surveillance imaging with CT is recommended after 1 month and 12 months and, if stable, annually thereafter.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02349,2022,68,2A,B-NR,"In patients treated with TEVAR, longitudinal surveillance with MRI is a reasonable alterna- tive to CT for reduction of long-term radiation exposure or avoidance of an iodinated con- trast allergy.6-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02350,2022,68,2A,B-NR,"In patients treated with open repair of the thoracic aorta without residual aortopathy, surveillance imaging with a CT or MRI within",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02351,2022,68,2A,C-EO,"In patients treated with open repair of the thoracic aorta who have residual aortopa- thy or abnormal findings on surveillance imaging, annual surveillance imaging is ­reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02352,2022,69,Class 1,B-NR,"In patients with AAA treated with EVAR, baseline surveillance imaging with CT is recommended at 1 month postopera- tively1,2; if there is no evidence of endoleak or sac enlargement, continued surveil- lance with duplex ultrasound at 12 months and then annually thereafter is recom- mended.1,3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02353,2022,69,2A,C-LD,"In patients with AAA treated with EVAR who are undergoing annual surveillance imaging duplex ultrasound, additional cross-sectional imaging with CT or MRI of the abdomen and pelvis every 5 years postoperatively is reason- able.5-8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02354,2022,69,2A,C-LD,"In patients with AAA treated with EVAR and abnormal findings (Table 21) on any surveil- lance duplex ultrasound, additional cross-sec- tional imaging with CT or MRI is reasonable.9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02355,2022,69,2A,C-LD,"In patients with AAA treated with complex EVAR, a modified surveillance imaging plan that combines cross-sectional imaging and duplex ultrasound of target vessels is reason- able.10,11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02356,2022,69,2A,C-LD,"In patients with AAA who have undergone open repair, surveillance imaging with CT or MRI of the abdominopelvic aorta within 1 year postoperatively and then every 5 years there- after is reasonable.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02357,2022,71,Class 1,C-LD,"In patients with a suspected AAS, CT is rec- ommended for initial diagnostic imaging, given its wide availability, accuracy, and speed, as well as the extent of anatomic detail it pro- vides.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02358,2022,71,2A,C-LD,"In patients with a suspected AAS, TEE and MRI are reasonable alternatives for initial diagnostic imaging.1-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02359,2022,72,Class 1,B-NR,"In patients presenting to the hospital with AAS, prompt treatment with anti-impulse therapy with invasive monitoring of BP with an arterial line in an ICU setting is recommended as initial treatment to decrease aortic wall stress.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02360,2022,72,Class 1,C-LD,"Patients with AAS should be treated to an SBP <120 mm Hg or to lowest BP that main- tains adequate end-organ perfusion, as well as to a target heart rate of 60 to 80 bpm.3,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02361,2022,72,Class 1,B-NR,"In patients with AAS, initial management should include intravenous beta blockers, except in patients with contraindications.2,5,7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02362,2022,72,Class 1,C-LD,"In patients with AAS, initial management should include intravenous vasodilators if the BP is not well controlled after initiation of intravenous beta-blocker therapy.8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02363,2022,72,Class 1,C-EO,"Patients with AAS should be treated with pain control, as needed, to help with hemodynamic management.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02364,2022,73,Class 1,B-NR,"In patients with AAS, it is recommended to treat with long-term beta blockers (unless contraindicated) to control heart rate and BP to reduce late aortic-related adverse events.1-7 Additional antihypertensive agents (particu- larly ARBs and ACEIs) should be added, as necessary, to adequately control BP.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02365,2022,74,Class 1,B-NR,"In patients presenting with suspected or con- firmed acute type A aortic dissection, emer- gency surgical consultation and evaluation and immediate surgical intervention is recom- mended because of the high risk of associated life-threatening complications.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02366,2022,74,2A,B-NR,"In patients presenting with acute type A aortic dissection, who are stable enough for transfer, transfer from a low- to a high- volume aortic center is reasonable to improve survival.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02367,2022,74,2A,B-NR,"In patients presenting with nonhemorrhagic stroke complicating acute type A aortic dis- section, surgical intervention is reasonable over medical therapy to reduce mortality and improve neurologic outcomes.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02368,2022,75,Class 1,B-NR,"In patients with acute type A aortic dissection presenting with renal, mesenteric, or lower extremity malperfusion, it is recommended to proceed to immediate operative repair of the ascending aorta.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02369,2022,75,2A,C-LD,"In patients with acute type A aortic dissection presenting with clinically significant mesen- teric (celiac, SMA) malperfusion, either imme- diate operative repair of the ascending aorta or immediate mesenteric revascularization via endovascular or open surgical intervention by those with this expertise before ascending aortic repair is reasonable.3-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02370,2022,76,Class 1,B-NR,"In patients with acute type A aortic dissection and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is recommended over valve replacement.1-5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02371,2022,76,Class 1,B-NR,"In patients with acute type A aortic dissection who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aor- tic disorder, aortic root replacement is recom- mended with a mechanical or biological valved conduit.6-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02372,2022,76,Class 1,B-NR,"In patients with acute type A aortic dissec- tion undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase false-lumen thrombosis rates.12-15",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02373,2022,76,Class 1,B-NR,"In patients with acute type A aortic dissec- tion without an intimal tear in the arch or a significant arch aneurysm, hemiarch repair is recommended over more extensive arch replacement.16-18",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02374,2022,76,2B,C-LD,"In patients with acute type A aortic dissec- tion and a dissection flap extending through the arch into the descending thoracic aorta, an extended aortic repair with antegrade stenting of the proximal descending thoracic aorta may be considered to treat malperfu- sion and reduce late distal aortic complica- tions.19,20 Perfusion and Cannulation Strategies",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02375,2022,76,2A,B-NR,"In patients with acute type A aortic dissection undergoing surgical repair, axillary cannula- tion, when feasible, is reasonable over femoral cannulation to reduce the risk of stroke or retrograde malperfusion.21,22",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02376,2022,76,2A,B-NR,"In patients with acute type A aortic dis- section undergoing surgical repair who require circulatory arrest, cerebral perfusion is reasonable to improve neurologic out- comes.23-25",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02377,2022,76,2A,B-NR,"In patients with acute type A aortic dis- section undergoing surgical repair, direct aortic26,27 or innominate artery28 cannula- tion with imaging guidance is reasonable as an alternative to femoral or axillary ­cannulation.29-31",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02378,2022,78,Class 1,B-NR,"In all patients with uncomplicated acute type B aortic dissection, medical therapy is recommended as the initial management strategy.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02379,2022,78,Class 1,C-LD,"In patients with acute type B aortic dissection and rupture or other complications (Table 27), intervention is recommended.4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02380,2022,78,2B,B-R,"In patients with uncomplicated acute type B aortic dissection who have high-risk anatomic features (Table 28), endovascular manage- ment may be considered.8,9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02381,2022,79,Class 1,B-NR,"In patients with complicated (Table 29) acute type A or type B aortic IMH, urgent repair is recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02382,2022,79,Class 1,B-NR,"In patients with uncomplicated acute type A IMH, prompt open surgical repair is recom- mended.1,4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02383,2022,79,Class 1,B-NR,"In patients with uncomplicated acute type B IMH, medical therapy as the initial manage- ment strategy is recommended.1-3,13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02384,2022,79,2A,C-LD,"In patients with type B IMH who require repair of the distal aortic arch or descending thoracic aorta (zones 2-5) and have favorable anatomy, endo- vascular repair is reasonable when performed by surgeons with endovascular expertise.2,14",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02385,2022,79,2A,C-LD,"In patients with type B IMH who require repair of the distal aortic arch or descending tho- racic aorta (zones 2-5) and have unfavorable anatomy for endovascular repair, open surgical repair is reasonable.2,3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02386,2022,79,2B,C-LD,"In patients with uncomplicated type B IMH and high-risk imaging features (Table 30), intervention may be reasonable.13-16",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02387,2022,81,Class 1,B-NR,"In patients with PAU of the aorta with rupture, urgent repair is recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02388,2022,81,Class 1,B-NR,"In patients with PAU of the ascending aorta with associated IMH, urgent repair is recom- mended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02389,2022,81,2A,C-LD,"In patients with PAU of the aortic arch or descending thoracic aorta with associated IMH, urgent repair is reasonable.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02390,2022,81,2B,C-LD,"In patients with PAU of the abdominal aorta with associated IMH, urgent repair may be considered.4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02391,2022,82,Class 1,B-NR,"In patients with isolated PAU who are symp- tomatic and have persistent pain that is clini- cally correlated with the radiologic findings, repair is recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02392,2022,82,2B,C-LD,"In patients with isolated PAU who are asymp- tomatic but have high-risk imaging features (Table 31), elective repair may be consid- ered.1,2,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02393,2022,83,Class 1,C-LD,"In patients who require repair of a PAU in the ascending aorta or proximal aortic arch (zones 0-1), open surgical repair is ­recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02394,2022,83,2A,C-LD,"In patients who require repair of a PAU in the distal aortic arch (zones 2-3), descend- ing thoracic aorta, or abdominal aorta, either open surgical repair1-3 or endovascular repair is reasonable, based on anatomy and medical comorbidities.4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02395,2022,83,Class 1,C-EO,"In patients with BTTAI, management and treatment at a trauma center with the facili- ties and expertise to treat aortic pathology is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02396,2022,83,Class 1,C-LD,"In patients with BTTAI, anti-impulse therapy to reduce the risk of injury extension and rupture should be implemented, except in patients with hypotension or hypovolemic shock.1,2 Downloaded from http://ahajournals.org by on June 19, 2025",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02397,2022,84,Class 1,C-LD,"In patients with grade 1 BTTAI (Figure 23), nonoperative management and follow-up imaging are recommended.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02398,2022,84,Class 1,C-LD,"In patients with grade 3 to 4 BTTAI (Figure 23) and nonprohibitive comorbidities or inju- ries, aortic intervention is recommended.1,3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02399,2022,84,2A,C-LD,"In patients with grade 2 BTTAI (Figure 23) and with high-risk imaging features (Table 32), aortic intervention is reasonable.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02400,2022,84,2B,C-LD,"In patients with grade 2 BTTAI (Figure 23) and without high-risk imaging features (Table 32), nonoperative management and follow-up surveillance imaging may be ­reasonable.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02401,2022,85,Class 1,B-NR,"In patients with BTTAI who meet indica- tions for repair and with appropriate anat- omy, TEVAR is recommended over open repair.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02402,2022,86,Class 1,C-LD,"In patients with grade 1 to 2 BAAI (Table 33) without malperfusion, anti- impulse therapy, if clinically tolerated, and repeat imaging within 24 to 48 hours of the initial scan is recommended to reduce risk of injury progression.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02403,2022,86,Class 1,C-LD,"In patients with grade 4 BAAI (Table 33), repair should be performed to address life- threatening aortic injury.2-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02404,2022,86,2A,C-LD,"In patients with grade 2 BAAI (Table 33) and associated malperfusion, it is reasonable to consider repair.1",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02405,2022,86,2A,C-LD,"In patients with BAAI, treatment with either endovascular or open repair is reasonable and depends on degree of injury, aortic anatomy, and the patient’s overall clinical status.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02406,2022,86,2B,C-LD,"In patients with grade 3 BAAI (Table 33), it may be reasonable to consider repair to reduce risk of progression to life-threatening injury.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02407,2022,86,Class 3: Harm,B-NR,"In patients with BAAI, the usefulness of routine application of resuscitative endovascular balloon occlusion of the aorta (REBOA) for hemorrhage control is unclear and, in some cases, may cause harm.6-8",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02408,2022,88,2A,C-LD,"In patients with BTAI who have undergone aortic repair, surveillance imaging at intervals appropriate for the repair approach and loca- tion (see Section 7.8, “Long-Term Manage- ment and Surveillance Imaging Following AAS”) is reasonable.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02409,2022,88,2B,C-LD,"In patients with BTAI who have not undergone repair, surveillance imaging with a CT at 1 month, 6 months, and 12 months after the diagnosis and, if stable, at appropriate inter- vals thereafter (depending on the type and extent of the injury), may be ­reasonable.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02410,2022,88,Class 1,B-NR,"In patients who have had an acute aortic dis- section and IMH treated with either open or endovascular aortic repair and have residual aortic disease, surveillance imaging with a CT (or MRI) is recommended after 1 month, 6 months, and 12 months and then, if stable, annually thereafter.1-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02411,2022,88,Class 1,B-NR,"In patients who have had an acute aortic dis- section and IMH that was managed with medi- cal therapy alone, surveillance imaging with a CT (or MRI) is recommended after 1 month, 6 months, and 12 months and then, if stable, annually thereafter.7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02412,2022,89,Class 1,B-NR,"In patients with a previous acute aortic dissection and IMH, whether initially treated medically or with intervention, who have chronic residual TAD and an aneurysm with a total aortic diameter of ≥5.5 cm, elective thoracic aortic repair is ­recommended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02413,2022,89,2A,C-LD,"In patients with a PAU who have under- gone aortic repair, surveillance imaging at intervals appropriate for the repair approach and location (see Section 6.5.6, “Surveillance After Aneurysm Repair”) is reasonable.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02414,2022,89,2A,C-LD,"In patients with a PAU that is being managed medically, surveillance imaging with a CT is reasonable at 1 month after the diagnosis and, if stable, every 6 months for 2 years, and then at appropriate intervals thereafter (depending on patient age and PAU charac- teristics).1,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02415,2022,90,Class 1,C-LD,"In patients with genetic aortopathies attributable to syndromic (Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome) and nsHTAD and who are contemplating preg- nancy, genetic counseling before pregnancy to discuss the heritable nature of their condition is recommended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02416,2022,90,Class 1,C-LD,"In patients with syndromic and nsHTAD, Turner syndrome, BAV with aortic dilation, and other aortopathy conditions, aortic imaging (with TTE, MRI or CT, or both as appropriate) before pregnancy is recommended to determine aortic ­diameters.1-3,5-13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02417,2022,90,Class 1,C-LD,"In patients with syndromic and nsHTAD, Turner syndrome, BAV with aortic dilation, and other aortopathy conditions, who are contem- plating pregnancy, counseling about the risks of aortic dissection related to pregnancy is recommended.2-5,10,12,14 During Pregnancy",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02418,2022,90,2A,C-EO,"In patients with aortic aneurysms, or at increased risk of aortic dissection, or both, it is recom- mended that pregnancy be managed by a multidisciplinary team including a maternal fetal medicine specialist and cardiologist, and, if logistically feasible, that delivery be planned in a hospital where the capability for emergency aortic repair is available.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02419,2022,90,Class 1,C-LD,"In patients with aortopathies who are preg- nant, guideline-directed treatment of hyper- tension is recommended.61517",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02420,2022,90,Class 1,C-EO,"In patients with syndromic and nsHTAD, beta-blocker therapy during pregnancy and postpartum is recommended, unless contrain- dicated.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02421,2022,90,Class 1,C-LD,"In pregnant patients with aortic disease who require surveillance imaging of the aortic arch, descending, abdominal aorta, or all 3, MRI with- out gadolinium is recommended over CT to avoid radiation exposure to the fetus.19,20",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02422,2022,91,Class 1,C-EO,"In pregnant patients with a history of chronic aortic dissection, cesarean delivery is recom- mended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02423,2022,91,Class 1,C-EO,"In pregnant patients with an aortopathy and an aortic diameter of <4.0 cm, vaginal delivery (when otherwise appropriate) is recom- mended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02424,2022,91,2A,C-EO,"In pregnant patients with a diameter of the aortic root, ascending aorta, or both, of ≥4.5 cm, cesarean delivery is reasonable. Downloaded from http://ahajournals.org by on June 19, 2025",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02425,2022,92,2B,C-EO,"In pregnant patients with a diameter of the aortic root, ascending aorta, or both, of 4.0 cm to 4.5 cm, vaginal delivery with regional anes- thesia, expedited second stage, and assisted delivery may be reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02426,2022,92,2B,C-EO,"In pregnant patients with syndromic and nsHTAD, and a diameter of the aortic root, ascending aorta, or both, of 4.0 cm to 4.5 cm, cesarean delivery may be considered.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02427,2022,92,Class 1,C-LD,"In patients with Marfan syndrome and an aortic root diameter of >4.5 cm, aortic surgery before pregnancy is recommended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02428,2022,92,2A,C-EO,"In patients with Loeys-Dietz syndrome attributable to pathogenic variants in TGFB2 or TGFB3 and an aortic diameter of ≥4.5 cm, surgery before pregnancy is rea- sonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02429,2022,92,Class 1,C-EO,"In patients with nsHTAD and an aortic diam- eter of ≥4.5 cm, surgery before pregnancy is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02430,2022,93,Class 1,C-LD,"In patients with Turner syndrome and ASI of ≥2.5 cm/m2, surgery before pregnancy is rec- ommended.9-11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02431,2022,93,Class 1,C-EO,"In patients with a BAV (in the absence of Turner syndrome or an HTAD) and an aortic diameter of ≥5.0 cm, surgery before preg- nancy is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02432,2022,93,Class 1,C-EO,"In patients with sporadic aortic root aneu- rysms, ascending aortic aneurysms, or both and a diameter of ≥5.0 cm, surgery before pregnancy is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02433,2022,94,Class 1,C-LD,"In patients experiencing an acute type A aortic dissection during the first or second trimester of pregnancy, urgent aortic surgery with fetal monitoring is ­recommended.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02434,2022,94,Class 1,C-LD,"In patients experiencing an acute type A aortic dissection during the third trimester of pregnancy, urgent cesarean delivery imme- diately followed by aortic surgery is recom- mended.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02435,2022,94,Class 1,C-EO,"In patients experiencing an acute type B aortic dissection during pregnancy, medical therapy is recommended, unless endovascular or surgical therapy is required to manage acute complications.5",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02436,2022,94,2B,C-EO,"In patients with progressive aortic dilation during pregnancy, prophylactic aortic surgery may be considered, depending on individual circumstances.1,2,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02437,2022,95,Class 1,C-LD,"In patients with large vessel vasculitis (LVV), prompt evaluation of the entire aorta and branch vessels with MRI or CT, with or without 18F-FDG positron emission tomography (FDG-PET), is ­recommended.1-6 Treatment",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02438,2022,95,Class 1,B-NR,"In patients with active GCA or Takayasu arteri- tis, initial medical therapy should include high- dose glucocorticoids.7-12",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02439,2022,95,Class 1,B-R,"In patients with GCA who have evidence of active aortitis, tocilizumab is recommended as adjunctive therapy to glucocorticoids, with methotrexate as an alternative.7,13,14",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02440,2022,95,Class 1,C-LD,"In all patients with Takayasu arteritis, non- biological disease-modifying anti-rheumatic drugs (DMARD) should be given in combina- tion with glucocorticoids.7,15,16",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02441,2022,95,Class 1,C-LD,"In patients with active GCA or Takayasu arteritis, treatment efficacy should be periodically assessed by monitoring inflam- matory serum markers (C-reactive protein and erythrocyte sedimentation rate), imag- ing with CT, MRI, or FDG-PET, and clinical symptoms.1,7,15,17-20",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02442,2022,95,2A,C-LD,"In patients with GCA or Takayasu arteritis who are in remission, elective endovascular or open surgical intervention is reasonable to treat aortic and branch vessel complica- tions.7,21",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02443,2022,99,Class 1,C-EO,"In patients with infectious aortitis and associ- ated aneurysms or dissection of the thoracic or abdominal aorta, open surgical repair is recommended.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02444,2022,99,2A,C-EO,"In patients with infectious aortitis compli- cated by rupture, either open or endovas- cular repair is reasonable, based on the patient’s status at presentation and institu- tional expertise.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02445,2022,99,2B,C-EO,"In patients with infectious aortitis, intravenous antimicrobial therapy of at least 6 weeks’ duration may be considered, with lifelong sup- pressive therapy in select cases not amenable to interventional repair or who have recurrent infection.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02446,2022,101,2A,B-NR,"In patients with a prosthetic aortic graft, who have signs and symptoms or culture evidence of unexplained infection or have unexplained gastrointestinal bleeding, cross-sectional imaging is reasonable to evaluate for an underlying aortic graft infection.1-6 Treatment",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02447,2022,101,2A,B-NR,"In patients with an infected prosthetic aor- tic graft who are hemodynamically stable and have appropriate anatomy, it is reason- able to perform open surgery with either in situ reconstruction or extra-anatomic bypass.7-13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02448,2022,101,2A,B-NR,"In patients with an infected prosthetic aortic graft who are hemodynamically unstable, it is reasonable to perform open surgery with either explant or in situ ­reconstruction.7",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02449,2022,101,2A,C-LD,"In patients with an infected prosthetic aortic graft, endovascular therapy is reasonable, either as bridge therapy in those with hemo- dynamic instability or as long-term therapy in those who are unsuitable candidates for open surgery.13-15 Late Management",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02450,2022,101,Class 1,C-LD,"In patients who have undergone treatment of an acute prosthetic aortic graft infection, targeted intravenous antimicrobial therapy of at least 6 weeks’ duration, with prolonged suppressive oral therapy in select cases, plus a consultation and follow-up with an infectious disease specialist, is recommen ded.7,11,12,16,17",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02451,2022,101,2B,C-LD,"In patients with an infected prosthetic aor- tic graft and either an extensive perigraft abscess or an infection caused by methicillin- resistant S. aureus, Pseudomonas aeruginosa, or a multidrug-resistant microorganism, or who have undergone in situ reconstruction, lifelong suppressive oral antimicrobial therapy may be considered after the initial course of therapy.14,15,18,19",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02452,2022,102,Class 1,C-LD,"In patients with aortic atherosclerotic disease and concomitant coronary artery disease, PAD or both, it is recommended to prescribe antiplatelet therapy, anticoagu- lant therapy or both, guided by the clinical ­setting.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02453,2022,102,2A,C-LD,"In patients with aortic atherosclerotic disease and risk factors for confirmed coronary artery disease, it is reasonable to prescribe a moderate- or high-intensity statin.4-6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02454,2022,102,2B,C-LD,"In patients with aortic atheromas of a thick- ness ≥4 mm, statin therapy may be reason- able.1,7-9",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02455,2022,104,Class 1,B-NR,"In patients with CoA, including those who have undergone surgical or endovascular intervention, an MRI or CT is recommended for initial, surveillance, and follow-up aortic imaging.1-4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02456,2022,104,Class 1,C-EO,"In patients with CoA, BPs should be mea- sured in both arms and one of the lower extremities.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02457,2022,104,Class 1,B-NR,"In patients with significant native or recurrent CoA (Table 37) and hypertension, endovascular stenting or open surgical repair of the coarcta- tion is ­recommended.2,3,5-12",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02458,2022,104,Class 1,C-EO,"In patients with CoA, guideline-directed medi- cal therapy is recommended for the treatment of hypertension.13",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02459,2022,104,2B,B-NR,"In adult patients with CoA, screening for intracranial aneurysms by MRI or CT may be reasonable.14-18",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02460,2022,105,2A,C-LD,"In patients discovered to have an ASCA in the absence of thoracic aortic imaging, dedicated imaging to assess for TAA is ­reasonable.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02461,2022,105,2B,C-LD,"In patients with Kommerell’s diverticulum, depending on patient anatomy and comor- bidities, repair may be reasonable when the diverticulum orifice is >3.0 cm, the combined diameter of the diverticulum and adjacent descending aorta is >5.0 cm, or both (Figure 27).3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02462,2022,106,2A,C-EO,"In patients with an aberrant left vertebral artery origin arising directly from the thoracic aorta who require aortic repair involving recon- struction or coverage of the vertebral artery origin, revascularization of the vertebral artery is reasonable.",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02463,2022,107,2B,C-LD,"In patients with bovine arch (common innominate and left carotid artery), imaging to assess for TAA may be ­reasonable.1-3",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02464,2022,108,Class 1,C-EO,"For patients with significant aortic dis- ease, education and guidance should be provided about avoiding intense isomet- ric exercises (eg, heavy weightlifting or activities requiring the Valsalva maneuver), burst exertion and activities, and collision sports.1,2",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02465,2022,108,Class 1,C-EO,"For patients who have undergone sur- gery for aortic aneurysm or dissection, postoperative cardiac rehabilitation is ­recommended.3,4",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02466,2022,108,2A,C-LD,"In patients with thoracic or abdominal aortic aneurysms whose BP is adequately con- trolled, it is reasonable to encourage 30 to 60 minutes of mild-to-moderate intensity aerobic activity at least 3 to 4 days per week.5,6",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02467,2022,108,2A,C-LD,"For patients with clinically significant aortic disease, it is reasonable to screen for anxiety, depression, and posttraumatic stress disorder and, when indicated, provide resources for support7,8; it is also reason- able to provide education and resources to minimize patients’ concerns, support opti- mal decision-making, and enhance quality of life.5,9-11",isselbacher-et-al-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the-american.pdf
id_02468,2024,9,Class 1,B-NR,"In individuals 40–79 years of age, estimation of risk for atherosclerotic CVD (ie, nonfatal MI, non- fatal stroke, and fatal CVD) every 1 to 5 years is beneficial to guide decisions on treatments and lifestyle recommendations that may reduce risk for stroke.58",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02469,2024,10,Class 1,B-NR,"In individuals with AF, calculation of the CHA2DS2- VASc score is recommended to guide decisions on prescription of oral anticoagulation to reduce risk for stroke.59",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02470,2024,10,Class 1,C-EO,"In individuals ≥18 years of age, periodic screening for modifiable behaviors and medical conditions that increase stroke risk is recommended to reduce risk for stroke.60,61",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02471,2024,10,Class 1,C-EO,"In individuals ≥18 years of age, periodic screening for SDOH (eg, food insecurity, lack of transporta- tion) is beneficial to identify additional factors that contribute to stroke risk.35,62–65",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02472,2024,12,Class 1,B-R,"In adults without prior CVD and who are at high or intermediate CVD risk, a Mediterranean diet is recommended to reduce the risk of incident stroke.86,87",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02473,2024,12,2A,B-R,"In adults who are ≥60 years of age and have uncontrolled BP (systolic BP [SBP] ≥140 mm Hg if taking antihypertensive medication or ≥160 mm Hg if not), compared with using 100% sodium chloride, salt substitution (75% sodium chloride and 25% potassium chloride) is reasonable to reduce the risk of incident stroke.88",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02474,2024,12,2B,B-NR,"In adults, folic acid supplementation and B- complex (folic acid, B12, B6) vitamins supplementa- tion for reducing the risk of stroke are not well established.89–91",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02475,2024,12,Class 3: No Benefit,B-R,"In adults without prior CVD, long-chain fatty acids are not effective for reducing the risk of stroke.89,91–96",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02476,2024,12,Class 3: No Benefit,B-R,"In adults, vitamin C, vitamin E, selenium, anti- oxidants, calcium, calcium with vitamin D, and multivitamin supplementation are not effective for reducing the risk of stroke.89–91,97–99",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02477,2024,14,Class 1,C-EO,"In adults, screening for physical activity is recom- mended as part of a comprehensive effort to estimate stroke risk.104–107 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02478,2024,14,Class 1,C-LD,"In adults, counseling patients to engage in at least 150 minutes of moderate-intensity physical activity, 75 minutes of vigorous-intensity physical activity, or an equivalent combination per week is recommended to reduce the risk of stroke.108–111",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02479,2024,14,Class 1,C-LD,"In adults, counseling to avoid excessive time spent in sedentary behavior (characterized by low- energy expenditure while sitting, reclining, or lying while awake) is recommended to reduce the risk of stroke.112–115",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02480,2024,16,Class 1,B-NR,"In adults >18 years of age, screening for over- weight and obesity is recommended to inform the risk of stroke.158–162 Other intervention",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02481,2024,16,2B,C-LD,"In patients with class II obesity (35–39.9 kg/m2) or greater, bariatric surgical procedures to pro- mote weight loss may be considered to reduce the risk of stroke.163–167",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02482,2024,17,2B,B-R,The effectiveness of screening adults for OSA to prevent stroke is unclear.191 Other intervention,bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02483,2024,17,2B,C-LD,"In patients with OSA, continuous positive airway pressure (CPAP) might be reasonable to reduce the risk of stroke.192–194",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02484,2024,18,Class 1,C-LD,"In asymptomatic adults ≥18 years of age who have overweight, obesity, or atherosclerotic CVD, screening for prediabetes and diabetes is recom- mended to inform stroke risk.202–204 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02485,2024,18,Class 1,A,"In patients with diabetes and high cardiovascular risk or established CVD and hemoglobin A1c ≥7%, treatment with a GLP-1 receptor agonist is effective to reduce the risk of stroke.180,205–208 Downloaded from http://ahajournals.org by on June 19, 2025",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02486,2024,19,Class 3: No Benefit,B-R,"In patients with type 1 diabetes or diabetes, intensive glycemic control (targeting a hemo- globin A1c ≤6.5%) is not beneficial for stroke prevention.209–215",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02487,2024,20,Class 1,C-LD,"In adults ≥18 years of age, screening for hyper- tension is recommended to identify individuals at increased risk for stroke and eligible for antihy- pertensive treatment.221 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02488,2024,20,Class 1,A,"In adults with stage 2 hypertension or stage 1 hypertension with a higher risk for atherosclerotic CVD, lifestyle improvement and antihypertensive drug treatment to a SBP/diastolic BP (DBP) <130/80 mm Hg are recommended to prevent stroke.222–229",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02489,2024,20,Class 1,A,"In adults with hypertension, thiazide and thiazide- like diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers are recommended as initial antihypertensive drug therapies to pre- vent stroke.68,230–232",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02490,2024,20,Class 1,A,"In most adults with hypertension, antihypertensive drug treatment incorporating ≥2 antihypertensive medications is indicated to achieve the BP control necessary to prevent stroke.224,229,234–237",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02491,2024,22,Class 1,A,"In adults who qualify for treatment with lipid- lowering therapy according to the 2019 ACC/ AHA guideline on the primary prevention of CVD (eg, 20–75 years of age with LDL cholesterol [LDL-C] level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk ≥20%, or 10-year ASCVD risk ≥7.5%–<20% plus ≥1 risk enhancers), treat- ment with a statin is recommended to reduce the risk of a first stroke.243,244",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02492,2024,22,2B,A,"In adults without CVD who qualify for treatment with lipid-lowering therapy, according to the 2019 ACC/AHA guideline on the primary prevention of CVD (eg, 20–75 years of age with LDL-C level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk ≥20%, or 10-year ASCVD risk ≥7.5%–<20% plus ≥1 risk enhancers), who cannot reach goals or cannot tolerate other therapies such as statins, the benefit of treatment with alirocumab or evo- locumab compared with other active lipid-lowering therapy for the reduction of the risk of a first stroke is uncertain.245",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02493,2024,22,2B,B-R,"In adults who do not tolerate statin therapy and who have LDL-C >100 mg/dL and elevated car- diovascular risk, treatment with bempedoic acid to reduce the risk of a first stroke is not well estab- lished.246",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02494,2024,22,Class 3: No Benefit,A,"In adults with moderate or low intake of long-chain omega-3 fatty acid, supplementation is not recom- mended to reduce the risk of a first stroke.92",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02495,2024,24,Class 1,B-NR,"In all patients, screening for cigarette smoking, use of other forms of tobacco, use of electronic nicotine delivery systems such as electronic ciga- rettes (e-cigarettes) and vapes, and environmental tobacco smoke exposure (secondhand smoke exposure) is effective to inform stroke risk and target cessation interventions.254–270 Prevention intervention",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02496,2024,24,Class 1,B-NR,"For patients who are nonusers of tobacco products, continued complete abstention from cigarette smoking, in addition to other tobacco products and electronic nicotine delivery systems, and avoidance of exposure to environmental tobacco smoke (secondhand smoke exposure) are recommended to avoid the associated increased risk of stroke.254,255,257–263,265–270 Cessation intervention",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02497,2024,24,Class 1,A,"For patients who are active cigarette smokers, smoking cessation pharmacotherapy delivered along with behavioral counseling is recommended, in preference to behavioral counseling alone, to facilitate smoking cessation.271–277",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02498,2024,24,Class 1,C-LD,"For patients who are active cigarette smokers and users of other tobacco products (eg, electronic nicotine delivery systems), assistance with cessation is recommended to reduce the risk of stroke.260,271,278–286",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02499,2024,24,2A,B-R,"For patients who are active cigarette smokers encountered in the hospital setting, providing smoking cessation pharmacotherapy along with behavioral counseling as the default treatment (“opt-out”), in preference to providing such treat- ment only for patients expressing a willingness to quit smoking (“opt-in”), can be beneficial to facili- tate short-term smoking cessation and to increase engagement in smoking cessation treatment.287,288",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02500,2024,24,2B,B-R,"For patients who are active cigarette smokers, the long-term health benefits of using e-cigarettes in place of nicotine replacement therapy to facilitate cigarette smoking cessation are not well estab- lished.289–291",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02501,2024,26,Class 3: No Benefit,B-NR,"In the asymptomatic population, routine screen- ing for carotid artery stenosis is not recom- mended to reduce the risk of stroke.306,307 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02502,2024,26,Class 1,C-EO,"In patients with asymptomatic carotid artery stenosis (ACS) >70%, shared decision-making between the patient and the health care team to decide between the 2 courses of treatment (carotid revascularization or medical manage- ment) is recommended to determine the best method of reducing stroke risk.",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02503,2024,26,2A,B-NR,"In patients with asymptomatic atherosclerotic carotid artery stenosis, medical treatment with statin can be beneficial to reduce the risk of stroke.308–311",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02504,2024,26,2B,B-R,"In patients with asymptomatic atherosclerotic carotid artery stenosis >70% and low periopera- tive risk, the use of carotid revascularization, in addition to intensive medical therapy, may be reasonable to reduce the risk of stroke.309,312–314",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02505,2024,26,2B,B-NR,"In patients with ACS >50%, annual carotid duplex ultrasound every 6 to 12 months might be reasonable to assess progression of disease and subsequent increased risk of stroke.308,315–318",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02506,2024,26,2B,B-NR,"In patients with asymptomatic atherosclerotic carotid artery stenosis and high perioperative risk, the effectiveness of carotid revascular- ization to reduce risk of stroke is not estab- lished.314,319,320",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02507,2024,29,Class 1,C-LD,"In adults with asymptomatic cerebral SVD (CSVD), including silent infarcts, assessment and management of risk factors (eg, hypertension, dyslipidemia, tobacco use, and diabetes) are recommended to reduce stroke risk.336–341",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02508,2024,29,2B,B-NR,"In adults with silent cerebral infarcts (SCIs) who do not have an indication for statin therapy according to the 2019 ACC/AHA guideline (eg, 20–75 years of age with LDL-C level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk ≥20%, or 10-year ASCVD risk ≥7.5%–<20% plus ≥1 more risk enhancers), use of low-dose statin therapy might be considered to reduce the risk of ischemic stroke.342–345",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02509,2024,29,2B,C-LD,"In adults with SCI, the benefit of antiplatelet therapy to reduce the risk of ischemic stroke is uncertain.346,347",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02510,2024,30,Class 1,C-LD,"In adults 18 to 64 years of age with migraine with or without aura, evaluation and modification of vascular risk factors are recommended to address the elevated risk of stroke in this patient population.362–369",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02511,2024,30,Class 1,C-LD,"In adults with migraine with aura who desire contraception, progestin-only or nonhormonal forms are recommended to avoid the increased risk of ischemic stroke associated with combined hormonal contraception.370–372",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02512,2024,31,Class 1,B-R,"In children 2 to 16 years of age with SCD (Hb SS or Hb S-beta0-thalassemia), transcranial Doppler (TCD) screening at a frequency based on the highest mean flow velocity in the terminal portion of the internal carotid or the proximal portion of the middle cerebral artery is recommended.381–384 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02513,2024,31,Class 1,B-R,"In children 2 to 16 years of age with SCD at elevated risk per TCD measurements, regularly scheduled transfusion therapy (target reduction of hemoglobin S <30%) is effective for reducing stroke risk.382,383",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02514,2024,31,2A,B-R,"In children 2 to 16 years of age and young adults with Hb SS or Hb S-beta0-thalassemia, an MRI of the brain without sedation should be performed as soon as possible to evaluate for SCI and to deter- mine the need for chronic red cell transfusions (CRCTs) for stroke prevention.385,386",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02515,2024,31,2A,B-R,"In children 2 to 16 years of age with SCD whose TCD velocities revert to normal, continued transfu- sion therapy can be beneficial to reduce the risk of stroke.384",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02516,2024,31,2A,B-NR,"In children 2 to 16 years of age with SCD and normalized mean flow velocities and no intra- cranial stenosis, transition from transfusion to hydroxyurea therapy can be considered to prevent stroke.387",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02517,2024,31,2B,B-NR,"In children 2 to 16 years of age with SCD at high risk for stroke (TCD mean flow velocities ≥200 cm/s) but without intracranial stenosis who are unable to continue or cannot be treated with periodic red cell transfusion, hydroxyurea or bone marrow transplantation may be reasonable to prevent stroke.387–390",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02518,2024,34,Class 1,C-LD,"In patients with CADASIL, counseling on smok- ing cessation and treatment of hypertension and other vascular risk factors are beneficial to reduce the risk of incident stroke.407–412",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02519,2024,34,2A,B-NR,"In adults with hereditary hemorrhagic telangiecta- sia (HHT), screening for pulmonary arteriovenous malformations (PAVMs) is reasonable to identify the need for multidisciplinary evaluation to man- age stroke risk.413–421",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02520,2024,34,2B,C-LD,"In patients with Fabry disease, the effectiveness of enzyme replacement therapy (ERT) to reduce the risk of stroke is not well established.422–427",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02521,2024,36,2B,B-R,"In adults with a recent MI, the addition of low- dose colchicine to intensive statin therapy might be reasonable to decrease the risk of ischemic stroke.457,458",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02522,2024,37,Class 1,B-NR,"In patients without a history of stroke and no clini- cal indication for anticoagulation, with a high-risk aPL profile (ie, triple-positive antiphospholipid testing [lupus anticoagulant, anticardiolipin anti- body, anti–β2 glycoprotein 1] or double-positive [any combination] or isolated lupus anticoagulant or isolated persistently positive anticardiolipin antibody at medium to high titers), prophylactic treatment with aspirin (75–100 mg daily) is rec- ommended to reduce the risk of stroke.462,463",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02523,2024,37,Class 1,B-NR,"In patients with systemic lupus erythematosus (SLE) and no history of thrombosis or pregnancy complications and with a high-risk antiphospholipid profile (ie, lupus anticoagulant, anticardiolipin antibody, anti–β2-glycoprotein 1, or double-positive [any combination] or isolated lupus anticoagulant or isolated persistently positive anticardiolipin antibody at medium to high titers), prophylactic treatment with aspirin (75–100 mg daily) is rec- ommended to reduce the risk of stroke.462,463",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02524,2024,37,2A,B-R,"In patients with antiphospholipid syndrome (APS) with prior unprovoked venous thrombosis, it is reasonable to choose vitamin K antagonist (VKA) therapy with a target international normalized ratio of 2 to 3 in preference to aspirin or direct oral anticoagulants for prevention of recurrent throm- botic events, including stroke.457,458.464,465",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02525,2024,37,2B,B-R,"In patients with rheumatoid arthritis, statin treat- ment may be reasonable to reduce major adverse cardiovascular events, including stroke.466,467",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02526,2024,37,2B,B-NR,"In nonpregnant adults with a history of obstetric APS only, prophylactic treatment with aspirin (75–100 mg daily) after adequate risk/benefit evaluation (ie, aPL profile, coexistent traditional cardiovascular risk fac- tors, intolerance, or contraindication to aspirin) may be considered to reduce the risk of stroke.462,468",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02527,2024,37,2B,C-LD,"In patients with SLE and no history of thrombosis or pregnancy complications and with a low-risk antiphospholipid profile (ie, isolated anticardiolipin antibody or anti–β2-glycoprotein 1 antibodies at low to medium titers, particularly if transiently pos- itive), prophylactic treatment with aspirin (75–100 mg daily) may be considered to reduce the risk of stroke.462,463,469,470",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02528,2024,39,2A,B-NR,"In patients with periodontal disease (PD), good oral hygiene and regular dental care can be ben- eficial to lower stroke risk.486–488",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02529,2024,39,Class 3: No Benefit,B-R,"In patients hospitalized with COVID-19, treat- ment with full-dose anticoagulation (eg, enoxa- parin, apixaban) is not recommended to prevent stroke.489,490",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02530,2024,40,Class 1,B-NR,"In all adults, screening for substance misuse and substance use disorders (eg, alcohol, cannabis, cocaine, opioids, amphetamines) is recommended to inform stroke risk.506–520 Other interventions",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02531,2024,40,2A,C-LD,"In patients who use recreational drugs (eg, cannabis, synthetic cannabinoids, cocaine, heroin, methamphet- amine), misuse alcohol or prescription medications (eg, stimulants and opioids), or have a substance use disorder, counseling to stop or appropriate substance use disorder treatments (eg, pharmacological, behav- ioral, or multimodal) as appropriate are reasonable to reduce stroke risk.521–531 Downloaded from http://ahajournals.org by on June 19, 2025",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02532,2024,42,Class 1,B-NR,"In pregnant or early postpartum (within 6 weeks of delivery), patients with severe hypertension (2 measurements of SBP ≥160 mm Hg or DBP ≥110 mm Hg, 15 minutes apart), BP-lowering treatment to a target <160/110 mm Hg as soon as possible is recommended to reduce the risk of fatal maternal ICH.551–558",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02533,2024,42,2A,C-LD,"In patients with HDP, including chronic hyperten- sion in pregnancy, treatment with antihypertensive medication to a goal BP of <140/90 mm Hg is reasonable to reduce the risk of pregnancy- associated stroke.559–566",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02534,2024,44,Class 1,C-EO,"In adults, screening for a history of certain adverse pregnancy outcomes (APOs), including HDP, preterm birth, gestational diabetes, and placental disorders, followed by subsequent evalu- ation and management of vascular risk factors, is recommended to reduce the risk of stroke. Other intervention",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02535,2024,44,Class 1,C-LD,"In patients with a history of HDP or other APOs, early evaluation and management of chronic hypertension are recommended to reduce the risk of stroke.609–613",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02536,2024,47,2A,B-NR,"In adults, screening for a history of endometriosis is reasonable to inform the risk of stroke.649–653 Other intervention",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02537,2024,47,2A,C-LD,"In individuals with endometriosis, vascular risk factor evaluation and modification of vascular risk factors are reasonable to reduce the risk of stroke.649–653",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02538,2024,48,Class 1,B-NR,"In individuals considering CHC, lower doses of ethinyl estradiol are recommended to minimize potential increased stroke risk.658–663",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02539,2024,48,Class 1,C-EO,"In individuals with specific stroke risk factors (ie, age >35 years, tobacco use, hypertension, or migraine with aura) who are considering contra- ception, shared decision-making is recommended to determine the best contraceptive choice to bal- ance the risk of stroke from contraception and the risk of stroke with pregnancy.",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02540,2024,48,2A,C-LD,"In individuals with specific stroke risk factors (ie, age >35 years, tobacco use, hypertension, or migraine with aura) who are considering contra- ception, progestin-only contraception or nonhor- monal contraception is reasonable to prevent the increased stroke risk associated with estrogen- containing contraception.370,661–670",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02541,2024,49,Class 1,B-NR,Screening for a history of premature ovarian failure (before 40 years of age) and early meno- pause (before 45 years of age) can be beneficial to inform the risk of stroke.674–678 Other interventions,bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02542,2024,49,Class 1,C-LD,"In patients with premature ovarian failure (meno- pause before 40 years of age) or early meno- pause (before 45 years of age), evaluation and modification of vascular risk factors are recom- mended to reduce the elevated stroke risk in this population.674,675,677–679",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02543,2024,51,2A,C-LD,"In transgender women and gender-diverse indi- viduals taking estrogens for gender affirmation, evaluation and modification of risk factors can be beneficial to reduce the risk of stroke.700–703",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02544,2024,52,2A,B-R,"In men 45 to 80 years of age with confirmed hypogonadism who are considering testosterone therapy, initiation or continuation of testosterone replacement therapy is reasonable and does not increase the risk of stroke.704–706",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02545,2024,53,Class 3: No Benefit,B-R,"In patients with left ventricular systolic dysfunction (ejection fraction ≤35%–40%) and no evidence of AF or left ventricular thrombus, anticoagulation is not indicated to prevent stroke and is associ- ated with a higher bleeding risk.706,708–711",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02546,2024,54,2B,A,"In patients with diabetes or other common vascular risk factors and no prior stroke, the use of aspirin to prevent a first stroke is not well established.727–731",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02547,2024,54,2B,B-R,"In patients with established, stable coronary artery disease and a low bleeding risk, the addition of ticagrelor to aspirin beyond 12 months for a period up to 3 years may be beneficial to reduce the rate of ischemic stroke.732",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02548,2024,54,Class 3: No Benefit,A,"In individuals ≥70 years of age with at least 1 additional cardiovascular risk factor, the use of aspi- rin is not beneficial to prevent a first stroke.360,733",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02549,2024,54,Class 3: No Benefit,B-NR,"In patients with chronic kidney disease, the use of aspirin is not effective to prevent a first stroke.734",bushnell-et-al-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from-the-american-heart-association.pdf
id_02550,2023,4,Class 1,B-R,We recommend that epinephrine be administered for patients in cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02551,2023,4,2A,B-R,It is reasonable to administer epinephrine 1 mg every 3 to 5 minutes for cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02552,2023,4,2A,C-LD,"With respect to timing, for cardiac arrest with a nonshockable rhythm, it is reasonable to administer epinephrine as soon as feasible.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02553,2023,4,2B,B-R,Vasopressin alone or vasopressin+ methylprednisolone in combination with epinephrine may be considered in cardiac arrest but offers no advantage as a substitute for epinephrine.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02554,2023,4,2B,C-LD,"With respect to timing, for cardiac arrest with a shockable rhythm, it may be reasonable to administer epinephrine after initial defibrillation attempts have failed.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02555,2023,4,Class 3: No Benefit,B-R,High-dose epinephrine is not recommended for routine use in cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02556,2023,6,2B,B-R,Amiodarone or lidocaine may be considered for ventricular fibrillation/pulseless ventricular tachycardia that is unresponsive to defibrillation.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02557,2023,6,2B,C-LD,"For patients with OHCA, use of steroids during CPR is of uncertain benefit.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02558,2023,6,Class 3: No Benefit,B-R,Routine administration of calcium for treatment of cardiac arrest is not recommended.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02559,2023,6,Class 3: No Benefit,B-R,Routine use of sodium bicarbonate is not recommended for patients in cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02560,2023,6,Class 3: No Benefit,B-R,Routine use of magnesium for cardiac arrest is not recommended.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02561,2023,7,2A,B-R,Use of ECPR for patients with cardiac arrest refractory to standard ACLS is reasonable in select patients when provided within an appropriately trained and equipped system of care.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02562,2023,8,Class 1,B-NR,Coronary angiography should be performed emergently for all cardiac arrest patients with suspected cardiac cause of arrest and,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02563,2023,8,2A,B-NR,"Emergent coronary angiography is reasonable for selected adult patients without ST-elevation on electrocardiogram but with elevated risk of significant coronary artery disease where revascularization may provide benefit, such as those with shock, electrical instability, signs of significant ongoing myocardial damage, or ongoing ischemia.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02564,2023,8,2A,C-LD,"Independent of a patient’s neurologic status, coronary angiography is reasonable in all post–cardiac arrest patients for whom coronary angiography is otherwise indicated.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02565,2023,8,Class 3: No Benefit,B-R,"Emergent coronary angiography is not recommended over a delayed or selective strategy in patients with ROSC after cardiac arrest in the absence of ST-segment elevation, shock, electrical instability, signs of significant myocardial damage, and ongoing ischemia.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02566,2023,10,Class 1,B-R,"We recommend all adults who do not follow commands after ROSC, irrespective of arrest location or presenting rhythm, receive treatment that includes a deliberate strategy for temperature control.",perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02567,2023,11,Class 1,B-R,We recommend selecting and maintaining a constant temperature between 32° C and 37.5° C during postarrest temperature control.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02568,2023,11,Class 1,B-NR,We recommend hospitals develop protocols for postarrest temperature control.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02569,2023,11,2A,B-NR,It is reasonable that temperature control be maintained for at least 24 h after achieving target temperature.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02570,2023,11,2B,B-NR,There is insufficient evidence to recommend a specific therapeutic temperature for different subgroups of cardiac arrest patients.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02571,2023,11,2B,C-LD,It may be reasonable to actively prevent fever in patients unresponsive to verbal commands after initial temperature control.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02572,2023,11,2B,C-EO,Patients with spontaneous hypothermia after ROSC unresponsive to verbal commands should not routinely be actively or passively rewarmed faster than 0.5° C per hour.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02573,2023,11,2B,B-R,The benefit of strategies other than rapid infusion of cold intravenous fluids for prehospital cooling is unclear.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02574,2023,11,Class 3: No Benefit,B-R,We do not recommend the routine use of rapid infusion of cold intravenous fluids for prehospital cooling of patients after ROSC. Recommendation-Specific Supportive Text,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02575,2023,13,Class 1,C-LD,We recommend treatment of clinically apparent seizures in adult survivors of cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02576,2023,13,Class 1,C-LD,We recommend promptly performing and interpreting electroencephalography (EEG) for the diagnosis of seizures in patients who do not follow commands after ROSC.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02577,2023,13,2A,C-LD,Monitoring EEG repeatedly or continuously is reasonable for patients who do not follow commands after ROSC.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02578,2023,13,2A,B-R,Treatment of nonconvulsive seizures (diagnosed by EEG only) is reasonable in adult survivors of cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02579,2023,13,2B,C-EO,A therapeutic trial of a nonsedating antiseizure medication may be reasonable in adult survivors of cardiac arrest with EEG patterns on the ictal-interictal continuum.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02580,2023,13,2B,C-LD,The same antiseizure medications used for treatment of seizures caused by other etiologies may be considered for seizures detected after cardiac arrest.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02581,2023,13,Class 3: No Benefit,B-R,Seizure prophylaxis in adult survivors of cardiac arrest is not recommended.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02582,2023,16,Class 1,B-NR,Organ donation should be considered in all patients resuscitated from cardiac arrest who meet neurological criteria for death.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02583,2023,16,Class 1,B-NR,Organ donation should be considered in all patients resuscitated from cardiac arrest before planned withdrawal of life-sustaining therapies.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02584,2023,16,Class 1,C-EO,Decisions about organ donation should follow local legal and regulatory requirements.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02585,2023,16,Class 1,C-EO,Organ donation is an important outcome that should be considered in the development and evaluation of systems of care.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02586,2023,17,2A,C-EO,It is reasonable for researchers studying cardiac arrest to develop and implement methods to promote recruitment and representation of participants from diverse backgrounds.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02587,2023,17,2A,C-EO,It is beneficial for researchers studying cardiac arrest to collect and report complete demographic data.,perman-et-al-2023-american-heart-association-focused-update-on-adult-advanced-cardiovascular-life-support-an-update-to.pdf
id_02588,2022,8,Class 1,B-R,"In patients with stroke, including spontaneous ICH, design and implementation of stroke public education programs for diverse popula- tions focused on early recognition and the need to seek emergency care rapidly is useful to reduce time to diagnosis and treatment.31–35",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02589,2022,8,Class 1,B-R,"In patients with sudden onset of neurological symptoms or signs attributable to potential spontaneous ICH, use of stroke recogni- tion and severity tools is recommended for dispatch personnel and first responders to identify potential stroke and facilitate rapid transport to reduce time to diagnosis and treatment.36–41",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02590,2022,8,Class 1,B-NR,"In patients with stroke symptoms attributable to potential spontaneous ICH, immediate activation of the emergency response system (9-1-1 in North America) is recommended to reduce time to diagnosis and treatment.32,42",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02591,2022,8,Class 1,B-NR,"In patients with potential spontaneous ICH, early notification by emergency medical ser- vices (EMS) staff to the receiving hospital is recommended to improve time to diagnosis and treatment.43,44",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02592,2022,8,Class 1,C-LD,"In patients with spontaneous ICH, regional systems of stroke care are recommended so all potentially beneficial therapies can be made available when appropriate as rapidly as possible‚ including, at minimum, (a) health care facilities that provide initial spontaneous ICH care, including diagnosis and treatment, and (b) health care facilities with neurocritical care and neurosurgical capabilities.45",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02593,2022,8,2A,B-R,"In patients with potential stroke, including spontaneous ICH, in geographic regions where mobile stroke units (MSUs) operate, such mobile units are reasonable to enable more rapid diagnosis and treatment than achievable by ambulance transfer to the clos- est stroke-capable facility.46,47",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02594,2022,8,2A,C-LD,"In patients with potential spontaneous ICH, first responder training in stroke evaluation and care with the ability to provide airway and circulatory support when necessary is reason- able to detect and manage prehospital neuro- logical deterioration (ND).48,49",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02595,2022,10,Class 1,C-LD,"In patients with spontaneous ICH, focused history, physical examination, and routine labo- ratory work and tests on hospital admission (eg, complete blood count, prothrombin time/ international normalized ratio [INR]/partial thromboplastin time, creatinine/estimated glomerular filtration rate, glucose, cardiac tro- ponin and ECG, toxicology screen, and inflam- matory markers) should be performed to help identify the type of hemorrhage, active medical issues, and risk of unfavorable outcomes.67–72",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02596,2022,12,Class 1,B-NR,"In patients presenting with stroke-like symp- toms, rapid neuroimaging with CT or MRI is recommended to confirm the diagnosis of spontaneous ICH.94–96",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02597,2022,12,2A,B-NR,"In patients with spontaneous ICH and/or IVH, serial head CT can be useful within the first 24 hours after symptom onset to evaluate for hemorrhage expansion.97–99",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02598,2022,12,2A,C-LD,"In patients with spontaneous ICH and/or IVH and with low GCS score or ND, serial head CT can be useful to evaluate for hemorrhage expansion, development of hydrocephalus, brain swelling, or herniation.100–102 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02599,2022,13,2B,B-NR,"In patients with spontaneous ICH, CT angiog- raphy (CTA) within the first few hours of ICH onset may be reasonable to identify patients at risk for subsequent HE.103–108",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02600,2022,13,2B,B-NR,"In patients with spontaneous ICH, using non- contrast computed tomography (NCCT) mark- ers of HE to identify patients at risk for HE may be reasonable.106",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02601,2022,14,Class 1,B-NR,"In patients with lobar spontaneous ICH and age <70 years, deep/posterior fossa spon- taneous ICH and age <45 years, or deep/ posterior fossa and age 45 to 70 years with- out history of hypertension, acute CTA plus consideration of venography is recommended to exclude macrovascular causes or cerebral venous thrombosis.117,118",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02602,2022,14,Class 1,B-NR,"In patients with spontaneous IVH and no detectable parenchymal hemorrhage, catheter intra-arterial digital subtraction angiography (DSA) is recommended to exclude a macro- vascular cause.119",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02603,2022,14,Class 1,C-LD,"In patients with spontaneous ICH and a CTA or magnetic resonance angiography (MRA) suggestive of a macrovascular cause, catheter intra-arterial DSA should be performed as soon as possible to confirm and manage underlying intracranial vascular malformations.117,118,120–122",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02604,2022,14,2A,B-NR,"In patients with (a) lobar spontaneous ICH and age <70 years, (b) deep/posterior fossa ICH and age <45 years, or (c) deep/posterior fossa and age 45 to 70 years without history of hypertension and negative noninvasive imaging (CTA±venography and MRI/MRA), catheter intra-arterial DSA is reasonable to exclude a macrovascular cause.117,118,120–122",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02605,2022,14,2A,B-NR,"In patients with spontaneous ICH with a negative CTA/venography, it is reasonable to perform MRI and MRA to establish a nonmac- rovascular cause of ICH (such as CAA, deep perforating vasculopathy, cavernous malforma- tion, or malignancy).118,123,124",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02606,2022,14,2A,C-LD,"In patients with spontaneous ICH who undergo CT or MRI at admission, CTA plus consideration of venography or MRA plus con- sideration of venography performed acutely can be useful to exclude macrovascular causes or cerebral venous thrombosis.118",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02607,2022,14,2B,C-LD,"In patients with spontaneous ICH and a nega- tive catheter intra-arterial DSA and no clear microvascular diagnosis or other defined structural lesion, it may be reasonable to per- form a repeat catheter intra-arterial DSA 3 to 6 months after ICH onset to identify a previ- ously obscured vascular lesion.125",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02608,2022,16,2A,B-NR,"In patients with spontaneous ICH requiring acute BP lowering, careful titration to ensure continuous smooth and sustained control of BP, avoiding peaks and large variability in SBP, can be beneficial for improving functional out- comes.138",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02609,2022,16,2A,C-LD,"In patients with spontaneous ICH in whom acute BP lowering is considered, initiating treatment within 2 hours of ICH onset and reaching target within 1 hour can be beneficial to reduce the risk of HE and improve func- tional outcome.139,140 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02610,2022,17,2B,B-R,"In patients with spontaneous ICH of mild to moderate severity presenting with SBP between 150 and 220 mm Hg, acute lower- ing of SBP to a target of 140 mm Hg with the goal of maintaining in the range of 130 to 150 mm Hg is safe and may be reasonable for improving functional outcomes.138,141–147",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02611,2022,17,2B,C-LD,"In patients with spontaneous ICH presenting with large or severe ICH or those requir- ing surgical decompression, the safety and efficacy of intensive BP lowering are not well established.148",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02612,2022,17,Class 3: Harm,B-R,"In patients with spontaneous ICH of mild to moderate severity presenting with SBP >150 mm Hg, acute lowering of SBP to <130 mm Hg is potentially harmful.146,149,150",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02613,2022,19,Class 1,C-LD,"In patients with anticoagulant-associated spontaneous ICH, anticoagulation should be discontinued immediately and rapid reversal of anticoagulation should be performed as soon as possible after diagnosis of spontaneous ICH to improve survival.162 VKAs",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02614,2022,19,Class 1,B-R,"In patients with VKA-associated spontaneous ICH and INR ≥2.0, 4-factor (4-F) prothrombin complex concentrate (PCC) is recommended in preference to fresh-frozen plasma (FFP) to achieve rapid correction of INR and limit HE.163",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02615,2022,19,Class 1,C-LD,"In patients with VKA-associated spontaneous ICH, intravenous vitamin K should be adminis- tered directly after coagulation factor replace- ment (PCC or other) to prevent later increase in INR and subsequent HE.164,165",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02616,2022,19,2B,C-LD,"In patients with VKA-associated spontaneous ICH with INR of 1.3 to 1.9, it may be reason- able to use PCC to achieve rapid correction of INR and limit HE.162,164 DOACs",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02617,2022,19,2A,B-NR,"In patients with direct factor Xa inhibitor–asso- ciated spontaneous ICH, andexanet alfa is reasonable to reverse the anticoagulant effect of factor Xa inhibitors.166,167",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02618,2022,19,2A,B-NR,"In patients with dabigatran-associated spon- taneous ICH, idarucizumab is reasonable to reverse the anticoagulant effect of dabiga- tran.168",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02619,2022,19,2B,B-NR,"In patients with direct factor Xa inhibitor– associated spontaneous ICH, a 4-F PCC or activated PCC (aPCC) may be considered to improve hemostasis.169–171",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02620,2022,19,2B,C-LD,"In patients with dabigatran- or factor Xa inhibi- tor–associated spontaneous ICH, when the DOAC agent was taken within the previous few hours, activated charcoal may be reason- able to prevent absorption of the DOAC.172–174",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02621,2022,19,2B,C-LD,"In patients with dabigatran-associated sponta- neous ICH, when idarucizumab is not available, aPCC or PCCs may be considered to improve hemostasis.175,176",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02622,2022,19,2B,C-LD,"In patients with dabigatran-associated spontaneous ICH, when idarucizumab is not available, renal replacement therapy (RRT) may be considered to reduce dabigatran concentration.177 Heparins",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02623,2022,19,2A,C-LD,"In patients with unfractionated heparin (UFH)– associated spontaneous ICH, intravenous protamine is reasonable to reverse the antico- agulant effect of heparin.178",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02624,2022,19,2B,C-LD,"In patients with low-molecular-weight heparin (LMWH)–associated spontaneous ICH, intrave- nous protamine may be considered to partially reverse the anticoagulant effect of heparin.178",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02625,2022,23,2B,C-LD,"For patients with spontaneous ICH being treated with aspirin and who require emer- gency neurosurgery, platelet transfusion might be considered to reduce postoperative bleed- ing and mortality.206",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02626,2022,23,2B,C-LD,"For patients with spontaneous ICH being treated with antiplatelet agents, the effective- ness of desmopressin with or without platelet transfusions to reduce the expansion of the hematoma is uncertain.207–209",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02627,2022,23,Class 3: Harm,B-R,"For patients with spontaneous ICH being treated with aspirin and not scheduled for emergency surgery, platelet transfusions are potentially harmful and should not be adminis- tered.210",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02628,2022,24,2B,B-R,"In patients with spontaneous ICH (with or without the spot sign), the effectiveness of recombinant factor VIIa to improve functional outcome is unclear.218,219",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02629,2022,24,2B,B-R,"In patients with spontaneous ICH (with or without the spot sign, black hole sign, or blend sign), the effectiveness of TXA to improve functional outcome is not well estab- lished.220–222",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02630,2022,25,Class 1,A,"In patients with spontaneous ICH, provision of care in a specialized inpatient (eg, stroke) unit with a multidisciplinary team is recommended to improve outcomes and reduce mortality.231,232",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02631,2022,25,Class 1,B-NR,"In patients with spontaneous ICH, provision of care at centers that can provide the full range of high-acuity care and expertise is recom- mended to improve outcomes.233",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02632,2022,25,Class 1,B-NR,"In patients with spontaneous ICH and clini- cal hydrocephalus, transfer to centers with neurosurgical capabilities for definitive hydro- cephalus management (eg, EVD placement and monitoring) is recommended to reduce mortality.233,234",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02633,2022,25,Class 1,C-LD,"In patients with spontaneous ICH, care delivery that includes multidisciplinary teams trained in neurological assessment is recom- mended to improve outcomes.99,235,236",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02634,2022,25,Class 1,C-EO,"In hospitalized patients with spontaneous ICH who require hospital transfer but do not have adequate airway protection, cannot support adequate gas exchange, and/or do not have a stable hemodynamic profile, appropriate life-sustaining therapies should be initiated before transportation to prevent acute medical decompensation in transport.",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02635,2022,25,2A,B-NR,"In patients with spontaneous ICH without indi- cations for ICU admission at presentation, ini- tial provision of care in a stroke unit compared with a general ward is reasonable to reduce mortality and improve outcomes.231,237,238",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02636,2022,25,2A,B-NR,"In patients with moderate to severe spontaneous ICH, IVH, hydrocephalus, or infratentorial loca- tion, provision of care in a neuro-specific ICU compared with a general ICU is reasonable to improve outcomes and reduce mortality.235,239–241",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02637,2022,25,2B,B-NR,"In patients with IVH or infratentorial ICH loca- tion, transfer to centers with neurosurgical capabilities might be reasonable to improve outcomes.102,233,234",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02638,2022,25,2B,C-LD,"In patients with larger supratentorial ICH, transfer to centers with neurosurgical capa- bilities may be reasonable to improve out- comes.233,234",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02639,2022,27,Class 1,B-R,"In patients with spontaneous ICH, the use of standardized protocols and/or order sets is recommended to reduce disability and mortal- ity.256–259",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02640,2022,27,Class 1,B-NR,"In patients with spontaneous ICH, a formal dysphagia screening protocol should be imple- mented before initiation of oral intake to reduce disability and the risk of pneumonia.256,260–265",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02641,2022,27,2A,C-LD,"In patients with spontaneous ICH, continu- ous cardiac monitoring for the first 24 to 72 hours of admission is reasonable to monitor for cardiac arrhythmias and new cardiac ischemia.266–268",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02642,2022,27,2A,C-LD,"In patients with spontaneous ICH, diagnos- tic laboratory and radiographic testing for infection on admission and throughout the hospital course is reasonable to improve out- comes.269–273 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02643,2022,29,Class 1,B-R,"In nonambulatory patients with spontaneous ICH, intermittent pneumatic compression (IPC) starting on the day of diagnosis is recommended for VTE (DVT and pulmonary embolism [PE]) prophylaxis.275,276",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02644,2022,29,2A,C-LD,"In nonambulatory patients with spontaneous ICH, low-dose UFH or LMWH can be useful to reduce the risk for PE.277–280",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02645,2022,29,2B,C-LD,"In nonambulatory patients with spontaneous ICH, initiating low-dose UFH or LMWH prophy- laxis at 24 to 48 hours from ICH onset may be reasonable to optimize the benefits of prevent- ing thrombosis relative to the risk of HE.277,281,282",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02646,2022,29,Class 3: No Benefit,B-R,"In nonambulatory patients with spontaneous ICH, graduated compression stockings of knee-high or thigh-high length alone are not beneficial for VTE prophylaxis.276,278,283,284 Treatment",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02647,2022,29,2A,C-LD,"For patients with acute spontaneous ICH and proximal DVT who are not yet candidates for anticoagulation, the temporary use of a retrievable filter is reasonable as a bridge until anticoagulation can be initiated.285",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02648,2022,29,2B,C-LD,"For patients with acute spontaneous ICH and proximal DVT or PE, delaying treatment with UFH or LMWH for 1 to 2 weeks after the onset of ICH might be considered.286,287",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02649,2022,31,Class 1,C-LD,"In patients with spontaneous ICH, frequent neurological assessments (including GCS) should be performed by ED nurses in the early hyperacute phase of care to assess change in status, neurological examination, or level of consciousness.61,292–294",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02650,2022,31,2A,C-LD,"In patients with spontaneous ICH, frequent neurological assessments in the ICU and stroke unit are reasonable for up to 72 hours of admission to detect early ND.99,245,292,294",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02651,2022,31,2A,C-LD,"In patients with spontaneous ICH, specialized nurse stroke competencies can be effective in improving outcome and mortality.295–297",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02652,2022,32,Class 1,C-LD,"In patients with spontaneous ICH, monitoring serum glucose is recommended to reduce the risk of hyperglycemia and hypoglycemia.256,299",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02653,2022,32,Class 1,C-LD,"In patients with spontaneous ICH, treating hypoglycemia (<40–60 mg/d, <2.2–3.3 mmol/L) is recommended to reduce mortal- ity.299–301",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02654,2022,32,2A,C-LD,"In patients with spontaneous ICH, treating moderate to severe hyperglycemia (>180– 200 mg/dL, >10.0–11.1 mmol/L) is reason- able to improve outcomes.78,302–307",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02655,2022,33,2B,C-LD,"In patients with spontaneous ICH, pharma- cologically treating an elevated temperature may be reasonable to improve functional out- comes.311–313",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02656,2022,33,2B,C-LD,"In patients with spontaneous ICH, the usefulness of therapeutic hypothermia (<35° C/95 °F) to decrease peri-ICH edema is unclear.314–317",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02657,2022,34,Class 1,C-LD,"In patients with spontaneous ICH, impaired consciousness, and confirmed electrographic seizures, antiseizure drugs should be adminis- tered to reduce morbidity.325,326",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02658,2022,34,Class 1,C-EO,"In patients with spontaneous ICH and clinical seizures, antiseizure drugs are recommended to improve functional outcomes and prevent brain injury from prolonged recurrent seizures.",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02659,2022,34,2A,C-LD,"In patients with spontaneous ICH and unex- plained abnormal or fluctuating mental status or suspicion of seizures, continuous electro- encephalography (≥24 hours) is reasonable to diagnose electrographic seizures and epilepti- form discharges.327",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02660,2022,34,Class 3: No Benefit,B-NR,"In patients with spontaneous ICH without evidence of seizures, prophylactic antiseizure medication is not beneficial to improve func- tional outcomes, long-term seizure control, or mortality.328–331 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02661,2022,35,Class 1,B-NR,"In patients with spontaneous ICH or IVH and hydrocephalus that is contributing to decreased level of consciousness, ventricular drainage should be performed to reduce mor- tality.347–350",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02662,2022,35,2B,B-NR,"In patients with moderate to severe spon- taneous ICH or IVH with a reduced level of consciousness, ICP monitoring and treatment might be considered to reduce mortality and improve outcomes.159,351–356",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02663,2022,35,2B,B-NR,"In patients with spontaneous ICH, the efficacy of early prophylactic hyperosmolar therapy for improving outcomes is not well estab- lished.357–361",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02664,2022,35,2B,C-LD,"In patients with spontaneous ICH, bolus hyperosmolar therapy may be considered for transiently reducing ICP.362–364",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02665,2022,35,Class 3: No Benefit,B-R,"In patients with spontaneous ICH, corticoste- roids should not be administered for treatment of elevated ICP.365–369 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02666,2022,37,2A,B-R,"For patients with supratentorial ICH of >20- to 30-mL volume with GCS scores in the moder- ate range (5–12), minimally invasive hematoma evacuation with endoscopic or stereotactic aspiration with or without thrombolytic use can be useful to reduce mortality compared with medical management alone.379–388",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02667,2022,37,2B,B-R,"For patients with supratentorial ICH of >20- to 30-mL volume with GCS scores in the moderate range (5–12) being considered for hematoma evacuation, it may be reasonable to select minimally invasive hematoma evacu- ation over conventional craniotomy to improve functional outcomes.382,383,385–387,389,390",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02668,2022,37,2B,B-R,"For patients with supratentorial ICH of >20- to 30-mL volume with GCS scores in the moderate range (5–12), the effectiveness of minimally invasive hematoma evacuation with endoscopic or stereotactic aspiration with or without thrombolytic use to improve functional outcomes is uncertain.379–385,387,388 Downloaded from http://ahajournals.org by on June 19, 2025",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02669,2022,39,Class 1,B-NR,"For patients with spontaneous ICH, large IVH, and impaired level of consciousness, EVD is recommended in preference to medical man- agement alone to reduce mortality.347–349",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02670,2022,39,2A,B-R,"For patients with a GCS score >3 and primary IVH or IVH extension from spontaneous supra- tentorial ICH of <30-mL volume requiring EVD, minimally invasive IVH evacuation with EVD plus thrombolytic is safe and is reasonable compared with EVD alone to reduce mortality.415–418",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02671,2022,39,2B,B-R,"For patients with a GCS score >3 and pri- mary IVH or IVH extension from spontane- ous supratentorial ICH of <30-mL volume requiring EVD, the effectiveness of minimally invasive IVH evacuation with EVD plus throm- bolytic use to improve functional outcomes is uncertain.382,407,415–419",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02672,2022,39,2B,B-NR,"For patients with severe spontaneous ICH‚ large IVH, and impaired level of consciousness, the efficacy of EVD for improving functional out- comes is not well established.347–349",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02673,2022,39,2B,C-LD,"For patients with spontaneous supratentorial ICH of <30-mL volume and IVH requiring EVD, the usefulness of minimally invasive IVH evacuation with neuroendoscopy plus EVD, with or without thrombolytic, to improve func- tional outcomes and reduce permanent shunt dependence is uncertain.419,420",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02674,2022,41,2B,A,"For most patients with spontaneous supra- tentorial ICH of moderate or greater severity, the usefulness of craniotomy for hemorrhage evacuation to improve functional outcomes or mortality is uncertain.380,382,384,393,429–431",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02675,2022,41,2B,C-LD,"In patients with supratentorial ICH who are deteriorating, craniotomy for hematoma evacu- ation might be considered as a lifesaving measure.382,384,429,432",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02676,2022,42,Class 1,B-NR,"For patients with cerebellar ICH who are deteriorating neurologically, have brainstem compression and/or hydrocephalus from ventricular obstruction, or have cerebellar ICH volume ≥15 mL, immediate surgical removal of the hemorrhage with or without EVD is recom- mended in preference to medical management alone to reduce mortality.442–444",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02677,2022,43,2B,C-LD,"In patients with supratentorial ICH who are in a coma, have large hematomas with significant midline shift, or have elevated ICP refractory to medical management, decompressive crani- ectomy with or without hematoma evacuation may be considered to reduce mortality.453–460",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02678,2022,43,2B,C-LD,"In patients with supratentorial ICH who are in a coma, have large hematomas with significant midline shift, or have elevated ICP refractory to medical management, effectiveness of decompressive craniectomy with or without hematoma evacuation to improve functional outcomes is uncertain.458–462",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02679,2022,44,Class 1,B-NR,"In patients with spontaneous ICH, administer- ing a baseline measure of overall hemorrhage severity is recommended as part of the initial evaluation to provide an overall measure of clinical severity.472–474",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02680,2022,44,2B,B-NR,"In patients with spontaneous ICH, a baseline severity score might be reasonable to provide a general framework for communication with the patient and their caregivers.472,473",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02681,2022,44,Class 3: No Benefit,B-NR,"In patients with spontaneous ICH, a baseline severity score should not be used as the sole basis for forecasting individual prognosis or limiting life-sustaining treatment.475,476",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02682,2022,45,2A,B-NR,"In patients with spontaneous ICH who do not have preexisting documented requests for life- sustaining therapy limitations, aggressive care, including postponement of new DNAR orders or withdrawal of medical support until at least the second full day of hospitalization, is reasonable to decrease mortality and improve functional outcome.479–484",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02683,2022,45,2A,C-LD,"In patients with spontaneous ICH who are unable to fully participate in medical decision- making, use of a shared decision-making model between surrogates and physicians is reasonable to optimize the alignment of care with patient wishes and surrogate satisfac- tion.485",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02684,2022,45,Class 3: Harm,B-NR,"In patients with spontaneous ICH who have DNAR status, limiting other medical and surgi- cal interventions, unless explicitly specified by the patient or surrogate, is associated with increased patient mortality.180,479,486,487",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02685,2022,47,Class 1,A,"In patients with spontaneous ICH, multidisci- plinary rehabilitation, including regular team meetings and discharge planning, should be performed to improve functional outcome and reduce morbidity and mortality.231,232",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02686,2022,47,Class 1,A,"In patients with spontaneous ICH with mild to moderate severity, early supported discharge is beneficial to increase the likelihood of patients living at home at 3 months.490",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02687,2022,47,2B,B-R,"In patients with spontaneous ICH with moder- ate severity, early rehabilitation beginning 24 to 48 hours after onset (including ADL train- ing, stretching, functional task training) may be considered to improve functional outcome and reduce mortality.491,492",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02688,2022,47,Class 3: No Benefit,A,"In patients with spontaneous ICH without depression, fluoxetine therapy is not effective to enhance poststroke functional status.493–497",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02689,2022,47,Class 3: Harm,B-R,"In patients with spontaneous ICH, very early and intense mobilization within the first 24 hours is associated with lower likelihood of good recovery.498,499",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02690,2022,48,Class 1,B-R,"In patients with spontaneous ICH and mod- erate to severe depression, appropriate evidence-based treatments including psycho- therapy and pharmacotherapy are useful to reduce symptoms of depression.507,508",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02691,2022,48,Class 1,B-NR,"In patients with spontaneous ICH, administra- tion of depression and anxiety screening tools in the postacute period is recommended to identify patients with poststroke depression and anxiety.509",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02692,2022,48,Class 1,B-NR,"In patients with spontaneous ICH, administra- tion of a cognitive screening tool in the post- acute period is useful to identify patients with cognitive impairment and dementia.510",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02693,2022,48,2A,B-NR,"In patients with spontaneous ICH and cogni- tive impairment, referral for cognitive therapy is reasonable to improve cognitive out- comes.511–515",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02694,2022,48,2A,B-NR,"In patients with spontaneous ICH and pre- existing or new mood disorders requiring pharmacotherapy, continuation or initiation of SSRIs after ICH can be beneficial for the treatment of mood disorders.508,516–518",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02695,2022,48,2B,C-LD,"In patients with spontaneous ICH and cogni- tive impairment, treatment with cholinesterase inhibitors or memantine might be considered to improve cognitive outcomes.519–521",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02696,2022,50,2A,B-NR,"In patients with spontaneous ICH in whom the risk for recurrent ICH may facilitate prognosti- cation or management decisions, it is reason- able to incorporate the following risk factors for ICH recurrence into decision-making: (a) lobar location of the initial ICH; (b) older age; (c) presence, number, and lobar location of microbleeds on MRI; (d) presence of dissemi- nated cortical superficial siderosis on MRI; (e) poorly controlled hypertension; (f) Asian or Black race; and (g) presence of apolipopro- tein E ε2 or ε4 alleles.562–571",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02697,2022,51,Class 1,B-R,"In patients with spontaneous ICH, BP control is recommended to prevent hemorrhage recur- rence.563,581",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02698,2022,51,2A,B-NR,"In patients with spontaneous ICH, it is reason- able to lower BP to an SBP of 130 mm Hg and diastolic BP (DBP) of 80 mm Hg for long- term management to prevent hemorrhage recurrence.581,582",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02699,2022,52,2A,C-LD,"In patients with spontaneous ICH and condi- tions placing them at high risk of thromboem- bolic events, for example, a mechanical valve or LVAD, early resumption of anticoagulation to prevent thromboembolic complications is reasonable.586,587",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02700,2022,52,2B,B-R,"In patients with spontaneous ICH with an indi- cation for antiplatelet therapy, resumption of antiplatelet therapy may be reasonable for the prevention of thromboembolic events based on consideration of benefit and risk.588,589",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02701,2022,52,2B,B-NR,"In patients with nonvalvular atrial fibrillation (AF) and spontaneous ICH, the resumption of anti- coagulation to prevent thromboembolic events and reduce all-cause mortality may be consid- ered based on weighing benefit and risk.590–595",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02702,2022,52,2B,C-LD,"In patients with AF and spontaneous ICH in whom the decision is made to restart antico- agulation, initiation of anticoagulation ≈7 to 8 weeks after ICH may be considered after weighing specific patient characteristics to optimize the balance of risks and benefits.596,597",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02703,2022,52,2B,C-LD,"In patients with AF and spontaneous ICH deemed ineligible for anticoagulation, left atrial appendage closure may be considered to reduce the risk of thromboembolic events.598–602",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02704,2022,54,2B,B-NR,"In patients with spontaneous ICH and an estab- lished indication for statin pharmacotherapy, the risks and benefits of statin therapy on ICH out- comes and recurrence relative to overall preven- tion of cardiovascular events are uncertain.605–609",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02705,2022,54,Class 3: Harm,B-NR,"In patients with spontaneous ICH, regular long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is potentially harmful because of the increased risk of ICH.610,611",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02706,2022,55,2A,C-LD,"In patients with spontaneous ICH, lifestyle modification is reasonable to reduce BP.632",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02707,2022,55,2A,C-LD,"In patients with spontaneous ICH, avoiding heavy alcohol consumption is reasonable to reduce hypertension and risk of ICH recurrence.633–635",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02708,2022,55,2B,C-LD,"In patients with spontaneous ICH, lifestyle modification, including supervised training and counseling, may be reasonable to improve functional recovery.636,637 Patient and caregiver education",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02709,2022,55,2A,C-LD,"In patients with spontaneous ICH, psychoso- cial education for the caregiver can be ben- eficial to increase patients’ activity level and participation and/or quality of life.638",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02710,2022,55,2A,C-LD,"In patients with spontaneous ICH, practical sup- port and training for the caregiver are reason- able to improve patients’ standing balance.639",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02711,2022,56,2B,C-LD,"When considering primary prevention of ICH, it may be reasonable to incorporate any available MRI results demonstrating cerebral microbleed burden or cortical superficial sid- erosis to inform shared decision-making about stroke prevention treatment plans.25,564,644–648",greenberg-et-al-2022-guideline-for-the-management-of-patients-with-spontaneous-intracerebral-hemorrhage-a-guideline.pdf
id_02712,2020,5,Class 1,B-NR,"For patients with HCM or at risk for HCM, shared decision-making is recommended in developing a plan of care (including but not limited to decisions regarding genetic evaluation, activity, lifestyle, and therapy choices) that includes a full disclosure of the risks, benefits, and anticipated outcomes of all options, as well the opportunity for the patient to express their goals and concerns.4–9",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02713,2020,5,Class 1,C-LD,"In patients with HCM in whom septal reduc- tion therapy (SRT) is indicated, the procedure should be performed at experienced centers (comprehensive or primary HCM centers) with demonstrated excellence in clinical out- comes for these procedures10–12 (Table 3 and",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02714,2020,5,2A,C-LD,"In patients with HCM, consultation with or referral to a comprehensive or primary HCM center is reasonable to aid in complex disease-related management decisions13–22 (Table 3).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02715,2020,5,Class 1,B-NR,"In patients with suspected HCM, compre- hensive physical examination and complete medical and 3-generation family history is recommended as part of the initial diagnostic assessment23–28 (Table 5 and Table 6). Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02716,2020,7,Class 1,B-NR,"In patients with suspected HCM, a transtho- racic echocardiogram (TTE) is recommended in the initial evaluation.29–34",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02717,2020,7,Class 1,B-NR,"For patients with HCM who experience a change in clinical status or a new clinical event, repeat TTE is recommended.35,38,43–46",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02718,2020,7,Class 1,B-NR,"For patients with HCM and resting left ventricular outflow tract gradient <50 mm Hg, a TTE with provocative maneuvers is recommended.47–50",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02719,2020,7,Class 1,B-NR,"For symptomatic patients with HCM who do not have a resting or provocable outflow tract gradient ≥50 mm Hg on TTE, exercise TTE is recommended for the detection and quantifi- cation of dynamic LVOTO.49–54",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02720,2020,7,Class 1,B-NR,"For patients with HCM undergoing surgical septal myectomy, intraoperative transesopha- geal echocardiogram (TEE) is recommended to assess mitral valve anatomy and function and adequacy of septal myectomy.55–58",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02721,2020,7,Class 1,B-NR,"For patients with HCM undergoing alcohol septal ablation, TTE or intraoperative TEE with intracoronary ultrasound-enhancing contrast injection of the candidate’s septal perforator(s) is recommended.31,59–63",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02722,2020,7,Class 1,B-NR,"For patients with HCM who have undergone SRT, TTE within 3 to 6 months after the proce- dure is recommended to evaluate the proce- dural results.17,64–66",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02723,2020,7,Class 1,B-NR,"Screening: In first-degree relatives of patients with HCM, a TTE is recommended as part of initial family screening and periodic follow-up 31–33,35,36,61 (Figure 1, Table 6).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02724,2020,7,Class 1,B-NR,"Screening: In individuals who are genotype- positive or phenotype-negative, serial echocar- diography is recommended at periodic intervals depending on age (1 to 2 years in children and adolescents, 3 to 5 years in adults) and change in clinical status (Table 6; Figure 1).28,67,69–71",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02725,2020,7,2A,C-LD,"For patients with HCM, TEE can be useful if TTE is inconclusive in clinical decision-making regarding medical therapy, and in situations such as planning for myectomy, exclusion of subaortic membrane or mitral regurgitation secondary to structural abnormalities of the mitral valve apparatus, or in the assessment of the feasibility of alcohol septal ablation.55–58",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02726,2020,7,2A,B-NR,"For patients with HCM in whom the diagnoses of apical HCM, apical aneurysm, or atypical patterns of hypertrophy is inconclusive on TTE, the use of an intravenous ultrasound-enhanc- ing agent is reasonable particularly if other imaging modalities such as cardiovascular mag- netic resonance (CMR) are not readily available or contraindicated.72,73",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02727,2020,7,2A,C-LD,"For asymptomatic patients with HCM who do not have a resting or provocable outflow tract gradient ≥50 mm Hg on standard TTE, exer- cise TTE is reasonable for the detection and quantification of dynamic LVOTO.43,48,49,51–54",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02728,2020,7,Class 1,B-NR,"For patients suspected to have HCM in whom echocardiography is inconclusive, CMR imaging is indicated for diagnostic clarification.74–80",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02729,2020,7,Class 1,B-NR,"For patients with left ventricular hypertrophy in whom there is a suspicion of alternative diagnoses including infiltrative or storage disease as well as athlete’s heart, CMR imag- ing is useful74–80 (Figure 1).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02730,2020,7,Class 1,B-NR,"For patients with HCM who are not oth- erwise identified as high risk for sudden cardiac death (SCD), or in whom a decision to proceed with implantable cardioverter-defibrillator (ICD) remains uncertain after clinical assessment that includes personal/family history, echocar- diography, and ambulatory electrocar- diographic monitoring, CMR imaging is beneficial to assess for maximum left ven- tricular (LV) wall thickness, ejection frac- tion (EF), LV apical aneurysm, and extent of myocardial fibrosis with late gadolinium enhancement.38,74–87",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02731,2020,7,Class 1,B-NR,"For patients with obstructive HCM in whom the anatomic mechanism of obstruction is inconclusive on echocardiography, CMR imag- ing is indicated to inform the selection and planning of SRT.88–92",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02732,2020,7,2B,C-EO,"For patients with HCM, repeat contrast- enhanced CMR imaging on a periodic basis (every 3 to 5 years) for the purpose of SCD risk stratification may be considered to evaluate changes in late gadolinium enhancement and other morphologic changes, including EF, development of api- cal aneurysm, or LV wall thickness (Figure 1,",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02733,2020,7,2B,C-LD,"In adult patients with suspected HCM, cardiac CT may be considered for diagnosis if the echocardiogram is not diagnostic and CMR imaging is unavailable.34,93,94 Recommendations for Echocardiography (Continued) COR LOE Recommendations Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02734,2020,8,Class 1,B-NR,"In patients with HCM, a 12-lead ECG is recommended in the initial evalu- ation and as part of periodic follow-up (every 1 to 2 years)95–97 (Figure 1,",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02735,2020,8,Class 1,B-NR,"In patients with HCM, 24- to 48-hour ambu- latory electrocardiographic monitoring is recommended in the initial evaluation and as part of periodic follow-up (every 1 to 2 years) to identify patients who are at risk for SCD and guide management of arrhythmias (Figure 1).98–100",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02736,2020,8,Class 1,B-NR,"In patients with HCM who develop palpita- tions or lightheadedness, extended (>24 hours) electrocardiographic monitoring or event recording is recommended, which should not be considered diagnostic unless patients have had symptoms while being monitored.101",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02737,2020,8,Class 1,B-NR,"In first-degree relatives of patients with HCM, a 12-lead ECG is recommended as a component of the screening algorithm95–97 (Figure 1, Table 6).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02738,2020,8,2A,B-NR,"In patients with HCM who have additional risk factors for atrial fibrillation (AF), such as left atrial dilatation, advanced age, and New York Heart Association (NYHA) class III to class IV heart failure (HF), and who are eligible for anticoagulation, extended ambu- latory monitoring is reasonable to screen for AF as part of initial evaluation and peri- odic follow-up (every 1 to 2 years)102–106 (Figure 1).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02739,2020,8,2B,B-NR,"In adult patients with HCM without risk factors for AF and who are eligible for anticoagulation, extended ambulatory monitoring may be considered to assess for asymptomatic paroxysmal AF as part of initial evaluation and periodic follow-up (every 1 to 2 years).102–106",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02740,2020,8,Class 1,B-NR,"For patients with HCM who are candidates for SRT and for whom there is uncertainty regarding the presence or severity of LVOTO on nonin- vasive imaging studies, invasive hemodynamic assessment with cardiac catheterization is recommended.45,107–109",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02741,2020,8,Class 1,B-NR,"In patients with HCM with symptoms or evidence of myocardial ischemia, coronary angiography (CT or invasive) is recommended.110",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02742,2020,8,Class 1,B-NR,"In patients with HCM who are at risk of coro- nary atherosclerosis, coronary angiography (CT or invasive) is recommended before surgi- cal myectomy.111",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02743,2020,8,Class 1,B-NR,"For symptomatic patients with HCM who do not have resting or provocable outflow tract gradient ≥50 mm Hg on TTE, exercise TTE is recommended for the detection and quantification of dynamic LVOTO.50,112",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02744,2020,8,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite guideline-directed management and therapy), cardiopulmonary exercise stress testing should be performed to quantify the degree of functional limi- tation and aid in selection of patients for heart trans- plantation or mechanical circulatory support.113,114",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02745,2020,8,2A,B-NR,"In patients with HCM, exercise stress testing is reasonable to determine functional capacity and to provide prognostic information as part of initial evaluation.113,114",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02746,2020,8,2A,C-LD,"For asymptomatic patients with HCM who do not have a resting or provocable outflow tract gradient ≥50 mm Hg on standard TTE, exercise TTE is reasonable for the detection and quantifi- cation of dynamic LVOTO.49,51–54,115",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02747,2020,8,2B,C-EO,"In patients with obstructive HCM, who are being considered for SRT, and in whom functional capac- ity or symptom status is uncertain, exercise stress testing may be reasonable (Figure 1).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02748,2020,8,2B,C-EO,"In patients with HCM in whom functional capacity or symptom status is uncertain, exercise stress test- ing may be considered every 2 to 3 years (Figure 1).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02749,2020,8,Class 1,B-NR,"In patients with HCM, evaluation of familial inheritance, including a 3-generation family history, is recommended as part of the initial assessment.23,25–28,117,118",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02750,2020,8,Class 1,B-NR,"In patients with HCM, genetic testing is bene- ficial to elucidate the genetic basis to facilitate the identification of family members at risk for developing HCM (cascade testing).119–122",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02751,2020,8,Class 1,B-NR,"In patients with an atypical clinical presentation of HCM or when another genetic condition is suspected to be the cause, a work-up includ- ing genetic testing for HCM and other genetic causes of unexplained cardiac hypertrophy (“HCM phenocopies”) is recommended.123–125",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02752,2020,8,Class 1,B-NR,"In patients with HCM who choose to undergo genetic testing, pre- and posttest genetic coun- seling by an expert in the genetics of cardio- vascular disease is recommended so that risks, benefits, results, and their clinical significance can be reviewed and discussed with the patient in a shared decision-making process.23–25,117",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02753,2020,8,Class 1,B-NR,"When performing genetic testing in an HCM proband, the initial tier of genes tested should include genes with strong evidence to be disease-causing in HCM.*119,122,127,128 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02754,2020,9,Class 1,B-NR,"In first-degree relatives of patients with HCM, both clinical screening (ECG and 2D echocar- diogram) and cascade genetic testing (when a pathogenic/likely pathogenic variant has been identified in the proband) should be offered.23,67,123,130–132",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02755,2020,9,Class 1,B-NR,"In families where a sudden unexplained death has occurred with a postmortem diagnosis of HCM, postmortem genetic testing is benefi- cial to facilitate cascade genetic testing and clinical screening in first-degree relatives.133,134",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02756,2020,9,Class 1,B-NR,"In patients with HCM who have undergone genetic testing, serial reevaluation of the variant(s) identified is recommended to assess for variant reclassification, which may impact diagnosis and cascade genetic testing in family members.135–137 (Figure 1 and Figure 2)",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02757,2020,9,Class 1,B-NR,"In affected families with HCM, preconception and prenatal reproductive and genetic counsel- ing should be offered.23–25,117",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02758,2020,9,2B,B-NR,"In patients with HCM, the usefulness of genetic testing in the assessment of risk of SCD is uncertain.121,137–139",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02759,2020,9,2B,B-NR,"In patients with HCM who harbor a variant of uncertain significance, the usefulness of clinical genetic testing of phenotype-negative relatives for the purpose of variant reclassifi- cation is uncertain.28,70,118,119",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02760,2020,9,Class 3: No Benefit,B-NR,"For patients with HCM who have undergone genetic testing and were found to have no pathogenic variants (ie, harbor only benign/ likely benign variants), cascade genetic testing of the family is not useful.118–121",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02761,2020,9,Class 3: No Benefit,B-NR,"Ongoing clinical screening is not indicated in genotype-negative relatives in families with genotype-positive HCM, unless the disease- causing variant is downgraded to variant of uncertain significance, likely benign, or benign variant during follow-up.15,135,140,142,143 *Strong evidence HCM genes include, at the time of this publication,",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02762,2020,10,Class 1,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, serial clinical assessment, electrocardiography, and cardiac imaging are recommended at periodic intervals depending on age (every 1 to 2 years in chil- dren and adolescents, and every 3 to 5 years in adults) and change in clinical status.28,67,69–71 (Figure 1 and Figure 2, Table 6)",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02763,2020,10,2A,C-LD,"In individuals who are genotype-positive, phe- notype-negative for HCM, participation in com- petitive athletics of any intensity is reasonable.132",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02764,2020,10,Class 3: No Benefit,B-NR,"In individuals who are genotype-positive, phenotype-negative for HCM, ICD is not recom- mended for primary prevention.28,69–71,132,145",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02765,2020,10,Class 1,B-NR,"In patients with HCM, a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1 to 2 years there- after is recommended and should include eval- uation of these risk factors38,78,79,81,83–87,99,146–160 (Figure 1 and Figure 3, Table 7): a.  Personal history of cardiac arrest or sus- tained ventricular arrhythmias b.  Personal history of syncope suspected by clinical history to be arrhythmic c.  Family history in close relative of prema- ture HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias d.  Maximal LV wall thickness, EF, LV apical aneurysm e.  Nonsustained ventricular tachycardia epi- sodes on continuous ambulatory electro- cardiographic monitoring",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02766,2020,10,Class 1,B-NR,"For patients with HCM who are not otherwise identified as high risk for SCD, or in whom a decision to proceed with ICD placement remains uncertain after clinical assess- ment that includes personal/family history, echocardiography, and ambulatory electro- cardiographic monitoring, CMR imaging is beneficial to assess for maximum LV wall thickness, EF, LV apical aneurysm, and extent of myocardial fibrosis with late gadolinium enhancement78,79,81,83–86,146,155 (Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02767,2020,10,2A,B-NR,"For patients who are ≥16 years of age with HCM, it is reasonable to obtain echocardiog- raphy-derived left atrial diameter and maximal left ventricular outflow tract gradient to aid in calculating an estimated 5-year sudden death risk that may be useful during shared deci- sion-making for ICD placement147,157 (Table 7). 4.2. Patient Selection for ICD Placement Recommendations for ICD Placement in High-Risk Patients With HCM Referenced studies that support the recommendations are summarized in Online Data Supplement 12. COR LOE Recommendations",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02768,2020,10,Class 1,C-EO,"In patients with HCM, application of indi- vidual clinical judgment is recommended when assessing the prognostic strength of conventional risk marker(s) within the clinical profile of the individual patient, as well as a thorough and balanced discussion of the evidence, benefits, and estimated risks to engage the fully informed patient’s active par- ticipation in ICD decision-making.13,146,161–163",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02769,2020,10,Class 1,B-NR,"For patients with HCM, and previous documented cardiac arrest or sustained ven- tricular tachycardia, ICD placement is recom- mended146,148,161–163 (Figure 3, Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02770,2020,10,2A,B-NR,"For adult patients with HCM with ≥1 major risk factors for SCD, it is reasonable to offer an ICD. These major risk factors in- clude38,81,87,99,146,149–157,159–161 (Figure 3, Table 7): a.  Sudden death judged definitively or likely attributable to HCM in ≥1 first-degree or close relatives who are ≤50 years of age; b.  Massive left ventricular hypertrophy ≥30 mm in any left ventricular segment; c.  ≥1 Recent episodes of syncope suspected by clinical history to be arrhythmic (ie, unlikely to be of neurocardiogenic [vaso- vagal] etiology, or related to LVOTO); d.  LV apical aneurysm, independent of size; e.  LV systolic dysfunction (EF <50%).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02771,2020,10,2A,B-NR,"For children with HCM who have ≥1 con- ventional risk factors, including unexplained syncope, massive left ventricular hypertrophy, nonsustained ventricular tachycardia, or family history of early HCM-related SCD, ICD placement is reasonable after considering the relatively high complication rates of long-term ICD placement in younger patients164–171 (Figure 3, Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02772,2020,10,2A,B-NR,"For patients ≥16 years of age with HCM and with ≥1 major SCD risk factors, discussion of the estimated 5-year sudden death risk and mortality rates can be useful during the shared decision-making process for ICD place- ment157,161 (Figure 3, Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02773,2020,10,2B,B-NR,"In select adult patients with HCM and without major SCD risk factors after clinical assessment, or in whom the decision to proceed with ICD placement remains otherwise uncertain, ICD may be considered in patients with extensive late gadolinium enhancement by contrast- enhanced CMR imaging or nonsustained ventricular tachycardia present on ambulatory monitoring84–86,99,146,157,161,170 (Figure 3, Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02774,2020,10,2B,C-LD,"In select pediatric patients with HCM in whom risk stratification is otherwise less cer- tain, it may be useful to consider additional factors such as extensive late gadolinium enhancement on contrast-enhanced CMR imaging and systolic dysfunction in risk strati- fication172,173 (Figure 3, Table 7).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02775,2020,10,Class 3: Harm,B-NR,"In patients with HCM without risk factors, ICD placement should not be performed.85,146",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02776,2020,10,Class 3: Harm,B-NR,"In patients with HCM, ICD placement for the sole purpose of participation in competitive athletics should not be performed.174 Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02777,2020,11,Class 1,B-NR,"In patients with HCM who are receiving an ICD, either a single chamber transve- nous ICD or a subcutaneous ICD is recom- mended after a shared decision-making discussion that takes into consideration patient preferences, lifestyle, and expected potential need for pacing for bradycardia or ventricular tachycardia termination.175–190",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02778,2020,11,Class 1,B-NR,"In patients with HCM who are receiving an ICD, single-coil ICD leads are recommended in preference to dual coil leads.187",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02779,2020,11,2A,B-NR,"In patients with HCM who are receiving an ICD, dual-chamber ICDs are reasonable for patients with a need for atrial or atrioven- tricular sequential pacing for bradycardia/ conduction abnormalities, or as an attempt to relieve symptoms of obstructive HCM (most commonly in patients >65 years of age).191–198",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02780,2020,11,2A,C-LD,"In selected adult patients with nonob- structive HCM receiving an ICD who have NYHA class II to ambulatory class IV HF, left bundle branch block (LBBB), and LV ejection fraction (LVEF) <50%, cardiac resynchro- nization therapy for symptom reduction is reasonable.199–203",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02781,2020,11,2B,C-LD,"In patients with HCM in whom a decision has been made for ICD implantation and who have paroxysmal atrial tachycardias or AF, dual-chamber ICDs may be reasonable, but this decision must be balanced against higher complication rates of dual chamber devices.191–198 Table 7.  Established Clinical Risk Factors for HCM Sudden Death Risk Stratification Family history of sudden death from HCM Sudden death judged definitively or likely attributable to HCM in ≥1 first-degree or close relatives who are ≤50 y of age. Close relatives would generally be second-degree relatives; however, multiple SCDs in tertiary relatives should also be considered relevant. Massive LVH Wall thickness ≥30 mm in any segment within the chamber by echocardiography or CMR imaging; consideration for this morphologic marker is also given to borderline values of ≥28 mm in individual patients at the discretion of the treating cardiologist. For pediatric patients with HCM, an absolute or z-score threshold for wall thickness has not been established; however, a maximal wall that corresponds to a z-score ≥20 (and >10 in conjunction with other risk factors) appears reasonable. Unexplained syncope ≥1 Unexplained episodes involving acute transient loss of consciousness, judged by history unlikely to be of neurocardiogenic (vasovagal) etiology, nor attributable to LVOTO, and especially when occurring within 6 mo of evaluation (events beyond 5 y in the past do not appear to have relevance). HCM with LV systolic dysfunction",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02782,2020,12,Class 1,B-NR,"In patients with obstructive HCM and symptoms* attributable to LVOTO, nonva- sodilating beta blockers, titrated to effec- tiveness or maximally tolerated doses, are recommended.204–206",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02783,2020,12,Class 1,B-NR,"For patients with obstructive HCM who have persistent severe symptoms* attrib- utable to LVOTO despite beta blockers or non-dihydropyridine calcium channel blockers, either adding disopyramide in combination with 1 of the other drugs, or SRT performed at experienced centers,† is recommended.17,50,210–213",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02784,2020,12,Class 1,C-LD,"For patients with obstructive HCM and acute hypotension who do not respond to fluid administration, intravenous phenylephrine (or other vasoconstrictors without inotropic activity), alone or in combination with beta-blocking drugs, is recommended.214",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02785,2020,12,2B,C-EO,"For patients with obstructive HCM and persistent dyspnea with clinical evidence of volume overload and high left-sided filling pressures despite other HCM guideline- directed management and therapy, cau- tious use of low-dose oral diuretics may be considered.",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02786,2020,12,2B,C-EO,"For patients with obstructive HCM, discon- tinuation of vasodilators (eg, angiotensin- converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers) or digoxin may be rea- sonable because these agents can worsen symptoms caused by dynamic outflow tract obstruction.",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02787,2020,12,Class 3: Harm,C-LD,"For patients with obstructive HCM and severe dyspnea at rest, hypotension, very high rest- ing gradients (eg, >100 mm Hg), as well as all children <6 weeks of age, verapamil is poten- tially harmful.207,215 *Symptoms include effort-related dyspnea or chest pain; and occasionally other exertional symptoms (eg, syncope, near syncope) that are attributed to",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02788,2020,12,Class 1,B-NR,"In patients with obstructive HCM who remain severely symptomatic despite guideline-directed management and therapy, SRT in eligible patients,* performed at experienced centers,† is recommended for relieving LVOTO17,50,213 (Table 3 and Table 4).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02789,2020,12,Class 1,B-NR,"In symptomatic patients with obstructive HCM who have associated cardiac disease requiring sur- gical treatment (eg, associated anomalous papillary muscle, markedly elongated anterior mitral leaflet, intrinsic mitral valve disease, multivessel coronary artery disease, valvular aortic stenosis), surgical myectomy, performed at experienced centers,† is recommended92,216–218 (Table 3 and Table 4).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02790,2020,12,Class 1,C-LD,"In adult patients with obstructive HCM who remain severely symptomatic, despite guideline- directed management and therapy and in whom surgery is contraindicated or the risk is considered unacceptable because of serious comorbidities or advanced age, alcohol septal ablation in eligible patients,* performed at experienced centers,† is recommended219–221 (Table 3 and Table 4).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02791,2020,12,2B,B-NR,"In patients with obstructive HCM, earlier (NYHA class II) surgical myectomy performed at com- prehensive HCM centers (Table 3 and Table 4), may be reasonable in the presence of additional clinical factors, including17,222–233: a.  Severe and progressive pulmonary hypertension thought to be attributable to LVOTO or associ- ated mitral regurgitation. b.  Left atrial enlargement with ≥1 episodes of symptomatic AF. c.  Poor functional capacity attributable to LVOTO as documented on treadmill exercise testing. d.  Children and young adults with very high resting LVOT gradients (>100 mm Hg).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02792,2020,12,2B,C-LD,"For severely symptomatic patients with obstructive HCM, SRT in eligible patients,* performed at expe- rienced centers† (Table 3 and Table 4), may be con- sidered as an alternative to escalation of medical therapy after shared decision-making including risks and benefits of all treatment options.10,213,221,234,235",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02793,2020,12,Class 3: Harm,C-LD,"For patients with HCM who are asymptomatic and have normal exercise capacity, SRT is not recommended.224,232",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02794,2020,12,Class 3: Harm,B-NR,"For symptomatic patients with obstructive HCM in whom SRT is an option, mitral valve replace- ment should not be performed for the sole pur- pose of relief of LVOTO.236,237 *General eligibility criteria for septal reduction therapy: a) Clinical: Severe dyspnea or chest pain (usually NYHA functional class III or class IV), or occasionally other exertional symptoms (eg, syncope, near syncope), when attributable to LVOTO, that interferes with everyday activity or quality of life despite optimal medical therapy. b) Hemodynamic: Dynamic LVOT gradient at rest or with physiologic provocation with approximate peak gradient of ≥50 mm Hg, associated with septal hypertrophy and SAM of mitral valve. c) Anatomic: Targeted anterior septal thickness sufficient to perform the procedure safely and effectively in the judgment of the individual operator. †Comprehensive or primary HCM centers with demonstrated excellence in clinical outcomes for these procedures (Table 3 and Table 4). Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02795,2020,14,Class 1,C-LD,"In patients with nonobstructive HCM with pre- served EF and symptoms of exertional angina or dyspnea, beta blockers or non-dihydropyridine cal- cium channel blockers are recommended.209,238–246",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02796,2020,14,2A,C-EO,"In patients with nonobstructive HCM with preserved EF, it is reasonable to add oral diuretics when exertional dyspnea persists despite the use of beta blockers or non- dihydropyridine calcium channel blockers.",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02797,2020,14,2B,C-LD,"In patients with nonobstructive HCM with preserved EF, the usefulness of angiotensin- converting enzyme inhibitors and angiotensin receptor blockers in the treatment of symptoms (angina and dyspnea) is not well established.247",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02798,2020,14,2B,C-LD,"In highly selected patients with apical HCM with severe dyspnea or angina (NYHA class III or class IV) despite maximal medical therapy, and with preserved EF and small LV cavity size (LV end-diastolic volume <50 mL/m2 and LV stroke volume <30 mL/m2), apical myectomy by expe- rienced surgeons at comprehensive centers may be considered to reduce symptoms.248",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02799,2020,14,2B,C-EO,"In asymptomatic patients with non-obstruc- tive HCM, the benefit of beta blockers or cal- cium channel blockers is not well established. 5.3. Management of Patients With HCM and Atrial Fibrillation Recommendations for Management of Atrial Fibrillation Referenced studies that support the recommendations are summarized in Online Data Supplement 16. COR LOE Recommendations",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02800,2020,14,Class 1,B-NR,"In patients with HCM and clinical AF, antico- agulation is recommended with direct-acting oral anticoagulants as first-line option and vitamin K antagonists as second-line option, independent of CHA2DS2-VASc score.249–253",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02801,2020,14,Class 1,C-LD,"In patients with HCM and subclinical AF detected by internal or external cardiac device or monitor of >24 hours’ duration for a given episode, anti- coagulation is recommended with direct-acting oral anticoagulants as first-line option and vitamin K antagonists as second-line option, independent of CHA2DS2-VASc score.102,103,249,254",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02802,2020,14,Class 1,C-LD,"In patients with AF in whom rate control strategy is planned, either beta blockers, verapamil, or diltiazem are recommended, with the choice of agents according to patient preferences and comorbid conditions.104,255",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02803,2020,14,2A,C-LD,"In patients with HCM and subclinical AF detected by internal or external device or moni- tor, of >5 minutes’ but <24 hours’ duration for a given episode, anticoagulation with direct-act- ing oral anticoagulants as first-line option and vitamin K antagonists as second-line option can be beneficial, taking into consideration duration of AF episodes, total AF burden, underlying risk factors, and bleeding risk.102,103,249,254,256",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02804,2020,14,2A,B-NR,"In patients with HCM and poorly tolerated AF, a rhythm control strategy with cardiover- sion or antiarrhythmic drugs can be beneficial with the choice of an agent according to AF symptom severity, patient preferences, and comorbid conditions.104,210,257–268",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02805,2020,14,2A,B-NR,"In patients with HCM and symptomatic AF, as part of a AF rhythm control strategy, catheter ablation for AF can be effective when drug therapy is ineffective, contraindicated, or not the patient’s preference.257,269,270",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02806,2020,14,2A,B-NR,"In patients with HCM and AF who require surgical myectomy, concomitant surgical AF ablation procedure can be beneficial for AF rhythm control.104,258,271–273 5.4. Management of Patients With HCM and Ventricular Arrhythmias Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Referenced studies that support the recommendations are summarized in Online Data Supplement 17. COR LOE Recommendations",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02807,2020,14,Class 1,B-NR,"In patients with HCM and recurrent poorly tolerated life-threatening ventricular tachyarrhythmias refractory to maximal anti- arrhythmic drug therapy and ablation, heart transplantation assessment is indicated in accordance with current listing criteria.21,274",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02808,2020,14,Class 1,C-LD,"In children with HCM and recurrent ven- tricular arrhythmias despite beta-blocker use, antiarrhythmic drug therapy (amio- darone,275,276 mexiletine,278 sotalol275,276) is recommended, with the choice of agent guided by age, underlying comorbidities, severity of disease, patient preferences, and balance of efficacy and safety.",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02809,2020,14,Class 1,C-LD,"In patients with HCM and pacing-capable ICDs, programming antitachycardia pac- ing is recommended to minimize risk of shocks.279,280",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02810,2020,14,2A,C-LD,"In patients with HCM and recurrent symp- tomatic sustained monomorphic ventricu- lar tachycardia, or recurrent ICD shocks despite optimal device programming, and in whom antiarrhythmic drug therapy is either ineffective, not tolerated, or not preferred, catheter ablation can be useful for reducing arrhythmia burden.20,281,282 5.5. Management of Patients With HCM and Advanced HF",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02811,2020,16,Class 1,C-LD,"In patients with HCM who develop systolic dysfunction with an LVEF <50%, guideline- directed therapy for HF with reduced EF is recommended.38,283,284",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02812,2020,16,Class 1,C-LD,"In patients with HCM and systolic dys- function, diagnostic testing to assess for concomitant causes of systolic dysfunc- tion (such as coronary artery disease) is recommended.22,36,285",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02813,2020,16,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite guideline-directed therapy) cardio- pulmonary exercise test should be performed to quantify the degree of functional limita- tion and aid in selection of patients for heart transplantation or mechanical circulatory support.113,114",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02814,2020,16,Class 1,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA class III to class IV despite guideline-directed therapy) or with life- threatening ventricular arrhythmias refractory to maximal guideline-directed therapy, assess- ment for heart transplantation in accordance with current listing criteria is recommended.21,274,286,287",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02815,2020,16,2A,C-EO,"For patients with HCM who develop systolic dysfunction (LVEF <50%), it is reasonable to discontinue previously indicated negative inotropic agents (specifically, verapamil, diltia- zem, or disopyramide).",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02816,2020,16,2A,B-NR,"In patients with nonobstructive HCM and advanced HF (NYHA functional class III to class IV despite GDMT) who are candidates for heart transplantation, continuous-flow LV assist device therapy is reasonable as a bridge to heart transplantation.288–291",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02817,2020,16,2A,C-LD,"In patients with HCM and LVEF <50%, ICD placement can be beneficial.284",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02818,2020,16,2A,C-LD,"In patients with HCM and LVEF <50%, NYHA functional class II to class IV symptoms despite guideline-direct therapy, and LBBB, CRT can be beneficial to improve symptoms.199–203",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02819,2020,16,Class 1,B-NR,"For most patients with HCM, mild- to moderate-intensity recreational* exercise is beneficial to improve cardiorespiratory fit- ness, physical functioning, and quality of life, and for their overall health in keeping with physical activity guidelines for the general population.292–294",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02820,2020,16,Class 1,C-EO,"For athletes with HCM, a comprehensive evaluation and shared discussion of potential risks of sports participation by an expert provider is recommended.295",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02821,2020,16,2A,C-EO,"For most patients with HCM, participa- tion in low-intensity competitive sports is reasonable.2,297",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02822,2020,16,2A,C-LD,"In individuals who are genotype-positive, phenotype-negative for HCM, participation in competitive athletics of any intensity is reasonable.2,174,297–301",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02823,2020,16,2B,C-LD,"For patients with HCM, participation in high-intensity recreational activities or mod- erate- to high-intensity competitive sports activities may be considered after a compre- hensive evaluation and shared discussion, repeated annually with an expert provider who conveys that the risk of sudden death and ICD shocks may be increased, and with the understanding that eligibility decisions for competitive sports participation often involve third parties (eg, team physicians, consultants, and other institutional leader- ship) acting on behalf of the schools or teams.174,295,298–301",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02824,2020,16,Class 3: Harm,B-NR,"In patients with HCM, ICD placement for the sole purpose of participation in competitive athletics should not be performed.2,174,302 *Recreational exercise is done for the purpose of leisure with no requirement for systematic training and without the purpose to excel or compete against others. 6.2. Occupation Recommendations for Occupation in Patients With HCM COR LOE Recommendations",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02825,2020,16,2A,C-EO,"For patients with HCM, it is reasonable to follow Federal Motor Carrier Safety Administration cardiovascular disease guidelines that permit driving commercial motor vehicles, if they do not have an ICD or any major risk factors for SCD and are following a guideline-directed manage- ment plan.303",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02826,2020,16,2A,C-EO,"For pilot aircrew with a diagnosis of HCM, it is reasonable to follow Federal Aviation Administration guidelines that permit consid- eration of multicrew flying duties, provided they are asymptomatic, are deemed low risk for SCD, and can complete a maximal tread- mill stress test at 85% peak heart rate.304",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02827,2020,16,2B,C-EO,"Patients with HCM may consider occupations that require manual labor, heavy lifting, or a high level of physical performance after a comprehensive clinical evaluation, risk stratification for SCD, and implementation of guideline-directed management. Before a shared decision between a clinician and patient is reached, the clinician should convey that risks associated with the physi- cal requirements of these occupations are uncertain. Recommendations for Sports and Activity (Continued) COR LOE Recommendations Downloaded from http://ahajournals.org by on June 19, 2025",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02828,2020,17,Class 1,B-NR,"For pregnant women with HCM and AF or other indications for anticoagulation, low-molecular- weight heparin or vitamin K antagonists (at maximum therapeutic dose of <5 mg daily) are recommended for stroke prevention.249,250,305",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02829,2020,17,Class 1,C-LD,"In pregnant women with HCM, selected beta blockers should be administered for symptoms related to outflow tract obstruction or arrhyth- mias, with monitoring of fetal growth.306,307",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02830,2020,17,Class 1,C-LD,"In most pregnant women with HCM, vaginal delivery is recommended as the first-choice delivery option.306,308",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02831,2020,17,Class 1,B-NR,"In affected families with HCM, preconcep- tional and prenatal reproductive and genetic counseling should be offered.302,306,307,308",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02832,2020,17,Class 1,C-EO,"For pregnant women with HCM, care should be coordinated between their cardiologist and an obstetrician. For patients with HCM who are deemed high risk, consultation is advised with an expert in maternal-fetal medicine.",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02833,2020,17,2A,C-LD,"For women with clinically stable HCM who wish to become pregnant, it is reasonable to advise that pregnancy is generally safe as part of a shared discussion regarding potential maternal and fetal risks, and initiation of guideline-directed therapy.309–312",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02834,2020,17,2A,C-LD,"In pregnant women with HCM, cardioversion for new or recurrent AF, particularly if symp- tomatic, is reasonable.302,313",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02835,2020,17,2A,C-LD,"In pregnant women with HCM, general or epidural anesthesia is reasonable, with precautions to avoid hypotension.310",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02836,2020,17,2A,C-EO,"In pregnant women with HCM, it is reason- able to perform serial echocardiography, par- ticularly during the second or third trimester when hemodynamic load is highest, or if clini- cal symptoms develop.309",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02837,2020,17,2B,C-EO,"In pregnant women with HCM, fetal echocar- diography may be considered for diagnosis of fetal HCM in the context of prenatal counseling. 6.4. Comorbidities Table 9 addresses lifestyle considerations for patients with HCM. Recommendations for Patients With Comorbidities Referenced studies that support the recommendations are summarized in Online Data Supplement 21. COR LOE Recommendations",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02838,2020,17,Class 1,C-EO,"In patients with HCM, adherence to the guidelines on the prevention of atheroscle- rotic cardiovascular disease is recommended to reduce risk of cardiovascular events.294",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02839,2020,17,Class 1,B-NR,"In patients with HCM who are overweight or obese, counseling and comprehensive lifestyle interventions are recommended for achieving and maintaining weight loss294 and possibly lowering the risk of developing LVOTO, HF, and AF.314–316",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02840,2020,17,Class 1,C-LD,"In patients with HCM and hypertension, lifestyle modifications and medical therapy for hypertension are recommended294 with preference for beta blockers and non-dihydro- pyridine calcium channel blockers in patients with obstructive HCM.310,316–319",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
id_02841,2020,17,Class 1,C-LD,"In patients with HCM, assessment for symptoms of sleep disordered breathing is recommended and, if present, referral to a sleep medicine specialist for evaluation and treatment.320–323 ACC/AHA JOINT COMMITTEE MEMBERS",ommen-et-al-2020-aha-acc-guideline-for-the-diagnosis-and-treatment-of-patients-with-hypertrophic-cardiomyopathy.pdf
